<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000980.pub4" GROUP_ID="ARI" ID="810299081614143052" MERGED_FROM="" MODIFIED="2013-04-17 00:39:40 +0100" MODIFIED_BY="Liz Dooley" REVIEW_NO="A066" REVMAN_SUB_VERSION="5.2.3 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="16.0">
<COVER_SHEET MODIFIED="2013-04-17 00:39:40 +0100" MODIFIED_BY="Liz Dooley">
<TITLE>Vitamin C for preventing and treating the common cold</TITLE>
<CONTACT MODIFIED="2013-04-17 00:39:40 +0100" MODIFIED_BY="Liz Dooley"><PERSON ID="B45E8D7D82E26AA2000223243A3234EC" ROLE="AUTHOR"><FIRST_NAME>Harri</FIRST_NAME><LAST_NAME>Hemilä</LAST_NAME><SUFFIX>PhD, MD</SUFFIX><POSITION>Docent, Associate Professor</POSITION><EMAIL_1>harri.hemila@helsinki.fi</EMAIL_1><URL>www.ltdk.helsinki.fi/users/hemila/</URL><MOBILE_PHONE>+358 9 041 532 9987</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Public Health, POB 41</DEPARTMENT><ORGANISATION>University of Helsinki</ORGANISATION><ADDRESS_1>Mannerheimintie 172</ADDRESS_1><CITY>Helsinki</CITY><ZIP>FIN-00014</ZIP><COUNTRY CODE="FI">Finland</COUNTRY><PHONE_1>+358 9 191 27573</PHONE_1><FAX_1>+358 9 191 27570</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-04-17 00:39:40 +0100" MODIFIED_BY="Liz Dooley"><PERSON ID="B45E8D7D82E26AA2000223243A3234EC" ROLE="AUTHOR"><FIRST_NAME>Harri</FIRST_NAME><LAST_NAME>Hemilä</LAST_NAME><SUFFIX>PhD, MD</SUFFIX><POSITION>Docent, Associate Professor</POSITION><EMAIL_1>harri.hemila@helsinki.fi</EMAIL_1><URL>www.ltdk.helsinki.fi/users/hemila/</URL><MOBILE_PHONE>+358 9 041 532 9987</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Public Health, POB 41</DEPARTMENT><ORGANISATION>University of Helsinki</ORGANISATION><ADDRESS_1>Mannerheimintie 172</ADDRESS_1><CITY>Helsinki</CITY><ZIP>FIN-00014</ZIP><COUNTRY CODE="FI">Finland</COUNTRY><PHONE_1>+358 9 191 27573</PHONE_1><FAX_1>+358 9 191 27570</FAX_1></ADDRESS></PERSON><PERSON ID="19368" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Elizabeth</FIRST_NAME><LAST_NAME>Chalker</LAST_NAME><EMAIL_1>elizabeth.chalker@gmail.com</EMAIL_1><ADDRESS><ORGANISATION/><ADDRESS_1>20 Gregson Place</ADDRESS_1><CITY>Curtin</CITY><ZIP>2605</ZIP><REGION>ACT</REGION><COUNTRY CODE="AU">Australia</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2012-12-20 00:47:20 +1000" MODIFIED_BY="Harri Hemilä">
<UP_TO_DATE>
<DATE DAY="29" MONTH="11" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="29" MONTH="11" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="29" MONTH="11" YEAR="2014"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="1998"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="1998"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2013"/>
</DATES>
<WHATS_NEW MODIFIED="2013-04-17 09:37:33 +1000" MODIFIED_BY="Harri Hemilä">
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2013-04-17 09:37:33 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="17" MONTH="4" YEAR="2013"/>
<DESCRIPTION>
<P>Feedback comment and reply added to the review</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-04-17 09:37:09 +1000" MODIFIED_BY="Jenny Bellorini">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2013-04-17 09:37:09 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="29" MONTH="11" YEAR="2012"/>
<DESCRIPTION>
<P>Seven placebo-controlled trials, which were previously excluded because there were no data suitable for our meta-analyses, have been included (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). Their exclusion was inconsistent with the Methods section. This change did not result in changes to our conclusions (<LINK REF="STD-Abbott-1968" TYPE="STUDY">Abbott 1968</LINK>; <LINK REF="STD-Asfora-1977" TYPE="STUDY">Asfora 1977</LINK>; <LINK REF="STD-Briggs-1984" TYPE="STUDY">Briggs 1984</LINK>; <LINK REF="STD-Elliot-1973" TYPE="STUDY">Elliot 1973</LINK>; <LINK REF="STD-Regnier-1968" TYPE="STUDY">Regnier 1968</LINK>; <LINK REF="STD-Scheunert-1949" TYPE="STUDY">Scheunert 1949</LINK>; <LINK REF="STD-Tebrock-1956" TYPE="STUDY">Tebrock 1956</LINK>).</P>
<P>In previous versions 'prophylactic' was used to indicate the trials in which vitamin C was administered every day. 'Prophylactic' is relevant when measuring the incidence of episodes. However, that term is confusing when measuring the duration of episodes that occur during the trial. Therefore, in the 2012 version, we changed to the term 'regular supplementation' to indicate trials in which vitamin C was administered every day.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-04-17 09:37:04 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="29" MONTH="11" YEAR="2012"/>
<DESCRIPTION>
<P>Searches conducted. We included one new trial (<LINK REF="STD-Constantini-2011a" TYPE="STUDY">Constantini 2011a</LINK>; <LINK REF="STD-Constantini-2011b" TYPE="STUDY">Constantini 2011b</LINK>) and excluded two new trials (<LINK REF="STD-Maggini-2012" TYPE="STUDY">Maggini 2012</LINK>; <LINK REF="STD-Schmidt-2011" TYPE="STUDY">Schmidt 2011</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-12-10 01:56:48 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="2" MONTH="2" YEAR="2010"/>
<DESCRIPTION>
<P>No new trials identified in this updated search. However, one trial with marathon runners was excluded because of the high level of drop-outs and severe bias in the drop-out rate between the study arms (<LINK REF="STD-Himmelstein-1998b" TYPE="STUDY">Himmelstein 1998b</LINK>). We excluded the <LINK REF="STD-Audera-2001c" TYPE="STUDY">Audera 2001c</LINK> trial arm because flavonoids were administered in addition to vitamin C. We restricted the review to purely vitamin C comparisons. The conclusions remain unchanged since the last update (<LINK REF="REF-Douglas-2007" TYPE="REFERENCE">Douglas 2007</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2012-09-18 21:55:30 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="13" MONTH="11" YEAR="2009"/>
<DESCRIPTION>
<P>Feedback comment and reply added.<BR/>
</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2012-09-18 21:55:34 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="13" MONTH="6" YEAR="2008"/>
<DESCRIPTION>
<P>Feedback comment and reply added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-11-13 16:09:07 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="12" MONTH="6" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2008-06-13 16:08:22 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="23" MONTH="7" YEAR="2007"/>
<DESCRIPTION>
<P>Feedback added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2008-06-13 16:08:26 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="15" MONTH="11" YEAR="2005"/>
<DESCRIPTION>
<P>Feedback added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2008-06-13 16:06:30 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="27" MONTH="8" YEAR="2004"/>
<DESCRIPTION>
<P>Feedback comment added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2010-01-26 22:26:17 +1000" MODIFIED_BY="Jenny Bellorini">
<DATE DAY="11" MONTH="6" YEAR="2004"/>
<DESCRIPTION>
<P>Substantive amendment.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Australian National University (until 2004)</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Commonwealth Department of Health and Ageing</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2012-12-12 07:15:43 +1000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini">
<TITLE>Vitamin C for preventing and treating the common cold</TITLE>
<SUMMARY_BODY MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini">
<P>The common cold is a major cause of visits to a doctor in high-income countries and of absenteeism from work and school. There are over 200 viruses which can cause the common cold symptoms including runny nose, congestion, sneezing, sore throat, cough, and sometimes headache, fever and red eyes. Symptoms vary from person to person and cold to cold. Since the common cold is usually caused by one of the respiratory viruses, antibiotics are useless and therefore other potential treatment options are of substantial public health interest.</P>
<P>Vitamin C has been proposed for treating respiratory infections since it was isolated in the 1930s. It became particularly popular in the 1970s when Nobel laureate Linus Pauling concluded from earlier placebo-controlled trials that vitamin C would prevent and alleviate the common cold. Over two dozen new trials were undertaken thereafter. Vitamin C has been widely sold and used as a preventive and therapeutic agent.</P>
<P>This review is restricted to placebo-controlled trials testing 0.2 g/day or more of vitamin C. Regular ingestion of vitamin C had no effect on common cold incidence in the ordinary population, based on 29 trial comparisons involving 11,306 participants. However, regular supplementation had a modest but consistent effect in reducing the duration of common cold symptoms, which is based on 31 study comparisons with 9745 common cold episodes. In five trials with 598 participants exposed to short periods of extreme physical stress (including marathon runners and skiers) vitamin C halved the common cold risk. The published trials have not reported adverse effects of vitamin C.</P>
<P>Trials of high doses of vitamin C administered therapeutically, starting after the onset of symptoms, showed no consistent effect on the duration or severity of common cold symptoms. However, only a few therapeutic trials have been carried out and none have examined children, although the effect of prophylactic vitamin C has been greater in children. One large trial with adults reported benefit from an 8 g therapeutic dose at the onset of symptoms, and two therapeutic trials using five-day supplementation reported benefit. More trials are necessary to settle the possible role of therapeutic vitamin C, meaning administration immediately after the onset of symptoms.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2012-12-11 18:09:52 +1000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2012-09-18 16:10:24 +1000" MODIFIED_BY="[Empty name]">
<P>Vitamin C (ascorbic acid) for preventing and treating the common cold has been a subject of controversy for 70 years.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2012-12-11 18:09:52 +1000" MODIFIED_BY="[Empty name]">
<P>To find out whether vitamin C reduces the incidence, the duration or severity of the common cold when used either as a continuous regular supplementation every day or as a therapy at the onset of cold symptoms.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>We searched CENTRAL 2012, Issue 11, MEDLINE (1966 to November week 3, 2012), EMBASE (1990 to November 2012), CINAHL (January 2010 to November 2012), LILACS (January 2010 to November 2012) and Web of Science (January 2010 to November 2012). We also searched the U.S. National Institutes of Health trials register and WHO ICTRP on 29 November 2012.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>We excluded trials which used less than 0.2 g per day of vitamin C and trials without a placebo comparison. We restricted our review to placebo-controlled trials.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2012-12-10 01:57:50 +1000" MODIFIED_BY="[Empty name]">
<P>Two review authors independently extracted data. We assessed 'incidence' of colds during regular supplementation as the proportion of participants experiencing one or more colds during the study period. 'Duration' was the mean number of days of illness of cold episodes.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini">
<P>Twenty-nine trial comparisons involving 11,306 participants contributed to the meta-analysis on the risk ratio (RR) of developing a cold whilst taking vitamin C regularly over the study period. In the general community trials involving 10,708 participants, the pooled RR was 0.97 (95% confidence interval (CI) 0.94 to 1.00). Five trials involving a total of 598 marathon runners, skiers and soldiers on subarctic exercises yielded a pooled RR of 0.48 (95% CI 0.35 to 0.64).</P>
<P>Thirty-one comparisons examined the effect of regular vitamin C on common cold duration (9745 episodes). In adults the duration of colds was reduced by 8% (3% to 12%) and in children by 14% (7% to 21%). In children, 1 to 2 g/day vitamin C shortened colds by 18%. The severity of colds was also reduced by regular vitamin C administration.</P>
<P>Seven comparisons examined the effect of therapeutic vitamin C (3249 episodes). No consistent effect of vitamin C was seen on the duration or severity of colds in the therapeutic trials.</P>
<P>The majority of included trials were randomised, double-blind trials. The exclusion of trials that were either not randomised or not double-blind had no effect on the conclusions.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2012-09-18 21:26:46 +1000" MODIFIED_BY="Harri Hemilä">
<P>The failure of vitamin C supplementation to reduce the incidence of colds in the general population indicates that routine vitamin C supplementation is not justified, yet vitamin C may be useful for people exposed to brief periods of severe physical exercise. Regular supplementation trials have shown that vitamin C reduces the duration of colds, but this was not replicated in the few therapeutic trials that have been carried out. Nevertheless, given the consistent effect of vitamin C on the duration and severity of colds in the regular supplementation studies, and the low cost and safety, it may be worthwhile for common cold patients to test on an individual basis whether therapeutic vitamin C is beneficial for them. Further therapeutic RCTs are warranted.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2012-12-12 07:15:43 +1000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2012-12-10 02:04:33 +1000" MODIFIED_BY="Jenny Bellorini">
<CONDITION MODIFIED="2012-09-21 14:14:58 +1000" MODIFIED_BY="Jenny Bellorini">
<P>The term &#8216;the common cold&#8217; does not denote any precisely defined disease, but this illness is familiar to most people. Typically symptoms of the common cold consist of some combination of nasal discharge and obstruction, sore throat, cough, lethargy and malaise, with or without fever. The common cold is the leading cause of acute morbidity and of visits to a physician in high-income countries, and a major cause of absenteeism from work and school.</P>
<P>The common cold is usually caused by respiratory viruses (rhino, corona, adeno, parainfluenza, influenza, respiratory syncytial), which overall have some 200 serotypes (<LINK REF="REF-Eccles-2005" TYPE="REFERENCE">Eccles 2005</LINK>; <LINK REF="REF-Eccles-2009" TYPE="REFERENCE">Eccles 2009</LINK>; <LINK REF="REF-Gwaltney-2005" TYPE="REFERENCE">Gwaltney 2005</LINK>; <LINK REF="REF-Heikkinen-2003" TYPE="REFERENCE">Heikkinen 2003</LINK>). Thus, the term &#8216;the common cold&#8217; does not refer to a single entity but to a group of diseases caused by numerous unrelated aetiological agents. The most frequent agent causing the common cold is rhinovirus, which is found in 30% to 50% of sufferers. In a third of participants with cold symptoms, the aetiology remains undefined even when extensive virological tests are used. It is not clear to what extent this latter group is explained by the low sensitivity of the tests, unidentified viruses, or similar symptoms arising from non-viral aetiology, such as allergic or mechanical irritation of the airways. Different respiratory viruses have different symptom profiles, but the patterns are not consistent enough to validate aetiological conclusions from the patients&#8217; symptoms.</P>
<P>Although the great majority of common cold episodes are caused by the respiratory virus group, the symptom-based definition of the &#8216;common cold&#8217; also covers some diseases caused by other viruses (varicella, measles, rubella, cytomegalo, Epstein-Barr) and some bacterial infections. For example, since streptococcal pharyngitis cannot be differentiated from viral pharyngitis on clinical grounds, it can also be included within the broad definition of the common cold. Symptoms of illnesses caused by <I>Mycoplasma pneumoniae (M. pneumoniae) </I>and <I>Chlamydia pneumoniae (C. pneumoniae) </I>may also be similar to the symptoms caused by the respiratory viruses.</P>
<P>The manifestations of the common cold are so typical that usually the clinical diagnosis of the common cold can be made reliably by adult patients themselves. Allergic and vasomotor rhinitis can sometimes mimic the common cold, but these conditions can usually be easily differentiated (<LINK REF="REF-Heikkinen-2003" TYPE="REFERENCE">Heikkinen 2003</LINK>).</P>
<P>In common cold trials an operational definition of the common cold is used for logistic reasons; for example, based on the duration and the set of symptoms to yield an explicitly defined outcome. However, such limits are biologically arbitrary. There is no exact minimum duration or combination of symptoms which is meaningful when drawing a conclusion as to whether the symptoms should be explained by a viral infection, or by allergic or mechanical irritation of nasal airways or throat.</P>
<P>The use of antibiotics for a typical acute common cold episode is useless since the vast majority of colds are caused by viruses. Nevertheless, according to some surveys about 50% of common cold patients in the USA received antibiotics (<LINK REF="REF-Gonzales-1997" TYPE="REFERENCE">Gonzales 1997</LINK>; <LINK REF="REF-Mainous-1996" TYPE="REFERENCE">Mainous 1996</LINK>). In this respect, the alternative treatment options for the common cold are of substantial public health interest.</P>
</CONDITION>
<INTERVENTION MODIFIED="2012-12-10 02:04:33 +1000" MODIFIED_BY="Jenny Bellorini">
<P>Numerous animal studies with different species have shown that vitamin C affects resistance to diverse infections by viruses and bacteria (<LINK REF="REF-Hemil_x00e4_-2006a" TYPE="REFERENCE">Hemilä 2006a</LINK>; <LINK REF="REF-Hemil_x00e4_-1997c" TYPE="REFERENCE">Hemilä 1997c</LINK>). Therefore this vitamin might play a similar role in infections in human beings. Since the early 1940s, a number of controlled trials have been carried out to examine the possible effects of vitamin C on the common cold.</P>
<P>In 1970, the publication of Linus Pauling's book <I>Vitamin C and the Common Cold</I> generated huge public interest which persists today (<LINK REF="REF-Pauling-1970a" TYPE="REFERENCE">Pauling 1970a</LINK>). Pauling had won Nobel Prizes in Chemistry (1954) and Peace (1962), and his book had a great influence. <LINK REF="REF-Pauling-1971a" TYPE="REFERENCE">Pauling 1971a</LINK> also carried out a meta-analysis in which he combined the P values derived from four placebo-controlled trials by Fisher's method and found that there was strong evidence that vitamin C decreased the 'incidence of colds' (P = 0.003). In a second meta-analysis, <LINK REF="REF-Pauling-1971b" TYPE="REFERENCE">Pauling 1971b</LINK> focused on 'days of illness per person' in the best two trials (<LINK REF="STD-Cowan-1942" TYPE="STUDY">Cowan 1942</LINK>; <LINK REF="STD-Ritzel-1961" TYPE="STUDY">Ritzel 1961</LINK>) and by combining the P values by Fisher's method led him to conclude that "the null hypothesis of equal effectiveness of ascorbic acid and placebo [on total morbidity] is rejected at the level P less than 0.001."</P>
<P>
<LINK REF="STD-Ritzel-1961" TYPE="STUDY">Ritzel 1961</LINK> had reported a brief randomised trial of children at a ski school in the Swiss Alps in which he administered 1 g of vitamin C daily and found significantly reduced incidence and duration of colds in children who were administered vitamin C. <LINK REF="REF-Pauling-1971a" TYPE="REFERENCE">Pauling 1971a</LINK> put much weight on the Ritzel trial. On the basis of Ritzel's trial, Pauling proposed that mega-dose supplementation might profoundly influence both the incidence and severity of the common cold over all the population. Pauling also presented data suggesting that human diets might not provide sufficient intake of vitamin C for best health (<LINK REF="REF-Pauling-1970b" TYPE="REFERENCE">Pauling 1970b</LINK>; <LINK REF="REF-Pauling-1976a" TYPE="REFERENCE">Pauling 1976a</LINK>).</P>
<P>Pauling's advocacy of vitamin C led to numerous careful trials in different countries in the following decade, the largest of which were performed on healthy adult volunteers in Canada (<LINK REF="STD-Anderson-1972" TYPE="STUDY">Anderson 1972</LINK>; <LINK REF="STD-Anderson-1974a" TYPE="STUDY">Anderson 1974a</LINK>; <LINK REF="STD-Anderson-1975a" TYPE="STUDY">Anderson 1975a</LINK>). The evidence emerging from all the published trials was confusing (<LINK REF="REF-Anderson-1977" TYPE="REFERENCE">Anderson 1977</LINK>), but generally failed to support Pauling's hope that vitamin C would be a panacea.</P>
<P>In a meta-analysis, <LINK REF="REF-Chalmers-1975" TYPE="REFERENCE">Chalmers 1975</LINK> calculated an unweighted average of the treatment effect in seven placebo-controlled trials and found that colds in vitamin C groups were 0.11 ± 0.24 (standard error (SE)) days shorter which is not a statistically or clinically significant difference. In a qualitative review on vitamin C and the common cold published in the same year, <LINK REF="REF-Dykes-1975" TYPE="REFERENCE">Dykes 1975</LINK> also concluded that vitamin C had no effect on colds.</P>
<P>However, it has subsequently been pointed out that the influential reviews by <LINK REF="REF-Chalmers-1975" TYPE="REFERENCE">Chalmers 1975</LINK> and <LINK REF="REF-Dykes-1975" TYPE="REFERENCE">Dykes 1975</LINK> contain serious errors (<LINK REF="REF-Hemil_x00e4_-1995" TYPE="REFERENCE">Hemilä 1995</LINK>; <LINK REF="REF-Hemil_x00e4_-1996c" TYPE="REFERENCE">Hemilä 1996c</LINK>; <LINK REF="REF-Hemil_x00e4_-2006a" TYPE="REFERENCE">Hemilä 2006a</LINK>). <LINK REF="REF-Hemil_x00e4_-1995" TYPE="REFERENCE">Hemilä 1995</LINK> showed that after extraction of correct data from the trial reports, correction of errors in calculations, and restriction to trials in which at least 1 g/day of vitamin C had been used, as Pauling had proposed, <LINK REF="REF-Chalmers-1975" TYPE="REFERENCE">Chalmers 1975</LINK> would have calculated an eight times higher estimate of the vitamin C effect: 0.93 ± 0.22 (SE) days reduction in the duration of colds. Furthermore, both <LINK REF="REF-Chalmers-1975" TYPE="REFERENCE">Chalmers 1975</LINK> and <LINK REF="REF-Dykes-1975" TYPE="REFERENCE">Dykes 1975</LINK> placed considerable weight on the double-blind, placebo-controlled trial carried out by <LINK REF="STD-Karlowski-1975a" TYPE="STUDY">Karlowski 1975a</LINK> at the National Institutes of Health (NIH), which concluded that a statistically significant benefit of vitamin C supplementation was simply explained by the placebo effect. However, it has been shown that the placebo effect explanation in the <LINK REF="STD-Karlowski-1975a" TYPE="STUDY">Karlowski 1975a</LINK> paper was not consistent with their own data (<LINK REF="REF-Chalmers-1996" TYPE="REFERENCE">Chalmers 1996</LINK>; <LINK REF="REF-Hemil_x00e4_-1996a" TYPE="REFERENCE">Hemilä 1996a</LINK>; <LINK REF="REF-Hemil_x00e4_-1996d" TYPE="REFERENCE">Hemilä 1996d</LINK>; <LINK REF="REF-Hemil_x00e4_-2006a" TYPE="REFERENCE">Hemilä 2006a</LINK>; <LINK REF="REF-Hemil_x00e4_-2006c" TYPE="REFERENCE">Hemilä 2006c</LINK>).</P>
<P>
<LINK REF="REF-Hemil_x00e4_-1997b" TYPE="REFERENCE">Hemilä 1997b</LINK> claimed that the highly cited reviews of <LINK REF="REF-Chalmers-1975" TYPE="REFERENCE">Chalmers 1975</LINK> and <LINK REF="REF-Dykes-1975" TYPE="REFERENCE">Dykes 1975</LINK> and the trial by <LINK REF="STD-Karlowski-1975a" TYPE="STUDY">Karlowski 1975a</LINK> quelled interest in real, but modest effects of vitamin C on the common cold after the mid-1970s. <LINK REF="REF-Hemil_x00e4_-1997a" TYPE="REFERENCE">Hemilä 1997a</LINK> pooled the results of the six largest trials using &#8805; 1 g/day of vitamin C found no effect on the common cold incidence (pooled risk ratio (RR) 0.99; 95% confidence interval (CI) 0.93 to 1.04), which refuted Pauling&#8217;s proposal as to the prophylactic effect of gram-dose vitamin C for the general population. However, four trials with UK males found a moderate reduction in common cold incidence with vitamin C (pooled RR 0.70; 95% CI 0.60 to 0.81), which was explained by the particularly low dietary vitamin C intake in the UK rather than high doses of supplements. Also, three trials with participants under heavy acute physical stress found a reduction in the incidence of colds with vitamin C (pooled RR 0.50; 95% CI 0.35 to 0.69) (<LINK REF="REF-Hemil_x00e4_-1996b" TYPE="REFERENCE">Hemilä 1996b</LINK>). Thus, it is possible that vitamin C has an effect on common cold incidence in restricted subpopulations.</P>
<P>Although regular vitamin C supplementation at doses of &#8805; 1 g/day has consistently decreased the duration or alleviated the symptoms of the common cold, there was substantial heterogeneity in the results (<LINK REF="REF-Hemil_x00e4_-1994" TYPE="REFERENCE">Hemilä 1994</LINK>). A further meta-analysis found a trend for trials with children to show greater benefit than trials with adults, and another trend for trials with &#8805; 2 g/day to show greater benefit than trials with 1 g/day, suggesting dose-dependency (<LINK REF="REF-Hemil_x00e4_-1999a" TYPE="REFERENCE">Hemilä 1999a</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2012-09-21 11:40:24 +1000" MODIFIED_BY="Jenny Bellorini">
<P>Dozens of studies have found that vitamin C may affect, for example, phagocytosis and chemotaxis of leucocytes, replication of viruses, and production of interferon (<LINK REF="REF-Hemil_x00e4_-2006a" TYPE="REFERENCE">Hemilä 2006a</LINK>; <LINK REF="REF-Hemil_x00e4_-1997c" TYPE="REFERENCE">Hemilä 1997c</LINK>; <LINK REF="REF-Thomas-1978" TYPE="REFERENCE">Thomas 1978</LINK>; <LINK REF="REF-Webb-2007" TYPE="REFERENCE">Webb 2007</LINK>). Vitamin C is an efficient water-soluble antioxidant and the effects on the immune system can be explained by the protection against oxidative stress generated during infections (<LINK REF="REF-Akaike-2001" TYPE="REFERENCE">Akaike 2001</LINK>; <LINK REF="REF-Castro-2006" TYPE="REFERENCE">Castro 2006</LINK>; <LINK REF="REF-Hemil_x00e4_-1992" TYPE="REFERENCE">Hemilä 1992</LINK>). Phagocytes have a specific transport system by which the oxidised form of vitamin C (dehydroascorbic acid) is imported into the cells, where the reduced form of vitamin C is regenerated (<LINK REF="REF-Nualart-2003" TYPE="REFERENCE">Nualart 2003</LINK>; <LINK REF="REF-Wang-1997" TYPE="REFERENCE">Wang 1997</LINK>). If the major role of vitamin C in the immune system is that of a physiological antioxidant protecting various host cells against oxidative stress during an infection, it could have important effects in certain conditions even though the mechanisms are apparently non-specific. Furthermore, heavy physical stress generates oxidative stress (<LINK REF="REF-Ji-1999" TYPE="REFERENCE">Ji 1999</LINK>) and the antioxidant role of vitamin C can thus also explain its effects on respiratory symptoms in physically stressed people. Dozens of animal studies found that vitamin C reduces the incidence and severity of bacterial and viral infections indicating that the vitamin has physiological effects on infections, and not just on laboratory measures of the immune system (<LINK REF="REF-Hemil_x00e4_-2006a" TYPE="REFERENCE">Hemilä 2006a</LINK>).</P>
<P>For brief notes on the history of this Cochrane Review, see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>. Links to the publications cited in this section, for which full-text versions are available, can be found at <A HREF="http://www.mv.helsinki.fi/home/hemila/CC/">www.mv.helsinki.fi/home/hemila/CC/</A>.</P>
</THEORY>
<IMPORTANCE MODIFIED="2012-08-22 17:44:40 +1000" MODIFIED_BY="Harri Hemilä">
<P>The common cold causes enormous morbidity worldwide and the search for simple and effective preventive or therapeutic agents has been elusive. Even if vitamin C might have modest effects in restricted population groups, that could be important from a public health point of view.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>To find out whether vitamin C reduces the incidence, the duration or severity of the common cold when used either as a continuous regular supplementation every day or as a therapy at the onset of cold symptoms.</P>
</OBJECTIVES>
<METHODS MODIFIED="2012-12-10 02:51:20 +1000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2012-12-10 02:07:02 +1000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2012-09-21 11:23:22 +1000" MODIFIED_BY="[Empty name]">
<P>We included placebo-controlled trials. We did not restrict to randomised controlled trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Trials of children and adults of either gender and any age were considered eligible.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2012-12-10 02:07:02 +1000" MODIFIED_BY="Harri Hemilä">
<P>The intervention considered was orally administered vitamin C of at least 0.2 g daily for a single day or for a period. The limit of 0.2 g/day was selected as a choice of convenience. If a trial with a lower dose finds a negative result, the negative findings can be attributed to the low dose. Thus, trials with large doses are more critical for testing Pauling's proposal that gram doses of vitamin C would reduce morbidity due to common cold infections. On the other hand, under certain conditions vitamin C doses lower than 0.2 g/day might have effects (<I>see</I> <LINK TAG="DISCUSSION" TYPE="SECTION">Discussion</LINK>: Possible role of marginal vitamin C deficiency). Thus, our selection criterion for dose does not mean that all excluded trials are irrelevant to the question of the effects of vitamin C. All trials that used a vitamin C dose lower than 0.2 g/day are listed and briefly described in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table.</P>
<P>In a few instances the placebo included a low dose of vitamin C; <LINK REF="STD-Carr-1981a" TYPE="STUDY">Carr 1981a</LINK> used 70 mg/day and a few others used 50 mg/day or less. This was done to ensure that participants were not 'vitamin C deficient', recognising that dietary intake of vitamin C is highly variable. Thus, the goal of these investigators was to test the effects of large doses for properly nourished participants.</P>
<P>We may include studies in which vitamin C has a co-intervention if the control group has only the co-intervention so that the only difference is vitamin C administration.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2012-09-26 08:07:21 +1000" MODIFIED_BY="Jenny Bellorini">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2012-09-26 08:07:18 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>'Incidence' of colds during regular supplementation was assessed as the proportion of participants experiencing one or more colds during the study period.</LI>
<LI>'Duration' was the mean number of days of illness of cold episodes.</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2012-09-26 08:07:21 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>'Severity' of these episodes was assessed in two ways: a) days confined indoors, or off work or off school per episode and b) symptom severity scores.</LI>
<LI>'Evidence of possible medication side effects' was available from seven large regular supplementation studies, with the number of participants reporting possible medication side effects in the intervention and control groups.</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>For this 2012 update we searched the Cochrane Central Register of Controlled Trials (CENTRAL) 2012, Issue 11, part of <I>The Cochrane Library, </I>
<A HREF="http://www.thecochranelibrary.com">thecochranelibrary</A> (accessed 29 May 2012), which contains the Acute Respiratory Infections Group's Specialised Register, MEDLINE (January 2010 to November week 3, 2012), Embase.com (January 2010 to November 2012), CINAHL (January 2010 to November 2012), LILACS (January 2010 to November 2012) and Web of Science (January 2010 to November 2012). See <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for details of previous searches.</P>
<P>We used the following search strategy to search CENTRAL and MEDLINE. The search strategy was adapted to search EMBASE (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>), CINAHL (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>), LILACS (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>) and Web of Science (<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">MEDLINE (OVID)</HEADING>
<P>1 Common Cold/<BR/>2 common cold*.tw.<BR/>3 Rhinovirus/<BR/>4 rhinovir*.tw.<BR/>5 coryza.tw.<BR/>6 "acute rhinitis".tw.<BR/>7 ((viral or virus*) adj2 rhinit*).tw.<BR/>8 or/1-7<BR/>9 exp Ascorbic Acid/<BR/>10 ascorb*.tw,nm.<BR/>11 (vitamin* adj5 c).tw.<BR/>12 or/9-11<BR/>13 8 and 12</P>
<P>There were no language or publication type restrictions in the literature searches. <BR/>
</P>
</SUBSECTION>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2012-11-29 11:07:10 +1000" MODIFIED_BY="[Empty name]">
<P>The review authors screened the reference lists incorporated in two systematic reviews of the literature published by <LINK REF="STD-Briggs-1984" TYPE="STUDY">Briggs 1984</LINK> and <LINK REF="REF-Kleijnen-1989" TYPE="REFERENCE">Kleijnen 1989</LINK> (for the search strategy of the latter, <I>see </I>
<LINK REF="REF-Kleijnen-1992" TYPE="REFERENCE">Kleijnen 1992</LINK>) and the references in all identified studies. Furthermore, one of the review authors (HH) has a research involvement spanning three decades in this topic and has assembled a personal reference list of papers published in the grey literature or listed in indexing services that preceded electronic searching.</P>
<P>We also searched the U.S. National Institutes of Health trials register <A HREF="http://www.clinicaltrials.gov">www.clinicaltrials.gov</A> and the WHO ICTRP <A HREF="http://www.who.int/ictrp">www.who.int/ictrp</A> on 29 May 2012 (<I>see</I> <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for search details).</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2012-12-10 02:51:20 +1000" MODIFIED_BY="Jenny Bellorini">
<STUDY_SELECTION MODIFIED="2012-09-26 04:21:06 +1000" MODIFIED_BY="Harri Hemilä">
<P>For the 2004 version of this review, HH and Bob Douglas (BD) searched the literature and independently assessed the titles and abstracts to identify potentially relevant articles (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>). They obtained and scrutinised full versions of all potentially eligible articles. When they disagreed on the relevance of an article, they discussed it until they reached a consensus. For the 2007 and 2009 updates, the first review author (HH) searched the literature and assessed the titles and abstracts to identify potentially relevant articles. For the 2012 update, two review authors (HH, EC) searched the literature and assessed titles and abstracts to identify potentially relevant articles.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>For the 2004 version of this review, two review authors (HH, BD) independently extracted pertinent data from the articles selected and entered data into the Review Manager program (<I>see</I> <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>) (<LINK REF="REF-Douglas-2004" TYPE="REFERENCE">Douglas 2004</LINK>; <LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>). They sought consensus when they differed in the interpretation of study findings. Only one new trial satisfying the selection criteria (<LINK REF="STD-Constantini-2011a" TYPE="STUDY">Constantini 2011a</LINK>; <LINK REF="STD-Constantini-2011b" TYPE="STUDY">Constantini 2011b</LINK>) has been published since the preceding version of this review (<LINK REF="REF-Hemil_x00e4_-2010" TYPE="REFERENCE">Hemilä 2010</LINK>) and it was included in this 2012 update.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2012-09-26 08:20:18 +1000" MODIFIED_BY="Jenny Bellorini">
<P>Most of the included trials were double-blind. Double-blind means that the participant and others directly involved in treatment do not know to which treatment group the participant has been allocated, i.e. there must be allocation concealment. Double-blind also means that there must be blinding of participants and personnel. Finally, since the outcomes were recorded by personnel or the participant, double-blinding also implies that there is blinding of outcome assessment.</P>
<P>Studies are classified as randomised on the basis of the study reports, but only a few studies described the actual method of randomisation.</P>
<P>
<LINK REF="REF-Chalmers-1975" TYPE="REFERENCE">Chalmers 1975</LINK> proposed that the benefits of vitamin C supplementation on the common cold might be caused by "the result of the power of suggestion." His proposal was based on the <LINK REF="STD-Karlowski-1975a" TYPE="STUDY">Karlowski 1975a</LINK> trial, in which placebo consisted of lactose which is sweet and differs by taste from ascorbic acid which was used in the vitamin C capsules. Therefore, we collected data on the reported indistinguishability of vitamin C and placebo preparations.</P>
<P>When the methodological description was unambiguous, one review author (HH) entered the methodological description to the 'Risk of bias' tables in <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>. When the description of methods was ambiguous, HH discussed the issue with the co-author (EC) to reach a consensus. The overall risk of bias is summarised in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2012-09-26 04:21:06 +1000" MODIFIED_BY="Jenny Bellorini">
<P>For the community trials, we selected two primary outcomes and one secondary outcome to compare vitamin C with placebo groups, resulting in five tables.</P>
<P>
<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>: the measure of the treatment effect is the risk ratio (RR) of 'incidence' of colds in vitamin C and placebo groups. Incidence is defined as the proportion of participants with at least one cold during the study.</P>
<P>
<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK> and <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>: the measure of treatment effect is the mean difference (MD) in common cold 'duration'. Since duration of cold episodes varied appreciably across trials, we standardised the mean values and standard deviations (SD) in each group against the mean of the respective placebo group. In this way, the placebo group of each trial gets a value of 100%, and therefore the difference between the vitamin C and placebo group is the effect of vitamin C in percentages.</P>
<P>
<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK> and <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>: there are two measures of effect on 'severity': a) the difference in the mean number of days that the patient was absent from work or school or confined to bed; and b) the difference in the mean symptom severity score derived from patient kept records.</P>
<P>In analysing dichotomous data with only a few cases in the trial groups, the mid-P value is the most appropriate method to calculate the P values for the differences in the treatment groups (<LINK REF="REF-Hemil_x00e4_-2006a" TYPE="REFERENCE">Hemilä 2006a</LINK>) and was used when comparing groups with small numbers of cases. Two-tailed P values are used in this review.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2012-09-26 08:48:21 +1000" MODIFIED_BY="[Empty name]">
<P>In four of the trials (<LINK REF="STD-Anderson-1974a" TYPE="STUDY">Anderson 1974a</LINK>; <LINK REF="STD-Anderson-1975a" TYPE="STUDY">Anderson 1975a</LINK>; <LINK REF="STD-Audera-2001a" TYPE="STUDY">Audera 2001a</LINK>; <LINK REF="STD-Karlowski-1975a" TYPE="STUDY">Karlowski 1975a</LINK>) more than one vitamin C group was compared with a single placebo group. Where multiple active arms were analysed in the same meta-analysis, the vitamin C arms were combined as one entry which appears in the figures, identified as the lowest lettered trial that the entry contained.</P>
<P>
<LINK REF="STD-Miller-1977a" TYPE="STUDY">Miller 1977a</LINK> and <LINK REF="STD-Carr-1981a" TYPE="STUDY">Carr 1981a</LINK> studied twins and the comparison is paired. The SD values used in this meta-analysis are calculated from the SE and P values, respectively, of reported paired tests, so the two trials get proper weight in pooling.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2012-12-10 02:11:21 +1000" MODIFIED_BY="Jenny Bellorini">
<P>Some trials presented the mean duration or severity of colds, but not the respective SD. In some trials the P value for the difference of interest was reported and the SD was calculated from it. In the <LINK REF="STD-Anderson-1972" TYPE="STUDY">Anderson 1972</LINK>, <LINK REF="STD-Anderson-1974a" TYPE="STUDY">Anderson 1974a</LINK> and <LINK REF="STD-Anderson-1975a" TYPE="STUDY">Anderson 1975a</LINK> trials, Fieller's theorem was used to estimate the SD for individual common cold episodes from the SD values presented in papers that were based on a per person experience. In the other trials with missing SD, we estimated SD as identical with the mean of the treatment group. This is based on our analysis that for trials reporting the SD, the ratio of SD to mean is on average 0.7 so that our ratio of 1.0 used in the SD imputation is somewhat conservative. The consequence of this is that we are putting slightly reduced weight in our estimates of effect on these trials with missing SD values, compared to the average.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2012-12-10 02:51:20 +1000" MODIFIED_BY="Jenny Bellorini">
<P>We assessed heterogeneity using the Chi<SUP>2 </SUP>test and the I<SUP>2 </SUP>statistic (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>; <LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). The Chi<SUP>2 </SUP>test is known to be poor at detecting true heterogeneity among studies. While a statistically significant result indicates heterogeneity, a non-significant result is not evidence of no heterogeneity. The I<SUP>2 </SUP>statistic examines the percentage of total variation across studies that is due to heterogeneity rather than chance. A value of about 50% for I<SUP>2 </SUP>indicates a moderate level of heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2012-09-26 04:21:06 +1000" MODIFIED_BY="[Empty name]">
<P>We used the Review Manager (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>) software to pool the results of the three outcomes of the included trials. A pooled fixed-effect RR of the probability of experiencing at least one cold while taking vitamin C was computed for &#8216;incidence&#8217;. We computed a pooled fixed-effect MD in common cold &#8216;duration&#8217; to derive an estimate of the percentage of days of illness by which vitamin C reduced the average common cold.</P>
<P>We considered separately two different approaches to the assessment of severity in the meta-analysis by treating the two measures of severity as separate subgroups. We computed a standardised mean difference (SMD) for the two subgroups and for all the trials for which severity data were available. The SMD calculation method leads to quantitative results but the estimates do not have any relevant clinical interpretation. Rather the primary statistical result of the SMD method is the P value for the combined set.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Harri Hemilä">
<P>We considered three factors as possible explanations for heterogeneity observed across the results of these trials. These were vitamin C dosage, age of the participants (children and adults), and the presence or absence of heavy, short-term physical stress.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini">
<P>We undertook sensitivity analyses in <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK> and <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK> to test the robustness of our conclusions regarding the methodological quality of the trials, in which we excluded all studies which were not randomised and double-blind.</P>
<P>In seven trials in <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK> ('Duration of colds in regular supplementation trials') we imputed the SD values assuming that SD is equal to the mean of the group (<LINK REF="STD-Briggs-1984" TYPE="STUDY">Briggs 1984</LINK>; <LINK REF="STD-Coulehan-1974a" TYPE="STUDY">Coulehan 1974a</LINK>; <LINK REF="STD-Coulehan-1974b" TYPE="STUDY">Coulehan 1974b</LINK>; <LINK REF="STD-Coulehan-1976" TYPE="STUDY">Coulehan 1976</LINK>; <LINK REF="STD-Peters-1996a" TYPE="STUDY">Peters 1996a</LINK>; <LINK REF="STD-Peters-1996b" TYPE="STUDY">Peters 1996b</LINK>; <LINK REF="STD-Pitt-1979" TYPE="STUDY">Pitt 1979</LINK>). When we excluded these seven trials in a sensitivity analysis of <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>, the pooled results indicated a slightly greater effect of vitamin C: for adults 8.6% (4% to 13%); for children 14.6% (7% to 22%). Thus, inclusion of the trials with imputed SD values does not lead to an increase in the estimate of benefit, but leads to a slight reduction in the calculated benefit.</P>
<P>We also tested whether the exclusion of the <LINK REF="STD-Anderson-1974a" TYPE="STUDY">Anderson 1974a</LINK> trial might affect the estimates of <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK> and <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>. That trial had two placebo groups and we selected for our comparisons the placebo group #4 which was close to the vitamin C groups on the basis of baseline data (<I>see</I> <LINK REF="REF-Hemil_x00e4_-2006a" TYPE="REFERENCE">Hemilä 2006a</LINK> and <LINK TAG="RESULTS" TYPE="SECTION">Results</LINK> section 4). Exclusion of the <LINK REF="STD-Anderson-1974a" TYPE="STUDY">Anderson 1974a</LINK> trial had minimal effects on the pooled estimates (not shown).</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2012-12-12 07:15:43 +1000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2012-12-12 07:15:43 +1000" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2012-12-12 07:15:43 +1000" MODIFIED_BY="[Empty name]">
<P>The 2012 MEDLINE (Ovid) search identified 17 results, EMBASE 58, CENTRAL 6, CINAHL 20, LILACS 0, Web of Science 13, Clinicaltrials.gov 3 and WHO Trials Register (ICTRP) 1 search results. With duplicates removed there were 90 search results. One new trial satisfying our inclusion criteria was identified in the 2012 search (<LINK REF="STD-Constantini-2011a" TYPE="STUDY">Constantini 2011a</LINK>) and two new trials were added to the excluded trials list (<LINK REF="STD-Maggini-2012" TYPE="STUDY">Maggini 2012</LINK>; <LINK REF="STD-Schmidt-2011" TYPE="STUDY">Schmidt 2011</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini">
<P>Sixty-three separate comparisons of vitamin C against placebo, reported in 44 publications, met our selection criteria. Eleven of these publications presented the results of two to six different study comparisons. Included in the selected papers are the four trials identified originally by <LINK REF="REF-Pauling-1971a" TYPE="REFERENCE">Pauling 1971a</LINK> to justify his proposals for mega-dose regular supplementation and therapy (<LINK REF="STD-Cowan-1942" TYPE="STUDY">Cowan 1942</LINK>; <LINK REF="STD-Franz--1956" TYPE="STUDY">Franz 1956</LINK>; <LINK REF="STD-Ritzel-1961" TYPE="STUDY">Ritzel 1961</LINK>; <LINK REF="REF-Wilson-1969" TYPE="REFERENCE">Wilson 1969</LINK>). We have used the <LINK REF="STD-Wilson-1973a" TYPE="STUDY">Wilson 1973a</LINK> final report of his boarding school trials rather than the preliminary communication which <LINK REF="REF-Pauling-1971a" TYPE="REFERENCE">Pauling 1971a</LINK> had available to him.<BR/>
</P>
<P>In <LINK REF="STD-Anderson-1974a" TYPE="STUDY">Anderson 1974a</LINK>, <LINK REF="STD-Anderson-1975a" TYPE="STUDY">Anderson 1975a</LINK>, <LINK REF="STD-Audera-2001a" TYPE="STUDY">Audera 2001a</LINK> and <LINK REF="STD-Karlowski-1975a" TYPE="STUDY">Karlowski 1975a</LINK> more than one active arm is compared with a single placebo arm. This explains why the total number of participants is less in the placebo groups than in the vitamin C groups.</P>
<P>The 63 included trials which have contributed data to this review fall into four groups.</P>
<OL>
<LI>Forty-three community regular supplementation trial arms which evaluated the effects of regular daily supplementation with vitamin C (i.e. vitamin C each day over the study irrespective of the presence of colds) on reducing the incidence or duration or severity of naturally occurring colds.</LI>
<LI>Ten community therapeutic trial arms that evaluated the therapeutic effects of high-dosage vitamin C after natural common cold symptoms had commenced.</LI>
<LI>Seven community trials did not report data suitable for our meta-analysis and these trials are presented qualitatively.</LI>
<LI>Three laboratory trials (<LINK REF="STD-Dick-1990" TYPE="STUDY">Dick 1990</LINK>; <LINK REF="STD-Schwartz-1973" TYPE="STUDY">Schwartz 1973</LINK>; <LINK REF="STD-Walker-1967" TYPE="STUDY">Walker 1967</LINK>) in which volunteers were intentionally exposed to known viruses after vitamin C or placebo administration. As they are qualitatively different from the community-based trials on natural common cold infections, they are not included in the meta-analyses but are presented qualitatively.</LI>
</OL>
<P>Brief details of the circumstances, dosage and quality assessment of the trials are available in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table. Links to the trial reports and translations can be found at <A HREF="http://www.mv.helsinki.fi/home/hemila/CC/">www.mv.helsinki.fi/home/hemila/CC/</A>.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini">
<P>We excluded 25 studies. The major reasons for exclusion were the lack of placebo control (12 trials) and vitamin C dose &lt; 0.2 g/day (seven trials). For details, please see the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini">
<ALLOCATION MODIFIED="2012-09-26 04:21:06 +1000" MODIFIED_BY="[Empty name]">
<P>Most of the identified trials were randomised controlled trials (RCTs) (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). Most of the studies also had allocation concealment (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>Most of the identified trials blinded participants and personnel and the outcome was assessed by either of the two so that the outcome assessment was also blinded (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2012-09-26 04:21:07 +1000" MODIFIED_BY="Jenny Bellorini">
<P>In many trials there were no drop-outs, and in those trials in which there were, the number of drop-outs was not substantially different between the study groups.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini">
<P>When there are one or a few trials with a positive finding on a poorly justified outcome, the possibility of publication bias is an important concern. In our review we have two large groups of trials with the same well-justified primary outcomes: incidence and duration of colds (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK> and <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>). We do not see any basis to speculate that the consistency in these two outcomes could be explained by selective reporting. There is no unambiguous definition for severity which we classify as a secondary outcome, and there might be more problems with selective reporting on that outcome (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>). However, severity has a lower priority in our review and the findings are consistent with the effect on duration (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2012-09-18 17:56:50 +1000" MODIFIED_BY="[Empty name]">
<P>The great majority of the trials reported that vitamin C tablets (usually ascorbic acid) and placebo tablets (usually citric acid) were indistinguishable (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table). Thus there is no basis to assume that difference in taste or appearance between the tablets could have generated substantial bias in the trials.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2012-12-12 07:08:22 +1000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">1. Community regular supplementation trials: incidence of colds</HEADING>
<P>
<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK> (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>) presents the meta-analysis of the risk ratio of at least one cold developing for a participant while on regular vitamin C supplementation. Regular supplementation means that vitamin C was administered each day over the study period. The entry in the meta-analysis for <LINK REF="STD-Anderson-1974a" TYPE="STUDY">Anderson 1974a</LINK> represents four separate trial arms (<LINK REF="STD-Anderson-1974a" TYPE="STUDY">Anderson 1974a</LINK>; <LINK REF="STD-Anderson-1974b" TYPE="STUDY">Anderson 1974b</LINK>; <LINK REF="STD-Anderson-1974c" TYPE="STUDY">Anderson 1974c</LINK>; <LINK REF="STD-Anderson-1974d" TYPE="STUDY">Anderson 1974d</LINK>) in which different vitamin C dosages ranging from 0.25 to 2 g/day were compared with one placebo group. Thus the 29 entries in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> represent 32 vitamin C arms in trials.</P>
<P>The 29 entries represent 11,306 participants, of whom 6105 used vitamin C for periods ranging from two weeks to five years. The pooled risk ratio (RR) for all trials was 0.95 (95% confidence interval (CI) 0.92 to 0.98). Although the overall difference between vitamin C and placebo participants is statistically highly significant (P = 0.001), indicating a biological effect of vitamin C, the narrow CI precludes any clinically relevant effect over wide population groups.</P>
<SUBSECTION>
<HEADING LEVEL="4">Heterogeneity of results</HEADING>
<P>Among all the studies included in <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK> there is substantial heterogeneity, as indicated by the Chi<SUP>2 </SUP>test (P = 0.02) and the rather high I<SUP>2 </SUP>statistic (38%). Heterogeneity refutes the notion that vitamin C is universally equivalent to placebo.</P>
<P>Five of the 29 comparisons recorded statistically significant (P &lt; 0.05) protection favouring the vitamin C group: <LINK REF="STD-Peters-1996a" TYPE="STUDY">Peters 1996a</LINK> (RR 0.39), <LINK REF="STD-Peters-1993a" TYPE="STUDY">Peters 1993a</LINK> (RR 0.50), <LINK REF="STD-Ritzel-1961" TYPE="STUDY">Ritzel 1961</LINK> (RR 0.55), <LINK REF="STD-Charleston-1972" TYPE="STUDY">Charleston 1972</LINK> (RR 0.77) and <LINK REF="STD-Anderson-1972" TYPE="STUDY">Anderson 1972</LINK> (RR 0.91). Four other trials recorded a non-significant RR &lt; 0.80 (<LINK REF="STD-Moolla-1996a" TYPE="STUDY">Moolla 1996a</LINK>; <LINK REF="STD-Moolla-1996b" TYPE="STUDY">Moolla 1996b</LINK>; <LINK REF="STD-Peters-1996b" TYPE="STUDY">Peters 1996b</LINK>; <LINK REF="STD-Sabiston-1974" TYPE="STUDY">Sabiston 1974</LINK>). None of the 29 comparisons significantly favoured the placebo.</P>
<P>Of the eight relatively small trials with RR &lt; 0.8, three were with marathon runners (<LINK REF="STD-Moolla-1996a" TYPE="STUDY">Moolla 1996a</LINK>; <LINK REF="STD-Peters-1993a" TYPE="STUDY">Peters 1993a</LINK>; <LINK REF="STD-Peters-1996a" TYPE="STUDY">Peters 1996a</LINK>), two with sedentary controls for marathon runners (<LINK REF="STD-Moolla-1996b" TYPE="STUDY">Moolla 1996b</LINK>; <LINK REF="STD-Peters-1996b" TYPE="STUDY">Peters 1996b</LINK>), one with students in a skiing school in the Swiss Alps (<LINK REF="STD-Ritzel-1961" TYPE="STUDY">Ritzel 1961</LINK>), one with Canadian army troops on subarctic operations (<LINK REF="STD-Sabiston-1974" TYPE="STUDY">Sabiston 1974</LINK>), and one with staff and students at Glasgow University, UK (<LINK REF="STD-Charleston-1972" TYPE="STUDY">Charleston 1972</LINK>).</P>
<P>The bottom of <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK> shows a subgroup of five studies which involved marathon runners, skiers and Canadian soldiers in a subarctic exercise. Division of the 29 trials to the two subgroups resulted in two distinct groups of trials which were significantly different from each other in their pooled estimates of effect. Furthermore, the two subgroups were homogeneous within the two pools, as indicated by the high P values in the Chi<SUP>2 </SUP>test, and the zero values for the I<SUP>2 </SUP>statistic.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Subgroups: general community trials and heavy acute physical stress trials</HEADING>
<P>Based on 24 entries with 10,708 participants from the general community who had no heavy short-term physical stress, the narrow CI, which is located close to the zero effect, refutes the possibility that regular vitamin C supplementation could reduce the average incidence of colds in the general community: RR 0.97 (95% CI 0.94 to 1.00) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
<P>When the general community meta-analysis was restricted to 17 entries with vitamin C dose &#8805; 1 g/day, the prophylactic benefit of vitamin C supplementation was also refuted (RR 0.98; 95% CI 0.95 to 1.01; based on 6661 participants).</P>
<P>In the <LINK REF="STD-Karlowski-1975a" TYPE="STUDY">Karlowski 1975a</LINK> trial, the dose of vitamin C was the highest, 3 g/day. This study is not included in <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK> because the number of participants who caught a cold during the trial was not reported; instead the total number of cold episodes per group was reported. Nevertheless, 3 g/day vitamin C had no effect on the number of common cold episodes, with RR 0.93 (95% CI 0.73 to 1.20)<B> </B>(<LINK REF="REF-Hemil_x00e4_-1997a" TYPE="REFERENCE">Hemilä 1997a</LINK>).</P>
<P>In five trials with participants undergoing heavy acute physical activity in the subgroup at the bottom of <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>, vitamin C halved the incidence of colds: RR 0.48 (95% CI 0.35 to 0.64) (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>, Analysis 1.1.2). All of these five studies were randomised and double-blind. In three of these studies, the vitamin C dose was less than 1 g/day so that the benefit in this subgroup cannot explained by particularly high vitamin C doses, but by the extraordinary conditions of the participants.</P>
<P>Two trials had participants exposed to long-term physical stress. <LINK REF="STD-Pitt-1979" TYPE="STUDY">Pitt 1979</LINK> examined 674 US marine recruits for two months and <LINK REF="STD-Constantini-2011a" TYPE="STUDY">Constantini 2011a</LINK> studied 39 competitive young swimmers for three months. Neither of these trials found effect of vitamin C on common cold incidence.</P>
<P>To test the effect of study quality on the findings in <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>, we undertook a sensitivity analysis in which we removed five trials that were either not randomised or not double-blind from the general community meta-analyses and this had no effect on the estimate (RR 0.98; 95% CI 0.94 to 1.01). All trials with participants under heavy acute physical stress were randomised and double-blind. Thus, the effect of study quality as assessed by randomisation and double-blinding did not change the estimates of the two subgroups of <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. Community regular supplementation trials: duration of colds</HEADING>
<P>
<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK> (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>) presents the effect of vitamin C on the duration of colds which occurred while participants were taking vitamin C regularly, each day over the study. These trials are divided into two subgroups: adults and children. The division into child and adult trials was carried out for two reasons: a) children have a substantially higher incidence of colds reflecting differences in the immune system maturity, and b) children are on average smaller so that a fixed dose corresponds to a greater dose per weight.</P>
<P>For adults there were 17 entries representing 21 trial arms (four separate trial arms in <LINK REF="STD-Anderson-1974a" TYPE="STUDY">Anderson 1974a</LINK> and two in <LINK REF="STD-Karlowski-1975a" TYPE="STUDY">Karlowski 1975a</LINK>) and 7215 episodes of illness, and for children there were 14 trial comparisons including 2530 episodes of illness.</P>
<P>A consistent benefit was seen in the duration of colds. For children, the pooled effect was a 14.2% (7.3% to 21%) reduction in common cold duration, and for adults the pooled effect was a 7.7% (3.7% to 12%) reduction in cold duration. The Chi<SUP>2</SUP> test for trial heterogeneity was not significant in either of the subgroups.</P>
<P>In five of the 31 comparisons (<LINK REF="STD-Carr-1981b" TYPE="STUDY">Carr 1981b</LINK>; <LINK REF="STD-Constantini-2011a" TYPE="STUDY">Constantini 2011a</LINK>; <LINK REF="STD-Charleston-1972" TYPE="STUDY">Charleston 1972</LINK>; <LINK REF="STD-Ludvigsson-1977a" TYPE="STUDY">Ludvigsson 1977a</LINK>; <LINK REF="STD-Ritzel-1961" TYPE="STUDY">Ritzel 1961</LINK>) the effect of vitamin C was statistically significant within the trial. In the <LINK REF="STD-Constantini-2011a" TYPE="STUDY">Constantini 2011a</LINK> trial, common cold duration was significantly shorter in male swimmers, but not in female swimmers, there being a statistically significant interaction between vitamin C effect and sex.</P>
<P>Five comparisons (<LINK REF="STD-Carr-1981a" TYPE="STUDY">Carr 1981a</LINK>; <LINK REF="STD-Constantini-2011b" TYPE="STUDY">Constantini 2011b</LINK>; <LINK REF="STD-Peters-1993a" TYPE="STUDY">Peters 1993a</LINK>; <LINK REF="STD-Peters-1996b" TYPE="STUDY">Peters 1996b</LINK>; <LINK REF="STD-Wilson-1973b" TYPE="STUDY">Wilson 1973b</LINK>) recorded a point estimate favouring the placebo. <LINK REF="STD-Wilson-1973b" TYPE="STUDY">Wilson 1973b</LINK> used only 0.2 g/day vitamin C, which is the smallest dose in the analysis. <LINK REF="STD-Carr-1981a" TYPE="STUDY">Carr 1981a</LINK> examined twins living together, whereas the <LINK REF="STD-Carr-1981b" TYPE="STUDY">Carr 1981b</LINK> trial examined twins living apart; it is possible that the substantially divergent result in these twin groups is related to the living conditions - those living together might have exchanged or confused their tablets. The <LINK REF="STD-Peters-1996b" TYPE="STUDY">Peters 1996b</LINK> trial was very small and the CI is very wide.</P>
<P>The great majority of the trials in <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK> used 1 g/day of vitamin C and therefore a systematic examination of possible dose-dependency across the trials was not feasible. In the child subgroup, we used sensitivity analysis to test the possibility that low-dose vitamin C trials might dilute the pooled estimate. When we removed the trials using &lt; 1 g/day of vitamin C (<LINK REF="STD-Miller-1977b" TYPE="STUDY">Miller 1977b</LINK>; <LINK REF="STD-Miller-1977c" TYPE="STUDY">Miller 1977c</LINK>; <LINK REF="STD-Wilson-1973a" TYPE="STUDY">Wilson 1973a</LINK>; <LINK REF="STD-Wilson-1973b" TYPE="STUDY">Wilson 1973b</LINK>), the pooled estimate of benefit was increased to a 18.1% (9% to 27%) reduction in the duration of colds in children suggesting that the 14.2% estimate for all studies of children may be biased downwards because low-dose trials are included. In the adult subgroup, the estimate of effect was essentially unchanged, 8.0% (3.8% to 12%), when the &lt; 1 g/day vitamin C trials were removed (<LINK REF="STD-Peters-1993a" TYPE="STUDY">Peters 1993a</LINK>; <LINK REF="STD-Peters-1993b" TYPE="STUDY">Peters 1993b</LINK>; <LINK REF="STD-Peters-1996a" TYPE="STUDY">Peters 1996a</LINK>; <LINK REF="STD-Peters-1996b" TYPE="STUDY">Peters 1996b</LINK>); these are small trials with doses of 0.5 to 0.6 g/day.</P>
<P>In sensitivity analyses, we removed the studies which were not randomised and double-blind. Exclusion of two trials from the adult subgroup had no material effect on the estimated benefit of 7% (3% to 11%), and exclusion of two trials from the child subgroup similarly had no substantial effect on the estimated benefit of 14% (7% to 21%). Thus, excluding four trials with lower quality had no effect on the conclusions of <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.</P>
<P>In summary, this meta-analysis of the duration of colds occurring while participants were on regular vitamin C supplementation demonstrated a statistically highly significant, but modest, benefit to the vitamin C supplemented participants which was greater in children than in adults.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3. Community regular supplementation trials: severity of colds</HEADING>
<P>
<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK> presents the effect of vitamin C on the severity of common cold episodes occurring during regular vitamin C supplementation. Two measures of the severity of the common cold were available.</P>
<P>Subgroup 1 in <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK> consists of seven entries of 10 vitamin C study arms in which severity was measured by 'days confined to home' or 'days off work or school'. This included 5066 common cold episodes in adults and children. The large-scale trials by <LINK REF="STD-Anderson-1972" TYPE="STUDY">Anderson 1972</LINK> and <LINK REF="STD-Ludvigsson-1977b" TYPE="STUDY">Ludvigsson 1977b</LINK> reported statistically significant reductions in 'days confined to house per episode' with vitamin C supplementation. Subgroup 1 found a quantitatively modest, but statistically highly significant reduction in common cold severity. This subgroup exhibited significant heterogeneity between the studies as measured by the Chi<SUP>2 </SUP>test and I<SUP>2 </SUP>statistic.</P>
<P>Subgroup 2 in <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK> presents the results of symptom severity scores in nine trials with 2143 episodes. The large-scale trial by <LINK REF="STD-Pitt-1979" TYPE="STUDY">Pitt 1979</LINK> found a statistically significant, but small, 5% reduction in the severity score. There is a statistically highly significant reduction in common cold severity also in subgroup 2. There is no heterogeneity in this subgroup.</P>
<P>The measures of 'severity' that have been used in the included trials are variable. We calculated the standardised mean difference (SMD) which normalises the difference between the vitamin C and placebo groups to the units of standard deviations. Therefore the pooled results of <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK> are not practically useful, rather the significance level is of main importance in this analysis; P = 0.0004 for the studies that assessed days confined to home or off work or school, and P = 0.002 for studies which used severity scores, and P &lt; 0.00001 when the two subgroups were combined. Although the benefit with respect to days confined to home or off work or off school is statistically significant, it is modest in absolute terms.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">4. Community therapeutic studies: duration of colds when treatment commenced after common cold symptoms began</HEADING>
<P>
<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK> presents the findings of therapeutic trials, which means that vitamin C administration was started after the cold symptoms occurred. This meta-analysis contains seven entries that incorporate data from 10 different trial arms involving 3249 cold episodes where participants initiated supplementation at the onset of cold symptoms. <LINK REF="STD-Audera-2001a" TYPE="STUDY">Audera 2001a</LINK>, <LINK REF="STD-Anderson-1974e" TYPE="STUDY">Anderson 1974e</LINK> and <LINK REF="STD-Anderson-1975a" TYPE="STUDY">Anderson 1975a</LINK> contain two vitamin C arms.</P>
<P>The pooled result for these therapeutic trials did not exhibit a difference of vitamin C from placebo in the variety of therapeutic protocols that were used. The large trial by <LINK REF="STD-Anderson-1974e" TYPE="STUDY">Anderson 1974e</LINK> found a statistically significant but modest benefit but this was counterbalanced by the negative results in the other trials.</P>
<P>The <LINK REF="STD-Anderson-1974e" TYPE="STUDY">Anderson 1974e</LINK> entry combines two arms with different dosages. <LINK REF="STD-Anderson-1974e" TYPE="STUDY">Anderson 1974e</LINK> administered 4 g/day and <LINK REF="STD-Anderson-1974f" TYPE="STUDY">Anderson 1974f</LINK> administered 8 g/day on the first day of illness only. The mean duration of illness episodes for those in the 4 g/day arm was 3.17 days, while that for 8 g/day arm was 2.86 days compared with the duration in the placebo group #4 of 3.52 days. However, this trial was bedeviled by the fact that the investigators originally intended to compare results with two separate placebo groups. One of the two placebo groups (#6) had statistically significant baseline differences when compared with the six vitamin C groups. The comparisons presented here are with the placebo group #4 that was close to the vitamin C groups with respect to the baseline data (<I>see</I> <LINK REF="REF-Hemil_x00e4_-2006a" TYPE="REFERENCE">Hemilä 2006a</LINK>). If comparisons had been made with the placebo group #6 or a combination of the two placebo groups as the investigators had originally intended, the benefits would have been minimised as the mean episode duration for the placebo group #4 was 3.52 days, and for placebo group #6 was 2.83 days. Nevertheless, notwithstanding the placebo group problem, the proportion of 'short colds', that lasted for only a single day was significantly larger in the 8 g/day group (46%; 222 out of 483) compared with the 4 g/day group (39%; 164 out of 417) (P = 0.046), consistent with a greater benefit with the higher dose compared with the lower dose.</P>
<P>
<LINK REF="STD-Tyrrell-1977" TYPE="STUDY">Tyrrell 1977</LINK>, <LINK REF="STD-Elwood-1977" TYPE="STUDY">Elwood 1977</LINK> and <LINK REF="STD-Audera-2001a" TYPE="STUDY">Audera 2001a</LINK> failed to show an effect on duration. Tyrrell evaluated males and females separately using a dosage of 4 g/day for the first 2.5 days of illness (total 10 g), Elwood evaluated males and females separately using a dosage of 3 g/day for the first 3.3 days of illness (total 10 g), and Audera evaluated 1 and 3 g/day over the first 3 days (total 3 g and 9 g).</P>
<P>In summary, the therapeutic trials do not provide consistent evidence that the duration of colds could be reduced with the protocols that have been tested in the vitamin C trials. The benefit from the use of an 8 g single dose immediately after the onset of cold symptoms is interesting but indicates the need for further research rather than implying practical conclusions.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">5. Community therapeutic studies: severity of cold episodes when treatment commenced after common cold symptoms began</HEADING>
<P>
<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK> has four entries which represent seven trial arms that included 2708 separate common cold episodes for which cold severity was assessed. <LINK REF="STD-Audera-2001a" TYPE="STUDY">Audera 2001a</LINK>, <LINK REF="STD-Anderson-1974e" TYPE="STUDY">Anderson 1974e</LINK> and <LINK REF="STD-Anderson-1975a" TYPE="STUDY">Anderson 1975a</LINK> contain two vitamin C arms.</P>
<P>As with the regular supplementation studies, we separated the measures of severity into two subgroups: a) days confined to home, off work or school, and b) symptom severity scores, and we analysed these subgroups separately and together.</P>
<P>In subgroup 1, the only comparison which found a significant benefit to those taking vitamin C was that for <LINK REF="STD-Anderson-1975a" TYPE="STUDY">Anderson 1975a</LINK>. In that study, participants took 1.5 g/day for the first day of the common cold and 1 g/day for the following four days (total 5.5 g). <LINK REF="STD-Anderson-1974e" TYPE="STUDY">Anderson 1974e</LINK> and <LINK REF="STD-Tyrrell-1977" TYPE="STUDY">Tyrrell 1977</LINK> found no meaningful difference between vitamin C and placebo. The pooled effect for subgroup 1 shows a marginally significant benefit of vitamin C.</P>
<P>The only trial in subgroup 2, <LINK REF="STD-Audera-2001a" TYPE="STUDY">Audera 2001a</LINK>, found no difference between vitamin C and placebo.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">6. Community trials with no data suitable for our meta-analyses</HEADING>
<P>
<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> shows the findings in seven trials which did not report suitable data for our meta-analysis. Two of them were regular supplementation trials and five were therapeutic trials. All these are placebo-controlled trials which used &#8805; 0.2 g/day of vitamin C. The main findings of these trials are described in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
<P>In two therapeutic trials the authors claimed to be able to identify the vitamin C and placebo participants from the clinical progress of the patients (<LINK REF="STD-Asfora-1977" TYPE="STUDY">Asfora 1977</LINK>; <LINK REF="STD-Regnier-1968" TYPE="STUDY">Regnier 1968</LINK>). One therapeutic trial found a marginally significant effect on the duration of "nose colds" (<LINK REF="STD-Brown-1945" TYPE="STUDY">Brown 1945</LINK>), and two therapeutic trials reported no difference between vitamin C and placebo (<LINK REF="STD-Abbott-1968" TYPE="STUDY">Abbott 1968</LINK>; <LINK REF="STD-Tebrock-1956" TYPE="STUDY">Tebrock 1956</LINK>).</P>
<P>In a regular supplementation trial, <LINK REF="STD-Elliot-1973" TYPE="STUDY">Elliot 1973</LINK> found a significant effect of vitamin C on the morbidity for sore throats and productive coughs, but the study was carried out in a Polaris submarine so that the conditions were special. <LINK REF="STD-Scheunert-1949" TYPE="STUDY">Scheunert 1949</LINK> reported less respiratory morbidity in persons administered higher doses of vitamin C compared with lower doses, but the study is poorly reported and methodologically unsatisfactory.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">7. Laboratory trials with artificially infected volunteers</HEADING>
<P>
<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK> presents three laboratory trials which were volunteer transmission studies.</P>
<P>
<LINK REF="STD-Walker-1967" TYPE="STUDY">Walker 1967</LINK> and <LINK REF="STD-Schwartz-1973" TYPE="STUDY">Schwartz 1973</LINK> instilled virus into the noses of volunteers who had been pre-treated with vitamin C or placebo. <LINK REF="STD-Dick-1990" TYPE="STUDY">Dick 1990</LINK> used a more natural mechanism for the transmission of a rhinovirus: their experimental volunteers were housed for a week and worked closely with other volunteers who had been previously infected by nasal instillation of rhinovirus.</P>
<P>
<LINK REF="STD-Dick-1990" TYPE="STUDY">Dick 1990</LINK> found that fewer vitamin C treated volunteers became infected and the cumulative symptom severity score and mucus weights were significantly less (P = 0.03), but virus shedding was similar in both groups. <LINK REF="STD-Schwartz-1973" TYPE="STUDY">Schwartz 1973</LINK> found reduced common cold severity in the vitamin C group (P &lt; 0.02 at day 4), but no effect on symptom duration, whereas <LINK REF="STD-Walker-1967" TYPE="STUDY">Walker 1967</LINK> did not observe any benefit to those who took vitamin C.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">8. Adverse effects from high-dose vitamin C intake</HEADING>
<P>Seven large trials recorded data on symptoms which participants attributed to the medication they were using.</P>
<P>Over the trials, data were recorded for a total of 2490 recipients who had used &#8805; 1 g/day of vitamin C compared with 2066 who took a placebo. Altogether 5.8% of the vitamin C recipients reported adverse symptoms which they attributed to the medication compared with 6.0% of those who were taking placebo (data not shown). No serious symptoms were reported.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2012-12-10 02:49:27 +1000" MODIFIED_BY="Harri Hemilä">
<P>Despite the variation in methodology and the substantial heterogeneity in results from this large number of trial results carried out over a 70-year period, certain rather strong conclusions can be drawn.</P>
<SUBSECTION>
<HEADING LEVEL="2">Common cold incidence</HEADING>
<SUBSECTION>
<HEADING LEVEL="3">Trials within the general community</HEADING>
<P>An earlier meta-analysis pooled the results of the six largest trials in which &#8805; 1 g/day of vitamin C had been administered regularly over the study period and found no effect of vitamin C on the incidence of colds with a narrow confidence interval (CI) (risk ratio (RR) 0.99; 95% CI 0.93 to 1.04) (<LINK REF="REF-Hemil_x00e4_-1997a" TYPE="REFERENCE">Hemilä 1997a</LINK>). This earlier meta-analysis pooled the number of common cold episodes occurring during the trial, whereas this Cochrane meta-analysis used the number of participants catching at least one cold as the measure of common cold incidence. Nevertheless, this second outcome definition led to the same conclusion for the general community trials.</P>
<P>When the subgroup of marathon runners, skiers and soldiers on subarctic operations was excluded in this review (see below), there was strong evidence that vitamin C supplementation has no effect on the number of people who catch the common cold (RR 0.97; 95% CI 0.94 to 1.00). This estimate was based on trials in which the vitamin C dose was &#8805; 0.2 g/day. However, the negative finding is not explained by the inclusion of a few trials in which vitamin C dose was low. When restricting to trials in which the vitamin C dose was &#8805; 1 g/day, the estimate was essentially the same. Finally, the general community trial with the largest dose, 3 g/day of vitamin C, found no difference in the common cold incidence between the vitamin C and placebo groups (<LINK REF="REF-Hemil_x00e4_-1997a" TYPE="REFERENCE">Hemilä 1997a</LINK>; <LINK REF="STD-Karlowski-1975a" TYPE="STUDY">Karlowski 1975a</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Trials with people under heavy acute physical stress</HEADING>
<P>A previous meta-analysis identified three trials with participants under severe acute physical stress, and the pooling of results found that vitamin C supplementation halved the incidence of colds in this group (<LINK REF="REF-Hemil_x00e4_-1996b" TYPE="REFERENCE">Hemilä 1996b</LINK>). Two later trials with marathon runners (<LINK REF="STD-Moolla-1996a" TYPE="STUDY">Moolla 1996a</LINK>; <LINK REF="STD-Peters-1996a" TYPE="STUDY">Peters 1996a</LINK>) are included in our Cochrane Review and they have not changed the pooled estimate of effect: RR 0.48; 95% CI 0.35 to 0.64. All five trials in this group involved a brief exposure to high physical stress with or without cold stress. The doses of vitamin C were not particularly high, being between 0.25 and 1.0 g/day. Thus, the benefit in this subgroup cannot be explained by high vitamin C doses. Similar and higher doses in the general community have not affected the incidence of colds (see above).</P>
<P>Furthermore, in the general community the acute respiratory symptoms usually have a viral cause, but it is not obvious that similar symptoms occurring after heavy exercise are caused by a viral infection because they can also result from exercise-induced bronchoconstriction (EIB) symptoms caused by an injury to the airways because of exceptional ventilatory exertion (<LINK REF="REF-Anderson-2008" TYPE="REFERENCE">Anderson 2008</LINK>). In three trials, vitamin C supplementation reduced the decrease in pulmonary function associated with EIB (<LINK REF="REF-Hemil_x00e4_-2009c" TYPE="REFERENCE">Hemilä 2009c</LINK>). Thus the common cold studies of physically stressed people might have been measuring, at least in part, the effects of vitamin C on EIB instead of viral infections. Nevertheless, although the aetiology of symptoms is not clear in the physically stressed subgroup, the beneficial effect of vitamin C on acute respiratory symptoms in this subgroup is firm.</P>
<P>Two trials with two to three months physical stress on the participants found no effect of vitamin C on common cold incidence (<LINK REF="STD-Constantini-2011a" TYPE="STUDY">Constantini 2011a</LINK>; <LINK REF="STD-Pitt-1979" TYPE="STUDY">Pitt 1979</LINK>). It is thus possible that vitamin C has effects on short-term exposure to physical stress, but not on long-term physical stress.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Possible role of marginal vitamin C deficiency</HEADING>
<P>
<LINK REF="REF-Hemil_x00e4_-1997a" TYPE="REFERENCE">Hemilä 1997a</LINK> has suggested that some of the early benefits of vitamin C supplementation might be a explained by low dietary vitamin C intakes in the UK when the studies were carried out (<LINK REF="STD-Baird-1979" TYPE="STUDY">Baird 1979</LINK>; <LINK REF="STD-Bartley-1953" TYPE="STUDY">Bartley 1953</LINK>; <LINK REF="STD-Glazebrook-1942" TYPE="STUDY">Glazebrook 1942</LINK>). These trials were ruled ineligible for this review because the doses were lower than 0.2 g/day. Low dietary vitamin C intake might also explain the significant reduction in cold incidence in the <LINK REF="STD-Charleston-1972" TYPE="STUDY">Charleston 1972</LINK> UK trial which is included in <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>.</P>
<P>Four UK trials also found a reduction in the incidence of recurrent colds during the study period in males (pooled RR 0.54; 95% CI 0.40 to 0.74) but not in females (<LINK REF="REF-Hemil_x00e4_-1997a" TYPE="REFERENCE">Hemilä 1997a</LINK>). Nevertheless, a recent UK trial found a reduction in recurrent colds in a nine-week trial in both sexes (RR 0.13; 95% CI 0.03 to 0.53) (<LINK REF="STD-Van-Straten-2002" TYPE="STUDY">Van Straten 2002</LINK>) (<I>see</I> <LINK REF="REF-Hemil_x00e4_-2006a" TYPE="REFERENCE">Hemilä 2006a</LINK>). The most impressive trial in this UK group is the <LINK REF="STD-Baird-1979" TYPE="STUDY">Baird 1979</LINK> study, which was a randomised, double-blind, placebo-controlled trial, but was excluded from our Cochrane Review because the vitamin C dose was only 0.08 g/day. Thus, methodological weaknesses cannot explain the reduction in common cold incidence in males and the highly significant modification of vitamin C effect by sex (<LINK REF="REF-Hemil_x00e4_-1997a" TYPE="REFERENCE">Hemilä 1997a</LINK>; <LINK REF="REF-Hemil_x00e4_-2008" TYPE="REFERENCE">Hemilä 2008</LINK>). Significant sex differences in the effect of vitamin C were also found in a recent trial with competitive swimmers so that vitamin C was effective for males but not for females (<LINK REF="STD-Constantini-2011a" TYPE="STUDY">Constantini 2011a</LINK>).</P>
<P>The large trial by <LINK REF="STD-Anderson-1972" TYPE="STUDY">Anderson 1972</LINK> found a statistically significant but small reduction in common cold incidence (RR 0.91; 95% CI 0.85 to 0.98). This trial was conducted during the winter in Toronto, Canada, and participants were selected on the basis of having had problems with colds during previous winters. A cold Canadian winter might be a partial explanation for the benefit if cold along with physical stress makes a prophylactic benefit for vitamin C more likely. Furthermore, as regards the possible interaction between vitamin C supplementation and the level of dietary vitamin C intake, the <LINK REF="STD-Anderson-1972" TYPE="STUDY">Anderson 1972</LINK> trial is important as it found that vitamin C supplementation reduced the 'total days indoors' by 48% among participants in the vitamin C group who consumed &lt; 3 oz of fruit juice (common dietary source of vitamin C), whereas the reduction was only 22% among those who consumed more juice. A similar modifying effect with fruit juice was found in the therapeutic trial by <LINK REF="STD-Anderson-1975a" TYPE="STUDY">Anderson 1975a</LINK> (<I>see</I> <LINK REF="REF-Hemil_x00e4_-2006a" TYPE="REFERENCE">Hemilä 2006a</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Common cold duration and severity: regular supplementation trials</HEADING>
<P>Both in adults and in children, regular vitamin C supplementation resulted in a statistically highly significant reduction in the duration of common cold episodes that occurred during the prophylactic supplementation period. For adults the estimate of vitamin C effect was 8% and for children it was 14%. However, when restricting to children trials with &#8805; 1 g/day of vitamin C, the pooled estimate was an 18% decrease in the duration of colds.</P>
<P>Although the above findings point to a definite physiological effect from regular vitamin C supplementation on common cold duration, the practical significance of these findings is not convincing. It does not seem reasonable to ingest vitamin C regularly throughout the year if the anticipated benefit is to slightly shorten the duration of colds which occur for adults a few times per year and for children half a dozen times per year. The above estimates are not trivial, but instead of regular supplementation, it would seem much more fruitful to consider the possible benefits of therapeutic supplementation and carry out trials to test whether an equivalent benefit might be achieved in children through appropriate therapeutic supplementation.</P>
<P>In light of the consistent effect of vitamin C on the duration of colds, an obvious question is whether there might be dose dependency, as suggested by a previous meta-analysis (<LINK REF="REF-Hemil_x00e4_-1999a" TYPE="REFERENCE">Hemilä 1999a</LINK>). Across the available trials, there is more evidence for the difference between children and adults than on the variation of vitamin C effect by the dose used. Few trials have used more than 1 g/day of vitamin C in the child and adult groups separately. Nevertheless, <LINK REF="STD-Karlowski-1975a" TYPE="STUDY">Karlowski 1975a</LINK> and <LINK REF="STD-Coulehan-1974a" TYPE="STUDY">Coulehan 1974a</LINK> used two different doses within the same trials, that is, with the same outcome definitions. Coulehan found that for school children, 2 g/day caused about twice the benefit of 1 g/day. Karlowski found that for adults, 6 g/day was associated with a double benefit compared with 3 g/day and variance analysis showed that the linear trend over the 0 g/day, 3 g/day and 6 g/day doses was significant (<LINK REF="REF-Hemil_x00e4_-1996a" TYPE="REFERENCE">Hemilä 1996a</LINK>; <LINK REF="REF-Hemil_x00e4_-1999a" TYPE="REFERENCE">Hemilä 1999a</LINK>). Although these findings do not establish dose dependency, they support the examination of doses higher than 1 g/day and comparing different doses.</P>
<P>Regular vitamin C administration also led to decrease in cold severity when measured as days indoors or days off work or school, and when measured on severity score scales (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
<P>As regards the severity of colds, the <LINK REF="STD-Pitt-1979" TYPE="STUDY">Pitt 1979</LINK> paper is of further interest. This was a randomised, placebo-controlled, double-blind trial with 674 marine recruits during an eight-week period using 2 g/day of vitamin C. There was no difference in common cold incidence and only a 2% reduction in the duration of colds and a 5% reduction in cold severity (P = 0.023) for those in the vitamin C group. However, eight recruits developed pneumonia as a sequel to their colds and only one of these was in the vitamin C group (P = 0.044, <LINK REF="REF-Hemil_x00e4_-2004" TYPE="REFERENCE">Hemilä 2004</LINK>; <LINK REF="REF-Hemil_x00e4_-2007" TYPE="REFERENCE">Hemilä 2007</LINK>). Thus, in addition to the common cold, vitamin C might also affect other respiratory infections either independently of colds, or as complications of colds (<LINK REF="REF-Hemil_x00e4_-1999b" TYPE="REFERENCE">Hemilä 1999b</LINK>). A further important finding in the <LINK REF="STD-Pitt-1979" TYPE="STUDY">Pitt 1979</LINK> trial was that, although the vitamin C tablets were shown to be indistinguishable from the placebo tablets, 6% (40 out of 674; P = 0.013) of participants correctly inferred vitamin C or placebo tablets on the basis of subjective observations, indicating that this proportion of participants could identify vitamin C purely on the basis of its physiological effects (<LINK REF="REF-Hemil_x00e4_-2006a" TYPE="REFERENCE">Hemilä 2006a</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Common cold duration and severity: therapeutic trials</HEADING>
<P>Since the regular supplementation trials have unambiguously shown that vitamin C affects the duration and severity of colds without changing their incidence in the general population, it would seem rational to administer vitamin C therapeutically, starting immediately after the first symptoms. However, the therapeutic trials have mostly been negative (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>; <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>). The pooled estimates for the duration and severity of colds do not show any difference between vitamin C and placebo.</P>
<P>Technically the therapeutic trials are in several ways much more complicated than regular supplementation trials. If the timing of supplementation initiation, the duration of supplementation, or the dosage, influence the size of the benefit, false negative findings might result from inappropriate study protocols.</P>
<P>
<LINK REF="STD-Cowan-1950" TYPE="STUDY">Cowan 1950</LINK> used a therapeutic dose of about 3 g/day in the first two days of illness with no effect on common cold duration. <LINK REF="STD-Elwood-1977" TYPE="STUDY">Elwood 1977</LINK>, <LINK REF="STD-Tyrrell-1977" TYPE="STUDY">Tyrrell 1977</LINK> and <LINK REF="STD-Audera-2001a" TYPE="STUDY">Audera 2001a</LINK> used a three-day supplementation, and none of them found benefit of vitamin C on common cold duration. However, in their therapeutic trial, <LINK REF="STD-Tyrrell-1977" TYPE="STUDY">Tyrrell 1977</LINK> found a 40% reduction (P = 0.04) in the incidence of recurrent colds in men during the trial suggesting a beneficial effect in the way of protecting against new colds (<LINK REF="REF-Hemil_x00e4_-1997a" TYPE="REFERENCE">Hemilä 1997a</LINK>). A five-day therapeutic trial by <LINK REF="STD-Anderson-1975a" TYPE="STUDY">Anderson 1975a</LINK> found a 25% reduction in 'days spent indoors per subject' because of illness (P = 0.05) in the vitamin C group (1 to 1.5 g/day). Also, using a five-day therapeutic supplementation of 3 g/day in a 2 x 2 factorial design trial, <LINK REF="STD-Karlowski-1975c" TYPE="STUDY">Karlowski 1975c</LINK> found that colds were 0.73 days shorter (P = 0.10; <LINK REF="REF-Hemil_x00e4_-1996a" TYPE="REFERENCE">Hemilä 1996a</LINK>). The benefits in the five-day studies by Anderson and Karlowski suggest that two to three days might be too short a time for vitamin C to produce unambiguous benefits. However, <LINK REF="STD-Abbott-1968" TYPE="STUDY">Abbott 1968</LINK> used up to two week supplementation, yet found no therapeutic benefit of 3 g/day vitamin C. Nevertheless, it seems clear that future therapeutic trials should not use short supplementation, i.e. less than five days.</P>
<P>It is also possible that the rapidity of initiation of vitamin C supplementation may have an impact on the effect. <LINK REF="STD-Asfora-1977" TYPE="STUDY">Asfora 1977</LINK> gave the same participants either vitamin C (6 g/day for five days) or other medications (aspirin, etc.) during different common cold episodes, but not in a double-blinded design. When treatment started within 24 hours of the onset of symptoms, the mean duration of vitamin C treated colds was 3.6 days, whereas the duration was 6.9 days with the other medications (<LINK REF="REF-Hemil_x00e4_-2006a" TYPE="REFERENCE">Hemilä 2006a</LINK>). However, if vitamin C was initiated later than 24 hours following the onset of symptoms, there was no meaningful difference between the groups. <LINK REF="STD-Regnier-1968" TYPE="STUDY">Regnier 1968</LINK> concluded from his therapeutic study that "the sooner the better" and "vitamin C administration is not effective when started on the third or fourth day or later in the viral infection." <LINK REF="STD-Anderson-1974f" TYPE="STUDY">Anderson 1974f</LINK> found a benefit from an 8 g vitamin C dose compared with a 4 g dose when administered only on the first day of illness, which is also consistent with the possibility that rapid initiation with high doses might be essential.</P>
<P>In several therapeutic trials, tablets were given to participants to be taken at home so they could start taking them as soon as they experienced the first symptoms of what they anticipated would be a cold (<LINK REF="STD-Anderson-1975a" TYPE="STUDY">Anderson 1975a</LINK>; <LINK REF="STD-Audera-2001a" TYPE="STUDY">Audera 2001a</LINK>; <LINK REF="STD-Cowan-1950" TYPE="STUDY">Cowan 1950</LINK>; <LINK REF="STD-Elwood-1977" TYPE="STUDY">Elwood 1977</LINK>; <LINK REF="STD-Tyrrell-1977" TYPE="STUDY">Tyrrell 1977</LINK>). In the <LINK REF="STD-Karlowski-1975c" TYPE="STUDY">Karlowski 1975c</LINK> trial "if a cold developed, the volunteers were instructed to return to have their symptoms and clinical observations recorded and to receive supplemental study drug to be taken" and thus there was an unknown delay between the onset of symptoms and the initiation of treatment. <LINK REF="STD-Tebrock-1956" TYPE="STUDY">Tebrock 1956</LINK> carried out their trial "on participants reporting to several outpatient industrial clinics under the supervision of the physicians conducting the study" indicating a delay between symptom onset and treatment. In the briefly described <LINK REF="STD-Abbott-1968" TYPE="STUDY">Abbott 1968</LINK> trial, it seems that the tablets were administered by the doctors taking part in the trial and the average time between symptom onset and treatment initiation remains unknown. Consequently, even though the time between symptom onset and treatment initiation may influence the benefit of vitamin C, the data on this factor are limited.</P>
<P>The larger effect observed using 8 g compared with 4 g as a single dose in the <LINK REF="STD-Anderson-1974f" TYPE="STUDY">Anderson 1974f</LINK> trial and the dose dependency in the <LINK REF="STD-Karlowski-1975a" TYPE="STUDY">Karlowski 1975a</LINK> trial (<LINK REF="REF-Hemil_x00e4_-1996a" TYPE="REFERENCE">Hemilä 1996a</LINK>; <LINK REF="REF-Hemil_x00e4_-1999a" TYPE="REFERENCE">Hemilä 1999a</LINK>; <LINK REF="REF-Hemil_x00e4_-2006a" TYPE="REFERENCE">Hemilä 2006a</LINK>) suggest that future therapeutic trials with adults should use doses of at least 8 g/day. Similarly, the greater reported benefit of 2 g/day than 1 g/day in the prophylactic <LINK REF="STD-Coulehan-1974a" TYPE="STUDY">Coulehan 1974a</LINK> trial suggests that therapeutic trials with children should use doses of at least 2 g/day.</P>
<P>None of the therapeutic trials examined the effect of vitamin C on children, although children have a substantially higher incidence of the common cold. Furthermore, the effect of regular vitamin C on the duration of colds has been substantially greater in children, up to 18% reduction in duration by 1 g or 2 g/day, compared with adults (8%), which also motivates therapeutic trials in particular with children. Finally, although a tablet is a practical and the most common form of administering vitamin C, it is worth noting that administering vitamin C powder directly into the nose has also been proposed (<LINK REF="REF-Gotzsche-1989" TYPE="REFERENCE">Gotzsche 1989</LINK>).</P>
<P>Nevertheless, while the pooled results of our therapeutic trials do not justify routine vitamin C supplementation for the average person as a therapy for the common cold, the regular supplementation trials have shown unambiguously that vitamin C has a physiological effect on the duration and severity of colds. Furthermore, the results of controlled trials and the pooled results of trials apply to the average of the groups. We expect different sizes of vitamin C effects in different people, some having greater and some having smaller benefits than the average. Thus, given that vitamin C is safe and inexpensive, it does not seem unreasonable to test the effect of vitamin C on an individual basis as a therapy for the common cold soon after the onset of symptoms.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Trials with no data suitable for our meta-analyses</HEADING>
<P>Seven studies did not report data suitable for our meta-analyses (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). The findings in these trials were inconsistent. Although these trials should not be ignored, they do not add substantially to the findings of our meta-analyses discussed above.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Laboratory studies</HEADING>
<P>Three experimental studies have examined the effect of vitamin C on experimentally induced common cold infections (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). These trials which differed in their method of exposing volunteers to the infecting virus, are instructive. The study by <LINK REF="STD-Dick-1990" TYPE="STUDY">Dick 1990</LINK>, which has only been reported in conference proceedings, paid careful attention to the severity of the colds experienced by those who acquired them from fellow volunteers, who had been inoculated with a known rhinovirus. They also found that in these more natural circumstances of acquiring the virus, fewer, but not significantly fewer, volunteers on vitamin C developed cold symptoms but demonstrated similar viral shedding to the placebo group. The fragmentary descriptions of the Dick studies indicate a biological effect of vitamin C on experimentally caused colds. <LINK REF="STD-Schwartz-1973" TYPE="STUDY">Schwartz 1973</LINK> found a reduction in common cold severity in the vitamin C group, also indicating a biological effect.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Findings in the excluded studies</HEADING>
<P>Exclusion of a trial does not mean that the trial is necessarily uninformative. For example, we used a limit of 0.2 g/day for vitamin C as a pragmatic choice. If a trial with a lower dose finds a negative result, the negative findings can be attributed to the low dose. However, if a low dose does cause an effect, the effect may be explained, for example, by a particularly low dietary intake level (see above). Similarly, if a trial that has no placebo finds no difference between the intervention and control groups, it is not reasonable to explain the lack of difference by the placebo effect. Finally, since we were interested specifically in vitamin C, we excluded multiple antioxidant trials from our meta-analyses. However, if a multi-antioxidant formula has no effect on the common cold, it seems justified to conclude that there is a lack of effect by each constituent of the supplement (i.e. the finding is negative also for vitamin C if it is one of the components). In contrast, if a multi-antioxidant does have a beneficial effect, we cannot draw specific conclusions since the effect can be caused by any single antioxidant or the combination of several of them together. Therefore, the excluded trials can yield meaningful information. We do not summarise the findings of the excluded studies, but encourage the reader to look at those trials themselves.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Heterogeneity in the effects of vitamin C</HEADING>
<P>A major finding of <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK> was statistically significant heterogeneity in the effect of vitamin C supplementation on common cold incidence, indicating that vitamin C may influence common cold in some particular conditions.</P>
<P>Furthermore, <LINK REF="STD-Anderson-1972" TYPE="STUDY">Anderson 1972</LINK> found about an 8% increase in the proportion of participants who were 'not ill during the trial', 'not confined to the house' and 'not off work' in the vitamin C group. Accordingly, about one participant in 12 benefited from vitamin C supplementation in this particular setting (number needed to treat to benefit (NNTB) 12; <LINK REF="REF-Hemil_x00e4_-2006a" TYPE="REFERENCE">Hemilä 2006a</LINK>). Participants in this Canadian trial were asked not to enrol in the trial unless they normally experienced at least one cold in the wintertime and in this respect the participants do not represent the average population. <LINK REF="STD-Coulehan-1974a" TYPE="STUDY">Coulehan 1974a</LINK> studied Navajo school children and found a 16% higher proportion of children in the vitamin C group who were 'never ill on active surveillance' by a medically trained clerk or school nurse (NNTB 6; <LINK REF="REF-Hemil_x00e4_-2006a" TYPE="REFERENCE">Hemilä 2006a</LINK>). Thus, these two trials indicate that some individual participants of the two studied populations may have benefited, even though there is strong evidence that regular vitamin C does not affect the average incidence of colds in the general community (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
<P>In close parallel with vitamin C, lipid-soluble vitamin E is interesting as these two antioxidants interact. Vitamin C reduces the oxidised form of vitamin E under <I>in vitro</I> conditions (<LINK REF="REF-Hemil_x00e4_-2006a" TYPE="REFERENCE">Hemilä 2006a</LINK>) and modifies the vitamin E effect on mortality of older males (<LINK REF="REF-Hemil_x00e4_-2009b" TYPE="REFERENCE">Hemilä 2009b</LINK>). Therefore heterogeneity in the vitamin E effect on common cold incidence (<LINK REF="REF-Hemil_x00e4_-2006b" TYPE="REFERENCE">Hemilä 2006b</LINK>) and on pneumonia incidence (<LINK REF="REF-Hemil_x00e4_-2011" TYPE="REFERENCE">Hemilä 2011</LINK>) is relevant when considering the plausible heterogeneity of vitamin C effects on respiratory infections.</P>
<P>If the effects of vitamin C vary substantially between different subpopulations, the heterogeneity of the effect means a need for a careful consideration of goals when planning new trials. Assuming heterogeneity, further trials should try to identify and characterise the population groups or living conditions in which vitamin C might be beneficial, rather than re-examining the effects on ordinary Western people for whom the numerous trials already published have not found any substantial overall benefits from daily supplementation. Also, the notion that various factors may modify the effects of antioxidants is fundamentally important in restricting broad generalisations from individual trials, irrespective of whether the finding is positive or negative, and whether or not the trial is large and carefully conducted.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Potential for bias in the common cold trials</HEADING>
<P>Even though shortcomings in the design and conduct of trials can lead to erroneous conclusions, a recent meta-analysis of 276 randomised controlled trials found that double-blinding and allocation concealment, two quality measures that are frequently used in meta-analyses, were not associated with treatment effects (<LINK REF="REF-Balk-2002" TYPE="REFERENCE">Balk 2002</LINK>). Furthermore, there is evidence that the importance of the placebo effect has been substantially exaggerated (<LINK REF="REF-Hrobjartsson-2010" TYPE="REFERENCE">Hrobjartsson 2010</LINK>).</P>
<P>Nevertheless, we consider that given the expected small effects of vitamin C and the greatly subjective outcome definitions, only placebo-controlled trials can yield information of adequate rigour to meet the objectives of our review. Although we required only placebo control as an inclusion criterion, essentially all of the trials we identified were double-blind and randomised (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). Sensitivity analyses showed that our conclusions were not affected by the few trials that were methodologically less satisfactory.</P>
<P>
<LINK REF="REF-Chalmers-1975" TYPE="REFERENCE">Chalmers 1975</LINK> proposed that the effect of vitamin C on the common cold might be explained by "the result of the power of suggestion." As a support to this proposal he referred to the <LINK REF="STD-Karlowski-1975a" TYPE="STUDY">Karlowski 1975a</LINK> trial in which the placebo was made of lactose which is sweet and thus it could be distinguished by taste from ascorbic acid which was used in vitamin C capsules. However, it was shown that Karlowski's findings cannot be logically explained by the breaking of the blind code (<LINK REF="REF-Hemil_x00e4_-1996a" TYPE="REFERENCE">Hemilä 1996a</LINK>; <LINK REF="REF-Hemil_x00e4_-2006a" TYPE="REFERENCE">Hemilä 2006a</LINK>). Furthermore, in the great majority of other trials, placebo has contained citric acid which cannot be distinguished from ascorbic acid by taste and in most trials the indistinguishability of the vitamin C and placebo preparations was explicitly stated (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). Thus, Chalmers' proposal is refuted by the indistinguishability of vitamin C and placebo preparations in numerous double-blinded trials.</P>
<P>Some aspects of this Cochrane Review were commented on recently by two groups of commentators, to which Hemilä replied (<LINK REF="REF-Shamseer-2008" TYPE="REFERENCE">Shamseer 2008</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Safety of vitamin C</HEADING>
<P>None of the vitamin C common cold trials that reported on adverse effects found evidence that vitamin C might be harmful in doses that were tested.</P>
<P>In general, vitamin C is considered safe in doses up to several grams per day. Although there has been speculation about the potential harm of large doses, it has been shown to be unfounded (<LINK REF="REF-Dykes-1975" TYPE="REFERENCE">Dykes 1975</LINK>; <LINK REF="REF-Hemil_x00e4_-2006a" TYPE="REFERENCE">Hemilä 2006a</LINK>). For example, while 0.01 g/day of vitamin C protects against scurvy, in a recent pharmacokinetic study participants were administered up to 100 g of vitamin C intravenously within a few hours without any reported adverse effects, indicating the safety of such a very large dose in healthy people (<LINK REF="REF-Padayatty-2004" TYPE="REFERENCE">Padayatty 2004</LINK>).</P>
<P>
<LINK REF="REF-Bee-1980" TYPE="REFERENCE">Bee 1980</LINK> proposed 10 to 15 g/day for treating colds and <LINK REF="REF-Cathcart-1981" TYPE="REFERENCE">Cathcart 1981</LINK> reported that he had orally administered over 30 g/day vitamin C to common cold patients. Such reports indicate the safety of such high doses, even though uncontrolled observations do not provide valid evidence of benefit. There are few reports of severe harm caused by high-dose vitamin C administration, but they can usually be attributed to some other coinciding medical condition. For example, the death of a 68-year old African American man was not attributed to intravenous injection of 80 g of vitamin C on two consecutive days <I>per se</I> but to his coincident glucose-6-phosphate dehydrogenase deficiency (<LINK REF="REF-Campbell-1975" TYPE="REFERENCE">Campbell 1975</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Linus Pauling's contribution</HEADING>
<P>Among the four trials included in the <LINK REF="REF-Pauling-1971a" TYPE="REFERENCE">Pauling 1971a</LINK> meta-analysis, the largest dose, 1 g/day, was used by <LINK REF="STD-Ritzel-1961" TYPE="STUDY">Ritzel 1961</LINK>. Pauling based his optimistic quantitative expectations on this rather small and short trial, which was randomised, double-blind and placebo-controlled. Ritzel found significant reduction in the incidence (- 45%) and duration (- 31%) of colds, and Pauling calculated a combination of the duration and incidence, which he labelled 'integrated morbidity', referring to the total sickness days per person during the trial.</P>
<P>The 'integrated morbidity' was reduced by 61% in the Ritzel trial, and <LINK REF="REF-Pauling-1971a" TYPE="REFERENCE">Pauling 1971a</LINK> used this finding to extrapolate the effect of vitamin C to a broader community. The present analysis suggests that 'integrated morbidity' is not a good outcome measure, since the effects on incidence and duration/severity seem to have quite different patterns, though in the case of the Ritzel study, they moved together.</P>
<P>Ritzel carried out his trial with school children in a skiing school in the Swiss Alps, and such children are not a representative selection of the general population. In our analysis, Ritzel's trial is included in the group of five trials with participants exposed to short physical stress (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>) which highlights the special character of this trial. Thus, it was not a misjudgement by <LINK REF="REF-Pauling-1971a" TYPE="REFERENCE">Pauling 1971a</LINK> to put the greatest weight on this trial, but his error was to extrapolate the findings to the general population (<LINK REF="REF-Hemil_x00e4_-1997b" TYPE="REFERENCE">Hemilä 1997b</LINK>; <LINK REF="REF-Hemil_x00e4_-2006a" TYPE="REFERENCE">Hemilä 2006a</LINK>).</P>
<P>Pauling pointed out various errors in the influential review by <LINK REF="REF-Dykes-1975" TYPE="REFERENCE">Dykes 1975</LINK>, but did not contribute thereafter to the vitamin C and common cold field (<LINK REF="REF-Pauling-1976b" TYPE="REFERENCE">Pauling 1976b</LINK>; <LINK REF="REF-Pauling-1976c" TYPE="REFERENCE">Pauling 1976c</LINK>).</P>
<P>Pauling's vigorous advocacy was undoubtedly the stimulus for the wave of methodologically good trials, which now enable us to understand better the rather confusing role that vitamin C plays in the defence against the common cold. Significant uncertainties still persist, which further research should clarify.</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini">
<IMPLICATIONS_PRACTICE MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini">
<P>The lack of effect of regularly administered vitamin C on the incidence of the common cold in the general population throws doubt on the usefulness of this practice. In special circumstances, where people are engaged in extreme physical exertion or exposed to significant cold stress, or both, vitamin C supplementation seems to have a beneficial prophylactic effect, but caution should be exercised in generalising this finding.</P>
<P>The regular supplementation trials found that &#8805; 0.2 g/day vitamin C reduced common cold duration by 8% in adults and by 14% in children, and 1 to 2 g/day vitamin C reduced common cold duration by 18% in children. The practical relevance of these findings is not clear. In our opinion, this level of benefit does not justify long-term supplementation in its own right. So far, therapeutic supplementation has not been shown to be effective. Nevertheless, given the consistent effect of vitamin C on common cold duration and severity in the regular supplementation studies, and the low cost and safety, it may be worthwhile for common cold patients to test on an individual basis whether therapeutic vitamin C is beneficial for them.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini">
<P>It does not seem worthwhile to carry out further regular supplementation trials in the general population. However, the findings in marathon runners, skiers, swimmers and soldiers operating in subarctic conditions warrant further research.</P>
<P>None of the therapeutic trials carried out so far have examined the effect of vitamin C on children, even though the regular supplementation trials have found substantially greater benefit for children than for adults. Furthermore, the incidence of the common cold in children is substantially higher in children compared with adults. Therefore, therapeutic trials are warranted in particular in children.</P>
<P>The findings in the <LINK REF="STD-Anderson-1974a" TYPE="STUDY">Anderson 1974a</LINK> study on the greater benefit of a single 8 g dose compared with a 4 g dose on the first day of the common cold, and the findings of the <LINK REF="STD-Karlowski-1975a" TYPE="STUDY">Karlowski 1975a</LINK> trial on the greater benefit of 6 g/day compared with 3 g/day, suggest that doses in further therapeutic trials with adults should be at least 8 g/day.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2012-12-09 23:08:19 +1000" MODIFIED_BY="Jenny Bellorini">
<P>This review was initiated in the mid 1990s by Bob Douglas and the first version was published in <I>The Cochrane Library</I> (<LINK REF="REF-Douglas-1998" TYPE="REFERENCE">Douglas 1998</LINK>). Bob Douglas screened the retrieved papers against inclusion criteria, appraised the quality of papers, abstracted data, entered data into Review Manager, analysed and interpreted the data, wrote the first version of the review and participated in several updates (<LINK REF="REF-Douglas-1998" TYPE="REFERENCE">Douglas 1998</LINK>; <LINK REF="REF-Douglas-2004" TYPE="REFERENCE">Douglas 2004</LINK>; <LINK REF="REF-Douglas-2007" TYPE="REFERENCE">Douglas 2007</LINK>).</P>
<P>Harri Hemilä took charge of the review in 2004. In 2012 Professor Douglas decided to retire from updating the review. We (Hemilä and Chalker) are very grateful to Professor Douglas for his role in the initiation and update of this review.</P>
<P>Professor Charles McGilchrist and Dr Keith Dear provided valuable statistical advice, and Ms Robyn Savory and Ms Leonie Hoorweg undertook a range of assistant duties in the first publication of this review. Mr Bob Galloway provided translations for a number of papers. Ron D'Souza helped to assemble the update review database and assisted Bob Douglas in re-screening all papers and quality assessment, but he decided to remove his name in 2007. Barbara Treacy prepared overviews and summaries of published studies in preparation for the first version of the review, and participated in updating the earlier versions, but she decided to remove her name in 2009. </P>
<P>English translations of the <LINK REF="STD-Bessel_x002d_Lorck-1958" TYPE="STUDY">Bessel-Lorck 1958</LINK>, <LINK REF="STD-Ritzel-1961" TYPE="STUDY">Ritzel 1961</LINK>, <LINK REF="STD-Kimbarowski-1967" TYPE="STUDY">Kimbarowski 1967</LINK> and <LINK REF="STD-Bancalari-1984" TYPE="STUDY">Bancalari 1984</LINK> papers were kindly arranged by Eva Wintergerst from Roche Consumer Health LTD, Kaiseraugst, Switzerland. Finally, the review authors wish to thank the following people for reviewing the 2012 updated review: Bahi Takkouche, Anne Lyddiat and Mark Jones; and Sarah Thorning for help in literature searches.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2012-09-18 16:14:28 +1000" MODIFIED_BY="Jenny Bellorini">
<P>None of the other review authors have any conflict of interest to declare in this review.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2012-09-18 16:14:28 +1000" MODIFIED_BY="Jenny Bellorini">
<P>Harri Hemilä (HH) carefully reviewed drafts of the second edition of the review (<LINK REF="REF-Douglas-2004" TYPE="REFERENCE">Douglas 2004</LINK>), assisted in paper retrieval, proposed alterations to data presentation, checked data entries and contributed significant input to the text. After the 2004 revision, he took over responsibility for future updates of this review.</P>
<P>Elizabeth Chalker (EC) wrote the protocol for the first edition of the review (<LINK REF="REF-Douglas-1998" TYPE="REFERENCE">Douglas 1998</LINK>), developed the initial search strategy, undertook the searches, organised retrieval of papers, screened papers against inclusion criteria and appraised the quality of papers for the 1998 version. She has been involved in reviewing and rewriting the text for subsequent versions of this review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini">
<P>Full-text versions of references which are available either free or at the publishers' databases can be accessed via the home page of the contact author, Harri Hemilä: <A HREF="http://www.mv.helsinki.fi/home/hemila/CC/">www.mv.helsinki.fi/home/hemila/CC/</A>.</P>
<P>Seven placebo-controlled trials which were previously excluded because there were no data suitable for our meta-analyses have been included (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). Their exclusion was inconsistent with the Methods section. Their inclusion did not result in changes to our conclusions.</P>
<P>In previous versions "prophylactic" was used to indicate the trials in which vitamin C was administered every day. "Prophylactic" is relevant when measuring the incidence of episodes. However, that term is confusing when measuring the duration of episodes that occur during the trial. Therefore, in the 2012 version, we changed to the term "regular supplementation" to indicate trials in which vitamin C was administered every day.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2012-12-12 07:13:46 +1000" MODIFIED_BY="Jenny Bellorini">
<STUDIES MODIFIED="2012-12-12 07:13:46 +1000" MODIFIED_BY="Jenny Bellorini">
<INCLUDED_STUDIES MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini">
<STUDY DATA_SOURCE="PUB" ID="STD-Abbott-1968" MODIFIED="2012-09-26 04:21:24 +1000" MODIFIED_BY="Harri Hemilä" NAME="Abbott 1968" YEAR="1968">
<REFERENCE MODIFIED="2012-09-26 04:21:24 +1000" MODIFIED_BY="Harri Hemilä" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abbott P, Abrahams M, Adams MS, Adcock SJ, Addleston G, Aitken DG, et al</AU>
<TI>General practitioner clinical trials: ineffectiveness of vitamin C in treating coryza</TI>
<SO>Practitioner</SO>
<YR>1968</YR>
<VL>200</VL>
<PG>442-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anderson-1972" MODIFIED="2010-01-26 23:27:12 +1000" MODIFIED_BY="Jenny Bellorini" NAME="Anderson 1972" YEAR="1972">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anderson TW, Reid DBW, Beaton GH</AU>
<TI>Vitamin C and the common cold [correction]</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>1973</YR>
<VL>108</VL>
<PG>133</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Anderson TW, Reid DBW, Beaton GH</AU>
<TI>Vitamin C and the common cold: a double-blind trial</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>1972</YR>
<VL>107</VL>
<PG>503-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-28 01:59:48 +1000" MODIFIED_BY="Harri Hemilä" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anderson TW</AU>
<TI>Erratum [second correction]</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>1973</YR>
<VL>108</VL>
<PG>492</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anderson TW</AU>
<TI>Large-scale trials of vitamin C</TI>
<SO>Annals of the New York Academy of Sciences</SO>
<YR>1975</YR>
<VL>258</VL>
<PG>498-504</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-26 23:27:12 +1000" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spero LM, Anderson TW</AU>
<TI>Ascorbic acid and common colds [letter]</TI>
<SO>British Medical Journal</SO>
<YR>1973</YR>
<VL>4</VL>
<PG>354</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anderson-1974a" NAME="Anderson 1974a" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anderson TW, Suranyi G, Beaton GH</AU>
<TI>The effect on winter illness of large doses of vitamin C</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>1974</YR>
<VL>111</VL>
<PG>31-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anderson-1974b" NAME="Anderson 1974b" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anderson TW, Suranyi G, Beaton GH</AU>
<TI>The effect on winter illness of large doses of vitamin C</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>1974</YR>
<VL>111</VL>
<PG>31-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anderson-1974c" NAME="Anderson 1974c" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anderson TW, Suranyi G, Beaton GH</AU>
<TI>The effect on winter illness of large doses of vitamin C</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>1974</YR>
<VL>111</VL>
<PG>31-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anderson-1974d" NAME="Anderson 1974d" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anderson TW, Suranyi G, Beaton GH</AU>
<TI>The effect on winter illness of large doses of vitamin C</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>1974</YR>
<VL>111</VL>
<PG>31-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anderson-1974e" NAME="Anderson 1974e" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anderson TW, Suranyi G, Beaton GH</AU>
<TI>The effect on winter illness of large doses of vitamin C</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>1974</YR>
<VL>111</VL>
<PG>31-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anderson-1974f" NAME="Anderson 1974f" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anderson TW, Suranyi G, Beaton GH</AU>
<TI>The effect on winter illness of large doses of vitamin C</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>1974</YR>
<VL>111</VL>
<PG>31-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anderson-1975a" NAME="Anderson 1975a" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anderson TW, Beaton GH, Corey P, Spero L</AU>
<TI>Winter illness and vitamin C: the effect of relatively low doses</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>1975</YR>
<VL>112</VL>
<PG>823-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anderson-1975b" NAME="Anderson 1975b" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anderson TW, Beaton GH, Corey P, Spero L</AU>
<TI>Winter illness and vitamin C: the effect of relatively low doses</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>1975</YR>
<VL>112</VL>
<PG>823-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Asfora-1977" MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Harri Hemilä" NAME="Asfora 1977" YEAR="1977">
<REFERENCE MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Harri Hemilä" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Asfora J</AU>
<TI>Vitamin C in high doses in the treatment of the common cold</TI>
<SO>International Journal for Vitamin and Nutrition Research</SO>
<YR>1977</YR>
<VL>Suppl 16</VL>
<PG>219-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Audera-2001a" NAME="Audera 2001a" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Audera C, Patulny RV, Sander BH, Douglas RM</AU>
<TI>Mega-dose vitamin C in treatment of the common cold: a randomised controlled trial</TI>
<SO>Medical Journal of Australia</SO>
<YR>2001</YR>
<VL>175</VL>
<PG>359-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Audera-2001b" NAME="Audera 2001b" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Audera C, Patulny RV, Sander BH, Douglas RM</AU>
<TI>Mega-dose vitamin C in treatment of the common cold: a randomised controlled trial</TI>
<SO>Medical Journal of Australia</SO>
<YR>2001</YR>
<VL>175</VL>
<PG>359-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bancalari-1984" MODIFIED="2012-05-29 05:03:12 +1000" MODIFIED_BY="[Empty name]" NAME="Bancalari 1984" YEAR="1984">
<REFERENCE MODIFIED="2012-05-29 05:03:12 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bancalari M, Seguel C, Flor NC, Inez RA, Carlos CM</AU>
<TI>The value of vitamin C in the prevention of acute respiratory infections in schoolchildren (English translation: http://www.mv.helsinki.fi/home/hemila/T6.pdf)</TI>
<TO>Valor profilactico de la vitamina C en infeccciones pespiratorias agudas del escolar</TO>
<SO>Revista Medica de Chile</SO>
<YR>1984</YR>
<VL>112</VL>
<PG>871-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Briggs-1984" NAME="Briggs 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Briggs M</AU>
<TI>Vitamin C and infectious disease: a review of the literature and the results of a randomised double blind prospective study over eight years</TI>
<SO>Recent Vitamin Research</SO>
<YR>1984</YR>
<PG>39-82</PG>
<ED>Briggs MH</ED>
<PB>CRC Press</PB>
<CY>Boca Raton, FL</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brown-1945" MODIFIED="2012-05-29 06:10:50 +1000" MODIFIED_BY="Harri Hemilä" NAME="Brown 1945" YEAR="1945">
<REFERENCE MODIFIED="2012-05-29 06:10:50 +1000" MODIFIED_BY="Harri Hemilä" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brown WMB, Mahoney F, Niedringhaus A, Locke A</AU>
<TI>Weather and susceptibility in relation to the spread of common cold; effect of ascorbic acid, in massive dosage, on duration</TI>
<SO>Journal of Immunology</SO>
<YR>1945</YR>
<VL>50</VL>
<PG>161-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carr-1981a" NAME="Carr 1981a" YEAR="1981">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Carr AB, Einstein R, Lai LY, Martin NG, Starmer GA</AU>
<TI>Vitamin C and the common cold: a second MZ Cotwin control study</TI>
<SO>Acta Geneticae Medicae et Gemellologiae (Roma)</SO>
<YR>1981</YR>
<VL>30</VL>
<PG>249-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carr AB, Einstein R, Lai LYC, Martin NG, Starmer GA</AU>
<TI>Vitamin C and the common cold: using identical twins as controls</TI>
<SO>Medical Journal of Australia</SO>
<YR>1981</YR>
<VL>2</VL>
<PG>411-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carr AB, Martin NG, Whitfield JB</AU>
<TI>Usefulness of the co-twin control design in investigations as exemplified in a study of effects of ascorbic acid on laboratory test results</TI>
<SO>Clinical Chemistry</SO>
<YR>1981</YR>
<VL>27</VL>
<PG>1469-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martin NG, Carr AB, Oakeshott JG, Clark P</AU>
<TI>Co-twin control studies: vitamin C and the common cold</TI>
<SO>Progress in Clinical and Biological Research</SO>
<YR>1982</YR>
<VL>103</VL>
<NO>Pt A</NO>
<PG>365-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carr-1981b" NAME="Carr 1981b" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carr AB, Einstein R, Lai LY, Martin NG, Starmer GA</AU>
<TI>Vitamin C and the common cold: a second MZ Cotwin control study</TI>
<SO>Acta Geneticae Medicae et Gemellologiae (Roma)</SO>
<YR>1981</YR>
<VL>30</VL>
<PG>249-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carson-1975" MODIFIED="2009-05-28 02:02:01 +1000" MODIFIED_BY="Harri Hemilä" NAME="Carson 1975" YEAR="1975">
<REFERENCE MODIFIED="2009-05-28 02:02:01 +1000" MODIFIED_BY="Harri Hemilä" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carson M, Corbett M, Cox H, Pollitt H</AU>
<TI>Vitamin C and the common cold [letter]</TI>
<SO>British Medical Journal</SO>
<YR>1974</YR>
<VL>1</VL>
<PG>577</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-28 02:01:52 +1000" MODIFIED_BY="Harri Hemilä" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Carson M, Cox H, Corbett M, Pollitt N</AU>
<TI>Vitamin C and the common cold</TI>
<SO>Journal of the Society of Occupational Medicine</SO>
<YR>1975</YR>
<VL>25</VL>
<PG>99-102</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Charleston-1972" MODIFIED="2009-09-18 21:12:05 +1000" MODIFIED_BY="Harri Hemilä" NAME="Charleston 1972" YEAR="1972">
<REFERENCE MODIFIED="2009-09-18 21:12:05 +1000" MODIFIED_BY="Harri Hemilä" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Charleston SS, Clegg KM</AU>
<TI>Ascorbic acid and the common cold</TI>
<SO>Lancet</SO>
<YR>1972</YR>
<VL>1</VL>
<NO>7765</NO>
<PG>1401-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-09-18 21:04:07 +1000" MODIFIED_BY="Harri Hemilä" NOTES="&lt;p&gt;Data of the Charleston and Clegg (1971) trial reported separately for males and females&lt;/p&gt;" NOTES_MODIFIED="2009-09-18 21:04:07 +1000" NOTES_MODIFIED_BY="Harri Hemilä" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clegg KM</AU>
<TI>Studies associated with ascorbic acid [data of the 1973 trial separately for males and females]</TI>
<SO>Acta Vitaminologica Enzymologica</SO>
<YR>1974</YR>
<VL>28</VL>
<PG>101-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clegg-1975" MODIFIED="2009-09-18 21:03:41 +1000" MODIFIED_BY="Harri Hemilä" NAME="Clegg 1975" YEAR="1975">
<REFERENCE MODIFIED="2009-09-18 21:03:41 +1000" MODIFIED_BY="Harri Hemilä" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clegg KM, Macdonald JM</AU>
<TI>D-isoscorbic acid investigated in a common cold survey [abstract]</TI>
<SO>Proceedings of the Nutrition Society</SO>
<YR>1975</YR>
<VL>34</VL>
<PG>7A-8A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-28 02:14:26 +1000" MODIFIED_BY="Harri Hemilä" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Clegg KM, Macdonald JM</AU>
<TI>L-Ascorbic acid and D-isoascorbic acid in a common cold survey</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1975</YR>
<VL>28</VL>
<PG>973-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Constantini-2011a" MODIFIED="2012-09-24 01:08:13 +1000" MODIFIED_BY="Harri HemilÃ¤" NAME="Constantini 2011a" YEAR="2011">
<REFERENCE MODIFIED="2012-09-24 01:08:13 +1000" MODIFIED_BY="Harri HemilÃ¤" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Constantini NW, Dubnov-Raz G, Eyal BB, Berry EM, Cohen AH, Hemilä H</AU>
<TI>The effect of vitamin C on upper respiratory infections in adolescent swimmers: a randomized trial</TI>
<SO>European Journal of Pediatrics</SO>
<YR>2011</YR>
<VL>170</VL>
<NO>1</NO>
<PG>59-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Constantini-2011b" MODIFIED="2012-09-24 01:08:04 +1000" MODIFIED_BY="Harri Hemilä" NAME="Constantini 2011b" YEAR="2011">
<REFERENCE MODIFIED="2012-09-24 01:08:04 +1000" MODIFIED_BY="Harri Hemilä" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Constantini NW, Dubnov-Raz G, Eyal BB, Berry EM, Cohen AH, Hemilä H</AU>
<TI>The effect of vitamin C on upper respiratory infections in adolescent swimmers: a randomized trial</TI>
<SO>European Journal of Pediatrics</SO>
<YR>2011</YR>
<VL>170</VL>
<NO>1</NO>
<PG>59-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Coulehan-1974a" NAME="Coulehan 1974a" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coulehan JL, Kapner L, Eberhard S, Taylor FH, Rogers KD</AU>
<TI>Vitamin C and upper respiratory illness in Navaho children: preliminary observations (1974)</TI>
<SO>Annals of the New York Academy of Sciences</SO>
<YR>1975</YR>
<VL>258</VL>
<PG>513-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Coulehan JL, Reisinger KS, Rogers KD, Bradley DW</AU>
<TI>Vitamin C prophylaxis in a boarding school</TI>
<SO>New England Journal of Medicine</SO>
<YR>1974</YR>
<VL>290</VL>
<PG>6-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Coulehan-1974b" NAME="Coulehan 1974b" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coulehan JL, Reisinger KS, Rogers KD, Bradley DW</AU>
<TI>Vitamin C prophylaxis in a boarding school</TI>
<SO>New England Journal of Medicine</SO>
<YR>1974</YR>
<VL>290</VL>
<PG>6-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Coulehan-1976" NAME="Coulehan 1976" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coulehan JL, Eberhard S, Kapner L, Taylor F, Rogers K, Garry P</AU>
<TI>Vitamin C and acute illness in Navajo school children</TI>
<SO>New England Journal of Medicine</SO>
<YR>1976</YR>
<VL>295</VL>
<PG>973-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coulehan JL</AU>
<TI>Vitamin C and the common cold [letter]</TI>
<SO>New England Journal of Medicine</SO>
<YR>1977</YR>
<VL>296</VL>
<PG>231</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cowan-1942" MODIFIED="2012-12-10 01:10:52 +1000" MODIFIED_BY="[Empty name]" NAME="Cowan 1942" YEAR="1942">
<REFERENCE MODIFIED="2012-12-10 01:10:52 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cowan D, Diehl HS, Baker AB</AU>
<TI>Vitamins for the prevention of colds</TI>
<SO>Journal of the American Medical Association</SO>
<YR>1942</YR>
<VL>120</VL>
<PG>1268-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cowan-1950" MODIFIED="2012-12-10 01:11:10 +1000" MODIFIED_BY="[Empty name]" NAME="Cowan 1950" YEAR="1950">
<REFERENCE MODIFIED="2012-12-10 01:11:10 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cowan DW, Diehl HS</AU>
<TI>Antihistaminic agents and ascorbic acid in the early treatment of the common cold</TI>
<SO>Journal of the American Medical Association</SO>
<YR>1950</YR>
<VL>143</VL>
<PG>421-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dahlberg-1944" NAME="Dahlberg 1944" YEAR="1944">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dahlberg G, Engel A, Rydin H</AU>
<TI>The value of ascorbic acid as a prophylactic against common colds</TI>
<SO>Acta Medica Scandinavica</SO>
<YR>1944</YR>
<VL>119</VL>
<PG>540-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dick-1990" MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]" NAME="Dick 1990" YEAR="1990">
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Dick EC, Mink KA, Olander D, Schult PA, Jennings LC, Inhorn SL</AU>
<TI>Amelioration of rhinovirus type 16 (RV 16) colds in ascorbic acid supplemented volunteers [abstract]</TI>
<SO>30th ICAAC Proceedings</SO>
<YR>1990</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mink KA, Dick EC, Jennings LC, Inhorn SL</AU>
<TI>Amelioration of rhinovirus colds by vitamin C (ascorbic acid) supplementation [abstract]</TI>
<SO>Medical Virology</SO>
<YR>1988</YR>
<VL>7</VL>
<PG>356</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Shult PA, Dick EC, Olander D, et al</AU>
<TI>The ameliorating effect of vitamin C supplementation on rhinovirus colds using an experimental epidemiological model [abstract 1285]</TI>
<SO>30th ICAAC Proceedings</SO>
<YR>1990</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Elliot-1973" MODIFIED="2012-05-29 06:10:42 +1000" MODIFIED_BY="Harri Hemilä" NAME="Elliot 1973" YEAR="1973">
<REFERENCE MODIFIED="2012-05-29 06:10:42 +1000" MODIFIED_BY="Harri Hemilä" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Elliot B</AU>
<TI>Ascorbic acid: efficacy in the prevention of symptoms of respiratory infection on a Polaris submarine</TI>
<SO>IRCS Journal of the International Research Communications: Medical Science</SO>
<YR>1973</YR>
<VL>1</VL>
<NO>3</NO>
<PG>12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-05-29 06:10:42 +1000" MODIFIED_BY="Harri Hemilä" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Pauling L</AU>
<TI>March 1972: Elliott's results [original data and analyses]</TI>
<SO>Linus Pauling Research Notebooks (Available http://osulibrary.orst.edu/specialcollections/rnb/18/18-091.html)</SO>
<YR>1972</YR>
<VL>18</VL>
<PG>91-2, 95-6</PG>
<PB>Oregon State University Libraries</PB>
<CY>Oregon</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Elwood-1976" NAME="Elwood 1976" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Elwood PC, Lee HP, St Leger AS, Baird M, Howard AN</AU>
<TI>A randomized controlled trial of vitamin C in the prevention and amelioration of the common cold</TI>
<SO>British Journal of Preventive and Social Medicine</SO>
<YR>1976</YR>
<VL>30</VL>
<PG>193-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Elwood-1977" NAME="Elwood 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Elwood P, Hughes SJ, Leger AS</AU>
<TI>A randomized controlled trial of the therapeutic effect of vitamin C in the common cold</TI>
<SO>Practitioner</SO>
<YR>1977</YR>
<VL>218</VL>
<PG>133-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Franz--1956" MODIFIED="2012-12-10 01:12:28 +1000" MODIFIED_BY="[Empty name]" NAME="Franz  1956" YEAR="1956">
<REFERENCE MODIFIED="2012-12-10 01:12:28 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Franz WL, Sands GW, Heyl HL, Hanover NH</AU>
<TI>Blood ascorbic acid level in bioflavonoid and ascorbic acid therapy of common cold</TI>
<SO>Journal of the American Medical Association</SO>
<YR>1956</YR>
<VL>162</VL>
<PG>1224-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Himmelstein-1998a" MODIFIED="2009-05-28 01:57:13 +1000" MODIFIED_BY="Harri Hemilä" NAME="Himmelstein 1998a" YEAR="1998">
<REFERENCE MODIFIED="2009-05-28 01:57:13 +1000" MODIFIED_BY="Harri Hemilä" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Himmelstein SA, Robergs RA, Koehler KM, Lewis SL, Qualls CR</AU>
<TI>Vitamin C supplementation and upper respiratory tract infections in marathon runners</TI>
<SO>Journal of Exercise Physiology Online</SO>
<YR>1998</YR>
<VL>1</VL>
<NO>2</NO>
<PG>1-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-28 01:57:00 +1000" MODIFIED_BY="Harri Hemilä" PRIMARY="NO" TYPE="BOOK">
<AU>Himmelstein SA</AU>
<SO>The effect of vitamin C supplementation on incidence of upper respiratory tract infections in marathon runners [PhD Thesis; 163 pp]</SO>
<YR>1996 [ProQuest document ID: 739521221]</YR>
<PB>University of New Mexico</PB>
<CY>Albuquerque, NM</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karlowski-1975a" MODIFIED="2010-01-26 23:28:10 +1000" MODIFIED_BY="Jenny Bellorini" NAME="Karlowski 1975a" YEAR="1975">
<REFERENCE MODIFIED="2009-05-28 02:04:04 +1000" MODIFIED_BY="Harri Hemilä" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Karlowski TR, Chalmers TC, Frenkel LD, Kapikian AZ, Lewis TL, Lynch JM</AU>
<TI>Ascorbic acid for the common cold: a prophylactic and therapeutic trial [see Hemilä 1996a, 2006a, 2006c]</TI>
<SO>JAMA</SO>
<YR>1975</YR>
<VL>231</VL>
<PG>1038-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-26 23:28:10 +1000" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lewis TL, Karlowski TR, Kapikian AZ, Lynch JM, Shaffer GW, George DA, et al</AU>
<TI>A controlled clinical trial of ascorbic acid for the common cold [additional data]</TI>
<SO>Annals of the New York Academy of Sciences</SO>
<YR>1975</YR>
<VL>258</VL>
<PG>505-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karlowski-1975b" NAME="Karlowski 1975b" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karlowski TR, Chalmers TC, Frenkel LD, Kapikian AZ, Lewis TL, Lynch JM</AU>
<TI>Ascorbic acid for the common cold</TI>
<SO>JAMA</SO>
<YR>1975</YR>
<VL>231</VL>
<PG>1038-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karlowski-1975c" NAME="Karlowski 1975c" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karlowski TR, Chalmers TC, Frenkel LD, Kapikian AZ, Lewis TL, Lynch JM</AU>
<TI>Ascorbic acid for the common cold</TI>
<SO>JAMA</SO>
<YR>1975</YR>
<VL>231</VL>
<PG>1038-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liljefors-1972" MODIFIED="2009-11-13 16:34:44 +1000" MODIFIED_BY="[Empty name]" NAME="Liljefors 1972" YEAR="1972">
<REFERENCE MODIFIED="2009-11-13 16:34:44 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liljefors I</AU>
<TI>Vitamin C and the common cold</TI>
<TO>Vitamin C vid förkylningssjukdom</TO>
<SO>Läkartidningen</SO>
<YR>1972</YR>
<VL>69</VL>
<PG>3304-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ludvigsson-1977a" NAME="Ludvigsson 1977a" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ludvigsson J, Hansson LO, Tibbling G</AU>
<TI>Vitamin C as a preventive medicine against common colds in children</TI>
<SO>Scandinavian Journal of Infectious Diseases</SO>
<YR>1977</YR>
<VL>9</VL>
<PG>91-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ludvigsson-1977b" NAME="Ludvigsson 1977b" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ludvigsson J, Hansson LO, Tibbling G</AU>
<TI>Vitamin C as a preventive medicine against common colds in children</TI>
<SO>Scandinavian Journal of Infectious Diseases</SO>
<YR>1977</YR>
<VL>9</VL>
<PG>91-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miller-1977a" MODIFIED="2009-09-18 21:04:34 +1000" MODIFIED_BY="Harri Hemilä" NAME="Miller 1977a" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller JZ, Nance WE, Kang KW</AU>
<TI>A co-twin control study of the effects of vitamin C</TI>
<SO>Progress in Clinical and Biological Research</SO>
<YR>1978</YR>
<VL>24</VL>
<NO>Pt C</NO>
<PG>151-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Miller JZ, Nance WE, Norton JA, Wolen RL, Griffith RS, Rose RJ</AU>
<TI>Therapeutic effect of vitamin C: a co-twin control study</TI>
<SO>JAMA</SO>
<YR>1977</YR>
<VL>237</VL>
<PG>248-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-09-18 21:04:34 +1000" MODIFIED_BY="Harri Hemilä" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller JZ, Norton JA, Nance WE</AU>
<TI>Vitamin C and growth [reply to a comment]</TI>
<SO>JAMA</SO>
<YR>1977</YR>
<VL>238</VL>
<PG>937</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miller-1977b" NAME="Miller 1977b" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller JZ, Nance WE, Norton JA, Wolen RL, Griffith RS, Rose RJ</AU>
<TI>Therapeutic effect of vitamin C</TI>
<SO>JAMA</SO>
<YR>1977</YR>
<VL>237</VL>
<PG>248-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miller-1977c" NAME="Miller 1977c" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller JZ, Nance WE, Norton JA, Wolen RL, Griffith RS, Rose RJ</AU>
<TI>Therapeutic effect of vitamin C</TI>
<SO>JAMA</SO>
<YR>1997</YR>
<VL>237</VL>
<PG>248-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Moolla-1996a" MODIFIED="2010-01-26 23:28:29 +1000" MODIFIED_BY="Jenny Bellorini" NAME="Moolla 1996a" YEAR="1996">
<REFERENCE MODIFIED="2010-01-26 23:28:29 +1000" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="BOOK">
<AU>Moolla ME</AU>
<SO>The effect of supplemental anti-oxidants on the incidence and severity of upper respiratory infections in Ultra Marathon runners [MSc thesis]</SO>
<YR>1996</YR>
<PB>University of Cape Town</PB>
<CY>Cape Town, South Africa</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Moolla-1996b" MODIFIED="2010-01-26 23:28:39 +1000" MODIFIED_BY="Jenny Bellorini" NAME="Moolla 1996b" YEAR="1996">
<REFERENCE MODIFIED="2010-01-26 23:28:39 +1000" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="BOOK">
<AU>Moolla ME</AU>
<SO>The effect of supplemental anti-oxidants on the incidence and severity of upper respiratory infections in Ultra Marathon runners [MSc thesis]</SO>
<YR>1996</YR>
<PB>University of Cape Town</PB>
<CY>Cape Town, South Africa</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peters-1993a" MODIFIED="2009-05-28 02:04:16 +1000" MODIFIED_BY="Harri Hemilä" NAME="Peters 1993a" YEAR="1993">
<REFERENCE MODIFIED="2009-05-28 02:04:16 +1000" MODIFIED_BY="Harri Hemilä" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Peters EM, Goetzsche JM, Grobbelaar B, Noakes TD</AU>
<TI>Vitamin C supplementation reduces the incidence of post-race symptoms of upper-respiratory-tract infection in ultramarathon runners</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1993</YR>
<VL>57</VL>
<PG>170-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peters EM, Noakes TD</AU>
<TI>Reply to SN Gershoff [letter]</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1994</YR>
<VL>59</VL>
<PG>132-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peters-1993b" NAME="Peters 1993b" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peters EM, Goetzsche JM, Grobbelaar B, Noakes TD</AU>
<TI>Vitamin C supplementation reduces the incidence of postrace symptoms of upper-respiratory-tract infection in ultramarathon runners</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1993</YR>
<VL>57</VL>
<PG>170-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peters-1996a" NAME="Peters 1996a" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peters EM, Goetzsche JM, Joseph LE, Noakes TD</AU>
<TI>Vitamin C as effective as combinations of antioxidant nutrients in reducing symptoms of upper respiratory tract infection in ultramarathon runners</TI>
<SO>South African Journal of Sports Medicine</SO>
<YR>1996</YR>
<VL>11</VL>
<PG>23-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peters-1996b" NAME="Peters 1996b" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peters EM, Goetzsche JM, Joseph LE, Noakes TD</AU>
<TI>Vitamin C as effective as combinations of antioxidant nutrients in reducing symptoms of upper respiratory tract infection in ultramarathon runners</TI>
<SO>South African Journal of Sports Medicine</SO>
<YR>1996</YR>
<VL>11</VL>
<PG>23-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pitt-1979" NAME="Pitt 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pitt HA, Costrini AM</AU>
<TI>Vitamin C prophylaxis in marine recruits</TI>
<SO>JAMA</SO>
<YR>1979</YR>
<VL>241</VL>
<PG>908-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Regnier-1968" MODIFIED="2012-05-29 06:10:21 +1000" MODIFIED_BY="Harri Hemilä" NAME="Regnier 1968" YEAR="">
<REFERENCE MODIFIED="2012-05-29 06:10:21 +1000" MODIFIED_BY="Harri Hemilä" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Regnier E</AU>
<TI>The administration of large doses of ascorbic acid in the prevention and treatment of the common cold: part II</TI>
<SO>Review of Allergy</SO>
<YR>1968</YR>
<VL>22</VL>
<PG>948-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ritzel-1961" MODIFIED="2012-05-29 05:04:06 +1000" MODIFIED_BY="[Empty name]" NAME="Ritzel 1961" YEAR="1961">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ritzel G</AU>
<TI>Ascorbic acid and the common cold [letter; explicit statement that the 1961 trial was randomized, double-blind placebo-controlled]</TI>
<SO>JAMA</SO>
<YR>1976</YR>
<VL>235</VL>
<NO>11</NO>
<PG>1108</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-05-29 05:04:06 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ritzel G</AU>
<TI>Critical analysis of the role of vitamin C in the prophylaxis and treatment of the common cold (English translation: http://www.mv.helsinki.fi/home/hemila/T3.pdf)</TI>
<TO>Kritische beurteilung des vitamins C als prophylacticum und therapeuticum der erkältungskrankheiten</TO>
<SO>Helvetica Medica Acta</SO>
<YR>1961</YR>
<VL>28</VL>
<PG>63-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sabiston-1974" MODIFIED="2012-05-29 05:05:09 +1000" MODIFIED_BY="Harri Hemilä" NAME="Sabiston 1974" YEAR="1974">
<REFERENCE MODIFIED="2012-05-29 05:05:09 +1000" MODIFIED_BY="Harri Hemilä" PRIMARY="NO" TYPE="BOOK">
<AU>Sabiston BH, Radomski MW</AU>
<SO>Health Problems and Vitamin C in Canadian Northern Military operations</SO>
<YR>1974 [10 pp] (Available: http://www.mv.helsinki.fi/home/hemila/CC/Sabiston_1974_ch.pdf)</YR>
<VL>DCIEM Report No 74-R-1012</VL>
<PB>Defence and Civil Institute of Environmental Medicine, Defence Research Board</PB>
<CY>Downsview, Ontario</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Sasazuki-2006" MODIFIED="2009-07-16 18:35:41 +1000" MODIFIED_BY="Harri Hemilä" NAME="Sasazuki 2006" YEAR="">
<REFERENCE MODIFIED="2009-07-16 18:35:41 +1000" MODIFIED_BY="Harri Hemilä" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sasazuki S, Sasaki S, Tsubono Y, Okubo S, Hayashi M, Tsugane S</AU>
<TI>Effect of vitamin C on common cold: randomized controlled trial</TI>
<SO>European Journal of Clinical Nutrition</SO>
<YR>2006</YR>
<VL>60</VL>
<PG>9-17</PG>
<IDENTIFIERS MODIFIED="2009-07-16 18:35:41 +1000" MODIFIED_BY="Harri Hemilä"/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tsubono Y, Okubo S, Hayashi M, Kakizoe T, Tsugane S</AU>
<TI>A randomized controlled trial for chemoprevention of gastric cancer in high-risk Japanese population; study design, feasibility and protocol modification [methods]</TI>
<SO>Japanese Journal of Cancer Research</SO>
<YR>1997</YR>
<VL>88</VL>
<PG>344-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Scheunert-1949" MODIFIED="2012-05-29 06:10:14 +1000" MODIFIED_BY="Harri Hemilä" NAME="Scheunert 1949" YEAR="1949">
<REFERENCE MODIFIED="2012-05-29 06:10:14 +1000" MODIFIED_BY="Harri Hemilä" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scheunert VA</AU>
<TI>Adult requirements for vitamin C</TI>
<TO>Der Tagesbedarf des Erwachsenen an Vitamin C</TO>
<SO>Internationale Zeitschrift für Vitaminforschung</SO>
<YR>1949</YR>
<VL>20</VL>
<PG>374-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schwartz-1973" NAME="Schwartz 1973" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schwartz AR, Togo Y, Hornick RB, Tominaga S, Gleckman RA</AU>
<TI>Evaluation of the efficacy of ascorbic acid in prophylaxis of induced rhinovirus 44 infection in man</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1973</YR>
<VL>128</VL>
<PG>500-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tebrock-1956" MODIFIED="2012-12-10 01:16:34 +1000" MODIFIED_BY="Harri Hemilä" NAME="Tebrock 1956" YEAR="1956">
<REFERENCE MODIFIED="2012-12-10 01:16:34 +1000" MODIFIED_BY="Harri Hemilä" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tebrock HE, Arminio JJ, Ossining NY, Johnston JH</AU>
<TI>Usefulness of bioflavonoids and ascorbic acid in treatments of common cold</TI>
<SO>Journal of the American Medical Association</SO>
<YR>1956</YR>
<VL>162</VL>
<PG>1227-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tyrrell-1977" NAME="Tyrrell 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tyrrell D, Craig JW, Meada TW, White T</AU>
<TI>A trial of ascorbic acid in the treatment of the common cold</TI>
<SO>British Journal of Preventive and Social Medicine</SO>
<YR>1977</YR>
<VL>31</VL>
<PG>189-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Straten-2002" NAME="Van Straten 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Straten M, Josling P</AU>
<TI>Preventing the common cold with a vitamin C supplement: a double-blind, placebo-controlled survey</TI>
<SO>Advances in Therapy</SO>
<YR>2002</YR>
<VL>19</VL>
<NO>3</NO>
<PG>151-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Walker-1967" MODIFIED="2009-09-18 21:05:56 +1000" MODIFIED_BY="Harri Hemilä" NAME="Walker 1967" YEAR="1967">
<REFERENCE MODIFIED="2009-09-18 21:05:56 +1000" MODIFIED_BY="Harri Hemilä" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Walker G, Bynoe ML, Tyrrell DA</AU>
<TI>Trial of ascorbic acid in prevention of colds</TI>
<SO>British Medical Journal</SO>
<YR>1967</YR>
<VL>1</VL>
<NO>5540</NO>
<PG>603-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wilson-1973a" MODIFIED="2009-09-18 21:11:10 +1000" MODIFIED_BY="Harri Hemilä" NAME="Wilson 1973a" YEAR="1973">
<REFERENCE MODIFIED="2009-09-18 21:11:10 +1000" MODIFIED_BY="Harri Hemilä" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kinlen L, Peto R</AU>
<TI>Vitamin C and colds [letter; criticism]</TI>
<SO>Lancet</SO>
<YR>1973</YR>
<VL>301</VL>
<NO>7809</NO>
<PG>944</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wilson C, Loh HS, Foster FG</AU>
<TI>Common cold symptomatology and vitamin C</TI>
<SO>European Journal of Clinical Pharmacology</SO>
<YR>1973</YR>
<VL>6</VL>
<PG>196-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wilson CWM, Loh HS, Foster FG</AU>
<TI>The beneficial effect of vitamin C on the common cold</TI>
<SO>European Journal of Clinical Pharmacology</SO>
<YR>1973</YR>
<VL>6</VL>
<PG>26-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-09-18 21:08:55 +1000" MODIFIED_BY="Harri Hemilä" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wilson CWM, Loh HS</AU>
<TI>Common cold and vitamin C [duplicate publication]</TI>
<SO>Lancet</SO>
<YR>1973</YR>
<VL>301</VL>
<NO>7804</NO>
<PG>638-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-09-18 21:08:24 +1000" MODIFIED_BY="Harri Hemilä" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wilson CWM, Loh HS</AU>
<TI>Vitamin C and colds [letter]</TI>
<SO>Lancet</SO>
<YR>1973</YR>
<VL>301</VL>
<NO>7811</NO>
<PG>1058-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wilson-1973b" NAME="Wilson 1973b" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wilson C, Loh HS, Foster FG</AU>
<TI>Common cold symptomatology and vitamin C</TI>
<SO>European Journal of Clinical Pharmacology</SO>
<YR>1973</YR>
<VL>6</VL>
<PG>196-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2012-12-12 07:13:46 +1000" MODIFIED_BY="Jenny Bellorini">
<STUDY DATA_SOURCE="PUB" ID="STD-Audera-2001c" MODIFIED="2009-11-13 16:36:57 +1000" MODIFIED_BY="[Empty name]" NAME="Audera 2001c" YEAR="2001">
<REFERENCE MODIFIED="2009-11-13 16:36:57 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Audera C, Patulny RV, Sander BH, Douglas RM</AU>
<TI>Mega-dose vitamin C in treatment of the common cold: a randomised controlled trial</TI>
<SO>Medical Journal of Australia</SO>
<YR>2001</YR>
<VL>175</VL>
<PG>359-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baird-1979" NAME="Baird 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baird IM, Hughes RE, Wilson HK, Davies JE, Howard AN</AU>
<TI>The effects of ascorbic acid and flavonoids on the occurrence of symptoms normally associated with the common cold</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1979</YR>
<VL>32</VL>
<PG>1686-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barnes-1961" NAME="Barnes 1961" YEAR="1961">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barnes FE</AU>
<TI>Vitamin supplements and the incidence of colds in high school basketball players</TI>
<SO>North Carolina Medical Journal</SO>
<YR>1961</YR>
<VL>22</VL>
<PG>22-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bartley-1953" NAME="Bartley 1953" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Bartley W, Krebs HA, O'Brien JRP</AU>
<TI>Incidence and duration of colds</TI>
<SO>Vitamin C Requirement of Human Adults: A report by the Vitamin C Subcommittee of the Accessory Food Factors Committee</SO>
<YR>1953</YR>
<PG>6-8 (Plan), 43-4 (Results), 134-5 (Table 44)</PG>
<PB>HMSO</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bendel-1955" NAME="Bendel 1955" YEAR="1955">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bendel A</AU>
<TO>Redoxon als Prophylaktikum bei Erkältungskrankheiten</TO>
<SO>Therapeutische Umschau und Medizinische Bibliographie</SO>
<YR>1955</YR>
<VL>12</VL>
<PG>87-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bergquist-1943" NAME="Bergquist 1943" YEAR="1943">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bergquist G</AU>
<TI>About prophylactic methods against so called common cold diseases</TI>
<TO>Om profylaktiska medel mot s.k. förkylningssjukdomar [see also: (1940);37:1669-73, 1860-4]</TO>
<SO>Svenska Läkartidningen</SO>
<YR>1943</YR>
<VL>40</VL>
<PG>2042-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bessel_x002d_Lorck-1958" MODIFIED="2009-11-13 16:37:47 +1000" MODIFIED_BY="[Empty name]" NAME="Bessel-Lorck 1958" YEAR="1959">
<REFERENCE MODIFIED="2009-11-13 16:37:47 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bessel-Lorck C</AU>
<TI>Prevention of colds in young subjects in ski camps</TI>
<TO>Erkältungsprophylaxe bei Jugendlichen im Skilager</TO>
<SO>Medizinische</SO>
<YR>1959</YR>
<VL>44</VL>
<PG>2126-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bibile-1966" MODIFIED="2009-09-18 21:14:52 +1000" MODIFIED_BY="Harri Hemilä" NAME="Bibile 1966" YEAR="1966">
<REFERENCE MODIFIED="2009-09-18 21:14:52 +1000" MODIFIED_BY="Harri Hemilä" NOTES="&lt;p&gt;Bibile S. Vitamin C in the prophylaxis and treatment of the common cold. Proceedings of the Ceylon Association of Advanced Science 1966;1(9):7.&lt;/p&gt;" NOTES_MODIFIED="2009-09-18 21:14:52 +1000" NOTES_MODIFIED_BY="Harri Hemilä" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bibile S</AU>
<TI>Vitamin C in the prophylaxis and treatment of the common cold [cited by Kleijnen 1989]</TI>
<SO>Proceedings of the Ceylon Association of Advanced Science</SO>
<YR>1966</YR>
<VL>1</VL>
<NO>9</NO>
<PG>7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boines-1956" NAME="Boines 1956" YEAR="1956">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boines GJ, Horoschak S</AU>
<TI>Hesperidin and ascorbic acid in the prevention of upper respiratory infections</TI>
<SO>International Record of Medicine and General Practice Clinics</SO>
<YR>1956</YR>
<VL>169</VL>
<PG>73-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chavance-1993" NAME="Chavance 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chavance M, Herbeth B, Lemoine A, Zhu BP</AU>
<TI>Does multivitamin supplementation prevent infections in healthy elderly subjects? A controlled trial</TI>
<SO>International Journal for Vitamin and Nutrition Research</SO>
<YR>1993</YR>
<VL>63</VL>
<PG>11-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cuendet-1946" NAME="Cuendet 1946" YEAR="1946">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cuendet O</AU>
<TO>Ernährungs- und Vitaminfragen im Saas-Tal</TO>
<SO>Praxis</SO>
<YR>1946</YR>
<VL>17</VL>
<PG>378-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dyllick-1967" NAME="Dyllick 1967" YEAR="1967">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dyllick H</AU>
<TO>Werkärztliche Erfahrungen mit Vitamin C</TO>
<SO>Medizinische Welt</SO>
<YR>1967</YR>
<VL>17</VL>
<PG>1098-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fogelholm-1998" NAME="Fogelholm 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fogelholm M, Vasankari T, Borg P, Katila R, Tuomi T</AU>
<TI>Lack of effect of long-term antioxidant supplementation on incidence of upper respiratory tract infections in athletes [abstract]</TI>
<SO>Proceedings of the Nutrition Society</SO>
<YR>1998</YR>
<VL>57</VL>
<PG>16A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Glazebrook-1942" NAME="Glazebrook 1942" YEAR="1942">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Glazebrook AJ, Thomson S</AU>
<TI>The administration of vitamin C in a large institution and its effect on general health and resistance to infection</TI>
<SO>Journal of Hygiene</SO>
<YR>1942</YR>
<VL>42</VL>
<PG>1-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gormly-1977" MODIFIED="2010-01-27 00:15:58 +1000" MODIFIED_BY="Jenny Bellorini" NAME="Gormly 1977" YEAR="1977">
<REFERENCE MODIFIED="2010-01-27 00:15:58 +1000" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gormly PJ</AU>
<TI>Megadosage of ascorbic acid in an Antarctic expedition</TI>
<SO>British Journal of Nutrition</SO>
<YR>1977</YR>
<VL>37</VL>
<PG>269-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gorton-1999" NAME="Gorton 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gorton H, Jarvis K</AU>
<TI>The effectiveness of vitamin C in preventing and relieving the symptoms of virus-induced respiratory infections</TI>
<SO>Journal of Manipulative and Physiological Therapeutics</SO>
<YR>1999</YR>
<VL>22</VL>
<PG>530-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Himmelstein-1998b" MODIFIED="2009-05-28 01:57:00 +1000" MODIFIED_BY="Harri Hemilä" NAME="Himmelstein 1998b" YEAR="1998">
<REFERENCE MODIFIED="2009-05-25 20:28:45 +1000" MODIFIED_BY="Harri Hemilä" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Himmelstein SA, Robergs RA, Koehler KM, Lewis SL, Qualls CR</AU>
<TI>Vitamin C supplementation and upper respiratory tract infections in marathon runners</TI>
<SO>Journal of Exercise Physiology Online</SO>
<YR>1998</YR>
<VL>1</VL>
<NO>2</NO>
<PG>1-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hopfeng_x00e4_rtner-1944" MODIFIED="2012-05-29 05:07:01 +1000" MODIFIED_BY="Harri Hemilä" NAME="Hopfengärtner 1944" YEAR="1944">
<REFERENCE MODIFIED="2012-05-29 05:07:01 +1000" MODIFIED_BY="Harri Hemilä" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hopfengärtner C</AU>
<TO>Vitaminprophylaxe bei Säuglingen</TO>
<SO>Monatsschrift für Kinderheilkunde</SO>
<YR>1944</YR>
<VL>92</VL>
<PG>330-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hunt-1994" NAME="Hunt 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hunt CN, Annan G, Habibzedeh N, Schorah CJ</AU>
<TI>The clinical effects of vitamin C supplementation in elderly hospitalised patients with acute respiratory infections</TI>
<SO>International Journal for Vitamin and Nutrition Research</SO>
<YR>1994</YR>
<VL>64</VL>
<PG>212-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kimbarowski-1967" MODIFIED="2009-11-13 16:41:44 +1000" MODIFIED_BY="[Empty name]" NAME="Kimbarowski 1967" YEAR="">
<REFERENCE MODIFIED="2009-11-13 16:41:44 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kimbarowski JA, Mokrow NJ</AU>
<TI>Colored precipitation reaction of the urine according to Kimbarowski as an index of the effect of ascorbic acid during treatment of viral influenza</TI>
<TO>Farbige Ausfällungsreaktion des Harns nach Kimbarowski, als Index der Wirkung von Ascorbinsäure bei Behandlung der Virusgrippe</TO>
<SO>Deutsche Gesundheitswese</SO>
<YR>1967</YR>
<VL>22</VL>
<PG>2413-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koytchev-2003" MODIFIED="2010-01-26 23:31:21 +1000" MODIFIED_BY="Jenny Bellorini" NAME="Koytchev 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-01-26 23:31:21 +1000" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koytchev R, Vlahov V, Bacratcheva N, Giesel B, Gawronska-Szklarz B, Wojcicki J, et al</AU>
<TI>Evaluation of the efficacy of a combined formulation (Grippostad-C) in the therapy of symptoms of common cold: a randomized, double-blind, multicenter trial</TI>
<SO>International Journal of Clinical Pharmacology and Therapeutics</SO>
<YR>2003</YR>
<VL>41</VL>
<PG>114-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maggini-2012" MODIFIED="2012-09-18 16:27:37 +1000" MODIFIED_BY="Harri Hemilä" NAME="Maggini 2012" YEAR="2012">
<REFERENCE MODIFIED="2012-09-18 16:27:37 +1000" MODIFIED_BY="Harri Hemilä" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maggini S, Beveridge S, Suter M</AU>
<TI>A combination of high-dose vitamin C plus zinc for the common cold</TI>
<SO>Journal of International Medical Research</SO>
<YR>2012</YR>
<VL>40</VL>
<PG>28-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Masek-1974" NAME="Masek 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Masek JHF, Neradilova M, Hejda S</AU>
<TI>The role of vitamin C in the treatment of acute infections of the upper respiratory pathways</TI>
<SO>Acta Vitaminologica et Enzymologica</SO>
<YR>1974</YR>
<VL>28</VL>
<PG>85-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Niemi-1951" MODIFIED="2009-11-13 16:42:02 +1000" MODIFIED_BY="[Empty name]" NAME="Niemi 1951" YEAR="1951">
<REFERENCE MODIFIED="2009-11-13 16:42:02 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Niemi TR</AU>
<TI>Acute respiratory infections and vitamin C</TI>
<TO>Äkilliset hengitystieinfektiot ja C-vitamiini</TO>
<SO>Duodecim</SO>
<YR>1951</YR>
<VL>67</VL>
<PG>360-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peters-1940" MODIFIED="2009-11-13 16:42:27 +1000" MODIFIED_BY="[Empty name]" NAME="Peters 1940" YEAR="1940">
<REFERENCE MODIFIED="2009-11-13 16:42:27 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peters M</AU>
<TI>About the increase in resistance by daily prophylactic vitamin C medication</TI>
<TO>Zur Frage der Resistenzsteigernden Wirkung Prophylaktischer Dauermedikation von Vitamin C</TO>
<SO>Zeitschrift für Kinderheilkunde</SO>
<YR>1940</YR>
<VL>61</VL>
<PG>179-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmidt-2011" MODIFIED="2012-12-12 07:13:46 +1000" MODIFIED_BY="[Empty name]" NAME="Schmidt 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-12-12 07:13:46 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schmidt K, Zirkler S</AU>
<TI>Dietary efficacy of a micronutrient combination in patients with recurrent upper respiratory tract infections. Results of a placebo-controlled double-blind study</TI>
<TO>Diätetische Wirksamkeit einer Mikronährstoffkombination bei rezidivierenden Atemwegsinfekten</TO>
<SO>MMW Fortschritte der Medizin</SO>
<YR>2011</YR>
<VL>153</VL>
<NO>Suppl 3</NO>
<PG>83-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2009-09-18 21:14:52 +1000" MODIFIED_BY="Harri Hemilä"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2012-09-26 08:46:05 +1000" MODIFIED_BY="Jenny Bellorini">
<ADDITIONAL_REFERENCES MODIFIED="2012-09-26 08:46:05 +1000" MODIFIED_BY="Jenny Bellorini">
<REFERENCE ID="REF-Akaike-2001" MODIFIED="2009-07-16 16:50:12 +1000" MODIFIED_BY="Harri Hemilä" NAME="Akaike 2001" TYPE="JOURNAL_ARTICLE">
<AU>Akaike T</AU>
<TI>Role of free radicals in viral pathogenesis and mutation</TI>
<SO>Reviews in Medical Virology</SO>
<YR>2001</YR>
<VL>11</VL>
<PG>87-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Anderson-1977" NAME="Anderson 1977" TYPE="JOURNAL_ARTICLE">
<AU>Anderson T</AU>
<TI>Large scale studies with vitamin C</TI>
<SO>Acta Vitaminologica et Enzymologica</SO>
<YR>1977</YR>
<VL>31</VL>
<PG>43-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Anderson-2008" MODIFIED="2010-01-05 09:27:00 +1000" MODIFIED_BY="[Empty name]" NAME="Anderson 2008" TYPE="JOURNAL_ARTICLE">
<AU>Anderson SD, Kippelen P</AU>
<TI>Airway injury as a mechanism for exercise-induced bronchoconstriction in elite athletes</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2008</YR>
<VL>122</VL>
<PG>225-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Balk-2002" MODIFIED="2009-11-13 16:43:44 +1000" MODIFIED_BY="[Empty name]" NAME="Balk 2002" TYPE="JOURNAL_ARTICLE">
<AU>Balk EM, Bonis PA, Moskowitz H, Schmid CH, Ioannidis JP, Wang C, et al</AU>
<TI>Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials</TI>
<SO>JAMA</SO>
<YR>2002</YR>
<VL>287</VL>
<PG>2973-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bee-1980" NAME="Bee 1980" TYPE="JOURNAL_ARTICLE">
<AU>Bee DM</AU>
<TI>The vitamin C controversy [letter]</TI>
<SO>Postgraduate Medicine</SO>
<YR>1980</YR>
<VL>67</VL>
<NO>2</NO>
<PG>64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Campbell-1975" NAME="Campbell 1975" TYPE="JOURNAL_ARTICLE">
<AU>Campbell GD, Steinberg MH, Bower JD</AU>
<TI>Ascorbic acid-induced hemolysis in G-6-PD deficiency [letter]</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1975</YR>
<VL>82</VL>
<PG>810</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Castro-2006" MODIFIED="2009-11-13 16:44:14 +1000" MODIFIED_BY="[Empty name]" NAME="Castro 2006" TYPE="JOURNAL_ARTICLE">
<AU>Castro SM, Guerrero-Plata A, Suarez-Real G, Adegboyega PA, Colasurdo GN, Khan AM, et al</AU>
<TI>Antioxidant treatment ameliorates respiratory syncytial virus-induced disease and lung inflammation</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2006</YR>
<VL>174</VL>
<PG>1361-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cathcart-1981" NAME="Cathcart 1981" TYPE="JOURNAL_ARTICLE">
<AU>Cathcart RF</AU>
<TI>Vitamin C, titrating to bowel tolerance, anascorbemia, and acute induced scurvy</TI>
<SO>Medical Hypotheses</SO>
<YR>1981</YR>
<VL>7</VL>
<PG>1359-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chalmers-1975" NAME="Chalmers 1975" TYPE="JOURNAL_ARTICLE">
<AU>Chalmers TC</AU>
<TI>Effects of ascorbic acid on the common cold: an evaluation of the evidence [see Hemilä 1995, 2006a]</TI>
<SO>American Journal of Medicine</SO>
<YR>1975</YR>
<VL>58</VL>
<PG>532-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chalmers-1996" NAME="Chalmers 1996" TYPE="JOURNAL_ARTICLE">
<AU>Chalmers TC</AU>
<TI>Dissent to the preceding article by H Hemilä</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>1996</YR>
<VL>49</VL>
<PG>1085</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dykes-1975" NAME="Dykes 1975" TYPE="JOURNAL_ARTICLE">
<AU>Dykes MH, Meier P</AU>
<TI>Ascorbic acid and the common cold: evaluation of its efficacy and toxicity</TI>
<SO>JAMA</SO>
<YR>1975</YR>
<VL>231</VL>
<PG>1073-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Eccles-2005" MODIFIED="2009-07-15 22:51:40 +1000" MODIFIED_BY="Harri Hemilä" NAME="Eccles 2005" TYPE="JOURNAL_ARTICLE">
<AU>Eccles R</AU>
<TI>Understanding the symptoms of the common cold and influenza</TI>
<SO>Lancet Infectious Diseases</SO>
<YR>2005</YR>
<VL>5</VL>
<PG>718-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Eccles-2009" MODIFIED="2012-05-29 03:24:09 +1000" MODIFIED_BY="Harri Hemilä" NAME="Eccles 2009" TYPE="BOOK">
<AU>Eccles R, Weber R (eds)</AU>
<SO>Common Cold</SO>
<YR>2009</YR>
<PB>Birkhauser</PB>
<CY>Basel</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gonzales-1997" MODIFIED="2009-07-14 16:48:43 +1000" MODIFIED_BY="Harri Hemilä" NAME="Gonzales 1997" TYPE="JOURNAL_ARTICLE">
<AU>Gonzales R, Steiner JF, Sande MA</AU>
<TI>Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians</TI>
<SO>JAMA</SO>
<YR>1997</YR>
<VL>278</VL>
<PG>901-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gotzsche-1989" NAME="Gotzsche 1989" TYPE="JOURNAL_ARTICLE">
<AU>Gotzsche AL</AU>
<TI>Pernasal vitamin C and the common cold [letter]</TI>
<SO>Lancet</SO>
<YR>1989</YR>
<VL>334</VL>
<PG>1039</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gwaltney-2005" MODIFIED="2009-07-16 18:33:29 +1000" MODIFIED_BY="Harri Hemilä" NAME="Gwaltney 2005" TYPE="BOOK_SECTION">
<AU>Gwaltney JM</AU>
<TI>The common cold</TI>
<SO>Principles and Practice of Infectious Diseases</SO>
<YR>2005</YR>
<PG>651-6</PG>
<EN>6th</EN>
<ED>Mandell GL, Bennett JE, Dolin R</ED>
<PB>Churchill Livingstone</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS MODIFIED="2009-07-16 18:33:29 +1000" MODIFIED_BY="Harri Hemilä"/>
</REFERENCE>
<REFERENCE ID="REF-Heikkinen-2003" MODIFIED="2009-11-13 16:45:19 +1000" MODIFIED_BY="[Empty name]" NAME="Heikkinen 2003" TYPE="JOURNAL_ARTICLE">
<AU>Heikkinen T, Järvinen A</AU>
<TI>The common cold</TI>
<SO>Lancet</SO>
<YR>2003</YR>
<VL>361</VL>
<PG>51-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hemil_x00e4_-1992" NAME="Hemilä 1992" TYPE="JOURNAL_ARTICLE">
<AU>Hemilä H</AU>
<TI>Vitamin C and the common cold</TI>
<SO>British Journal of Nutrition</SO>
<YR>1992</YR>
<VL>67</VL>
<PG>3-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hemil_x00e4_-1994" NAME="Hemilä 1994" TYPE="JOURNAL_ARTICLE">
<AU>Hemilä H</AU>
<TI>Does vitamin C alleviate the symptoms of the common cold? A review of current evidence</TI>
<SO>Scandinavian Journal of Infectious Diseases</SO>
<YR>1994</YR>
<VL>26</VL>
<PG>1-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hemil_x00e4_-1995" NAME="Hemilä 1995" TYPE="JOURNAL_ARTICLE">
<AU>Hemilä H, Herman ZS</AU>
<TI>Vitamin C and the common cold: a retrospective analysis of Chalmers' review</TI>
<SO>Journal of the American College of Nutrition</SO>
<YR>1995</YR>
<VL>14</VL>
<PG>116-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hemil_x00e4_-1996a" NAME="Hemilä 1996a" TYPE="JOURNAL_ARTICLE">
<AU>Hemilä H</AU>
<TI>Vitamin C, the placebo effect, and the common cold: a case study of how preconceptions influence the analysis of results [discussion: 1996;49:1985-7]</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>1996</YR>
<VL>49</VL>
<PG>1079-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hemil_x00e4_-1996b" NAME="Hemilä 1996b" TYPE="JOURNAL_ARTICLE">
<AU>Hemilä H</AU>
<TI>Vitamin C and common cold incidence: a review of studies with subjects under heavy physical stress</TI>
<SO>International Journal of Sports Medicine</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>379-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hemil_x00e4_-1996c" NAME="Hemilä 1996c" TYPE="JOURNAL_ARTICLE">
<AU>Hemilä H</AU>
<TI>Vitamin C supplementation and common cold symptoms: problems with inaccurate reviews</TI>
<SO>Nutrition</SO>
<YR>1996</YR>
<VL>12</VL>
<PG>804-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hemil_x00e4_-1996d" NAME="Hemilä 1996d" TYPE="JOURNAL_ARTICLE">
<AU>Hemilä H</AU>
<TI>Response to the dissent by Thomas Chalmers</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>1996</YR>
<VL>49</VL>
<PG>1087</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hemil_x00e4_-1997a" NAME="Hemilä 1997a" TYPE="JOURNAL_ARTICLE">
<AU>Hemilä H</AU>
<TI>Vitamin C intake and susceptibility to the common cold [discussion: 1997;78:857-66]</TI>
<SO>British Journal of Nutrition</SO>
<YR>1997</YR>
<VL>77</VL>
<PG>59-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hemil_x00e4_-1997b" NAME="Hemilä 1997b" TYPE="JOURNAL_ARTICLE">
<AU>Hemilä H</AU>
<TI>Vitamin C supplementation and the common cold: was Linus Pauling right or wrong?</TI>
<SO>International Journal for Vitamin and Nutrition Research</SO>
<YR>1997</YR>
<VL>67</VL>
<PG>329-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hemil_x00e4_-1997c" NAME="Hemilä 1997c" TYPE="BOOK_SECTION">
<AU>Hemilä H</AU>
<TI>Vitamin C and infectious diseases</TI>
<SO>Vitamin C in Health and Disease</SO>
<YR>1997</YR>
<PG>471-503</PG>
<ED>Packer L, Fuchs J</ED>
<PB>Marcel Dekker</PB>
<CY>NY</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hemil_x00e4_-1999a" NAME="Hemilä 1999a" TYPE="JOURNAL_ARTICLE">
<AU>Hemilä H</AU>
<TI>Vitamin C supplementation and common cold symptoms: factors affecting the magnitude of benefit</TI>
<SO>Medical Hypotheses</SO>
<YR>1999</YR>
<VL>52</VL>
<PG>171-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hemil_x00e4_-1999b" NAME="Hemilä 1999b" TYPE="JOURNAL_ARTICLE">
<AU>Hemilä H, Douglas RM</AU>
<TI>Vitamin C and acute respiratory infections</TI>
<SO>International Journal of Tuberculosis and Lung Disease</SO>
<YR>1999</YR>
<VL>3</VL>
<PG>756-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hemil_x00e4_-2004" MODIFIED="2012-05-29 05:13:30 +1000" MODIFIED_BY="Harri Hemilä" NAME="Hemilä 2004" TYPE="JOURNAL_ARTICLE">
<AU>Hemilä H</AU>
<TI>Vitamin C supplementation and respiratory infections: a systematic review</TI>
<SO>Military Medicine</SO>
<YR>2004</YR>
<VL>169</VL>
<PG>920-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hemil_x00e4_-2006a" NAME="Hemilä 2006a" TYPE="BOOK">
<AU>Hemilä H</AU>
<SO>Do vitamins C and E affect respiratory infections? [PhD thesis; 131 pp]</SO>
<YR>2006 [http://ethesis.helsinki.fi/julkaisut/laa/kansa/vk/hemila/]</YR>
<PB>University of Helsinki</PB>
<CY>Helsinki, Finland</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hemil_x00e4_-2006b" NAME="Hemilä 2006b" TYPE="JOURNAL_ARTICLE">
<AU>Hemilä H, Virtamo J, Albanes D, Kaprio J</AU>
<TI>The effect of vitamin E on common cold incidence is modified by age, smoking and residential neighborhood</TI>
<SO>Journal of the American College of Nutrition</SO>
<YR>2006</YR>
<VL>25</VL>
<PG>332-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hemil_x00e4_-2006c" MODIFIED="2009-11-13 16:46:28 +1000" MODIFIED_BY="[Empty name]" NAME="Hemilä 2006c" TYPE="JOURNAL_ARTICLE">
<AU>Hemilä H</AU>
<TI>Analysis of clinical data with breached blindness</TI>
<SO>Statistics in Medicine</SO>
<YR>2006</YR>
<VL>25</VL>
<PG>1434-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hemil_x00e4_-2007" MODIFIED="2012-09-23 16:56:41 +1000" MODIFIED_BY="Harri Hemilä" NAME="Hemilä 2007" TYPE="COCHRANE_REVIEW">
<AU>Hemilä H, Louhiala P</AU>
<TI>Vitamin C for preventing and treating pneumonia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2009-07-14 19:32:04 +1000" MODIFIED_BY="Harri Hemilä">
<IDENTIFIER MODIFIED="2009-07-14 19:32:04 +1000" MODIFIED_BY="Harri Hemilä" TYPE="DOI" VALUE="10.1002/14651858.CD005532.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hemil_x00e4_-2008" MODIFIED="2009-05-27 23:31:30 +1000" MODIFIED_BY="Harri Hemilä" NAME="Hemilä 2008" TYPE="JOURNAL_ARTICLE">
<AU>Hemilä H</AU>
<TI>Vitamin C and sex differences in respiratory tract infections</TI>
<SO>Respiratory Medicine</SO>
<YR>2008</YR>
<VL>102</VL>
<PG>625-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hemil_x00e4_-2009b" MODIFIED="2009-07-15 22:36:30 +1000" MODIFIED_BY="Harri Hemilä" NAME="Hemilä 2009b" TYPE="JOURNAL_ARTICLE">
<AU>Hemilä H, Kaprio J</AU>
<TI>Modification of the effect of vitamin E supplementation on the mortality of male smokers by age and dietary vitamin C</TI>
<SO>American Journal of Epidemiology</SO>
<YR>2009</YR>
<VL>169</VL>
<NO>8</NO>
<PG>946-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hemil_x00e4_-2009c" MODIFIED="2009-07-17 00:16:33 +1000" MODIFIED_BY="Harri Hemilä" NAME="Hemilä 2009c" TYPE="JOURNAL_ARTICLE">
<AU>Hemilä H</AU>
<TI>Vitamin C and exercise-induced bronchoconstriction in athletes</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2009</YR>
<VL>123</VL>
<PG>274-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hemil_x00e4_-2011" MODIFIED="2012-09-23 16:56:59 +1000" MODIFIED_BY="Harri Hemilä" NAME="Hemilä 2011" TYPE="JOURNAL_ARTICLE">
<AU>Hemilä H, Kaprio J</AU>
<TI>Subgroup analysis of large trials can guide further research: a case study of vitamin E and pneumonia</TI>
<SO>Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>3</VL>
<PG>51-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2009-11-17 02:00:30 +1000" MODIFIED_BY="Harri Hemilä" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analysis</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2012-09-26 08:46:05 +1000" MODIFIED_BY="Jenny Bellorini" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 [updated March 2011]. The Cochrane Collaboration</TI>
<SO>Available from http://www.cochrane-handbook.org</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hrobjartsson-2010" MODIFIED="2012-09-21 09:08:31 +1000" MODIFIED_BY="Harri Hemilä" NAME="Hrobjartsson 2010" TYPE="COCHRANE_REVIEW">
<AU>Hrobjartsson A, Gotzsche PC</AU>
<TI>Placebo interventions for all clinical conditions</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2012-05-29 05:13:09 +1000" MODIFIED_BY="Harri Hemilä">
<IDENTIFIER MODIFIED="2012-05-29 05:13:09 +1000" MODIFIED_BY="Harri Hemilä" TYPE="DOI" VALUE="10.1002/14651858.CD003974.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ji-1999" MODIFIED="2009-07-14 19:50:10 +1000" MODIFIED_BY="Harri Hemilä" NAME="Ji 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ji LL</AU>
<TI>Antioxidants and oxidative stress in exercise</TI>
<SO>Proceedings for the Society for Experimental Biology and Medicine</SO>
<YR>1999</YR>
<VL>222</VL>
<PG>283-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kleijnen-1989" MODIFIED="2009-05-28 02:10:32 +1000" MODIFIED_BY="Harri Hemilä" NAME="Kleijnen 1989" TYPE="JOURNAL_ARTICLE">
<AU>Kleijnen J, ter Riet G, Knipschild PG</AU>
<TI>Vitamin C and the common cold; review of a megadose of literature (English translation in Thesis (1991): "Food Supplements and Their Efficacy" Maastricht, Netherlands; ISBN 90-9004581-3)</TI>
<TO>Vitamine C en verkoudheid; overzicht an een megadosis literatuur (see comments: Hemilä 2006a)</TO>
<SO>Nederlands Tijdschrift voor Geneeskunde</SO>
<YR>1989</YR>
<VL>133</VL>
<PG>1532-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kleijnen-1992" NAME="Kleijnen 1992" TYPE="JOURNAL_ARTICLE">
<AU>Kleijnen J, Knipschild P</AU>
<TI>The comprehensiveness of Medline and Embase computer searches</TI>
<SO>Pharmaceutisch Weekblad. Scientific edition</SO>
<YR>1992</YR>
<VL>14</VL>
<PG>316-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mainous-1996" MODIFIED="2009-07-16 18:33:05 +1000" MODIFIED_BY="Harri Hemilä" NAME="Mainous 1996" TYPE="JOURNAL_ARTICLE">
<AU>Mainous AG, Hueston WJ, Clark JR</AU>
<TI>Antibiotics and upper respiratory infection: do some folks think there is a cure for the common cold?</TI>
<SO>Journal of Family Practice</SO>
<YR>1996</YR>
<VL>42</VL>
<PG>357-61</PG>
<IDENTIFIERS MODIFIED="2009-07-16 18:33:05 +1000" MODIFIED_BY="Harri Hemilä"/>
</REFERENCE>
<REFERENCE ID="REF-Nualart-2003" MODIFIED="2009-11-13 16:48:24 +1000" MODIFIED_BY="[Empty name]" NAME="Nualart 2003" TYPE="JOURNAL_ARTICLE">
<AU>Nualart FJ, Rivas CI, Montecinos VP, Godoy AS, Guaiquil VH, Golde DW, et al</AU>
<TI>Recycling of vitamin C by a bystander effect</TI>
<SO>Journal of Biological Chemistry</SO>
<YR>2003</YR>
<VL>278</VL>
<PG>10128-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Padayatty-2004" MODIFIED="2010-01-26 23:32:42 +1000" MODIFIED_BY="Jenny Bellorini" NAME="Padayatty 2004" TYPE="JOURNAL_ARTICLE">
<AU>Padayatty SJ, Sun H, Wang Y, Riordan HD, Hewitt SM, Katz A, et al</AU>
<TI>Vitamin C pharmacokinetics: implications for oral and intravenous use</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2004</YR>
<VL>140</VL>
<PG>533-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pauling-1970a" MODIFIED="2012-05-29 05:18:59 +1000" MODIFIED_BY="[Empty name]" NAME="Pauling 1970a" TYPE="BOOK">
<AU>Pauling L</AU>
<SO>Vitamin C and the Common Cold</SO>
<YR>1970 (Book reviews: http://www.mv.helsinki.fi/home/hemila/pauling.htm)</YR>
<PB>Freeman</PB>
<CY>San Francisco</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pauling-1970b" NAME="Pauling 1970b" TYPE="JOURNAL_ARTICLE">
<AU>Pauling L</AU>
<TI>Evolution and the need for ascorbic acid</TI>
<SO>Proceedings of the National Academy of Sciences of the USA</SO>
<YR>1970</YR>
<VL>67</VL>
<PG>1643-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pauling-1971a" NAME="Pauling 1971a" TYPE="JOURNAL_ARTICLE">
<AU>Pauling L</AU>
<TI>The significance of the evidence about ascorbic acid and the common cold</TI>
<SO>Proceedings of the National Academy of Sciences of the USA</SO>
<YR>1971</YR>
<VL>68</VL>
<PG>2678-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pauling-1971b" NAME="Pauling 1971b" TYPE="JOURNAL_ARTICLE">
<AU>Pauling L</AU>
<TI>Ascorbic acid and the common cold</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1971</YR>
<VL>24</VL>
<PG>1294-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pauling-1976a" MODIFIED="2012-05-29 05:18:41 +1000" MODIFIED_BY="Harri Hemilä" NAME="Pauling 1976a" TYPE="BOOK">
<AU>Pauling L</AU>
<SO>Vitamin C, Common Cold, and the Flu</SO>
<YR>1976 (Book reviews: http://www.mv.helsinki.fi/home/hemila/pauling.htm)</YR>
<PB>Freeman</PB>
<CY>San Francisco</CY>
<IDENTIFIERS MODIFIED="2009-07-16 18:34:00 +1000" MODIFIED_BY="Harri Hemilä"/>
</REFERENCE>
<REFERENCE ID="REF-Pauling-1976b" MODIFIED="2009-08-18 23:53:27 +1000" MODIFIED_BY="Harri Hemilä" NAME="Pauling 1976b" TYPE="JOURNAL_ARTICLE">
<AU>Pauling L</AU>
<TI>Ascorbic acid and the common cold: evaluation of its efficacy and toxicity. Part I</TI>
<SO>Medical Tribune</SO>
<YR>1976</YR>
<VL>17</VL>
<NO>12</NO>
<PG>18-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pauling-1976c" MODIFIED="2009-08-18 23:55:23 +1000" MODIFIED_BY="Harri Hemilä" NAME="Pauling 1976c" TYPE="JOURNAL_ARTICLE">
<AU>Pauling L</AU>
<TI>Ascorbic acid and the common cold. Part II</TI>
<SO>Medical Tribune</SO>
<YR>1976</YR>
<VL>17</VL>
<NO>13</NO>
<PG>37-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2011" MODIFIED="2012-09-21 09:09:30 +1000" MODIFIED_BY="Jenny Bellorini" NAME="RevMan 2011" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2011</YR>
<EN>5.1</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shamseer-2008" MODIFIED="2009-09-18 21:17:22 +1000" MODIFIED_BY="Harri Hemilä" NAME="Shamseer 2008" TYPE="JOURNAL_ARTICLE">
<AU>Shamseer L, Vohra S, Bax R, Spee L, Madderom M, Hemilä H</AU>
<TI>Commentaries on &#8216;Vitamin C for preventing and treating the common cold&#8217; with responses from the review author</TI>
<SO>Evidence Based Child Health</SO>
<YR>2008</YR>
<VL>3</VL>
<PG>723&#8211;8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thomas-1978" MODIFIED="2009-07-14 17:19:28 +1000" MODIFIED_BY="Harri Hemilä" NAME="Thomas 1978" TYPE="JOURNAL_ARTICLE">
<AU>Thomas WR, Holt PG</AU>
<TI>Vitamin C and immunity: an assessment of the evidence</TI>
<SO>Clinical and Experimental Immunology</SO>
<YR>1978</YR>
<VL>32</VL>
<PG>370-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wang-1997" MODIFIED="2009-07-14 20:24:08 +1000" MODIFIED_BY="Harri Hemilä" NAME="Wang 1997" TYPE="JOURNAL_ARTICLE">
<AU>Wang Y, Russo TA, Kwon O, Chanock S, Rumsey SC, Levine M</AU>
<TI>Ascorbate recycling in human neutrophils: induction by bacteria</TI>
<SO>Proceedings of the National Academy of Sciences of the USA</SO>
<YR>1997</YR>
<VL>94</VL>
<PG>13816-9</PG>
<IDENTIFIERS MODIFIED="2009-07-14 20:24:08 +1000" MODIFIED_BY="Harri Hemilä"/>
</REFERENCE>
<REFERENCE ID="REF-Webb-2007" MODIFIED="2009-09-18 21:17:33 +1000" MODIFIED_BY="Harri Hemilä" NAME="Webb 2007" TYPE="JOURNAL_ARTICLE">
<AU>Webb AL, Villamor E</AU>
<TI>Effects of antioxidant and non-antioxidant vitamin supplementation on immune function</TI>
<SO>Nutrition Reviews</SO>
<YR>2007</YR>
<VL>65</VL>
<PG>181-217</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilson-1969" NAME="Wilson 1969" TYPE="JOURNAL_ARTICLE">
<AU>Wilson CWM, Loh HS</AU>
<TI>Ascorbic acid and upper respiratory inflammation [abstract]</TI>
<SO>Acta Allergologica</SO>
<YR>1969</YR>
<VL>24</VL>
<PG>367-8</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2012-09-21 09:03:07 +1000" MODIFIED_BY="Harri Hemilä">
<REFERENCE ID="REF-Douglas-1998" MODIFIED="2009-10-09 23:45:48 +1000" MODIFIED_BY="Harri Hemilä" NAME="Douglas 1998" TYPE="COCHRANE_REVIEW">
<AU>Douglas RM, Chalker EB, Treacy B</AU>
<TI>Vitamin C for preventing and treating the common cold</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1998</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2009-10-09 23:45:48 +1000" MODIFIED_BY="Harri Hemilä">
<IDENTIFIER MODIFIED="2009-10-09 23:45:48 +1000" MODIFIED_BY="Harri Hemilä" TYPE="DOI" VALUE="10.1002/14651858.CD000980"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Douglas-2004" MODIFIED="2009-10-09 23:44:30 +1000" MODIFIED_BY="Harri Hemilä" NAME="Douglas 2004" TYPE="COCHRANE_REVIEW">
<AU>Douglas RM, Hemila H, D'Souza R, Chalker EB, Treacy B</AU>
<TI>Vitamin C for preventing and treating the common cold</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2009-10-09 23:44:30 +1000" MODIFIED_BY="Harri Hemilä">
<IDENTIFIER MODIFIED="2009-10-09 23:43:12 +1000" MODIFIED_BY="Harri Hemilä" TYPE="DOI" VALUE="10.1002/14651858.CD000980.pub2"/>
<IDENTIFIER MODIFIED="2009-10-09 23:44:30 +1000" MODIFIED_BY="Harri Hemilä" TYPE="PUBMED" VALUE="15495002"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Douglas-2007" MODIFIED="2009-10-09 23:44:25 +1000" MODIFIED_BY="Harri Hemilä" NAME="Douglas 2007" TYPE="COCHRANE_REVIEW">
<AU>Douglas RM, Hemilä H, Chalker E, Treacy B</AU>
<TI>Vitamin C for preventing and treating the common cold</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2009-10-09 23:44:25 +1000" MODIFIED_BY="Harri Hemilä">
<IDENTIFIER MODIFIED="2009-10-09 23:43:51 +1000" MODIFIED_BY="Harri Hemilä" TYPE="DOI" VALUE="10.1002/14651858.CD000980.pub3"/>
<IDENTIFIER MODIFIED="2009-10-09 23:44:25 +1000" MODIFIED_BY="Harri Hemilä" TYPE="PUBMED" VALUE="17636648"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hemil_x00e4_-2010" MODIFIED="2012-09-21 09:03:07 +1000" MODIFIED_BY="Harri Hemilä" NAME="Hemilä 2010" TYPE="COCHRANE_REVIEW">
<AU>Hemilä H, Chalker E, Douglas B</AU>
<TI>Vitamin C for preventing and treating the common cold</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2012-09-18 21:34:55 +1000" MODIFIED_BY="Harri Hemilä">
<IDENTIFIER MODIFIED="2012-09-18 21:34:55 +1000" MODIFIED_BY="Harri Hemilä" TYPE="DOI" VALUE="10.1002/14651858.CD000980.pub3"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2012-12-12 07:09:25 +1000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2012-12-10 02:50:20 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Harri Hemilä" STUDY_ID="STD-Abbott-1968">
<CHAR_METHODS MODIFIED="2012-05-30 20:04:26 +1000" MODIFIED_BY="Harri Hemilä">
<P>Double-blind RCT, treatment trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Harri Hemilä">
<P>Family members of 78 UK general practitioners. Males and females were in equal numbers; 52% were from 21 to 50 years. 147 vitamin C; 123 placebo (p 442)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Harri Hemilä">
<P>3 g/d vitamin C as effervescent tablets (1 g 3 times per day) was "started as soon as coryza symptoms appeared and continued for as long as necessary, up to a total of fourteen days"</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-30 20:02:07 +1000" MODIFIED_BY="Harri Hemilä">
<P>Sore throat, stuffy nose, sneezing, watery nasal discharge, headache, aching back and limbs (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 06:31:44 +1000" MODIFIED_BY="Harri Hemilä"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Anderson-1972">
<CHAR_METHODS MODIFIED="2012-08-24 22:51:32 +1000" MODIFIED_BY="[Empty name]">
<P>Double-blind RCT. Regular supplementation trial. Duration 3 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-14 13:29:39 +1000" MODIFIED_BY="[Empty name]">
<P>Canadian adults, both sexes. 407 vitamin C; 411 placebo. Recruitment specified previous cold proneness in the winter months</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>1 g/d vitamin C and 3 g/d extra for the first 3 days of illness</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-05 10:12:00 +1000" MODIFIED_BY="[Empty name]">
<P>Incidence (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>), duration (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>) and severity (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-26 23:07:05 +1000" MODIFIED_BY="Jenny Bellorini">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anderson-1974a">
<CHAR_METHODS MODIFIED="2012-09-21 09:26:40 +1000" MODIFIED_BY="[Empty name]">
<P>Double-blind RCT. Duration 3 months. 4 regular supplementation, 2 treatment and 2 placebo arms</P>
<P>This entry reports a regular supplementation arm</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-26 23:07:19 +1000" MODIFIED_BY="Jenny Bellorini">
<P>Canadian adults, both sexes. Data for this arm include 277 vitamin C; 285 placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>1 g/d vitamin C and 4 g/d at onset of illness on the 1st day only</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-05 10:12:09 +1000" MODIFIED_BY="[Empty name]">
<P>Incidence (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>), duration (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>) and severity (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini">
<P>Problems with the placebo group #6; see p 40 (Table 16) in <LINK REF="REF-Hemil_x00e4_-2006a" TYPE="REFERENCE">Hemilä 2006a</LINK>. Therefore comparison in this review is restricted to the placebo group #4 which had close baseline values for "usual days indoors" and "usual days off work" and "contact with children" consistent with the baseline values in the 6 vitamin C groups</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Anderson-1974b">
<CHAR_METHODS MODIFIED="2012-08-24 22:54:24 +1000" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="STD-Anderson-1974a" TYPE="STUDY">Anderson 1974a</LINK>. Regular supplementation arm</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-14 13:29:55 +1000" MODIFIED_BY="[Empty name]">
<P>275 vitamin C</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>1 g/d vitamin C</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-05 10:12:20 +1000" MODIFIED_BY="[Empty name]">
<P>Incidence (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>), duration (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>) and severity (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-26 23:07:34 +1000" MODIFIED_BY="Jenny Bellorini">
<P>&#8212;<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Anderson-1974c">
<CHAR_METHODS MODIFIED="2012-09-18 21:40:02 +1000" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="STD-Anderson-1974a" TYPE="STUDY">Anderson 1974a</LINK>. Regular supplementation arm</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-14 13:29:59 +1000" MODIFIED_BY="[Empty name]">
<P>308 vitamin C</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>2 g/d vitamin C</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-05 10:12:26 +1000" MODIFIED_BY="[Empty name]">
<P>Incidence (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>), duration (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>) and severity (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-26 23:07:46 +1000" MODIFIED_BY="Jenny Bellorini">
<P>&#8212;<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Anderson-1974d">
<CHAR_METHODS MODIFIED="2012-08-24 22:52:22 +1000" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="STD-Anderson-1974a" TYPE="STUDY">Anderson 1974a</LINK>. Regular supplementation arm</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-14 13:30:05 +1000" MODIFIED_BY="[Empty name]">
<P>331 vitamin C</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>0.25 g/d vitamin C</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-05 10:12:38 +1000" MODIFIED_BY="[Empty name]">
<P>Incidence (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>), duration (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>) and severity (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-26 23:07:52 +1000" MODIFIED_BY="Jenny Bellorini">
<P>&#8212;<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Anderson-1974e">
<CHAR_METHODS MODIFIED="2009-11-14 13:43:17 +1000" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="STD-Anderson-1974a" TYPE="STUDY">Anderson 1974a</LINK>. Therapeutic arm</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-14 13:30:09 +1000" MODIFIED_BY="[Empty name]">
<P>275 vitamin C</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>4 g/d vitamin C on the 1st day of illness only</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-05 10:19:16 +1000" MODIFIED_BY="[Empty name]">
<P>Duration (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>) and severity (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-26 23:07:57 +1000" MODIFIED_BY="Jenny Bellorini">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Anderson-1974f">
<CHAR_METHODS MODIFIED="2009-11-14 13:43:30 +1000" MODIFIED_BY="[Empty name]">
<P>See for <LINK REF="STD-Anderson-1974a" TYPE="STUDY">Anderson 1974a</LINK>. Therapeutic arm</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-14 13:30:14 +1000" MODIFIED_BY="[Empty name]">
<P>308 vitamin C</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>8 g/d vitamin C on the 1st day of illness only</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-05 10:19:28 +1000" MODIFIED_BY="[Empty name]">
<P>Duration (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>) and severity (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-26 23:08:09 +1000" MODIFIED_BY="Jenny Bellorini">
<P>&#8212;<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Anderson-1975a">
<CHAR_METHODS MODIFIED="2012-09-21 09:17:54 +1000" MODIFIED_BY="Jenny Bellorini">
<P>Double-blind RCT. Therapeutic trial. Duration 15 weeks. 2 active and 1 placebo arm</P>
<P>This arm used vitamin C tablets</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-14 13:30:21 +1000" MODIFIED_BY="[Empty name]">
<P>Canadian adults, both sexes. 150 vitamin C; 146 placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Harri Hemilä">
<P>0.5 g weekly and 1.5 g/d on the 1st day of illness and 1 g/d for the next 4 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-05 10:19:35 +1000" MODIFIED_BY="[Empty name]">
<P>Duration (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>) and severity (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini">
<P>Indistinguishability of treatments: (p 824) "three types of medication were used: a 500-mg tablet containing sodium and calcium ascorbate in an approximate 2:1 ratio, a placebo tablet of the same appearance and taste, and a capsule containing 500 mg of ascorbic acid in sustained-release form. ... It was not possible to obtain placebo capsules that were truly indistinguishable from the active sustained-release form because the contents of the capsules (ascorbic acid pellets) proved prohibitively expensive to imitate. The explanatory notes provided to the subjects were therefore deliberately phrased to give the impression that, as with the tablets, half of the capsules contained a placebo preparation. This subterfuge was successful ... "</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-26 23:08:49 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Anderson-1975b">
<CHAR_METHODS MODIFIED="2009-11-14 13:44:38 +1000" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="STD-Anderson-1975a" TYPE="STUDY">Anderson 1975a</LINK>. This arm used vitamin C capsules</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-14 13:30:26 +1000" MODIFIED_BY="[Empty name]">
<P>152 vitamin C</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-05 13:58:12 +1000" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="STD-Anderson-1975a" TYPE="STUDY">Anderson 1975a</LINK>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-05 10:19:39 +1000" MODIFIED_BY="[Empty name]">
<P>Duration (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>) and severity (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-26 23:08:49 +1000" MODIFIED_BY="Jenny Bellorini">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Harri Hemilä" STUDY_ID="STD-Asfora-1977">
<CHAR_METHODS MODIFIED="2012-05-30 20:51:54 +1000" MODIFIED_BY="Harri Hemilä">
<P>Initiated as a double-blind trial. Therapeutic trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-08-22 17:45:44 +1000" MODIFIED_BY="Harri Hemilä">
<P>Participants with age range between 14 and 89. 42 vitamin C; 41 placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Harri Hemilä">
<P>6 g/d vitamin C for 5 d (total 30 g)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 06:46:35 +1000" MODIFIED_BY="Harri Hemilä">
<P>Clinical progress (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 06:42:00 +1000" MODIFIED_BY="Harri Hemilä"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Audera-2001a">
<CHAR_METHODS>
<P>Double-blind RCT. Therapeutic trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-14 13:30:29 +1000" MODIFIED_BY="[Empty name]">
<P>Australian adults of both sexes. 47 vitamin C; 42 placebo<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>1 g/d vitamin C for 3 days. Placebo group received 30 mg/d vitamin C daily for 3 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-05 10:19:45 +1000" MODIFIED_BY="[Empty name]">
<P>Duration (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>) and severity (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-26 23:08:57 +1000" MODIFIED_BY="Jenny Bellorini">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Audera-2001b">
<CHAR_METHODS MODIFIED="2009-11-14 13:45:39 +1000" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="STD-Audera-2001a" TYPE="STUDY">Audera 2001a</LINK>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-14 13:30:36 +1000" MODIFIED_BY="[Empty name]">
<P>50 vitamin C</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>3 g/d vitamin C for 3 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-05 10:19:50 +1000" MODIFIED_BY="[Empty name]">
<P>Duration (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>) and severity (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-26 23:09:02 +1000" MODIFIED_BY="Jenny Bellorini">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Bancalari-1984">
<CHAR_METHODS MODIFIED="2012-08-24 22:52:23 +1000" MODIFIED_BY="[Empty name]">
<P>Double-blind RCT. Regular supplementation trial. Duration 84 days</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-14 13:30:40 +1000" MODIFIED_BY="[Empty name]">
<P>Chilean school children, male and female, age 10 to 12 years. 32 vitamin C; 30 placebo<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>2 g/d vitamin C<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-05 10:13:10 +1000" MODIFIED_BY="[Empty name]">
<P>Incidence (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>) and duration (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-26 23:09:05 +1000" MODIFIED_BY="Jenny Bellorini">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Briggs-1984">
<CHAR_METHODS MODIFIED="2012-08-24 22:52:24 +1000" MODIFIED_BY="Jenny Bellorini">
<P>Double-blind RCT. Regular supplementation trial. Over 8 winters for 3 or 6 months of commitment by each volunteer</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-14 13:30:47 +1000" MODIFIED_BY="[Empty name]">
<P>Australian adults, male and female. 265 vitamin C; 263 placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>1 g/d vitamin C plus 4 g/d when respiratory symptoms occurred. Placebo group received 50 mg/d plus 200 mg/d when ill</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-05 13:58:47 +1000" MODIFIED_BY="[Empty name]">
<P>Incidence (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>) and duration (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-28 01:21:59 +1000" MODIFIED_BY="Harri Hemilä">
<P>SD for duration was not published and it was estimated as SD = mean</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Harri Hemilä" STUDY_ID="STD-Brown-1945">
<CHAR_METHODS MODIFIED="2012-05-30 20:24:55 +1000" MODIFIED_BY="Harri Hemilä">
<P>Placebo-controlled alternative-allocation trial. Therapeutic trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-08-22 17:45:57 +1000" MODIFIED_BY="Harri Hemilä">
<P>US college students. 179 vitamin C, 119 placebo; 206 with nose colds and 92 with throat colds</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Harri Hemilä">
<P>1 g vitamin C at first examination at the start of the cold and then 1 g 24 hours later</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-08-22 17:44:41 +1000" MODIFIED_BY="Harri Hemilä">
<P>"Colds that did not develop" meaning that the cold lasted only a day. In contrast, those who still had symptoms on the next day were considered to have a cold. (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-09-21 09:19:29 +1000" MODIFIED_BY="Harri Hemilä">
<P>Alternate allocation is not consistent with the distribution of participants in the vitamin C and placebo groups</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Carr-1981a">
<CHAR_METHODS MODIFIED="2012-08-24 22:52:24 +1000" MODIFIED_BY="Jenny Bellorini">
<P>Double-blind RCT. Regular supplementation trial. Duration 100 days. Identical twins: one group living together and the other living apart. This deals with those living together</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Australian males and females age range 14 to 64 years (mean 25 years). 51 twin pairs living together</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>1 g/d vitamin C. Both groups received a multi-vitamin tablet containing 70 mg/d vitamin C</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-05 10:13:19 +1000" MODIFIED_BY="[Empty name]">
<P>Incidence (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>), duration (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>) and severity (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-28 01:22:16 +1000" MODIFIED_BY="Harri Hemilä">
<P>SD for duration was not published and the SD was calculated from the P value</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Carr-1981b">
<CHAR_METHODS MODIFIED="2009-11-14 13:46:28 +1000" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="STD-Carr-1981a" TYPE="STUDY">Carr 1981a</LINK>. This deals with those living apart</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>44 twin pairs living apart</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>1 g/d vitamin C</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-05 10:13:26 +1000" MODIFIED_BY="[Empty name]">
<P>Incidence (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>), duration (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>) and severity (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-26 23:09:48 +1000" MODIFIED_BY="Jenny Bellorini">
<P>&#8212;<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Carson-1975">
<CHAR_METHODS MODIFIED="2012-08-24 22:52:25 +1000" MODIFIED_BY="[Empty name]">
<P>Double-blind RCT. Regular supplementation trial. Duration 40 days</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-14 13:31:07 +1000" MODIFIED_BY="[Empty name]">
<P>UK adults. 121 vitamin C; 123 placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>1 g/d vitamin C</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-05 10:20:11 +1000" MODIFIED_BY="[Empty name]">
<P>Incidence (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-26 23:09:53 +1000" MODIFIED_BY="Jenny Bellorini">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Charleston-1972">
<CHAR_METHODS MODIFIED="2012-08-24 22:52:26 +1000" MODIFIED_BY="Jenny Bellorini">
<P>Single-blind, not randomised. Regular supplementation trial. Duration 15 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-26 23:10:07 +1000" MODIFIED_BY="Jenny Bellorini">
<P>Staff and students of the University of Strathclyde, UK. 47 vitamin C; 43 placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>1 g/d vitamin C</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-05 13:49:24 +1000" MODIFIED_BY="[Empty name]">
<P>Incidence (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>) and duration (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-26 23:10:09 +1000" MODIFIED_BY="Jenny Bellorini">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Clegg-1975">
<CHAR_METHODS MODIFIED="2012-08-24 22:52:26 +1000" MODIFIED_BY="[Empty name]">
<P>Double-blind RCT. Regular supplementation trial. Duration 15 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-09-24 03:42:21 +1000" MODIFIED_BY="[Empty name]">
<P>Scottish students. 67 vitamin C; 70 placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>1 g/d vitamin C</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-05 13:49:29 +1000" MODIFIED_BY="[Empty name]">
<P>Incidence (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>) and duration (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-26 23:10:13 +1000" MODIFIED_BY="Jenny Bellorini">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Harri Hemilä" STUDY_ID="STD-Constantini-2011a">
<CHAR_METHODS MODIFIED="2012-09-21 09:20:16 +1000" MODIFIED_BY="Harri Hemilä">
<P>Double-blind RCT. Regular supplementation trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-09-26 04:21:10 +1000" MODIFIED_BY="Harri Hemilä">
<P>Male competitive swimmers in Israel. 12 vitamin C; 10 placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Harri Hemilä">
<P>1 g/day vitamin C for 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-30 22:13:02 +1000" MODIFIED_BY="Harri Hemilä">
<P>Incidence of colds. Duration of colds (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>), severity of colds (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-22 17:44:41 +1000" MODIFIED_BY="Harri Hemilä">
<P>Trial is divided into males and females since there was significant heterogeneity in vitamin C effect (P = 0.003)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Harri Hemilä" STUDY_ID="STD-Constantini-2011b">
<CHAR_METHODS MODIFIED="2012-09-21 09:20:31 +1000" MODIFIED_BY="Harri Hemilä">
<P>Double-blind RCT. Regular supplementation trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-09-21 09:20:33 +1000" MODIFIED_BY="Harri Hemilä">
<P>Female competitive swimmers in Israel. 9 vitamin C, 8 placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Harri Hemilä">
<P>1 g/day vitamin C for 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-30 22:14:03 +1000" MODIFIED_BY="Harri Hemilä">
<P>Incidence of colds. Duration of colds (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>), severity of colds (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-22 17:44:41 +1000" MODIFIED_BY="Harri Hemilä">
<P>Trial is divided into males and females since there was significant heterogeneity in vitamin C effect (P = 0.003)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Coulehan-1974a">
<CHAR_METHODS MODIFIED="2012-08-24 22:52:29 +1000" MODIFIED_BY="[Empty name]">
<P>Double-blind, alternate allocation. Regular supplementation trial. Duration 14 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-14 13:31:18 +1000" MODIFIED_BY="[Empty name]">
<P>USA. Students at a Navajo Indian school. Older residential students. 131 vitamin C; 128 placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>2 g/d vitamin C</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-05 13:49:34 +1000" MODIFIED_BY="[Empty name]">
<P>Incidence (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>) and duration (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-09-18 21:40:21 +1000" MODIFIED_BY="Harri Hemilä">
<P>SD for duration was not published and it was estimated as SD = mean</P>
<P>Personal communication (13 September 1995), about table 4: "... you are right, it is quite obvious that there is a typographical error. What I am referring to in those columns is the number of children without days of sickness, rather than the number of days as such. The title of Table 4 is correct, but the labelling of the columns is incorrect."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Coulehan-1974b">
<CHAR_METHODS MODIFIED="2010-01-26 23:10:31 +1000" MODIFIED_BY="Jenny Bellorini">
<P>See <LINK REF="STD-Coulehan-1974a" TYPE="STUDY">Coulehan 1974a</LINK>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-14 13:31:24 +1000" MODIFIED_BY="[Empty name]">
<P>Younger residential students. 190 vitamin C; 192 placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>1 g/d vitamin C</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-05 13:49:39 +1000" MODIFIED_BY="[Empty name]">
<P>Incidence (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>) and duration (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-18 20:37:34 +1000" MODIFIED_BY="Harri Hemilä">
<P>SD for duration was not published and it was estimated as SD = mean<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Coulehan-1976">
<CHAR_METHODS MODIFIED="2012-08-24 22:52:30 +1000" MODIFIED_BY="[Empty name]">
<P>Double-blind RCT. Regular supplementation trial. Duration 18 weeks in one school and 15 weeks in another</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-26 23:10:46 +1000" MODIFIED_BY="Jenny Bellorini">
<P>USA. Children at 2 Navajo Indian residential schools, age 6 to 15 years. Both sexes. 428 vitamin C; 428 placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>1 g/d vitamin C</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-05 13:49:44 +1000" MODIFIED_BY="[Empty name]">
<P>Incidence (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>) and duration (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-28 01:23:54 +1000" MODIFIED_BY="Harri Hemilä">
<P>SD for duration was not published and it was estimated as SD = mean</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Cowan-1942">
<CHAR_METHODS MODIFIED="2012-08-24 22:52:30 +1000" MODIFIED_BY="Jenny Bellorini">
<P>Placebo-controlled, allocation method not clear. Regular supplementation trial. Duration 28 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-26 23:10:58 +1000" MODIFIED_BY="Jenny Bellorini">
<P>US college students. 208 vitamin C; 155 placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>0.2 g/d vitamin C</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-05 10:20:28 +1000" MODIFIED_BY="[Empty name]">
<P>Incidence (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-28 01:24:32 +1000" MODIFIED_BY="Harri Hemilä">
<P>SD for duration was not published and it was estimated as SD = mean</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Cowan-1950">
<CHAR_METHODS MODIFIED="2010-01-26 23:11:16 +1000" MODIFIED_BY="Jenny Bellorini">
<P>Probably double-blind RCT. Alternate allocation. Therapeutic trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-26 23:11:10 +1000" MODIFIED_BY="Jenny Bellorini">
<P>US college students. 76 vitamin C; 77 placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>0.67 g of vitamin C for every 4 hours, with a maximum of 10 doses (total 6.7 grams); i.e. about 3 g/d for 2 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-05 10:20:37 +1000" MODIFIED_BY="[Empty name]">
<P>Duration (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-26 23:11:20 +1000" MODIFIED_BY="Jenny Bellorini">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Dahlberg-1944">
<CHAR_METHODS MODIFIED="2012-08-24 22:52:31 +1000" MODIFIED_BY="[Empty name]">
<P>Double-blind RCT. Regular supplementation trial. Duration 57 days</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-14 13:31:42 +1000" MODIFIED_BY="[Empty name]">
<P>Swedish army. 1259 vitamin C; 1266 placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>0.2 g/d vitamin C during the first 24 days; 50 mg/d thereafter</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-05 13:59:37 +1000" MODIFIED_BY="[Empty name]">
<P>Incidence <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-26 23:11:29 +1000" MODIFIED_BY="Jenny Bellorini">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Dick-1990">
<CHAR_METHODS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini">
<P>Double-blind, placebo-controlled trial. Brief abstract report of 3 experimental regular supplementation studies using intense exposure to infected volunteers</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-14 13:31:47 +1000" MODIFIED_BY="[Empty name]">
<P>USA, adult volunteers. 24 vitamin C; 24 placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>2 g/d vitamin C</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-09-23 18:08:10 +1000" MODIFIED_BY="[Empty name]">
<P>Shown in <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>. Not included in meta-analyses</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Harri Hemilä">
<P>3 abstracts, no full paper</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Harri Hemilä" STUDY_ID="STD-Elliot-1973">
<CHAR_METHODS MODIFIED="2012-08-24 22:52:33 +1000" MODIFIED_BY="Harri Hemilä">
<P>Double-blind RCT. Regular supplementation trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-08-22 17:46:45 +1000" MODIFIED_BY="Harri Hemilä">
<P>Members of the crew of a Polaris submarine; 37 vitamin C, 33 placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Harri Hemilä">
<P>2 g/d vitamin C for 10 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Harri Hemilä">
<P>Incidence of runny nose or sneezing. Man-days of morbidity for hoarseness, sore throats, non-productive coughs and productive coughs (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 06:39:48 +1000" MODIFIED_BY="Harri Hemilä"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Elwood-1976">
<CHAR_METHODS MODIFIED="2012-08-24 22:52:33 +1000" MODIFIED_BY="[Empty name]">
<P>Double-blind RCT. Regular supplementation trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-14 13:31:52 +1000" MODIFIED_BY="[Empty name]">
<P>Wales, young mothers. 339 vitamin C; 349 placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>1 g/d vitamin C</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-05 13:49:57 +1000" MODIFIED_BY="[Empty name]">
<P>Incidence (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>) and duration (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-26 23:11:41 +1000" MODIFIED_BY="Jenny Bellorini">
<P>&#8212;<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Elwood-1977">
<CHAR_METHODS>
<P>Double-blind RCT. Therapeutic trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-09-26 04:21:12 +1000" MODIFIED_BY="[Empty name]">
<P>Wales, young mothers. 145 colds treated with vitamin C; 119 with placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>4 g/d vitamin C daily for the first 2.5 days of illness</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-05 10:14:01 +1000" MODIFIED_BY="[Empty name]">
<P>Duration (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>)<BR/>Colds were classified either as simple or chest colds</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-09-26 04:21:13 +1000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Franz--1956">
<CHAR_METHODS MODIFIED="2012-08-24 22:52:34 +1000" MODIFIED_BY="Jenny Bellorini">
<P>Double-blind. Regular supplementation study. 2 x 2 factorial: vitamin C and flavonoids. Duration 3 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>Medical students and student nurses. 44 vitamin C; 45 no vitamin C<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>0.2 g/d vitamin C</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-05 10:14:11 +1000" MODIFIED_BY="[Empty name]">
<P>Incidence (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini">
<P>In the vitamin C group 93% (13/14) of colds were cured or improved in 5 days versus 53% (8/15) in the no vitamin C group (P = 0.03; see p 14 <LINK REF="REF-Hemil_x00e4_-2006a" TYPE="REFERENCE">Hemilä 2006a</LINK>)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Himmelstein-1998a">
<CHAR_METHODS MODIFIED="2012-08-24 22:52:35 +1000" MODIFIED_BY="[Empty name]">
<P>Double-blind RCT. Regular supplementation trial. Duration 3 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-14 13:32:11 +1000" MODIFIED_BY="[Empty name]">
<P>US sedentary people. 23 vitamin C; 25 placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>1 g/d vitamin C</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-05 10:14:18 +1000" MODIFIED_BY="[Empty name]">
<P>Incidence (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>), duration (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>) and severity (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini">
<P>A parallel trial with marathon runners is excluded from our analysis, because the drop-out rate was very high and divergent in the trial arms (<LINK REF="STD-Himmelstein-1998b" TYPE="STUDY">Himmelstein 1998b</LINK>)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Karlowski-1975a">
<CHAR_METHODS MODIFIED="2012-09-21 09:23:16 +1000" MODIFIED_BY="Jenny Bellorini">
<P>Double-blind RCT. 2 x 2 factorial: regular supplementation and therapeutic vitamin C. Duration 9 months. We compared 3 different arms with the placebo arm. This is regular supplementation arm</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-14 13:32:18 +1000" MODIFIED_BY="[Empty name]">
<P>USA, employees of the NIH. 44 vitamin C; 46 placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>3 g/d vitamin C</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-05 10:14:27 +1000" MODIFIED_BY="[Empty name]">
<P>Duration (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-09-24 04:03:55 +1000" MODIFIED_BY="Jenny Bellorini">
<P>The authors believed that the benefits observed were attributable to the breaking of the patient blind: "we discovered that some of the volunteers had tasted the contents of their capsules and professed to know whether they were taking the ascorbic acid or the placebo". However, their interpretation was later shown to be erroneous, <I>see</I> <LINK REF="REF-Hemil_x00e4_-1996a" TYPE="REFERENCE">Hemilä 1996a</LINK>, <LINK REF="REF-Hemil_x00e4_-2006a" TYPE="REFERENCE">Hemilä 2006a</LINK>, <LINK REF="REF-Hemil_x00e4_-2006c" TYPE="REFERENCE">Hemilä 2006c</LINK>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Karlowski-1975b">
<CHAR_METHODS MODIFIED="2012-09-21 09:23:50 +1000" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="STD-Karlowski-1975a" TYPE="STUDY">Karlowski 1975a</LINK>. This is regular supplementation plus therapeutic arm</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-14 13:32:22 +1000" MODIFIED_BY="[Empty name]">
<P>57 vitamin C</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>3 g/d vitamin C and 3 g/d therapeutic from the onset of cold for 5 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-05 13:50:09 +1000" MODIFIED_BY="[Empty name]">
<P>Incidence (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>) and duration (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-26 23:13:38 +1000" MODIFIED_BY="Jenny Bellorini">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Karlowski-1975c">
<CHAR_METHODS MODIFIED="2009-11-14 13:54:41 +1000" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="STD-Karlowski-1975a" TYPE="STUDY">Karlowski 1975a</LINK>. This is therapeutic only arm<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-14 13:32:26 +1000" MODIFIED_BY="[Empty name]">
<P>43 vitamin C</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>3 g/d therapeutic vitamin C from the onset of cold for 5 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-05 10:14:40 +1000" MODIFIED_BY="[Empty name]">
<P>Duration (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-26 23:15:35 +1000" MODIFIED_BY="Jenny Bellorini">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Liljefors-1972">
<CHAR_METHODS MODIFIED="2012-09-21 09:27:50 +1000" MODIFIED_BY="Jenny Bellorini">
<P>Double-blind RCT. Cross-over regular supplementation trial. Duration 2 + 2 weeks. In the first 2 weeks 25 participants received vitamin C and 18 placebo. As participants became ill they were removed from the trial and 3 people withdrew. In the second period, 18 received placebo and 8 vitamin C</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-14 13:32:33 +1000" MODIFIED_BY="[Empty name]">
<P>Swedish army males. 33 vitamin C; 33 placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini">
<P>2 g/d vitamin C for 2 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-05 10:14:48 +1000" MODIFIED_BY="[Empty name]">
<P>Incidence (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-26 23:15:48 +1000" MODIFIED_BY="Jenny Bellorini">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ludvigsson-1977a">
<CHAR_METHODS MODIFIED="2012-08-24 22:52:44 +1000" MODIFIED_BY="[Empty name]">
<P>Double-blind RCT. Regular supplementation trial. Duration 7 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-14 13:32:37 +1000" MODIFIED_BY="[Empty name]">
<P>Swedish school children. 80 vitamin C; 78 placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>1 g/d vitamin C. Placebo contained 30 mg/d vitamin C</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-05 10:14:56 +1000" MODIFIED_BY="[Empty name]">
<P>Incidence (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>), duration (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>) and severity (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-11-14 13:55:31 +1000" MODIFIED_BY="[Empty name]">
<P>Pilot study to <LINK REF="STD-Ludvigsson-1977b" TYPE="STUDY">Ludvigsson 1977b</LINK>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Ludvigsson-1977b">
<CHAR_METHODS MODIFIED="2012-08-24 22:52:44 +1000" MODIFIED_BY="[Empty name]">
<P>Double-blind RCT. Regular supplementation trial. Duration 3 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-14 13:32:43 +1000" MODIFIED_BY="[Empty name]">
<P>Swedish school children. 304 vitamin C; 311 placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>1 g/d vitamin C. Placebo contained 10 mg/d vitamin C</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-05 10:15:06 +1000" MODIFIED_BY="[Empty name]">
<P>Incidence (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>), duration (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>) and severity (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-26 23:16:00 +1000" MODIFIED_BY="Jenny Bellorini">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Miller-1977a">
<CHAR_METHODS MODIFIED="2012-08-24 22:52:45 +1000" MODIFIED_BY="Jenny Bellorini">
<P>Double-blind RCT. Regular supplementation trial. Identical twins. Duration 5 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>US school children. 12 twin pairs "high body weight"</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>1 g/d vitamin C. Placebo contained 50 mg/d vitamin C</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-05 10:15:12 +1000" MODIFIED_BY="[Empty name]">
<P>Incidence (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>), duration (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>) and severity (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-26 23:16:28 +1000" MODIFIED_BY="Jenny Bellorini">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Miller-1977b">
<CHAR_METHODS MODIFIED="2009-11-14 13:56:07 +1000" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="STD-Miller-1977a" TYPE="STUDY">Miller 1977a</LINK>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>12 twin pairs "medium body weight"</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>0.75 g/d vitamin C</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-05 10:15:18 +1000" MODIFIED_BY="[Empty name]">
<P>Incidence (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>), duration (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>) and severity (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-26 23:16:34 +1000" MODIFIED_BY="Jenny Bellorini">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Miller-1977c">
<CHAR_METHODS MODIFIED="2009-11-14 13:56:25 +1000" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="STD-Miller-1977a" TYPE="STUDY">Miller 1977a</LINK>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>20 twin pairs "low body weight"</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>0.5 g/d vitamin C</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-05 10:15:24 +1000" MODIFIED_BY="[Empty name]">
<P>Incidence (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>), duration (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>) and severity (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-26 23:16:42 +1000" MODIFIED_BY="Jenny Bellorini">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Moolla-1996a">
<CHAR_METHODS MODIFIED="2012-08-24 22:52:46 +1000" MODIFIED_BY="[Empty name]">
<P>Double-blind RCT. Regular supplementation trial. Duration 6 weeks before and 2 weeks after the race</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-14 13:33:02 +1000" MODIFIED_BY="[Empty name]">
<P>South Africa. Ultra marathon runners. 13 vitamin C; 19 placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>0.25 g/d vitamin C</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-05 10:21:28 +1000" MODIFIED_BY="[Empty name]">
<P>Incidence (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-11-14 13:33:04 +1000" MODIFIED_BY="[Empty name]">
<P>1/4 of those who reported respiratory symptoms in the vitamin C group, and 8/13 of those who reported respiratory symptoms in the placebo group, reported that their respiratory symptoms were severe (P = 0.08)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Moolla-1996b">
<CHAR_METHODS MODIFIED="2009-11-14 13:56:54 +1000" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="STD-Moolla-1996a" TYPE="STUDY">Moolla 1996a</LINK>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-14 13:33:07 +1000" MODIFIED_BY="[Empty name]">
<P>Sedentary controls for marathon runners. 11 vitamin C; 19 placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>0.25 g/d vitamin C</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-05 10:15:34 +1000" MODIFIED_BY="[Empty name]">
<P>Incidence (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-26 23:17:10 +1000" MODIFIED_BY="Jenny Bellorini">
<P>0/6 of those who reported respiratory symptoms in the vitamin C group and 4/7 of those who reported respiratory symptoms in the placebo group reported that their respiratory symptoms were severe (P = 0.02)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Peters-1993a">
<CHAR_METHODS MODIFIED="2012-08-24 22:52:46 +1000" MODIFIED_BY="[Empty name]">
<P>Double-blind RCT. Regular supplementation trial. Duration 3 weeks before and 2 weeks after the race</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-26 23:16:59 +1000" MODIFIED_BY="Jenny Bellorini">
<P>South Africa. Ultra marathon runners. 43 vitamin C; 41 placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>0.6 g/d vitamin C</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-05 13:50:36 +1000" MODIFIED_BY="[Empty name]">
<P>Incidence (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>) and duration (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-26 23:17:04 +1000" MODIFIED_BY="Jenny Bellorini">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Peters-1993b">
<CHAR_METHODS MODIFIED="2009-11-14 13:57:20 +1000" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="STD-Peters-1993a" TYPE="STUDY">Peters 1993a</LINK>.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-14 13:33:17 +1000" MODIFIED_BY="[Empty name]">
<P>Sedentary controls for marathon runners. 34 vitamin C; 39 placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>0.6 g/d vitamin C</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-05 13:50:41 +1000" MODIFIED_BY="[Empty name]">
<P>Incidence (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>) and duration (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-26 23:17:20 +1000" MODIFIED_BY="Jenny Bellorini">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Peters-1996a">
<CHAR_METHODS MODIFIED="2012-08-24 22:52:47 +1000" MODIFIED_BY="[Empty name]">
<P>Double-blind RCT. Regular supplementation trial. Duration 21 days prior to the race</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-14 13:33:21 +1000" MODIFIED_BY="[Empty name]">
<P>South Africa. Ultra marathon runners. 44 vitamin C; 47 placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>0.5 g/d vitamin C</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-05 13:50:49 +1000" MODIFIED_BY="[Empty name]">
<P>Incidence (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>) and duration (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-28 01:43:54 +1000" MODIFIED_BY="Harri Hemilä">
<P>SD for duration was not published and it was estimated as SD = mean</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Peters-1996b">
<CHAR_METHODS MODIFIED="2009-11-14 13:57:43 +1000" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="STD-Peters-1996a" TYPE="STUDY">Peters 1996a</LINK>.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-14 13:33:25 +1000" MODIFIED_BY="[Empty name]">
<P>South Africa. Family controls for marathon runners. 41 vitamin C; 45 placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>0.5 g/d vitamin C</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-05 13:50:55 +1000" MODIFIED_BY="[Empty name]">
<P>Incidence (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>) and duration (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-26 23:17:37 +1000" MODIFIED_BY="Jenny Bellorini">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Pitt-1979">
<CHAR_METHODS MODIFIED="2012-08-24 22:52:47 +1000" MODIFIED_BY="[Empty name]">
<P>Double-blind RCT. Regular supplementation trial. Duration 8 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-26 23:17:45 +1000" MODIFIED_BY="Jenny Bellorini">
<P>USA marine recruits. 331 vitamin C; 343 placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>2 g/d vitamin C</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-05 10:15:45 +1000" MODIFIED_BY="[Empty name]">
<P>Incidence (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>), duration (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>) and severity (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-28 01:44:20 +1000" MODIFIED_BY="Harri Hemilä">
<P>SD for duration was not published and it was estimated as SD = mean</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 02:50:20 +1000" MODIFIED_BY="Harri Hemilä" STUDY_ID="STD-Regnier-1968">
<CHAR_METHODS MODIFIED="2012-09-21 09:29:38 +1000" MODIFIED_BY="Harri Hemilä">
<P>Initiated as a double-blind trial, but changed to a single-blind</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-08-22 17:47:06 +1000" MODIFIED_BY="Harri Hemilä">
<P>The number of participants for the double-blind part is not reported. In the single-blind stage, 22 subjects were included "The majority were adults whose ages ranged from 30 to 50, with the extremes being five children younger than 12" (p 949)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 02:50:20 +1000" MODIFIED_BY="Harri Hemilä">
<P>For the double-blind part: "ascorbic acid alone, ascorbic acid plus bioflavonoids, flavonoids only and, fourthly, a lactose placebo with the two 'vitamins' present either alone or together in 0.2 g quantities". In the single-blind stage, 0.6 g of vitamin C was administered every 3 h</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-30 20:44:37 +1000" MODIFIED_BY="Harri Hemilä">
<P>Clinical progress (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 06:48:49 +1000" MODIFIED_BY="Harri Hemilä"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ritzel-1961">
<CHAR_METHODS MODIFIED="2012-08-24 22:52:48 +1000" MODIFIED_BY="[Empty name]">
<P>Double-blind RCT. Regular supplementation trial. Duration 2 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-14 13:33:37 +1000" MODIFIED_BY="[Empty name]">
<P>Children attending ski school in Swiss Alps. 139 vitamin C; 140 placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>1 g/d vitamin C</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-05 13:51:03 +1000" MODIFIED_BY="[Empty name]">
<P>Incidence (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>) and duration (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-28 01:44:33 +1000" MODIFIED_BY="Harri Hemilä">
<P>SD for duration was not published and the SD was calculated from the P value</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Sabiston-1974">
<CHAR_METHODS MODIFIED="2012-08-24 22:52:48 +1000" MODIFIED_BY="[Empty name]">
<P>Double-blind RCT. Regular supplementation trial. Duration 2 to 3 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-14 13:33:43 +1000" MODIFIED_BY="[Empty name]">
<P>Canadian male military recruits during subarctic winter exercises. 56 vitamin C; 56 placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>1 g/d vitamin C</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-05 13:51:08 +1000" MODIFIED_BY="[Empty name]">
<P>Incidence (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>) and duration (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini">
<P>Personal communication from Manny Radomski (12 September 2009): "Tent group commanders [who were responsible for distributing the pills and recording the distribution] did not know what was in the vials... We [the authors] collected the data by symptoms on T-scan cards. We did not 'break the code' until after all cards had been assessed."<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Sasazuki-2006">
<CHAR_METHODS MODIFIED="2012-08-24 22:52:49 +1000" MODIFIED_BY="[Empty name]">
<P>Double-blind RCT. Regular supplementation trial. Duration 3.5 years</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-14 13:33:51 +1000" MODIFIED_BY="[Empty name]">
<P>Japanese males and females, mean age 57 years. 140 vitamin C; 133 placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>0.5 g/d vitamin C. Placebo contained 50 mg/d vitamin C</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-05 10:15:56 +1000" MODIFIED_BY="[Empty name]">
<P>Incidence (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>)<BR/>ITT results are shown<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-26 23:18:49 +1000" MODIFIED_BY="Jenny Bellorini">
<P>Additional data provided by authors<BR/>Duration and severity of colds were reported, but they were recorded on the period after supplementation had been stopped, with no rationale described for such a comparison</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Harri Hemilä" STUDY_ID="STD-Scheunert-1949">
<CHAR_METHODS MODIFIED="2012-05-30 20:42:45 +1000" MODIFIED_BY="Harri Hemilä">
<P>Prophylactic trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-30 20:40:38 +1000" MODIFIED_BY="Harri Hemilä">
<P>1066 factory workers in Germany between November 1942 and June 1943</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Harri Hemilä">
<P>Different doses of vitamin C were administered to 4 study groups (range 0.02 to 0.3 g/d) so that the lowest dose arm(s) might be used as the control group. Duration of the study was 244 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-08-22 17:44:42 +1000" MODIFIED_BY="Harri Hemilä">
<P>The common cold [Erkältungskrankheiten] was one of the outcomes and "The percentage monthly duration of people sick with the common cold" is listed (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 06:26:10 +1000" MODIFIED_BY="Harri Hemilä"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Schwartz-1973">
<CHAR_METHODS MODIFIED="2012-09-21 09:27:13 +1000" MODIFIED_BY="[Empty name]">
<P>Double-blind experimental regular supplementation study with nasal instillation of virus after 2 weeks of pre-treatment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-14 13:33:56 +1000" MODIFIED_BY="[Empty name]">
<P>Male US prison volunteers. 11 vitamin C; 10 placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>3 g/d vitamin C</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-09-23 18:08:52 +1000" MODIFIED_BY="[Empty name]">
<P>Shown in <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>. Not included in meta-analyses</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-26 23:18:54 +1000" MODIFIED_BY="Jenny Bellorini">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Harri Hemilä" STUDY_ID="STD-Tebrock-1956">
<CHAR_METHODS MODIFIED="2012-05-30 20:16:03 +1000" MODIFIED_BY="Harri Hemilä">
<P>Double-blinded alternative-allocation trial. Therapeutic trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Harri Hemilä">
<P>Adults from outpatient industrial clinics, and some college, seminary and private patients. 956 vitamin C, 960 placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Harri Hemilä">
<P>0.2 g/d vitamin C or/and flavonoids in a 2 x 2 factorial design for 3 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-30 20:17:47 +1000" MODIFIED_BY="Harri Hemilä">
<P>Running nose, sneezing, hoarseness, cough, malaise, headache, postnasal drip, sore throat (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-09-23 17:57:56 +1000" MODIFIED_BY="Harri Hemilä"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Tyrrell-1977">
<CHAR_METHODS MODIFIED="2009-11-16 14:52:02 +1000" MODIFIED_BY="[Empty name]">
<P>Double-blind RCT. Therapeutic trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-14 13:34:00 +1000" MODIFIED_BY="[Empty name]">
<P>UK, both sexes. 274 episodes treated with vitamin C; 329 placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>4 g/d vitamin C for the first 2.5 days of illness</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-05 12:44:04 +1000" MODIFIED_BY="[Empty name]">
<P>Duration (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>) and severity (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>) </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-26 23:19:00 +1000" MODIFIED_BY="Jenny Bellorini">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Van-Straten-2002">
<CHAR_METHODS MODIFIED="2012-08-24 22:52:52 +1000" MODIFIED_BY="[Empty name]">
<P>Double-blind RCT. Regular supplementation trial. Duration 60 days</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-14 13:34:04 +1000" MODIFIED_BY="[Empty name]">
<P>UK, both sexes. 84 vitamin C; 84 placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>1 g/d vitamin C. Ester-C ascorbate, a form that, according to authors, "allows cells to efficiently absorb and retain high levels of vitamin"</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-05 13:51:44 +1000" MODIFIED_BY="[Empty name]">
<P>Incidence (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>) and duration (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-26 23:19:04 +1000" MODIFIED_BY="Jenny Bellorini">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Walker-1967">
<CHAR_METHODS MODIFIED="2012-09-21 09:27:19 +1000" MODIFIED_BY="[Empty name]">
<P>Experimental regular supplementation study in which healthy volunteers were intranasally inoculated with viruses. Duration 3 days before and 6 days after nasal instillation of virus</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-14 13:34:10 +1000" MODIFIED_BY="[Empty name]">
<P>UK adults both sexes. 47 vitamin C; 44 placebo<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini">
<P>3 g/d vitamin C</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-09-23 18:09:07 +1000" MODIFIED_BY="Jenny Bellorini">
<P>Shown in <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>. Not included in meta-analyses</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-26 23:19:19 +1000" MODIFIED_BY="Jenny Bellorini">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wilson-1973a">
<CHAR_METHODS MODIFIED="2012-08-24 22:52:53 +1000" MODIFIED_BY="[Empty name]">
<P>Double-blind RCT. Regular supplementation trial. Duration 9 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-14 13:34:16 +1000" MODIFIED_BY="[Empty name]">
<P>UK boarding school girls. 70 vitamin C; 58 placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>0.2 g/d vitamin C</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-05 10:16:11 +1000" MODIFIED_BY="[Empty name]">
<P>Incidence (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>), duration (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>) and severity (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-28 01:46:51 +1000" MODIFIED_BY="Harri Hemilä">
<P>Complicated classification system makes comparison with other trials difficult</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Wilson-1973b">
<CHAR_METHODS MODIFIED="2009-11-14 17:22:06 +1000" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="STD-Wilson-1973a" TYPE="STUDY">Wilson 1973a</LINK>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-14 13:34:22 +1000" MODIFIED_BY="[Empty name]">
<P>UK boarding school boys. 88 vitamin C; 86 placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>0.2 g/d vitamin C</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-05 10:16:16 +1000" MODIFIED_BY="[Empty name]">
<P>Incidence (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>), duration (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>) and severity (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-26 23:19:35 +1000" MODIFIED_BY="Jenny Bellorini">
<P>&#8212;<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>g/d: grams per day<BR/>h: hours<BR/>mg/d: milligrams per day<BR/>SD: standard deviation<BR/>ITT: intention-to-treat<BR/>NIH: National Institutes for Health<BR/>RCT: randomised controlled trial<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2012-12-12 07:09:25 +1000" MODIFIED_BY="Jenny Bellorini" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Audera-2001c">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>Vitamin C was administered with flavonoids. Thus the comparison was not on vitamin C specifically. There was no difference between placebo and 3 g/day vitamin C + flavonoid groups. 2 other arms are included in our analyses (<LINK REF="STD-Audera-2001a" TYPE="STUDY">Audera 2001a</LINK>; <LINK REF="STD-Audera-2001b" TYPE="STUDY">Audera 2001b</LINK>)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Baird-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini">
<P>Low dose. 362 UK students aged 17 to 25 years were studied for 72 days in a double-blind RCT of regular supplementation. A daily drink contained either synthetic orange juice without ascorbic acid, synthetic juice with 0.08 g/d of ascorbic acid added, or natural orange juice with 0.08 g/d of ascorbic acid added. There was a highly significant reduction in common cold incidence among males (RR 0.63; 95% CI 0.50 to 0.78) but not in females (RR 1.24; 95% CI 0.95 to 1.61) (<LINK REF="REF-Hemil_x00e4_-1997a" TYPE="REFERENCE">Hemilä 1997a</LINK> and <LINK REF="REF-Hemil_x00e4_-2006a" TYPE="REFERENCE">Hemilä 2006a</LINK>). The heterogeneity between sexes was highly significant (<LINK REF="REF-Hemil_x00e4_-2008" TYPE="REFERENCE">Hemilä 2008</LINK>). The benefit of low-dose vitamin C supplementation may be explained by low dietary vitamin C intake in the UK (<LINK REF="REF-Hemil_x00e4_-1997a" TYPE="REFERENCE">Hemilä 1997a</LINK>)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Harri Hemilä" STUDY_ID="STD-Barnes-1961">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Harri Hemilä">
<P>No placebo comparison. A trial in the USA. A multivitamin preparation that included 0.2 g/d vitamin C was given to 23 members (10 boys, 13 girls) of a basketball team for 7 weeks; medication being received from the coaches. The cold outcomes were compared with those of 16 people (8 boys, 8 girls) of the same age and background. The controls reported to the coaches daily. Days sick from cold were counted in each group. The study took place over 8 weeks during which the basketball players took medication on an average of 43 days. The only usable outcome was "mean days per person" in the vitamin C group 1.48 (SD 2.65) and in the control group 6.87 (SD 8.57). However, there are serious doubts about the comparability of the controls who were apparently not basketball players</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Harri Hemilä" STUDY_ID="STD-Bartley-1953">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Harri Hemilä">
<P>Low dose. "The volunteers did not know to which group they belonged, nor did the physicians responsible for the clinical investigations. All the volunteers were given each day 7 supplementary tablets of identical taste and appearance, some containing vitamin C, others being dummies" (p 8). 3 participants received 0.07 g/d vitamin C and a total of 14 cold episodes were recorded among them in the follow up, 4 participants were administered 0.01 g/d vitamin C (18 colds), and 6 persons were administered no vitamin C (30 colds). The geometric mean length of colds in vitamin C deprived participants was 6.4 days, and in non-deprived participants 3.3 days, and the authors concluded "such evidence as there is definitely confirms the hypothesis that the absence of vitamin C tended to cause colds to last longer" (p 43)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Bendel-1955">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini">
<P>No placebo comparison and the control group was not parallel. 120 children at a summer camp for 2 weeks were given 0.2 g/d vitamin C daily and their cold experience was compared with that of participants in an earlier camp</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bergquist-1943">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>Low dose. A Swedish trial involving supplementation with only 0.03 g/d vitamin C</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bessel_x002d_Lorck-1958">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>No placebo comparison. Berlin school children in a skiing camp. Abridged summary: "26 subjects received 1 g of vitamin C daily during the first 9 days. Under this regimen only one student became sick. In 20 participants the regular supplementation did not begin until the 9th day. At this point in time 9 students were already sick with upper respiratory infections; and 3 others became infected within the first 3 days after the trial began. All of those who were sick were treated with 2 g of vitamin C per day. Within just 24 hours a rapid improvement in the general condition was evident so that elevated physical demands were met without particular difficulty. All participants displayed a significant increase in their capacity to perform physical activities while being treated with vitamin C." The Bessel-Lorck paper is available as a translation. This trial motivated <LINK REF="STD-Ritzel-1961" TYPE="STUDY">Ritzel 1961</LINK> to carry out his RCT (see Analysis 1.1.2)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-09-21 09:35:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bibile-1966">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-21 09:35:44 +1000" MODIFIED_BY="[Empty name]">
<P>This was cited by <LINK REF="REF-Kleijnen-1989" TYPE="REFERENCE">Kleijnen 1989</LINK>, but we have been unable to retrieve a copy through library orders</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Boines-1956">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo comparison. Study of poliomyelitis sufferers</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chavance-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>Low dose. Double-blind RCT of 0.09 g/d vitamin C in elderly participants. No benefit was demonstrated<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Cuendet-1946">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini">
<P>No placebo comparison. 200 children in 3 mountain parishes took vitamin C supplements up to 0.3 g/d</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Harri Hemilä" STUDY_ID="STD-Dyllick-1967">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Harri Hemilä">
<P>No placebo comparison. Cohort workplace study involving 200 recipients of 1 g/d of vitamin C whose respiratory experience was compared with those not receiving vitamin C</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Fogelholm-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini">
<P>Vitamin C in combination with other antioxidants. Finnish study involving 75 athletes. RCT of 1 g/d vitamin C with 0.3 g/d vitamin E and 0.09 g/d ubiquinone versus an undescribed placebo. Methodologically strong study but was excluded from the meta-analyses because there were 3 antioxidants in the active preparation which were each hypothesised to be potentially beneficial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Glazebrook-1942">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>Low dose. 1500 boys at a UK boarding school during World War II. The participants were allocated as administrative units and not on an individual basis. Vitamin C (0.05 to 0.3 g/d) was added to cocoa and milk in the kitchen to a group of 335 boys. Although ineffective powder was not added to the drinks of the control group, the control drinks served functionally as a placebo. The number of participants who had colds was 17% lower in the vitamin C group (72/335 versus 286/1100; P = 0.10, <LINK REF="REF-Hemil_x00e4_-2004" TYPE="REFERENCE">Hemilä 2004</LINK>) and the number of participants admitted to hospital because of the common cold was 23% lower (59/335 versus 253/1100; P = 0.04, <LINK REF="REF-Hemil_x00e4_-2011" TYPE="REFERENCE">Hemilä 2011</LINK>)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Gormly-1977">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini">
<P>No placebo comparison. 14 males of 29 members of a 1-year Antarctic expedition took 1 g/d vitamin C throughout their stay. Their health outcomes were compared with the remaining group who did not take vitamin C, and no difference was observed between the 2 groups</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Gorton-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini">
<P>No placebo comparison and the control group not parallel. A technical training facility in Chile was the site of this cohort study with 250 trainees who were given 3 g/d vitamin C during their 10-day course. The vitamin C group was compared with a control group of 463 students who had been monitored in a somewhat similar way during the previous year (sic)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-01-26 23:22:22 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Himmelstein-1998b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-01-26 23:22:22 +1000" MODIFIED_BY="Jenny Bellorini">
<P>There was an extreme and divergent drop-out rate in the <LINK REF="STD-Himmelstein-1998b" TYPE="STUDY">Himmelstein 1998b</LINK> trial. They started with 52 marathon runners in 2 groups, but 42% (22 of 52) of the vitamin C group, and 75% (38 of 52) of the placebo group dropped out during the trial (P = 0.003)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hopfeng_x00e4_rtner-1944">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>Low dose. Long-term hospital baby study in which supplementation of 0.05 g/d vitamin C was used</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hunt-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>Not focused on the common cold. Double-blind RCT. 57 elderly UK patients suffering from acute bronchitis or pneumonia who were admitted to hospital for treatment were administered 0.2 g/d of vitamin C (see <LINK REF="REF-Hemil_x00e4_-2007" TYPE="REFERENCE">Hemilä 2007</LINK>)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Kimbarowski-1967">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini">
<P>No placebo comparison. 216 Russian soldiers were hospitalised because of influenza A. 114 were administered 0.2 g/d vitamin C. There were 2 cases of pneumonia in the vitamin C group in comparison with 10 cases in the control group. Thus this trial found a lower incidence of complications of viral respiratory infection (<LINK REF="REF-Hemil_x00e4_-2004" TYPE="REFERENCE">Hemilä 2004</LINK>; <LINK REF="REF-Hemil_x00e4_-2007" TYPE="REFERENCE">Hemilä 2007</LINK>)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Koytchev-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>No placebo comparison. Double-blind RCT involving 1167 participants. 4 arms, colds treated with 0.9 g/d vitamin C plus or minus antihistamine and antipyretics</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Harri Hemilä" STUDY_ID="STD-Maggini-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Harri Hemilä">
<P>Vitamin C in combination with zinc. 1 g/d vitamin C and 10 mg/d zinc for 94 participants. The combination decreased the duration or rhinorrhoea</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Masek-1974">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini">
<P>Low dose. Two large studies of Czech coal miners comparing 0.1 g/d vitamin C and placebo over a period of 4 or 8 weeks. Excluded both on the basis of low dose and inadequacy of data for inclusion in meta-analyses. The trials were neither randomised nor blind. Authors claimed benefits to the active recipients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Niemi-1951">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Jenny Bellorini">
<P>Low dose and no placebo comparison. Finnish study with military recruits. 1036 people were observed during a 3-month period. 516 were administered 0.1 g/d vitamin C. No benefits of vitamin C</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-01-26 23:22:59 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Peters-1940">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-01-26 23:22:59 +1000" MODIFIED_BY="Jenny Bellorini">
<P>No placebo comparison. Short-term baby supplementation study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-12-12 07:09:25 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schmidt-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-12-12 07:09:25 +1000" MODIFIED_BY="[Empty name]">
<P>Vitamin C in combination with vitamin D, folic acid and selenium. Double-blind, placebo-controlled RCT with 192 patients with recurrent colds. Authors claimed benefits to the active recipients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>g/d: grams per day<BR/>RCT: randomised controlled trial<BR/>RR: risk ratio<BR/>SD: standard deviation</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2009-09-18 21:14:52 +1000" MODIFIED_BY="Harri Hemilä" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Harri Hemilä">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:30:19 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abbott-1968">
<DESCRIPTION>
<P>Randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:30:35 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-1972">
<DESCRIPTION>
<P>Randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:30:51 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-1974a">
<DESCRIPTION>
<P>Randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-23 17:20:23 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-1974b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-23 17:21:04 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-1974c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-23 17:21:24 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-1974d">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-23 17:21:31 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-1974e">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-23 17:21:57 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-1974f">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:30:52 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-1975a">
<DESCRIPTION>
<P>Randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-23 17:23:19 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-1975b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 04:21:08 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Asfora-1977">
<DESCRIPTION>
<P>"preparations were given to alternate patients"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:30:53 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Audera-2001a">
<DESCRIPTION>
<P>Randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-23 17:25:11 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Audera-2001b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:30:54 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bancalari-1984">
<DESCRIPTION>
<P>Randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:30:54 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Briggs-1984">
<DESCRIPTION>
<P>Randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 04:21:09 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brown-1945">
<DESCRIPTION>
<P>"alternately"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:30:55 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carr-1981a">
<DESCRIPTION>
<P>Randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-23 17:29:35 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carr-1981b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:30:55 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carson-1975">
<DESCRIPTION>
<P>Randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Charleston-1972">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:30:56 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Clegg-1975">
<DESCRIPTION>
<P>Randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 04:21:10 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Constantini-2011a">
<DESCRIPTION>
<P>"randomly selected plastic bottle"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-23 17:32:58 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Constantini-2011b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 04:21:10 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Coulehan-1974a">
<DESCRIPTION>
<P>Allocation was "alternatively, from an alphabetical listing by classroom to one of two study groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-23 18:09:44 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Coulehan-1974b">
<DESCRIPTION>
<P>?</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:30:57 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Coulehan-1976">
<DESCRIPTION>
<P>Randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 04:21:11 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cowan-1942">
<DESCRIPTION>
<P>"The students were assigned alternately and without selection to an experimental and to a control group." However, the discrepancy in the size of trial arms is not consistent with alternate allocation, see above (208 versus 155)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 04:21:11 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cowan-1950">
<DESCRIPTION>
<P>"The medicaments were given out in strict rotation to the students as they enrolled"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:30:57 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dahlberg-1944">
<DESCRIPTION>
<P>Randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 04:21:12 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dick-1990">
<DESCRIPTION>
<P>?</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:30:58 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Elliot-1973">
<DESCRIPTION>
<P>Randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:30:58 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Elwood-1976">
<DESCRIPTION>
<P>Randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:30:59 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Elwood-1977">
<DESCRIPTION>
<P>Randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 04:21:13 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Franz--1956">
<DESCRIPTION>
<P>"Groups were assigned in rotation"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:31:00 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Himmelstein-1998a">
<DESCRIPTION>
<P>Randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:31:00 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Karlowski-1975a">
<DESCRIPTION>
<P>Randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-23 17:45:12 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Karlowski-1975b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-23 17:45:19 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Karlowski-1975c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:31:01 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Liljefors-1972">
<DESCRIPTION>
<P>Randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:31:02 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ludvigsson-1977a">
<DESCRIPTION>
<P>Randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:31:02 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ludvigsson-1977b">
<DESCRIPTION>
<P>Randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:31:04 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Miller-1977a">
<DESCRIPTION>
<P>Randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-23 17:48:12 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Miller-1977b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-23 17:48:34 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Miller-1977c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:31:05 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moolla-1996a">
<DESCRIPTION>
<P>Randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-23 17:49:24 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moolla-1996b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:31:06 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peters-1993a">
<DESCRIPTION>
<P>Randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:31:07 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peters-1993b">
<DESCRIPTION>
<P>Randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:31:07 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peters-1996a">
<DESCRIPTION>
<P>Randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:31:08 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peters-1996b">
<DESCRIPTION>
<P>Randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:31:09 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pitt-1979">
<DESCRIPTION>
<P>Randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:33:21 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Regnier-1968">
<DESCRIPTION>
<P>Allocation method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:31:10 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ritzel-1961">
<DESCRIPTION>
<P>Randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:31:10 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sabiston-1974">
<DESCRIPTION>
<P>Randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:31:11 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sasazuki-2006">
<DESCRIPTION>
<P>Randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 04:21:17 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Scheunert-1949">
<DESCRIPTION>
<P>?</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 04:21:17 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schwartz-1973">
<DESCRIPTION>
<P>?</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tebrock-1956">
<DESCRIPTION>
<P>"assigned in rotation" to 8 groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:31:12 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tyrrell-1977">
<DESCRIPTION>
<P>Randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:31:12 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-Straten-2002">
<DESCRIPTION>
<P>Randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 04:21:18 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Walker-1967">
<DESCRIPTION>
<P>?</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:31:13 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wilson-1973a">
<DESCRIPTION>
<P>Randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-23 18:00:20 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wilson-1973b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2012-09-26 08:33:49 +1000" MODIFIED_BY="Harri Hemilä" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:31:38 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Abbott-1968">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:31:41 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Anderson-1972">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:31:42 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Anderson-1974a">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-23 17:20:57 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Anderson-1974b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-15 21:24:00 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Anderson-1974c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-15 21:24:20 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Anderson-1974d">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-15 21:24:45 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Anderson-1974e">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-23 17:22:58 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Anderson-1974f">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:31:44 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Anderson-1975a">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-15 21:25:21 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Anderson-1975b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:31:53 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Asfora-1977">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:31:55 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Audera-2001a">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-15 21:25:41 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Audera-2001b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:31:56 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Bancalari-1984">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:31:59 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Briggs-1984">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-18 16:18:35 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brown-1945">
<DESCRIPTION>
<P>?</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:32:16 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Carr-1981a">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-15 20:16:13 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Carr-1981b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:32:18 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Carson-1975">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 04:21:10 +1000" MODIFIED_BY="Harri Hemilä" RESULT="UNKNOWN" STUDY_ID="STD-Charleston-1972">
<DESCRIPTION>
<P>?</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:32:20 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Clegg-1975">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:32:22 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Constantini-2011a">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 04:21:10 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Constantini-2011b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:32:24 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Coulehan-1974a">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-15 20:20:07 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Coulehan-1974b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:32:26 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Coulehan-1976">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 04:21:11 +1000" MODIFIED_BY="Harri Hemilä" RESULT="UNKNOWN" STUDY_ID="STD-Cowan-1942">
<DESCRIPTION>
<P>?</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:32:31 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Cowan-1950">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:32:34 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Dahlberg-1944">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:32:37 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Dick-1990">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:32:40 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Elliot-1973">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:32:41 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Elwood-1976">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:32:44 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Elwood-1977">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:32:46 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Franz--1956">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:32:47 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Himmelstein-1998a">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:32:50 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Karlowski-1975a">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-15 21:26:44 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Karlowski-1975b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-15 21:27:17 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Karlowski-1975c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:32:52 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Liljefors-1972">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:32:54 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Ludvigsson-1977a">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:32:56 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Ludvigsson-1977b">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:32:58 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Miller-1977a">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-15 21:27:27 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Miller-1977b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-15 21:27:38 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Miller-1977c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:33:00 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Moolla-1996a">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-15 19:49:42 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Moolla-1996b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:33:02 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Peters-1993a">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:33:03 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Peters-1993b">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:33:05 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Peters-1996a">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:33:07 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Peters-1996b">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:33:08 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Pitt-1979">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-18 16:19:03 +1000" MODIFIED_BY="Harri Hemilä" RESULT="UNKNOWN" STUDY_ID="STD-Regnier-1968">
<DESCRIPTION>
<P>?</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:33:31 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Ritzel-1961">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:33:34 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Sabiston-1974">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:33:36 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Sasazuki-2006">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-18 16:18:51 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Scheunert-1949">
<DESCRIPTION>
<P>?</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:33:39 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Schwartz-1973">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:33:42 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Tebrock-1956">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:33:44 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Tyrrell-1977">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:33:47 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Van-Straten-2002">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-23 17:59:28 +1000" MODIFIED_BY="Harri Hemilä" RESULT="UNKNOWN" STUDY_ID="STD-Walker-1967">
<DESCRIPTION>
<P>?</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 08:33:49 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Wilson-1973a">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-15 21:10:04 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Wilson-1973b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2012-09-23 17:18:07 +1000" MODIFIED_BY="Harri Hemilä" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="GROUP" MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-09.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-26 08:31:39 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abbott-1968">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-26 08:31:41 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-1972">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-26 08:31:43 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-1974a">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-23 17:21:00 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-1974b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-23 17:21:07 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-1974c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-23 17:21:26 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-1974d">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-23 17:21:33 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-1974e">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-23 17:22:57 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-1974f">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-26 08:31:45 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-1975a">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-23 17:22:20 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-1975b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-26 08:31:53 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Asfora-1977">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-26 08:31:55 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Audera-2001a">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-23 17:25:13 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Audera-2001b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-26 08:31:57 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bancalari-1984">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-26 08:32:00 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Briggs-1984">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brown-1945">
<DESCRIPTION>
<P>"given... without knowledge on the subjects' part that placebos were being given." Indicates single-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-26 08:32:17 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carr-1981a">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-23 17:29:38 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carr-1981b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-26 08:32:19 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carson-1975">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Charleston-1972">
<DESCRIPTION>
<P>Participants were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-26 08:32:20 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Clegg-1975">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-26 08:32:23 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Constantini-2011a">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-23 17:33:02 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Constantini-2011b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-26 08:32:24 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Coulehan-1974a">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-23 17:34:16 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Coulehan-1974b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-26 08:32:26 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Coulehan-1976">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-26 04:21:11 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cowan-1942">
<DESCRIPTION>
<P>Single-blinded: "... placebo tablets of the same size, shape, appearance and taste as the ascorbic acid tablets. These students, of course, did not know that they were serving as controls."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-26 08:32:33 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cowan-1950">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-26 08:32:34 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dahlberg-1944">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-26 08:32:38 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dick-1990">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-26 08:32:40 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Elliot-1973">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-26 08:32:42 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Elwood-1976">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-26 08:32:44 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Elwood-1977">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-26 08:32:46 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Franz--1956">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-26 08:32:48 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Himmelstein-1998a">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-26 08:32:51 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Karlowski-1975a">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-23 17:45:10 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Karlowski-1975b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-23 17:45:25 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Karlowski-1975c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-26 08:32:52 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Liljefors-1972">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-26 08:32:54 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ludvigsson-1977a">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-26 08:32:57 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ludvigsson-1977b">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-26 08:32:59 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Miller-1977a">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-23 17:48:13 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Miller-1977b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-23 17:48:35 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Miller-1977c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-26 08:33:00 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moolla-1996a">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-23 17:49:26 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moolla-1996b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-26 08:33:02 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peters-1993a">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-26 08:33:04 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peters-1993b">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-26 08:33:05 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peters-1996a">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-26 08:33:07 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peters-1996b">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-26 08:33:09 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pitt-1979">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-26 08:33:24 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Regnier-1968">
<DESCRIPTION>
<P>Initiated as double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-26 08:33:32 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ritzel-1961">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-26 08:33:34 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sabiston-1974">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-26 08:33:37 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sasazuki-2006">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-26 04:21:17 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Scheunert-1949">
<DESCRIPTION>
<P>?</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-26 08:33:40 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schwartz-1973">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-26 08:33:43 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tebrock-1956">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-26 08:33:45 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tyrrell-1977">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-26 08:33:47 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-Straten-2002">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-26 04:21:18 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Walker-1967">
<DESCRIPTION>
<P>?</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-26 08:33:49 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wilson-1973a">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-23 18:00:21 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wilson-1973b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="GROUP" MODIFIED="2012-12-09 23:17:54 +1000" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-10.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-26 08:31:40 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abbott-1968">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-26 08:31:42 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-1972">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-26 08:31:44 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-1974a">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-23 17:21:01 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-1974b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-23 17:21:08 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-1974c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-23 17:21:38 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-1974d">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-23 17:21:47 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-1974e">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-23 17:22:55 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-1974f">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-26 08:31:46 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-1975a">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-23 17:22:22 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-1975b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-26 08:31:54 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Asfora-1977">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-26 08:31:56 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Audera-2001a">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-23 17:25:15 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Audera-2001b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-26 08:31:58 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bancalari-1984">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-26 08:32:16 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Briggs-1984">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-26 04:21:09 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brown-1945">
<DESCRIPTION>
<P>Subjects' observed outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-26 08:32:18 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carr-1981a">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-23 17:29:40 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carr-1981b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-26 08:32:19 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carson-1975">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-23 18:10:03 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Charleston-1972">
<DESCRIPTION>
<P>?</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-26 08:32:21 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Clegg-1975">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-26 08:32:23 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Constantini-2011a">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-23 17:33:03 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Constantini-2011b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-26 08:32:25 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Coulehan-1974a">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-23 17:34:18 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Coulehan-1974b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-26 08:32:27 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Coulehan-1976">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-12-09 23:17:54 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cowan-1942">
<DESCRIPTION>
<P>The students (who were blinded) were instructed to report whenever a cold developed<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-26 08:32:33 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cowan-1950">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-26 08:32:35 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dahlberg-1944">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-26 08:32:39 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dick-1990">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-26 08:32:41 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Elliot-1973">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-26 08:32:43 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Elwood-1976">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-26 08:32:45 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Elwood-1977">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-26 08:32:47 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Franz--1956">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-26 08:32:49 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Himmelstein-1998a">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-26 08:32:51 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Karlowski-1975a">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-23 17:45:08 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Karlowski-1975b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-23 17:45:26 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Karlowski-1975c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-26 08:32:53 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Liljefors-1972">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-26 08:32:55 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ludvigsson-1977a">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-26 08:32:57 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ludvigsson-1977b">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-26 08:32:59 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Miller-1977a">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-23 17:48:17 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Miller-1977b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-23 17:48:37 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Miller-1977c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-26 08:33:01 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moolla-1996a">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-23 17:49:28 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moolla-1996b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-26 08:33:03 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peters-1993a">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-26 08:33:04 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peters-1993b">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-26 08:33:06 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peters-1996a">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-26 08:33:08 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peters-1996b">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-26 08:33:09 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pitt-1979">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-26 04:21:16 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Regnier-1968">
<DESCRIPTION>
<P>?</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-26 08:33:32 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ritzel-1961">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-26 08:33:35 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sabiston-1974">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-26 08:33:38 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sasazuki-2006">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-26 04:21:17 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Scheunert-1949">
<DESCRIPTION>
<P>?</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-26 08:33:41 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schwartz-1973">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-26 08:33:44 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tebrock-1956">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-26 08:33:46 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tyrrell-1977">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-26 08:33:48 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-Straten-2002">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-26 04:21:18 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Walker-1967">
<DESCRIPTION>
<P>?</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-26 08:33:50 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wilson-1973a">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-09-23 18:00:23 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wilson-1973b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2012-09-26 04:21:18 +1000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:16:32 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abbott-1968">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:18:55 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-1972">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:19:35 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-1974a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:20:35 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-1974b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:21:12 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-1974c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:21:40 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-1974d">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:21:46 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-1974e">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:22:04 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-1974f">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:22:40 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-1975a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:23:22 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-1975b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:24:04 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Asfora-1977">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:24:35 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Audera-2001a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:25:16 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Audera-2001b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:26:13 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bancalari-1984">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:25:50 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Briggs-1984">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-26 04:21:09 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brown-1945">
<DESCRIPTION>
<P>?</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:28:15 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carr-1981a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:29:47 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carr-1981b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:30:08 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carson-1975">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-26 04:21:10 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Charleston-1972">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:31:45 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Clegg-1975">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:32:17 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Constantini-2011a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:33:05 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Constantini-2011b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:33:52 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Coulehan-1974a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:34:21 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Coulehan-1974b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:35:13 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Coulehan-1976">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-26 04:21:11 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cowan-1942">
<DESCRIPTION>
<P>?</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-26 04:21:11 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cowan-1950">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:39:30 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dahlberg-1944">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:41:11 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dick-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:40:44 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Elliot-1973">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:42:02 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Elwood-1976">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:42:31 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Elwood-1977">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:43:11 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Franz--1956">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:43:50 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Himmelstein-1998a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:44:41 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Karlowski-1975a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:45:07 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Karlowski-1975b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:45:31 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Karlowski-1975c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:46:11 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Liljefors-1972">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:46:38 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ludvigsson-1977a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:47:09 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ludvigsson-1977b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:47:46 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Miller-1977a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:48:22 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Miller-1977b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:48:38 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Miller-1977c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:48:49 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moolla-1996a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:49:30 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moolla-1996b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:49:42 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peters-1993a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:50:01 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peters-1993b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:50:24 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peters-1996a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:51:01 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peters-1996b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:51:29 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pitt-1979">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-26 04:21:16 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Regnier-1968">
<DESCRIPTION>
<P>?</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:53:24 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ritzel-1961">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:53:51 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sabiston-1974">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:55:06 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sasazuki-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-26 04:21:17 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Scheunert-1949">
<DESCRIPTION>
<P>?</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:56:22 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schwartz-1973">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 18:05:55 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tebrock-1956">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:58:22 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tyrrell-1977">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:58:54 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-Straten-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-26 04:21:18 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Walker-1967">
<DESCRIPTION>
<P>Laboratory study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 17:59:58 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wilson-1973a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 18:00:25 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wilson-1973b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-11" LEVEL="STUDY" MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Harri Hemilä" NO="11">
<NAME>Vitamin C and placebo indistinguishable?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 20:02:45 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Abbott-1968">
<DESCRIPTION>
<P>"similar placebo tablets were prepared"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-14 13:36:11 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-1972">
<DESCRIPTION>
<P>[Vitamin C tablets:] "The taste of this formulation was well matched by a placebo preparation...The effectiveness of the matching was established by asking 30 individuals to taste both tablets ..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-18 23:26:48 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Anderson-1974a">
<DESCRIPTION>
<P>Tablets: "taste test carried out with the help of a number of colleagues demonstrated that they were reasonably well matched in flavour, texture and appearance"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-15 21:23:50 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Anderson-1974b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-15 21:24:10 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Anderson-1974c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-15 21:24:35 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Anderson-1974d">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-15 21:25:01 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Anderson-1974e">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-15 21:25:10 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Anderson-1974f">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 04:21:08 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Anderson-1975a">
<DESCRIPTION>
<P>See Notes above</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-15 21:25:29 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Anderson-1975b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-18 16:18:29 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Asfora-1977">
<DESCRIPTION>
<P>?</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-15 19:36:19 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Audera-2001a">
<DESCRIPTION>
<P>"tablets with identical appearance and packaging"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-15 21:25:52 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Audera-2001b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-18 21:40:10 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Bancalari-1984">
<DESCRIPTION>
<P>"vitamin C tablets and the placebo tablets were identical in colour, taste, size and consistency"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-28 03:25:35 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Briggs-1984">
<DESCRIPTION>
<P>"identical opaque gelatin capsules (dark brown) and ... similar acidic taste, but lacking vitamin C activity. Citric acid was selected"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 20:21:12 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Brown-1945">
<DESCRIPTION>
<P>"citric acid as a placebo"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-28 03:01:42 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Carr-1981a">
<DESCRIPTION>
<P>"matching of the active and placebo tablets was checked for both appearance and taste"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-15 20:16:23 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Carr-1981b">
<DESCRIPTION>
<P>"matching of the active and placebo tablets was checked for both appearance and taste"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-14 19:04:13 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Carson-1975">
<DESCRIPTION>
<P>"tablets or matching lactose dummies"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-28 02:30:01 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Charleston-1972">
<DESCRIPTION>
<P>"placebo similar in appearance but containing lactose and 5% citric acid"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-28 03:23:41 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Clegg-1975">
<DESCRIPTION>
<P>"The placebo and ascorbic acid tablets were organoleptically indistinguishable"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 22:10:42 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Constantini-2011a">
<DESCRIPTION>
<P>"identical in appearance"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 04:21:10 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Constantini-2011b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-14 13:49:51 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Coulehan-1974a">
<DESCRIPTION>
<P>"Placebos were formulated from citric acid to be indistinguishable in taste and appearance from the vitamin C tablets"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 04:21:11 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Coulehan-1974b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-15 20:25:24 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Coulehan-1976">
<DESCRIPTION>
<P>"placebo tablets were formulated with citric acid to be identical in appearance and taste with ascorbic acid pills"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 04:21:11 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Cowan-1942">
<DESCRIPTION>
<P>"... placebo tablets of the same size, shape, appearance and taste as the ascorbic acid tablets. These students, of course, did not know that they were serving as controls."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-14 13:51:29 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cowan-1950">
<DESCRIPTION>
<P>"Placebo (citric acid to simulate the taste of ascorbic acid, lactose, cornstarch, sugar, talc and stearic acid)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-14 13:53:19 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dahlberg-1944">
<DESCRIPTION>
<P>"Control tablets, to which a suitable amount of citric acid had been added, to disguise any difference in taste"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-02 21:04:58 +1000" MODIFIED_BY="Harri Hemilä" RESULT="UNKNOWN" STUDY_ID="STD-Dick-1990">
<DESCRIPTION>
<P>?</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 20:08:18 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Elliot-1973">
<DESCRIPTION>
<P>"Both AA and placebo [citric acid] capsules looked identical and when opened the contents were similar in taste and appearance"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Elwood-1976">
<DESCRIPTION>
<P>"tablets ... These contained either 1 g ascorbic acid in an effervescent base or a matching placebo"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-02 21:07:46 +1000" MODIFIED_BY="Harri Hemilä" RESULT="UNKNOWN" STUDY_ID="STD-Elwood-1977">
<DESCRIPTION>
<P>?</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Franz--1956">
<DESCRIPTION>
<P>Tablets: "all looked and tasted alike"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-26 23:12:46 +1000" MODIFIED_BY="Jenny Bellorini" RESULT="YES" STUDY_ID="STD-Himmelstein-1998a">
<DESCRIPTION>
<P>"Placebo (similar looking and tasting tablets containing lactose)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-16 15:45:04 +1000" MODIFIED_BY="Harri Hemilä" RESULT="UNKNOWN" STUDY_ID="STD-Karlowski-1975a">
<DESCRIPTION>
<P>See Notes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 04:21:14 +1000" MODIFIED_BY="Harri Hemilä" RESULT="UNKNOWN" STUDY_ID="STD-Karlowski-1975b">
<DESCRIPTION>
<P>?</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 04:21:14 +1000" MODIFIED_BY="Harri Hemilä" RESULT="UNKNOWN" STUDY_ID="STD-Karlowski-1975c">
<DESCRIPTION>
<P>?</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-02 21:07:55 +1000" MODIFIED_BY="Harri Hemilä" RESULT="UNKNOWN" STUDY_ID="STD-Liljefors-1972">
<DESCRIPTION>
<P>?</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-28 03:07:58 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Ludvigsson-1977a">
<DESCRIPTION>
<P>"fizzy tablet which contained 1000 mg vitamin C; in the other group the fizzy tablet looked and tasted the same"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-28 03:08:14 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Ludvigsson-1977b">
<DESCRIPTION>
<P>"fizzy tablet which contained 1000 mg vitamin C; in the other group the fizzy tablet looked and tasted the same"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-02 21:08:03 +1000" MODIFIED_BY="Harri Hemilä" RESULT="UNKNOWN" STUDY_ID="STD-Miller-1977a">
<DESCRIPTION>
<P>?</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-02 21:08:07 +1000" MODIFIED_BY="Harri Hemilä" RESULT="UNKNOWN" STUDY_ID="STD-Miller-1977b">
<DESCRIPTION>
<P>?</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-02 21:08:11 +1000" MODIFIED_BY="Harri Hemilä" RESULT="UNKNOWN" STUDY_ID="STD-Miller-1977c">
<DESCRIPTION>
<P>?</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-15 19:50:40 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Moolla-1996a">
<DESCRIPTION>
<P>"placebo was identical in form to the ascorbic acid"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-15 19:50:10 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Moolla-1996b">
<DESCRIPTION>
<P>"placebo was identical in form to the ascorbic acid"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-28 03:12:10 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Peters-1993a">
<DESCRIPTION>
<P>"identical looking and tasting placebo containing citric acid"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-28 03:12:55 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Peters-1993b">
<DESCRIPTION>
<P>"identical looking and tasting placebo containing citric acid"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-14 19:02:27 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Peters-1996a">
<DESCRIPTION>
<P>"tablets of similar appearance"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-14 19:02:37 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Peters-1996b">
<DESCRIPTION>
<P>"tablets of similar appearance"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-28 03:13:43 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Pitt-1979">
<DESCRIPTION>
<P>"the placebo tablets were formulated from citric acid and were indistinguishable in appearance and taste from the vitamin C tablets"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 06:34:44 +1000" MODIFIED_BY="Harri Hemilä" RESULT="UNKNOWN" STUDY_ID="STD-Regnier-1968">
<DESCRIPTION>
<P>"lactose placebo"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-28 02:45:18 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Ritzel-1961">
<DESCRIPTION>
<P>"The placebo was indistinguishable from the 1-gm ascorbic acid tablet"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Sabiston-1974">
<DESCRIPTION>
<P>Personal communication (Radomski 12 September 2009): "Vitamin C and placebo were in identical capsules, so taste did not enter into the equation... In our pre-briefing to the troops, we believe that we told the troops that they would all be getting vitamin C but at different doses."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-02 21:08:22 +1000" MODIFIED_BY="Harri Hemilä" RESULT="UNKNOWN" STUDY_ID="STD-Sasazuki-2006">
<DESCRIPTION>
<P>?</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-18 16:18:48 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Scheunert-1949">
<DESCRIPTION>
<P>?</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-02 21:08:28 +1000" MODIFIED_BY="Harri Hemilä" RESULT="UNKNOWN" STUDY_ID="STD-Schwartz-1973">
<DESCRIPTION>
<P>?</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-18 16:20:36 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tebrock-1956">
<DESCRIPTION>
<P>?</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-28 02:51:48 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Tyrrell-1977">
<DESCRIPTION>
<P>"the tubes with 'placebo treatment', contained inert substances of identical appearance and taste"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-15 21:08:35 +1000" MODIFIED_BY="Harri Hemilä" RESULT="YES" STUDY_ID="STD-Van-Straten-2002">
<DESCRIPTION>
<P>Tablets: "ascorbate 500 mg or a matched placebo"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-02 21:08:36 +1000" MODIFIED_BY="Harri Hemilä" RESULT="UNKNOWN" STUDY_ID="STD-Walker-1967">
<DESCRIPTION>
<P>?</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-02 21:08:40 +1000" MODIFIED_BY="Harri Hemilä" RESULT="UNKNOWN" STUDY_ID="STD-Wilson-1973a">
<DESCRIPTION>
<P>?</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-02 21:08:41 +1000" MODIFIED_BY="Harri Hemilä" RESULT="UNKNOWN" STUDY_ID="STD-Wilson-1973b">
<DESCRIPTION>
<P>?</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2013-03-13 03:48:11 +1000" MODIFIED_BY="Jenny Bellorini">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2012-12-10 02:50:27 +1000" MODIFIED_BY="Harri Hemilä" NO="1">
<TITLE MODIFIED="2012-05-29 06:49:41 +1000" MODIFIED_BY="Harri Hemilä">Included trials with no data suitable for our meta-analysis</TITLE>
<TABLE COLS="2" ROWS="8">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Trial</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Findings</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Abbott-1968" TYPE="STUDY">Abbott 1968</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Therapeutic trial. The authors write: "with regard to the comparative results with the two preparations, there were virtually no differences at all in respect of any of these individual symptoms" [p 444]. The only numerical data reported were the severity of "sore throat in patients with a common cold" [their Table 1 on p 443]. It is not clear how long a delay there was between the onset of symptoms and the initiation of treatment. "The doctors taking part in the trial were asked to treat families in order, as colds appeared during the course of the winter" [p 442]; thus it seems that the doctor gave tablets only when he or she met the patient rather than patient keeping tablets ready at home for use when symptoms started.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Asfora-1977" TYPE="STUDY">Asfora 1977</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Therapeutic trial. The author writes: "a double-blind trial was conducted in which the preparations, numbered 1 and 8, were given to alternate patients as they presented themselves. .. When 42 patients had received substance No. 1 and 41 patients had received No. 8, there was no longer any point in continuing the double-blind trial, since in view of the clinical progress of the patients there was not the slightest doubt that substance No. 1 was vitamin C and No. 8 was the placebo" [p 224]. Thereafter the trial was continued as an open trial comparing vitamin C with other drugs.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Brown-1945" TYPE="STUDY">Brown 1945</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Therapeutic trial. Of the 206 "nasal colds", 62% (76/123) of the vitamin C group had a cold being cured overnight whereas 37% (31/83) of the placebo participants had colds that were cured overnight (P = 0.06). There was no difference in the curing of 92 "throat colds" (35/56 versus 22/36, respectively). The great difference in the distribution of participants is not consistent with reported alternate allocation.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Elliot-1973" TYPE="STUDY">Elliot 1973</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Prophylactic trial. The authors write: "There was no consistent difference between groups in the incidence of runny nose or sneezing. Man-days of morbidity for hoarseness, sore throats, non-productive coughs, and productive coughs was 36, 107, 42 and 72 in the placebo group with only 37%, 28%, 40% and 31% as much morbidity in the ascorbic acid group. The Wilcoxon Sequence Test with a one tailed test rejected the null hypothesis of equal effectiveness of ascorbic acid and placebo for sore throats and productive coughs (P = .0155 and .0327) but not for hoarseness or non-productive coughs" [p 12] (<LINK REF="REF-Hemil_x00e4_-2004" TYPE="REFERENCE">Hemilä 2004</LINK>).</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Regnier-1968" TYPE="STUDY">Regnier 1968</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Therapeutic trial. The author writes: "I initiated a double-blind study using ascorbic acid alone, ascorbic acid plus bioflavonoids, flavonoids only and, fourthly, a lactose placebo with the two "vitamins" present either alone or together in 200 mg quantities. It was shortly obvious that there was no need to continue double-blind techniques. The continued studies were done by the single blind method... "</P>
<P>"The 22 subjects mentioned have been studied systematically and under conditions which were as controlled as is possible in a clinical investigation of an infection such as the common cold. Some acted as what are commonly termed their own controls... None of the subjects was studied for less than three years... [p 950]." "Within the first 24 hours of a typical infection which the patient recognizes as his usual early symptoms of a cold, and the sooner the better, the beginning dose of ascorbic acid or 0.6 or 0.625 g is taken every three hours" (p 950). The author reports that "in 50 colds the treatment consisted of ascorbic acid alone ... the colds were nicely suppressed in 45 [of the 50]... In 22 of 24 instances in which the lactose-filled capsules alone were taken the colds were seemingly untempered and ordinary" [p 952].</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Scheunert-1949" TYPE="STUDY">Scheunert 1949</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Prophylactic trial. The common cold [Erkältungskrankheiten] was one of the outcomes and "The percentage monthly duration of people sick with the common cold [Prozentualer Monatsdurchschnitt der erkrankten Personen]" was 7.3% in the 0.02 g/d group, 7.2% in the 0.05 g/d group, 1.95% in the 0.1 g/d group, and 1.93% in the 0.3 g/d group suggesting that there were more days sick with the common cold when vitamin C doses were low. However, the data are presented ambiguously and it is a combination of incidence and duration. The methodology is not good.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Tebrock-1956" TYPE="STUDY">Tebrock 1956</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Therapeutic trial. The authors conclude "the overwhelming impression gained from the study is the singular lack of effect in altering the course of the common cold by ... the ascorbic acid". A number of tables were published but they could not be used in our meta-analyses.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2013-03-13 03:48:11 +1000" MODIFIED_BY="Jenny Bellorini" NO="2">
<TITLE MODIFIED="2012-05-29 06:12:49 +1000" MODIFIED_BY="Harri Hemilä">Three trials with experimentally induced colds</TITLE>
<TABLE COLS="4" ROWS="9">
<TR>
<TH VALIGN="BOTTOM">
<P>Study characteristics</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Walker 1967</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Schwartz 1973</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Dick 1990</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Number of participants</P>
</TD>
<TD VALIGN="TOP">
<P>91 healthy volunteers; 47 vitamin C and 44 placebo</P>
</TD>
<TD VALIGN="TOP">
<P>21 healthy male volunteers</P>
</TD>
<TD VALIGN="TOP">
<P>Altogether 48 participants. Three separate transmission experiments each involving 16 healthy volunteers (8 vitamin C; 8 placebo) housed closely for 1 week with 8 volunteers actively infected with rhinovirus</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Viruses used</P>
</TD>
<TD VALIGN="TOP">
<P>Rhinovirus (3 strains); 29 vitamin C and 26 placebo<BR/>Influenza B (8/8)<BR/>B814 virus (10/10)<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>Rhinovirus 44; 11 vitamin C and 10 placebo</P>
</TD>
<TD VALIGN="TOP">
<P>Rhinovirus 16; 24 vitamin C and 24 placebo</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Transmission method</P>
</TD>
<TD VALIGN="TOP">
<P>Nasal instillation</P>
</TD>
<TD VALIGN="TOP">
<P>Nasal instillation</P>
</TD>
<TD VALIGN="TOP">
<P>Close contact with infected volunteers over a period of a week</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Intervention</P>
</TD>
<TD VALIGN="TOP">
<P>3 g/d vitamin C for 3 days before and 6 days after inoculation</P>
</TD>
<TD VALIGN="TOP">
<P>3 g/d vitamin C or placebo for 2 weeks before and 1 week after inoculation</P>
</TD>
<TD VALIGN="TOP">
<P>2 g/d vitamin C for 3.5 weeks before exposure to infected volunteers</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Incidence outcome</P>
</TD>
<TD VALIGN="TOP">
<P>18 colds developed in each group</P>
</TD>
<TD VALIGN="TOP">
<P>All in both groups developed colds</P>
</TD>
<TD VALIGN="TOP">
<P>19/24 in vitamin C group and 22/24 in placebo group became infected</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Duration outcome</P>
</TD>
<TD VALIGN="TOP">
<P>Mean duration in each group 5 days</P>
</TD>
<TD VALIGN="TOP">
<P>Both groups resolved by 6 to 7 days</P>
</TD>
<TD VALIGN="TOP">
<P>Not provided</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Severity outcome</P>
</TD>
<TD VALIGN="TOP">
<P>Mean severity score 8 for vitamin C and 7 for placebo</P>
</TD>
<TD VALIGN="TOP">
<P>Severity peaked earlier for vitamin C group and resolution more advanced by day 4 (P = 0.02). Overall mean severity scores not significantly different in the 2 groups</P>
</TD>
<TD VALIGN="TOP">
<P>Mean cumulative severity score and mucus weights reduced in the vitamin C recipients (P = 0.03). Severity of colds reduced by 50% (P = 0.02; <LINK REF="STD-Dick-1990" TYPE="STUDY">Dick 1990</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Comments</P>
</TD>
<TD VALIGN="TOP">
<P>Not double-blind</P>
</TD>
<TD VALIGN="TOP">
<P>Double-blind. Nasal virus shedding similar in the 2 groups</P>
</TD>
<TD VALIGN="TOP">
<P>Double-blind. Viral shedding similar in these 2 groups. The studies are briefly described in a series of conference abstracts but no full published paper is available</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2012-12-11 18:25:00 +1000" MODIFIED_BY="Jenny Bellorini">
<COMPARISON ID="CMP-001" MODIFIED="2012-12-10 01:28:28 +1000" MODIFIED_BY="Jenny Bellorini" NO="1">
<NAME>Incidence of colds while taking &#8805; 0.2 g/day vitamin C regularly</NAME>
<DICH_OUTCOME CHI2="44.85217868462592" CI_END="0.9810491356742562" CI_START="0.9224772152988597" CI_STUDY="95" CI_TOTAL="95" DF="28" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9513125010994763" ESTIMABLE="YES" EVENTS_1="3068" EVENTS_2="2473" I2="37.572709239211115" I2_Q="95.60183702602669" ID="CMP-001.01" LOG_CI_END="-0.008309240512206138" LOG_CI_START="-0.03504435188129227" LOG_EFFECT_SIZE="-0.02167679619674921" METHOD="MH" MODIFIED="2012-12-10 01:28:28 +1000" MODIFIED_BY="Jenny Bellorini" NO="1" P_CHI2="0.02283494147814824" P_Q="1.8578093174959065E-6" P_Z="0.001481552355560943" Q="22.736765461344287" RANDOM="NO" SCALE="2.77" SORT_BY="EFFECT_SIZE" STUDIES="29" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="6105" TOTAL_2="5201" WEIGHT="100.0" Z="3.178272890605547">
<NAME>Proportion of participants developing &#8805; 1 cold episodes during the trial</NAME>
<GROUP_LABEL_1>Vitamin C</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vitamin C</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="17.750298929143053" CI_END="1.0008761850311105" CI_START="0.9414587285274352" DF="23" EFFECT_SIZE="0.9707129444757494" ESTIMABLE="YES" EVENTS_1="3020" EVENTS_2="2368" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="3.8035571746707157E-4" LOG_CI_START="-0.02619871374148833" LOG_EFFECT_SIZE="-0.01290917901201061" MODIFIED="2012-09-18 21:21:15 +1000" MODIFIED_BY="Harri Hemilä" NO="1" P_CHI2="0.7708893244312658" P_Z="0.05692731854920286" STUDIES="24" TAU2="0.0" TOTAL_1="5810" TOTAL_2="4898" WEIGHT="96.0844425562085" Z="1.9038684535282835">
<NAME>All eligible trials with exception of subgroup removed below</NAME>
<DICH_DATA CI_END="1.3143893071105017" CI_START="0.1893598649217657" EFFECT_SIZE="0.49889135254988914" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" LOG_CI_END="0.11872401734590812" LOG_CI_START="-0.7227120648791041" LOG_EFFECT_SIZE="-0.30199402376659806" ORDER="1" O_E="0.0" SE="0.4942637198747543" STUDY_ID="STD-Peters-1996b" TOTAL_1="41" TOTAL_2="45" VAR="0.24429662478442962" WEIGHT="0.4006942090234076"/>
<DICH_DATA CI_END="1.4976288673261715" CI_START="0.345855865556171" EFFECT_SIZE="0.7196969696969697" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="0.17540420265447074" LOG_CI_START="-0.4611048544884749" LOG_EFFECT_SIZE="-0.14285032591700209" ORDER="1" O_E="0.0" SE="0.37388857093641414" STUDY_ID="STD-Moolla-1996b" TOTAL_1="11" TOTAL_2="19" VAR="0.139792663476874" WEIGHT="0.33619221440012736"/>
<DICH_DATA CI_END="0.9725636493899911" CI_START="0.6041476652938468" EFFECT_SIZE="0.7665324899367453" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="37" LOG_CI_END="-0.012081966686783034" LOG_CI_START="-0.21885689849092346" LOG_EFFECT_SIZE="-0.11546943258885324" MODIFIED="2009-07-16 21:21:32 +1000" MODIFIED_BY="Harri Hemilä" ORDER="2" O_E="0.0" SE="0.12146061849417215" STUDY_ID="STD-Charleston-1972" TOTAL_1="47" TOTAL_2="43" VAR="0.014752681844986834" WEIGHT="1.4763592445500542"/>
<DICH_DATA CI_END="1.4813895359225875" CI_START="0.4704110477915068" EFFECT_SIZE="0.8347826086956521" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="23" LOG_CI_END="0.17066927260453982" LOG_CI_START="-0.32752248723262634" LOG_EFFECT_SIZE="-0.0784266073140433" MODIFIED="2009-07-16 21:21:34 +1000" MODIFIED_BY="Harri Hemilä" ORDER="2" O_E="0.0" SE="0.2926403058173352" STUDY_ID="STD-Coulehan-1974a" TOTAL_1="190" TOTAL_2="192" VAR="0.08563834858886346" WEIGHT="0.8740837559070421"/>
<DICH_DATA CI_END="0.97978209289236" CI_START="0.8458426880821833" EFFECT_SIZE="0.9103524148300268" ESTIMABLE="YES" EVENTS_1="302" EVENTS_2="335" LOG_CI_END="-0.008870502243540773" LOG_CI_START="-0.07271040061415007" LOG_EFFECT_SIZE="-0.040790451428845416" ORDER="3" O_E="0.0" SE="0.037499872315489416" STUDY_ID="STD-Anderson-1972" TOTAL_1="407" TOTAL_2="411" VAR="0.0014062404236780098" WEIGHT="12.735643329735874"/>
<DICH_DATA CI_END="1.7401257038635325" CI_START="0.48600288620169385" EFFECT_SIZE="0.9196228109564436" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="17" LOG_CI_END="0.24058062214604908" LOG_CI_START="-0.3133611516065392" LOG_EFFECT_SIZE="-0.036390264730245064" MODIFIED="2009-07-16 21:21:33 +1000" MODIFIED_BY="Harri Hemilä" ORDER="2" O_E="0.0" SE="0.32538813995827376" STUDY_ID="STD-Coulehan-1974b" TOTAL_1="131" TOTAL_2="128" VAR="0.10587744162550516" WEIGHT="0.6569849609240818"/>
<DICH_DATA CI_END="1.160872221708604" CI_START="0.7413058622244246" EFFECT_SIZE="0.9276644777321594" ESTIMABLE="YES" EVENTS_1="131" EVENTS_2="142" LOG_CI_END="0.06478441916936295" LOG_CI_START="-0.13000256547699998" LOG_EFFECT_SIZE="-0.03260907315381852" ORDER="1" O_E="0.0" SE="0.11441883899239814" STUDY_ID="STD-Dahlberg-1944" TOTAL_1="1259" TOTAL_2="1266" VAR="0.013091670716368329" WEIGHT="5.409880441586496"/>
<DICH_DATA CI_END="1.3213075299133505" CI_START="0.6651791729799932" EFFECT_SIZE="0.9375" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="21" LOG_CI_END="0.12100390996920536" LOG_CI_START="-0.17706135716969237" LOG_EFFECT_SIZE="-0.028028723600243537" ORDER="3" O_E="0.0" SE="0.17508501336425655" STUDY_ID="STD-Bancalari-1984" TOTAL_1="32" TOTAL_2="30" VAR="0.0306547619047619" WEIGHT="0.8281567744753869"/>
<DICH_DATA CI_END="1.0083243375066782" CI_START="0.8892337701512536" EFFECT_SIZE="0.9469086820683019" ESTIMABLE="YES" EVENTS_1="922" EVENTS_2="233" LOG_CI_END="0.0036002497015816233" LOG_CI_START="-0.05098405259489552" LOG_EFFECT_SIZE="-0.023691901446656952" ORDER="3" O_E="0.0" SE="0.03206308936560473" STUDY_ID="STD-Anderson-1974a" TOTAL_1="1191" TOTAL_2="285" VAR="0.001028041699666755" WEIGHT="14.36535293062924"/>
<DICH_DATA CI_END="1.7361271007882046" CI_START="0.5248216126455958" EFFECT_SIZE="0.9545454545454546" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" LOG_CI_END="0.2395815164340013" LOG_CI_START="-0.2799882886105753" LOG_EFFECT_SIZE="-0.02020338608828695" ORDER="1" O_E="0.0" SE="0.30519787539519855" STUDY_ID="STD-Franz--1956" TOTAL_1="44" TOTAL_2="45" VAR="0.09314574314574314" WEIGHT="0.5666160916856079"/>
<DICH_DATA CI_END="1.2254694762345018" CI_START="0.7586001638880122" EFFECT_SIZE="0.9641791044776119" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="67" LOG_CI_END="0.08830249839673468" LOG_CI_START="-0.11998706780821948" LOG_EFFECT_SIZE="-0.015842284705742365" ORDER="1" O_E="0.0" SE="0.12235032223877135" STUDY_ID="STD-Sasazuki-2006" TOTAL_1="140" TOTAL_2="133" VAR="0.014969601351931188" WEIGHT="2.625277198695633"/>
<DICH_DATA CI_END="1.0339543677266754" CI_START="0.9017669443390718" EFFECT_SIZE="0.9656013001083423" ESTIMABLE="YES" EVENTS_1="184" EVENTS_2="142" LOG_CI_END="0.01450137214108332" LOG_CI_START="-0.0449056884730635" LOG_EFFECT_SIZE="-0.015202158165990097" MODIFIED="2009-07-16 21:21:30 +1000" MODIFIED_BY="Harri Hemilä" ORDER="1" O_E="0.0" SE="0.034896001474442585" STUDY_ID="STD-Cowan-1942" TOTAL_1="208" TOTAL_2="155" VAR="0.0012177309189042992" WEIGHT="6.216988006838317"/>
<DICH_DATA CI_END="1.0704377059051116" CI_START="0.8979360356026658" EFFECT_SIZE="0.9804002192982456" ESTIMABLE="YES" EVENTS_1="230" EVENTS_2="240" LOG_CI_END="0.029561398609576402" LOG_CI_START="-0.04675459916143515" LOG_EFFECT_SIZE="-0.008596600275929381" ORDER="2" O_E="0.0" SE="0.04482839486097373" STUDY_ID="STD-Ludvigsson-1977b" TOTAL_1="304" TOTAL_2="311" VAR="0.002009584985811376" WEIGHT="9.064517355001216"/>
<DICH_DATA CI_END="1.050786576514701" CI_START="0.9504588210857641" EFFECT_SIZE="0.9993644834227945" ESTIMABLE="YES" EVENTS_1="298" EVENTS_2="309" LOG_CI_END="0.021514516166916478" LOG_CI_START="-0.022066694329971836" LOG_EFFECT_SIZE="-2.760890815276647E-4" ORDER="3" O_E="0.0" SE="0.02559981877634343" STUDY_ID="STD-Pitt-1979" TOTAL_1="331" TOTAL_2="343" VAR="6.553507213816257E-4" WEIGHT="11.594754348742454"/>
<DICH_DATA CI_END="1.278718556039651" CI_START="0.7820329151217789" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="98" EVENTS_2="98" LOG_CI_END="0.10677496745814925" LOG_CI_START="-0.10677496745814924" LOG_EFFECT_SIZE="0.0" ORDER="2" O_E="0.0" SE="0.1254402888590601" STUDY_ID="STD-Coulehan-1976" TOTAL_1="428" TOTAL_2="428" VAR="0.015735266069044438" WEIGHT="3.7439587512741452"/>
<DICH_DATA CI_END="1.2389664525877535" CI_START="0.8119502007686585" EFFECT_SIZE="1.0029850746268656" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="50" LOG_CI_END="0.09305954717245805" LOG_CI_START="-0.0904706064664605" LOG_EFFECT_SIZE="0.0012944703529987752" MODIFIED="2009-07-16 21:21:32 +1000" MODIFIED_BY="Harri Hemilä" ORDER="2" O_E="0.0" SE="0.1078065207364132" STUDY_ID="STD-Clegg-1975" TOTAL_1="67" TOTAL_2="70" VAR="0.011622245913290688" WEIGHT="1.8683542107505415"/>
<DICH_DATA CI_END="1.0851854752096817" CI_START="0.963603523165049" EFFECT_SIZE="1.022589138999426" ESTIMABLE="YES" EVENTS_1="296" EVENTS_2="298" LOG_CI_END="0.035503972263811" LOG_CI_START="-0.016101620786248775" LOG_EFFECT_SIZE="0.009701175738781116" ORDER="2" O_E="0.0" SE="0.030313380809410588" STUDY_ID="STD-Elwood-1976" TOTAL_1="339" TOTAL_2="349" VAR="9.189010560963422E-4" WEIGHT="11.219215738348858"/>
<DICH_DATA CI_END="1.2307710195249892" CI_START="0.8540666682730602" EFFECT_SIZE="1.0252611882114455" ESTIMABLE="YES" EVENTS_1="125" EVENTS_2="121" LOG_CI_END="0.09017726153661808" LOG_CI_START="-0.06850822704750537" LOG_EFFECT_SIZE="0.010834517244556358" ORDER="2" O_E="0.0" SE="0.09321264150015107" STUDY_ID="STD-Briggs-1984" TOTAL_1="265" TOTAL_2="263" VAR="0.008688596535435687" WEIGHT="4.640152959168423"/>
<DICH_DATA CI_END="1.2157969592255466" CI_START="0.8702774062182019" EFFECT_SIZE="1.0286304604486423" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="84" LOG_CI_END="0.08486105285561324" LOG_CI_START="-0.060342291304895414" LOG_EFFECT_SIZE="0.012259380775358921" ORDER="2" O_E="0.0" SE="0.0852931631280285" STUDY_ID="STD-Carson-1975" TOTAL_1="121" TOTAL_2="123" VAR="0.0072749236763844805" WEIGHT="3.182803341247107"/>
<DICH_DATA CI_END="1.478915226390979" CI_START="0.7165309832537555" EFFECT_SIZE="1.0294117647058822" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="34" LOG_CI_END="0.16994328030806025" LOG_CI_START="-0.14476502569201932" LOG_EFFECT_SIZE="0.012589127308020467" ORDER="2" O_E="0.0" SE="0.18486121677568584" STUDY_ID="STD-Van-Straten-2002" TOTAL_1="84" TOTAL_2="84" VAR="0.03417366946778712" WEIGHT="1.2989244647277647"/>
<DICH_DATA CI_END="1.4104576957753285" CI_START="0.8358646789923752" EFFECT_SIZE="1.0857954545454545" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="44" LOG_CI_END="0.14936006477932645" LOG_CI_START="-0.07786402629760039" LOG_EFFECT_SIZE="0.03574801924086301" ORDER="2" O_E="0.0" SE="0.13347255587597787" STUDY_ID="STD-Ludvigsson-1977a" TOTAL_1="80" TOTAL_2="78" VAR="0.01781492317206603" WEIGHT="1.7022390602538093"/>
<DICH_DATA CI_END="2.376736099037988" CI_START="0.5194383599147898" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.37598096250468926" LOG_CI_START="-0.28446598138333895" LOG_EFFECT_SIZE="0.04575749056067514" ORDER="3" O_E="0.0" SE="0.3879498041049261" STUDY_ID="STD-Liljefors-1972" TOTAL_1="33" TOTAL_2="33" VAR="0.1505050505050505" WEIGHT="0.34383294654558477"/>
<DICH_DATA CI_END="1.8244064615962117" CI_START="0.7211901362624564" EFFECT_SIZE="1.1470588235294117" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="18" LOG_CI_END="0.26112160173520715" LOG_CI_START="-0.1419502217667191" LOG_EFFECT_SIZE="0.05958568998424405" ORDER="1" O_E="0.0" SE="0.23676638436273656" STUDY_ID="STD-Peters-1993b" TOTAL_1="34" TOTAL_2="39" VAR="0.056058320764203105" WEIGHT="0.6405654894547881"/>
<DICH_DATA CI_END="2.8401343733334246" CI_START="0.6499882162510531" EFFECT_SIZE="1.358695652173913" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.4533388880106584" LOG_CI_START="-0.1870945166856561" LOG_EFFECT_SIZE="0.13312218566250117" ORDER="2" O_E="0.0" SE="0.37619375211509665" STUDY_ID="STD-Himmelstein-1998a" TOTAL_1="23" TOTAL_2="25" VAR="0.14152173913043478" WEIGHT="0.2928947322425352"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5977828887637725" CI_END="0.6363778117511971" CI_START="0.3549072607306738" DF="4" EFFECT_SIZE="0.4752421550729668" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="105" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="-0.19628497107763548" LOG_CI_START="-0.4498851157185927" LOG_EFFECT_SIZE="-0.32308504339811406" MODIFIED="2012-11-16 19:44:26 +1000" MODIFIED_BY="Jenny Bellorini" NO="2" P_CHI2="0.9633097719947743" P_Z="5.915230137864575E-7" STUDIES="5" TAU2="0.0" TOTAL_1="295" TOTAL_2="303" WEIGHT="3.915557443791499" Z="4.993964415125927">
<NAME>Short-term exposure to severe physical stress and/or cold</NAME>
<DICH_DATA CI_END="0.8438907810122613" CI_START="0.18352405585625245" EFFECT_SIZE="0.39354066985645936" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="19" LOG_CI_END="-0.0737137574893194" LOG_CI_START="-0.7363070014887647" LOG_EFFECT_SIZE="-0.40501037948904206" ORDER="1" O_E="0.0" SE="0.3892105514147293" STUDY_ID="STD-Peters-1996a" TOTAL_1="44" TOTAL_2="47" VAR="0.15148485333255768" WEIGHT="0.7019397883079581"/>
<DICH_DATA CI_END="1.0350260961242161" CI_START="0.1774578149049026" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="14" LOG_CI_END="0.014951299802473108" LOG_CI_START="-0.750904870391662" LOG_EFFECT_SIZE="-0.36797678529459443" MODIFIED="2009-07-16 21:21:36 +1000" MODIFIED_BY="Harri Hemilä" ORDER="2" O_E="0.0" SE="0.4498677054212187" STUDY_ID="STD-Sabiston-1974" TOTAL_1="56" TOTAL_2="56" VAR="0.20238095238095238" WEIGHT="0.5348512501820207"/>
<DICH_DATA CI_END="1.0741949264493045" CI_START="0.1882654724604532" EFFECT_SIZE="0.44970414201183434" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" LOG_CI_END="0.031083096819713486" LOG_CI_START="-0.7252293214854778" LOG_EFFECT_SIZE="-0.3470731123328822" MODIFIED="2012-11-16 19:44:26 +1000" MODIFIED_BY="[Empty name]" ORDER="1" O_E="0.0" SE="0.4442616583193193" STUDY_ID="STD-Moolla-1996a" TOTAL_1="13" TOTAL_2="19" VAR="0.19736842105263158" WEIGHT="0.40352616643197103"/>
<DICH_DATA CI_END="0.7689714119076374" CI_START="0.2955701803859134" EFFECT_SIZE="0.47674418604651164" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="28" LOG_CI_END="-0.11408980568822699" LOG_CI_START="-0.5293393833594375" LOG_EFFECT_SIZE="-0.3217145945238322" ORDER="1" O_E="0.0" SE="0.24391965744262953" STUDY_ID="STD-Peters-1993a" TOTAL_1="43" TOTAL_2="41" VAR="0.05949679928692974" WEIGHT="1.0951716075155664"/>
<DICH_DATA CI_END="0.9506203180347798" CI_START="0.3209178201008496" EFFECT_SIZE="0.5523323276862381" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="31" LOG_CI_END="-0.02199290757114928" LOG_CI_START="-0.49360616649256234" LOG_EFFECT_SIZE="-0.2577995370318558" ORDER="2" O_E="0.0" SE="0.2770279628137204" STUDY_ID="STD-Ritzel-1961" TOTAL_1="139" TOTAL_2="140" VAR="0.07674449218072005" WEIGHT="1.1800686313539823"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2012-12-11 18:25:00 +1000" MODIFIED_BY="Harri Hemilä" NO="2">
<NAME>Duration of the colds occurring when on regular &#8805; 0.2 g/day vitamin C</NAME>
<CONT_OUTCOME CHI2="34.921728583716984" CI_END="-5.898115942249019" CI_START="-12.858583727138166" CI_STUDY="95" CI_TOTAL="95" DF="30" EFFECT_MEASURE="MD" EFFECT_SIZE="-9.378349834693593" ESTIMABLE="YES" I2="14.093599553407694" I2_Q="60.41902872838666" ID="CMP-002.01" MODIFIED="2012-12-11 18:25:00 +1000" MODIFIED_BY="Harri Hemilä" NO="1" P_CHI2="0.24549967717491195" P_Q="0.11195096508539959" P_Z="1.2805561369341822E-7" Q="2.526466551661352" RANDOM="NO" SCALE="23.52755450921634" SORT_BY="EFFECT_SIZE" STUDIES="31" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="5530" TOTAL_2="4215" UNITS="" WEIGHT="100.00000000000003" Z="5.281607063916425">
<NAME>Duration of common cold symptoms (placebo group duration 100%)</NAME>
<GROUP_LABEL_1>Vitamin C</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors vitamin C</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="14.658756116101884" CI_END="-3.6882168456847078" CI_START="-11.757625150319868" DF="16" EFFECT_SIZE="-7.722920998002287" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.01" MODIFIED="2012-12-11 18:25:00 +1000" MODIFIED_BY="Harri Hemilä" NO="1" P_CHI2="0.549759251520362" P_Z="1.7570079754609228E-4" STUDIES="17" TAU2="0.0" TOTAL_1="4228" TOTAL_2="2987" WEIGHT="74.4035185199824" Z="3.751612618942074">
<NAME>Trials with adults</NAME>
<CONT_DATA CI_END="9.8217250320684" CI_START="-93.8217250320684" EFFECT_SIZE="-42.0" ESTIMABLE="YES" MEAN_1="58.0" MEAN_2="100.0" ORDER="2" SD_1="96.0" SD_2="150.0" SE="26.440141472410488" STUDY_ID="STD-Van-Straten-2002" TOTAL_1="37" TOTAL_2="50" WEIGHT="0.45101722963838337"/>
<CONT_DATA CI_END="8.352714597203843" CI_START="-88.35271459720384" EFFECT_SIZE="-40.0" ESTIMABLE="YES" MEAN_1="60.0" MEAN_2="100.0" ORDER="2" SD_1="26.0" SD_2="82.0" SE="24.670205666330546" STUDY_ID="STD-Himmelstein-1998a" TOTAL_1="14" TOTAL_2="12" WEIGHT="0.5180541320802519"/>
<CONT_DATA CI_END="-8.857462657856075" CI_START="-61.142537342143925" EFFECT_SIZE="-35.0" ESTIMABLE="YES" MEAN_1="65.0" MEAN_2="100.0" ORDER="2" SD_1="75.0" SD_2="75.0" SE="13.338274350117105" STUDY_ID="STD-Carr-1981b" TOTAL_1="57" TOTAL_2="71" WEIGHT="1.7722353301580904"/>
<CONT_DATA CI_END="19.818224887228418" CI_START="-75.81822488722841" EFFECT_SIZE="-28.0" ESTIMABLE="YES" MEAN_1="72.0" MEAN_2="100.0" MODIFIED="2009-08-31 17:45:36 +1000" MODIFIED_BY="Harri Hemilä" ORDER="2" SD_1="50.0" SD_2="50.0" SE="24.39750182371333" STUDY_ID="STD-Sabiston-1974" TOTAL_1="6" TOTAL_2="14" WEIGHT="0.529699988969416"/>
<CONT_DATA CI_END="6.264002550660841" CI_START="-56.26400255066084" EFFECT_SIZE="-25.0" ESTIMABLE="YES" MEAN_1="75.0" MEAN_2="100.0" MODIFIED="2012-12-11 18:25:00 +1000" MODIFIED_BY="[Empty name]" ORDER="1" SD_1="38.0" SD_2="56.0" SE="15.951314818673865" STUDY_ID="STD-Peters-1993b" TOTAL_1="18" TOTAL_2="18" WEIGHT="1.239160922417536"/>
<CONT_DATA CI_END="-1.719014703951876" CI_START="-30.280985296048122" EFFECT_SIZE="-16.0" ESTIMABLE="YES" MEAN_1="84.0" MEAN_2="100.0" MODIFIED="2009-08-31 17:45:35 +1000" MODIFIED_BY="Harri Hemilä" ORDER="2" SD_1="46.0" SD_2="20.0" SE="7.286350876186865" STUDY_ID="STD-Charleston-1972" TOTAL_1="44" TOTAL_2="80" WEIGHT="5.938824892636553"/>
<CONT_DATA CI_END="62.37412173803423" CI_START="-92.37412173803423" EFFECT_SIZE="-15.0" ESTIMABLE="YES" MEAN_1="85.0" MEAN_2="100.0" MODIFIED="2012-12-11 18:24:58 +1000" MODIFIED_BY="Harri Hemilä" ORDER="1" SD_1="85.0" SD_2="100.0" SE="39.47731812847146" STUDY_ID="STD-Peters-1996a" TOTAL_1="7" TOTAL_2="19" WEIGHT="0.2023137496566338"/>
<CONT_DATA CI_END="2.8726343823988625" CI_START="-28.072634382398853" EFFECT_SIZE="-12.599999999999994" ESTIMABLE="YES" MEAN_1="87.4" MEAN_2="100.0" ORDER="3" SD_1="51.5" SD_2="52.0" SE="7.894346275974978" STUDY_ID="STD-Karlowski-1975a" TOTAL_1="128" TOTAL_2="65" WEIGHT="5.059275596576403"/>
<CONT_DATA CI_END="3.396125257263499" CI_START="-17.3961252572635" EFFECT_SIZE="-7.0" ESTIMABLE="YES" MEAN_1="93.0" MEAN_2="100.0" ORDER="3" SD_1="102.0" SD_2="99.0" SE="5.3042430061301165" STUDY_ID="STD-Anderson-1974a" TOTAL_1="1823" TOTAL_2="437" WEIGHT="11.206599651671048"/>
<CONT_DATA CI_END="18.269754360351122" CI_START="-30.269754360351122" EFFECT_SIZE="-6.0" ESTIMABLE="YES" MEAN_1="94.0" MEAN_2="100.0" MODIFIED="2012-09-18 17:47:57 +1000" MODIFIED_BY="Harri Hemilä" ORDER="2" SD_1="94.0" SD_2="100.0" SE="12.382755270906939" STUDY_ID="STD-Briggs-1984" TOTAL_1="125" TOTAL_2="121" WEIGHT="2.056298234697085"/>
<CONT_DATA CI_END="4.207444281507918" CI_START="-16.207444281507918" EFFECT_SIZE="-6.0" ESTIMABLE="YES" MEAN_1="94.0" MEAN_2="100.0" ORDER="2" SD_1="90.0" SD_2="99.0" SE="5.207975433233945" STUDY_ID="STD-Elwood-1976" TOTAL_1="627" TOTAL_2="690" WEIGHT="11.624728760403142"/>
<CONT_DATA CI_END="5.018540471582154" CI_START="-15.018540471582154" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="95.0" MEAN_2="100.0" ORDER="3" SD_1="92.0" SD_2="82.0" SE="5.111594167345483" STUDY_ID="STD-Anderson-1972" TOTAL_1="561" TOTAL_2="609" WEIGHT="12.06724000102981"/>
<CONT_DATA CI_END="8.228842892745416" CI_START="-18.228842892745416" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="95.0" MEAN_2="100.0" MODIFIED="2009-07-16 21:02:11 +1000" MODIFIED_BY="Harri Hemilä" ORDER="2" SD_1="41.0" SD_2="39.0" SE="6.7495336634207765" STUDY_ID="STD-Clegg-1975" TOTAL_1="68" TOTAL_2="73" WEIGHT="6.921068485412338"/>
<CONT_DATA CI_END="8.628687467894292" CI_START="-13.82868746789428" EFFECT_SIZE="-2.5999999999999943" ESTIMABLE="YES" MEAN_1="97.4" MEAN_2="100.0" MODIFIED="2012-09-18 17:47:56 +1000" MODIFIED_BY="Harri Hemilä" ORDER="3" SD_1="100.0" SD_2="100.0" SE="5.729027449720882" STUDY_ID="STD-Pitt-1979" TOTAL_1="600" TOTAL_2="619" WEIGHT="9.60636039997857"/>
<CONT_DATA CI_END="30.70491413043939" CI_START="-28.70491413043939" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="101.0" MEAN_2="100.0" ORDER="2" SD_1="96.0" SD_2="96.0" SE="15.155846926141482" STUDY_ID="STD-Carr-1981a" TOTAL_1="94" TOTAL_2="70" WEIGHT="1.3726514135875922"/>
<CONT_DATA CI_END="20.925138531110083" CI_START="-14.925138531110083" EFFECT_SIZE="3.0" ESTIMABLE="YES" MEAN_1="103.0" MEAN_2="100.0" MODIFIED="2012-12-11 18:24:55 +1000" MODIFIED_BY="[Empty name]" ORDER="1" SD_1="17.0" SD_2="42.0" SE="9.145646895810987" STUDY_ID="STD-Peters-1993a" TOTAL_1="14" TOTAL_2="28" WEIGHT="3.769570089449303"/>
<CONT_DATA CI_END="169.0509667798465" CI_START="-97.0509667798465" EFFECT_SIZE="36.0" ESTIMABLE="YES" MEAN_1="136.0" MEAN_2="100.0" MODIFIED="2012-12-11 18:24:54 +1000" MODIFIED_BY="Harri Hemilä" ORDER="1" SD_1="136.0" SD_2="100.0" SE="67.88439370791278" STUDY_ID="STD-Peters-1996b" TOTAL_1="5" TOTAL_2="11" WEIGHT="0.0684196416202368"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="17.73650591595375" CI_END="-7.311439863585772" CI_START="-21.069217708408395" DF="13" EFFECT_SIZE="-14.190328785997083" ESTIMABLE="YES" I2="26.70484219607948" ID="CMP-002.01.02" MODIFIED="2012-09-18 21:21:03 +1000" MODIFIED_BY="Harri Hemilä" NO="2" P_CHI2="0.1677829797558238" P_Z="5.2732833080496395E-5" STUDIES="14" TAU2="0.0" TOTAL_1="1302" TOTAL_2="1228" WEIGHT="25.596481480017626" Z="4.043172329578325">
<NAME>Trials with children</NAME>
<CONT_DATA CI_END="-13.22313388687379" CI_START="-80.7768661131262" EFFECT_SIZE="-47.0" ESTIMABLE="YES" MEAN_1="53.0" MEAN_2="100.0" MODIFIED="2012-05-30 22:16:38 +1000" MODIFIED_BY="Harri Hemilä" ORDER="84" SD_1="48.0" SD_2="68.0" SE="17.233411623659322" STUDY_ID="STD-Constantini-2011a" TOTAL_1="30" TOTAL_2="21" WEIGHT="1.0616421661938333"/>
<CONT_DATA CI_END="-18.562632612641327" CI_START="-59.43736738735868" EFFECT_SIZE="-39.0" ESTIMABLE="YES" MEAN_1="61.0" MEAN_2="100.0" ORDER="2" SD_1="41.0" SD_2="67.0" SE="10.42741986514345" STUDY_ID="STD-Ludvigsson-1977a" TOTAL_1="62" TOTAL_2="55" WEIGHT="2.8997927534176484"/>
<CONT_DATA CI_END="-0.8328989389917396" CI_START="-61.16710106100826" EFFECT_SIZE="-31.0" ESTIMABLE="YES" MEAN_1="69.0" MEAN_2="100.0" ORDER="2" SD_1="51.0" SD_2="51.0" SE="15.39166091773242" STUDY_ID="STD-Ritzel-1961" TOTAL_1="17" TOTAL_2="31" WEIGHT="1.3309131245827415"/>
<CONT_DATA CI_END="29.906546995446803" CI_START="-87.9065469954468" EFFECT_SIZE="-29.0" ESTIMABLE="YES" MEAN_1="71.0" MEAN_2="100.0" MODIFIED="2012-09-18 17:47:53 +1000" MODIFIED_BY="Harri Hemilä" ORDER="2" SD_1="71.0" SD_2="100.0" SE="30.054912978041497" STUDY_ID="STD-Coulehan-1974b" TOTAL_1="16" TOTAL_2="17" WEIGHT="0.34905167989453795"/>
<CONT_DATA CI_END="3.2290934241852653" CI_START="-51.229093424185265" EFFECT_SIZE="-24.0" ESTIMABLE="YES" MEAN_1="76.0" MEAN_2="100.0" ORDER="2" SD_1="62.0" SD_2="65.0" SE="13.892649884877926" STUDY_ID="STD-Bancalari-1984" TOTAL_1="38" TOTAL_2="46" WEIGHT="1.6336179629081613"/>
<CONT_DATA CI_END="15.475132563952094" CI_START="-46.475132563952094" EFFECT_SIZE="-15.5" ESTIMABLE="YES" MEAN_1="84.5" MEAN_2="100.0" MODIFIED="2012-09-18 21:20:54 +1000" MODIFIED_BY="Harri Hemilä" ORDER="1" SD_1="131.0" SD_2="134.0" SE="15.803929464153416" STUDY_ID="STD-Wilson-1973a" TOTAL_1="160" TOTAL_2="126" WEIGHT="1.2623811959997568"/>
<CONT_DATA CI_END="5.5545540060743654" CI_START="-31.554554006074365" EFFECT_SIZE="-13.0" ESTIMABLE="YES" MEAN_1="87.0" MEAN_2="100.0" MODIFIED="2012-09-18 21:20:53 +1000" MODIFIED_BY="Harri Hemilä" ORDER="1" SD_1="73.0" SD_2="73.0" SE="9.466783141134387" STUDY_ID="STD-Miller-1977c" TOTAL_1="116" TOTAL_2="122" WEIGHT="3.5181619297630737"/>
<CONT_DATA CI_END="44.88494730379878" CI_START="-68.88494730379878" EFFECT_SIZE="-12.0" ESTIMABLE="YES" MEAN_1="88.0" MEAN_2="100.0" MODIFIED="2012-09-18 17:47:52 +1000" MODIFIED_BY="Harri Hemilä" ORDER="2" SD_1="88.0" SD_2="100.0" SE="29.023465610847946" STUDY_ID="STD-Coulehan-1974a" TOTAL_1="19" TOTAL_2="23" WEIGHT="0.3743019968230987"/>
<CONT_DATA CI_END="35.51445466534522" CI_START="-49.51445466534522" EFFECT_SIZE="-7.0" ESTIMABLE="YES" MEAN_1="93.0" MEAN_2="100.0" MODIFIED="2012-09-18 18:15:07 +1000" MODIFIED_BY="[Empty name]" ORDER="2" SD_1="105.0" SD_2="105.0" SE="21.691446884072263" STUDY_ID="STD-Miller-1977a" TOTAL_1="53" TOTAL_2="42" WEIGHT="0.6701062039713342"/>
<CONT_DATA CI_END="7.822074651286913" CI_START="-19.82207465128691" EFFECT_SIZE="-6.0" ESTIMABLE="YES" MEAN_1="94.0" MEAN_2="100.0" ORDER="2" SD_1="85.0" SD_2="114.0" SE="7.052208489703726" STUDY_ID="STD-Ludvigsson-1977b" TOTAL_1="423" TOTAL_2="398" WEIGHT="6.339724649786267"/>
<CONT_DATA CI_END="22.30847107559838" CI_START="-32.308471075598376" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="95.0" MEAN_2="100.0" MODIFIED="2012-09-18 17:47:51 +1000" MODIFIED_BY="Harri Hemilä" ORDER="2" SD_1="95.0" SD_2="100.0" SE="13.93314943080797" STUDY_ID="STD-Coulehan-1976" TOTAL_1="98" TOTAL_2="98" WEIGHT="1.6241348763845431"/>
<CONT_DATA CI_END="18.650622148796046" CI_START="-24.650622148796046" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="97.0" MEAN_2="100.0" MODIFIED="2012-09-18 21:20:51 +1000" MODIFIED_BY="Harri Hemilä" ORDER="1" SD_1="50.0" SD_2="50.0" SE="11.04643877110671" STUDY_ID="STD-Miller-1977b" TOTAL_1="42" TOTAL_2="40" WEIGHT="2.5839023852166636"/>
<CONT_DATA CI_END="35.92054984993845" CI_START="-19.92054984993845" EFFECT_SIZE="8.0" ESTIMABLE="YES" MEAN_1="108.0" MEAN_2="100.0" MODIFIED="2012-09-18 21:20:51 +1000" MODIFIED_BY="Harri Hemilä" ORDER="1" SD_1="150.0" SD_2="132.0" SE="14.245440258174224" STUDY_ID="STD-Wilson-1973b" TOTAL_1="205" TOTAL_2="187" WEIGHT="1.5537063141583332"/>
<CONT_DATA CI_END="71.3714076990638" CI_START="-39.371407699063795" EFFECT_SIZE="16.0" ESTIMABLE="YES" MEAN_1="116.0" MEAN_2="100.0" MODIFIED="2012-05-30 22:18:22 +1000" MODIFIED_BY="Harri Hemilä" ORDER="85" SD_1="74.0" SD_2="111.0" SE="28.251237336923733" STUDY_ID="STD-Constantini-2011b" TOTAL_1="23" TOTAL_2="22" WEIGHT="0.39504424091762735"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2012-09-21 09:11:52 +1000" MODIFIED_BY="Harri Hemilä" NO="3">
<NAME>Severity of the colds occurring when on regular &#8805; 0.2 g/day vitamin C</NAME>
<CONT_OUTCOME CHI2="27.759674333908052" CI_END="-0.06965193710026069" CI_START="-0.16839894684668674" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.11902544197347371" ESTIMABLE="YES" I2="45.9647839539756" I2_Q="0.0" ID="CMP-003.01" MODIFIED="2012-09-18 21:23:07 +1000" MODIFIED_BY="Harri Hemilä" NO="1" P_CHI2="0.02312274037083739" P_Q="0.6324802705492218" P_Z="2.3021241413939997E-6" Q="0.22871234977583388" RANDOM="NO" SCALE="0.24143133202156036" SORT_BY="EFFECT_SIZE" STUDIES="16" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="4297" TOTAL_2="2912" UNITS="" WEIGHT="100.0" Z="4.7249143059831">
<NAME>Indicators of common cold severity</NAME>
<GROUP_LABEL_1>Vitamin C</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vitamin C</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="17.72715995096297" CI_END="-0.049904736923497055" CI_START="-0.17103030405367953" DF="6" EFFECT_SIZE="-0.1104675204885883" ESTIMABLE="YES" I2="66.15363083202693" ID="CMP-003.01.01" MODIFIED="2012-05-29 05:54:14 +1000" MODIFIED_BY="Harri Hemilä" NO="1" P_CHI2="0.006951485778020405" P_Z="3.502188256342521E-4" STUDIES="7" TAU2="0.0" TOTAL_1="3240" TOTAL_2="1826" WEIGHT="66.46243665640534" Z="3.5750067760074464">
<NAME>Mean days indoors or off work or school</NAME>
<CONT_DATA CI_END="0.16342919544289758" CI_START="-1.8347178226594871" EFFECT_SIZE="-0.8356443136082947" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="2.4" ORDER="2" SD_1="0.8" SD_2="2.1" SE="0.5097407487748533" STUDY_ID="STD-Sabiston-1974" TOTAL_1="6" TOTAL_2="14" WEIGHT="0.2442266362417927"/>
<CONT_DATA CI_END="-0.14159224825983496" CI_START="-0.8797912596171754" EFFECT_SIZE="-0.5106917539385052" ESTIMABLE="YES" MEAN_1="0.95" MEAN_2="1.9" ORDER="2" SD_1="1.12" SD_2="2.42" SE="0.18831953474149526" STUDY_ID="STD-Ludvigsson-1977a" TOTAL_1="62" TOTAL_2="55" WEIGHT="1.78937344503051"/>
<CONT_DATA CI_END="0.009466477806700513" CI_START="-0.45889556297153217" EFFECT_SIZE="-0.22471454258241583" ESTIMABLE="YES" MEAN_1="4.52" MEAN_2="5.94" ORDER="1" SD_1="6.32" SD_2="6.28" SE="0.1194823079588739" STUDY_ID="STD-Wilson-1973a" TOTAL_1="160" TOTAL_2="126" WEIGHT="4.445130618497387"/>
<CONT_DATA CI_END="-0.08270781192729063" CI_START="-0.3572775828916003" EFFECT_SIZE="-0.21999269740944544" ESTIMABLE="YES" MEAN_1="1.47" MEAN_2="1.81" ORDER="2" SD_1="1.27" SD_2="1.79" SE="0.07004459600535544" STUDY_ID="STD-Ludvigsson-1977b" TOTAL_1="423" TOTAL_2="398" WEIGHT="12.93428611280835"/>
<CONT_DATA CI_END="-0.033647428910286326" CI_START="-0.2633573318601834" EFFECT_SIZE="-0.14850238038523486" ESTIMABLE="YES" MEAN_1="1.04" MEAN_2="1.32" ORDER="2" SD_1="1.75" SD_2="2.0" SE="0.058600541836946865" STUDY_ID="STD-Anderson-1972" TOTAL_1="561" TOTAL_2="609" WEIGHT="18.479425682228694"/>
<CONT_DATA CI_END="0.09842420243091375" CI_START="-0.11036058787018192" EFFECT_SIZE="-0.005968192719634083" ESTIMABLE="YES" MEAN_1="1.14" MEAN_2="1.15" ORDER="3" SD_1="1.71" SD_2="1.52" SE="0.05326240480640549" STUDY_ID="STD-Anderson-1974a" TOTAL_1="1823" TOTAL_2="437" WEIGHT="22.369186531853078"/>
<CONT_DATA CI_END="0.27859451737945795" CI_START="-0.11795718997965607" EFFECT_SIZE="0.08031866369990096" ESTIMABLE="YES" MEAN_1="4.2" MEAN_2="3.84" ORDER="1" SD_1="4.44" SD_2="4.51" SE="0.10116300873053365" STUDY_ID="STD-Wilson-1973b" TOTAL_1="205" TOTAL_2="187" WEIGHT="6.200807629745536"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="9.80380203316925" CI_END="-0.05072830388353408" CI_START="-0.22124158060453766" DF="8" EFFECT_SIZE="-0.13598494224403587" ESTIMABLE="YES" I2="18.399005070343502" ID="CMP-003.01.02" MODIFIED="2012-05-30 22:22:59 +1000" MODIFIED_BY="Harri Hemilä" NO="2" P_CHI2="0.27906749807555586" P_Z="0.0017710730828001105" STUDIES="9" TAU2="0.0" TOTAL_1="1057" TOTAL_2="1086" WEIGHT="33.53756334359465" Z="3.126156442048356">
<NAME>Mean symptom severity score</NAME>
<CONT_DATA CI_END="-0.0937513716554218" CI_START="-1.241199031774629" EFFECT_SIZE="-0.6674752017150255" ESTIMABLE="YES" MEAN_1="26.0" MEAN_2="66.0" MODIFIED="2012-05-30 22:22:12 +1000" MODIFIED_BY="Harri Hemilä" ORDER="86" SD_1="30.0" SD_2="85.0" SE="0.29272161865476304" STUDY_ID="STD-Constantini-2011a" TOTAL_1="30" TOTAL_2="21" WEIGHT="0.7405973215825418"/>
<CONT_DATA CI_END="0.23408635925248322" CI_START="-1.3422945860878905" EFFECT_SIZE="-0.5541041134177037" ESTIMABLE="YES" MEAN_1="16.1" MEAN_2="37.4" ORDER="2" SD_1="14.59" SD_2="52.65" SE="0.402145385776133" STUDY_ID="STD-Himmelstein-1998a" TOTAL_1="14" TOTAL_2="12" WEIGHT="0.3923968868032011"/>
<CONT_DATA CI_END="0.004775836878712303" CI_START="-0.6976694137552548" EFFECT_SIZE="-0.34644678843827126" ESTIMABLE="YES" MEAN_1="21.9" MEAN_2="33.6" ORDER="2" SD_1="33.57" SD_2="33.57" SE="0.17919850981313065" STUDY_ID="STD-Carr-1981b" TOTAL_1="57" TOTAL_2="71" WEIGHT="1.9761638269718118"/>
<CONT_DATA CI_END="0.03564703719218182" CI_START="-0.47424724928125933" EFFECT_SIZE="-0.21930010604453876" ESTIMABLE="YES" MEAN_1="14.6" MEAN_2="19.0" ORDER="1" SD_1="20.0" SD_2="20.0" SE="0.1300774632838721" STUDY_ID="STD-Miller-1977c" TOTAL_1="116" TOTAL_2="122" WEIGHT="3.750486575080677"/>
<CONT_DATA CI_END="-0.019089318095770358" CI_START="-0.24390636713126856" EFFECT_SIZE="-0.13149784261351946" ESTIMABLE="YES" MEAN_1="1.87" MEAN_2="1.97" ORDER="3" SD_1="0.76" SD_2="0.76" SE="0.05735234188200048" STUDY_ID="STD-Pitt-1979" TOTAL_1="600" TOTAL_2="619" WEIGHT="19.29254049670296"/>
<CONT_DATA CI_END="0.30054323028077884" CI_START="-0.5098261306688006" EFFECT_SIZE="-0.10464145019401085" ESTIMABLE="YES" MEAN_1="22.5" MEAN_2="27.3" ORDER="2" SD_1="45.5" SD_2="45.5" SE="0.20673067651795377" STUDY_ID="STD-Miller-1977a" TOTAL_1="53" TOTAL_2="42" WEIGHT="1.484847600009741"/>
<CONT_DATA CI_END="0.350970130113358" CI_START="-0.26794906959665854" EFFECT_SIZE="0.04151053025834971" ESTIMABLE="YES" MEAN_1="23.6" MEAN_2="22.2" ORDER="2" SD_1="33.57" SD_2="33.57" SE="0.1578904522205439" STUDY_ID="STD-Carr-1981a" TOTAL_1="94" TOTAL_2="70" WEIGHT="2.5455404101835377"/>
<CONT_DATA CI_END="0.39694925682773513" CI_START="-0.2915980566836754" EFFECT_SIZE="0.052675600072029885" ESTIMABLE="YES" MEAN_1="25.0" MEAN_2="22.0" MODIFIED="2012-05-30 22:22:59 +1000" MODIFIED_BY="Harri Hemilä" ORDER="87" SD_1="64.0" SD_2="52.0" SE="0.1756530525414201" STUDY_ID="STD-Constantini-2011b" TOTAL_1="51" TOTAL_2="89" WEIGHT="2.0567444312739784"/>
<CONT_DATA CI_END="0.538522739774318" CI_START="-0.3281307515367394" EFFECT_SIZE="0.10519599411878928" ESTIMABLE="YES" MEAN_1="48.6" MEAN_2="46.2" ORDER="1" SD_1="22.6" SD_2="22.6" SE="0.2210891368788175" STUDY_ID="STD-Miller-1977b" TOTAL_1="42" TOTAL_2="40" WEIGHT="1.2982457949861976"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2012-09-21 09:12:37 +1000" MODIFIED_BY="Harri Hemilä" NO="4">
<NAME>Duration of the colds after therapeutic &#8805; 0.2 g/day vitamin C</NAME>
<CONT_OUTCOME CHI2="10.515873319581008" CI_END="2.386404485386967" CI_START="-8.196084935632896" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.904840225122965" ESTIMABLE="YES" I2="42.943397874261734" I2_Q="0.0" ID="CMP-004.01" MODIFIED="2012-09-21 09:12:37 +1000" MODIFIED_BY="Harri Hemilä" NO="1" P_CHI2="0.10454184587488191" P_Q="1.0" P_Z="0.2819270264734852" Q="0.0" RANDOM="NO" SCALE="22.52" SORT_BY="EFFECT_SIZE" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1968" TOTAL_2="1281" UNITS="" WEIGHT="99.99999999999999" Z="1.0760005506408619">
<NAME>Duration of common cold symptoms (placebo group duration 100%)</NAME>
<GROUP_LABEL_1>Vitamin C</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vitamin C</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-3.9772230626923175" CI_START="-26.022776937307682" EFFECT_SIZE="-15.0" ESTIMABLE="YES" MEAN_1="85.0" MEAN_2="100.0" ORDER="3" SD_1="91.0" SD_2="99.0" SE="5.623969126093102" STUDY_ID="STD-Anderson-1974e" TOTAL_1="900" TOTAL_2="437" WEIGHT="23.04271545181953"/>
<CONT_DATA CI_END="6.586652737687629" CI_START="-26.58665273768763" EFFECT_SIZE="-10.0" ESTIMABLE="YES" MEAN_1="90.0" MEAN_2="100.0" ORDER="3" SD_1="41.0" SD_2="52.0" SE="8.462733432104379" STUDY_ID="STD-Karlowski-1975c" TOTAL_1="56" TOTAL_2="65" WEIGHT="10.176494217326226"/>
<CONT_DATA CI_END="11.55159250060065" CI_START="-17.55159250060065" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="97.0" MEAN_2="100.0" ORDER="2" SD_1="96.0" SD_2="84.0" SE="7.424418313490326" STUDY_ID="STD-Anderson-1975a" TOTAL_1="419" TOTAL_2="213" WEIGHT="13.221923679718362"/>
<CONT_DATA CI_END="14.263860050695632" CI_START="-16.263860050695634" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="99.0" MEAN_2="100.0" ORDER="3" SD_1="75.0" SD_2="51.0" SE="7.787826802479541" STUDY_ID="STD-Elwood-1977" TOTAL_1="145" TOTAL_2="119" WEIGHT="12.01674772104703"/>
<CONT_DATA CI_END="11.92179526501691" CI_START="-5.921795265016909" EFFECT_SIZE="3.0" ESTIMABLE="YES" MEAN_1="103.0" MEAN_2="100.0" ORDER="3" SD_1="57.0" SD_2="54.0" SE="4.552020004138286" STUDY_ID="STD-Tyrrell-1977" TOTAL_1="274" TOTAL_2="329" WEIGHT="35.17314389541588"/>
<CONT_DATA CI_END="41.69141624983604" CI_START="-21.691416249836035" EFFECT_SIZE="10.0" ESTIMABLE="YES" MEAN_1="110.0" MEAN_2="100.0" ORDER="3" SD_1="100.0" SD_2="100.0" SE="16.169387039666994" STUDY_ID="STD-Cowan-1950" TOTAL_1="77" TOTAL_2="76" WEIGHT="2.7876124741744417"/>
<CONT_DATA CI_END="48.95977696584864" CI_START="-6.95977696584864" EFFECT_SIZE="21.0" ESTIMABLE="YES" MEAN_1="121.0" MEAN_2="100.0" MODIFIED="2009-09-18 21:30:21 +1000" MODIFIED_BY="Harri Hemilä" ORDER="2" SD_1="80.0" SD_2="76.0" SE="14.265454460587945" STUDY_ID="STD-Audera-2001a" TOTAL_1="97" TOTAL_2="42" WEIGHT="3.5813625604985133"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2012-09-21 09:13:32 +1000" MODIFIED_BY="Jenny Bellorini" NO="5">
<NAME>Severity of the colds after therapeutic &#8805; 0.2 g/day vitamin C</NAME>
<CONT_OUTCOME CHI2="4.131122266059785" CI_END="0.00825507130240001" CI_START="-0.15006478808621831" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.07090485839190915" ESTIMABLE="YES" I2="27.38050808500122" I2_Q="32.95323684829995" ID="CMP-005.01" MODIFIED="2012-09-21 09:13:32 +1000" MODIFIED_BY="Jenny Bellorini" NO="1" P_CHI2="0.24764907592580143" P_Q="0.2219847998537634" P_Z="0.07916148931539159" Q="1.4914963124131726" RANDOM="NO" SCALE="0.27" SORT_BY="EFFECT_SIZE" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1687" TOTAL_2="1021" UNITS="" WEIGHT="100.0" Z="1.7555721602295111">
<NAME>Indicators of common cold severity</NAME>
<GROUP_LABEL_1>Vitamin C</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vitamin C</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.6396259536466133" CI_END="-8.254703744750569E-4" CI_START="-0.16306148310567464" DF="2" EFFECT_SIZE="-0.08194347674007485" ESTIMABLE="YES" I2="24.23168906802789" ID="CMP-005.01.01" MODIFIED="2012-09-18 18:43:09 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2671854261331956" P_Z="0.047713765587679674" STUDIES="3" TAU2="0.0" TOTAL_1="1590" TOTAL_2="979" WEIGHT="95.23054344077211" Z="1.979908905239708">
<NAME>Mean days indoors or off work or school</NAME>
<CONT_DATA CI_END="-0.028844735250818487" CI_START="-0.35981505550276777" EFFECT_SIZE="-0.19432989537679313" ESTIMABLE="YES" MEAN_1="0.86" MEAN_2="1.1" ORDER="2" SD_1="1.1" SD_2="1.46" SE="0.08443275561760341" STUDY_ID="STD-Anderson-1975a" TOTAL_1="416" TOTAL_2="213" WEIGHT="22.881931997437853"/>
<CONT_DATA CI_END="0.04912813535295535" CI_START="-0.17947572596177802" EFFECT_SIZE="-0.06517379530441134" ESTIMABLE="YES" MEAN_1="1.07" MEAN_2="1.17" MODIFIED="2012-09-18 18:43:09 +1000" MODIFIED_BY="[Empty name]" ORDER="3" SD_1="1.54" SD_2="1.52" SE="0.05831838317385713" STUDY_ID="STD-Anderson-1974e" TOTAL_1="900" TOTAL_2="437" WEIGHT="47.96270489586624"/>
<CONT_DATA CI_END="0.1508295695126264" CI_START="-0.16977222056592609" EFFECT_SIZE="-0.009471325526649843" ESTIMABLE="YES" MEAN_1="0.33" MEAN_2="0.34" MODIFIED="2012-09-18 18:43:09 +1000" MODIFIED_BY="[Empty name]" ORDER="3" SD_1="0.83" SD_2="1.21" SE="0.08178767380610524" STUDY_ID="STD-Tyrrell-1977" TOTAL_1="274" TOTAL_2="329" WEIGHT="24.38590654746803"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5119695347775967" CI_START="-0.21296860109130197" DF="0" EFFECT_SIZE="0.14950046684314736" ESTIMABLE="YES" I2="0.0" ID="CMP-005.01.02" MODIFIED="2012-05-29 05:54:01 +1000" MODIFIED_BY="Harri Hemilä" NO="2" P_CHI2="1.0" P_Z="0.41886744654042884" STUDIES="1" TAU2="0.0" TOTAL_1="97" TOTAL_2="42" WEIGHT="4.769456559227897" Z="0.808387684925114">
<NAME>Mean symptom severity score</NAME>
<CONT_DATA CI_END="0.5119695347775967" CI_START="-0.21296860109130197" EFFECT_SIZE="0.14950046684314736" ESTIMABLE="YES" MEAN_1="34.83" MEAN_2="29.0" MODIFIED="2009-09-18 21:30:34 +1000" MODIFIED_BY="Harri Hemilä" ORDER="3" SD_1="41.77" SD_2="30.67" SE="0.1849365961790926" STUDY_ID="STD-Audera-2001a" TOTAL_1="97" TOTAL_2="42" WEIGHT="4.769456559227897"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2012-12-11 18:25:01 +1000" MODIFIED_BY="Harri Hemilä">
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2012-12-10 01:51:29 +1000" MODIFIED_BY="Harri Hemilä" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAToAAAi3CAIAAAA+lkveAABhc0lEQVR42u3dv44Uy7qm8ZKQEAYG
xroCrgELISywuKe1TIwtsc11F4hLGHFmzMOx8BCH7tF0G9ugwZsZWjFVu7fW9KnOyoyMzMiOL/P3
qbTEKpqnsqviyfiTWfHudkqpQJWUUs0XXZWiq1KKrkrRVSlFV6UUXZWiq1KKrkopuipFV6UmNCk3
zNFVtd+Ycp5UdFX33JKK/1bRVSm6KpXXzWpadFVhXDUMpquiK12Voitd1TabFFfpqhRd6aoUXdV2
m5T7EOmq2m9Pt/+gadFVhdGVsXRVdKWrUnMbq2nRVSm6KqXoqrYzBpbARFelFF2VoqvSpIyE6api
zGD7n1F0VXSlq1ITjNW06KoCTFlNX+mqFF3pqhRdlVJ0VYquSim6qs01KZu/0FW1355O/UHRVdGV
rkrRla5qO3NXTYuuStFVKUVXtdnpq4krXVUYVxlLV0VXuio1b5OyMkxXpehKV6XoqjY/GNa66Kra
bU/eBLoqulrEoquKYGxnK91g06Wrqjtxnd66+gmbar10VYquSlUbZpu7KlVrPDy7qxscBtNV1e0A
5zWKrnRVdXWdUSq60lWF0fVoymruqtTMxmpadFWKrkqFaKwbvg+RriqGVPXWnOmqtj5xrTolrv1a
dFUz9FR0pStd2/1gcp7cprEGwypGi2/887IgRFe19bmromuY1r/luetfS8H6bbrGcDVQ36U50ZWu
MUzQB9KVrqKNO84FdFUtfjxGwkn6Dl1VIGPpSlcVae4qOZauwVq/N8GFHLo2Parc8ndQFF1D6pri
rDa5ikNXuqaI9/drXXTdorFBL+RoXXRVdKWrUg3PXa0M07XdPirWpYvax6aV0lXNf4qhK11VvGFw
1bua6Ko2NA8M1we6q4muwZr+lvdVU3SlK2Ppqio0/Yh3IM4+d/VtB7rGaPQb/6TcgEFXRVe6KkOD
uS/DhtO14n1dGpmaV6p66ekh5gWVFh3oqsLoGnfoPtdwg66KrkvMtPWuG5oHxrqxad4DDhq6UeMI
6bq5M7QKf/r2RtA13LvhQo5ibIuD4bg3jcx7WYuukSauW95aLeiZ69Qf6KoMWemqVKmxs9/TE+ss
QNdNj4eDDuBnOfi4Xyec902gq4Hl1t+NQPvX0ZWuVY529iOvIVUnqlkp6Ko/2WjTr3qKqTQpoOvm
5q61pfJ9er2rCjNkXeDklaqtOZu7KjWzUfOeXAJ9R5eu7TbNZbbYDreDcSBdZ199oKueKsAwmK50
jTfPDDH8W2DuWmkPpBpvxbx3YtE1QLussTg8u642W13g3aBrpN41RH8SbqwR7yzADbXZsUaKs8kO
XcN0KVE+psX2GZ6dXOmKrsHwRgfD7fcn1pyrngjoukVd6/Uny9xyEOWYfd9109O2DTbQxU4Et9/w
Zt9num663w4UjRH3WvGMJwK6MnbrNyHGG21pvo0PhpNth+UD0FV/UluqjbcuF3Lo2m5/oi1VfTfo
qndtuoGm+7iria6qoWYUzti75Ci57NLTVdP9yWLD7JbJvpGjKnaAW07fSXHuzaZrgK4vUE8Va0QQ
7ju6dNXBNv0dlNW8z+5qUgH67drMEMkG7hnell0p7J4PM74POU/SVa3kww5tbIqZx0dXugYbbBsf
zfXxeUPpquzVpDY5/At9WgzTHnxm+hMzzNmZ7mpSTfcnsW4VDNfB0jXM9DXWJqAzvtYC14rNXdWc
rkbpT5bsXSPOOAyG6dpWf2J5rN4Zx3u60d416BsS/RSjd11/A+Vqirk8RlfVen9ieazecICu8XqS
uTZYq9RA6w3gwy2P1TrJMqTlYXD/kxvR1fIYXTc6ZA3au0b/+KZ/jnTVknY1dpPg6t13YPrbQlcV
7xQz14lg+U3SJx48XVWtzqQSOfQm6XRVDfUnqf76bb3k2Bq/QuebTFfV4pS4xsBy/s0Z3OKvKrX+
9vuTxd6N9gfwdDUP3FZ/4oRL1+3qukB/Emiz1XDxmXTdqLG1D7jSTYixRgR03fQ4qv0QpyXXb6OM
NeiqZm5DIe4ZDjeKsZuEalrXtMhX8wKNYgyGtzseDkFecnaw0fZAjK31gSt4N1p+n+0zrIG6mWGJ
YbDBsGp3hpkqb/gQcTeJZt8Num66pwp0u/zyX3NrsN+m66b77do7KrV/V1OsLHm60rV6H9j+BkjB
RltacIMNyGZiPWeZbR4zXZUBfIryHV26BmigEYdtsQbwR4OaZo+ZrttaAon7fdfFdG2ZTNdIvas3
pOpSdr1h9lxYuqrWRwQLd9128VdtLYGkmns+BLruGrU9eCPan61t/K6mGn1gvegwt/hvXdcU80vk
jR9z1egwvStdmyangPc5Jwl0qvElkNCrQe1PjN3ir5y84mXbzbvwRtcYn3Q4qWw4nnzf1efd+DBb
W6Lrpsd+UeKhFtA1UD5ApTUCum76rF/76+mBjtleTWpzuoYeEbTfb9M1xlAq1YlvCDThXMdVaHNX
feBGJ/OBTgR6V7rO34BmvK3PN3LoStfW75INNA9c+EOkq+HfhgaWS/aBzS680VXFmG9XmhoI3VCM
rdgHxrq1g67bHQy7/zbF+UaOwbBVCievKq4aDKt2dbWDcU+/7a4m1YqxofcrNMyma6SJ6wYXV055
FeXiE10VqWaWyj7DKljX3bhUQe+g9n3XLUqVInwlla6D77MLOZZANqFrqnAhZ/n0dLrStTljN75f
IV3pOnPv6kJOPanMXbc+dw33xdEFmn6IXJ8q7YEYKso8sN5WOEI3VOt2pc2vOQcaH9E1Xn+1zabv
Qg5dI00Fa+zYFGvP3ij3HtF1667OO23zVe/7PeHSla73Oaeia+ZERu+6oU89hBIRm1OU9B26quq9
SpRRjC/QqTBemXRUXXgzd1XbmmHWvlbc/reI6ErXGP32khefmj0R0JWxFQeW29yiha5bn2GmIFt1
+np61X6brltcAgn99fQFEoOsDKtN6JpWcatg6301Nzala3L70eInr+RCznbmrrOvWAYNTY5176Rb
/NV2TzHhTgR0VcEGloGWx9o/edE1TOvf5lad9zJkbX3kQoxN9VSxTjFx5650pWukieu848Alj7nN
UwxdI7X+ED1VxBlm7WP2jRzVUDNibM77nKwMqxaa0W3z6y1iLTZkpatqaMga9Hb5iGsE896SSdeN
jv3C3dkbVNcqp29umKrVOOwQ0Rh0VRs1dsm7mlqeu9q41MR11+yWX9F1DdYkuLHNTjvivkd0pStd
N7eRSsT5Nl1jNNC0+W3KzLfpasg6cwhl6F386ar0gZsbstY7ZrrSdaM91fKT7elnBLpG+rxb7qni
fvHdbRJKHxjg5FX7FENXtV1dF3s3Wh9tacFRZj6xhtkhTjHxmgQ3dALNnmIWmBUbDKtND9vi/u5u
8VfNNVnp6Yu9zzNifVSRBpYheqoVDFnd1aQ2MbBcbNO2EAMNuqqmjV3yTixxzKrpwXDVtVa6hmkS
3Gi/Dwy3G3DL2+FX7QPpary60f4k+vvsQo5mtKH+JPT7PPsb69Pa0EJF9BNBuHeDripYA93mxqWV
jKUrXem60ODI3HUrg+G01e1OQutaqz0Qo+U+MNbmL/W+PWN5jK50VYuev+hK11aGrKrnE3QT4rbO
zeaBsdYIxDGrRnWNe29wvVEMXVWj/Xa9b8wt9l28qpMO38jZ1uQn7rJwy+QUakmPrmEWKlLMXfxD
DIl9I0dtUVdFV7pKYa1IFrqh5vx4YrlaqelXWs0WuqHiDKsETy01355zyU3z3eYwe+O9a7iBBl3p
uvW5a6pwV9MpiNskVHPGBn0rZlwmoKuqOHGVvkNXNb9X3pMQupq7Gq+qYPPtWjdj+sC2pqtOO/Bp
xRuxKWOrXm6JeJc/XVW7c9fam4D2TAubIrurSQUYDC9/M0ONtdba34Olq1r53JWudGVs4AH8vIPh
JckNTmfoGmni6pOKPjXQu6rRDciJgK5KzT/8W4xcyTGRVttt+hvsT5YhV7qcI9LKIK3RphlX13in
b2+EOVWIblCToOvmdF1y4lr19sZmZ8WVlvTousW5a/LVvJidNl033UA3eGMQXVVsXdN8NwlWWl9d
YDC82OyArisfA285Fea+3vA2zwJ0DTNOq3T5XgMItJRN10jNKEDa0lI3G4S4Vpzc1URXI4LU9q2C
5q7mVLsQTT9o6Ia5q9pivy10g64q0jA7YuiGuatqbuYTvemHm3S4CXHTfaAKN9YwGKarEUGYbVzp
ytimh38R34rFZvIGwxuauEoiD3rymnH3VrrqtNPGO9jaBzzXvdl0pevMvWvEr6fTVTU381lg+LeC
81fLX6XwaYU5N/uYIk4Nqpy+fWZbGEotcLQRv54e6MZJum5L13ARifcy6ag003YhZ0PG+phWMMw2
GFYtdlCBvp4e703W2kjlbbHPsJragKoOrlSycamasQHdPk9XbQTznmIq3SMxO7mSrpU+L7oG0LXS
B1Tvcsi8dx3UI9fuYGvd3MKQxnvXSm1ogYjU9nVdYCY/8/iFIRvRtd5kOHTvuuTMk6501buuXFS6
tv7p1h6kLfCNmcavuy6w4bi5q2r03K9qv6V0VSrasMsboRRdlVJ0VYquSim6qq73Xakxl5Hoem+6
IiOPJdOVrsh0VRooMl3pikxXRVdkuioNFJmu69b1+//9/vbs7Yv/ePHkvz/Z/bfd4397/Ozfn/3x
n3/84//8A3mzZLq2qOuf/+vP3/7Hb/vP+O5j/9n//X/+HXmbZLo2p+v+BNz5Md9+7H8GeYNkural
6/6sPPhJ3zxOnaGR10qOp2vOVkP5v85g9kxnJFHn9r+ZT/Yf5H62c2oE1Tmmuvzfl8gbIcfT9e72
QlV17d+Vu/Pf9j85eJBvz95mftI9AyrkVZLXo+vRr3BqH+2j7q7/vurOnccGzez/ycGP5MV/vOj4
UG+q68N+9u/PkDdCXomunamK/VGL+UGM+bp2njLG6nqz4p//YT/+t8fIGyEH03XiQHReXe/20p2v
Mnbu2v0x3647nzfyRsjxdL07cF1Y19ty1pi76k+Q9a5z6lp1qclsDXkNunb2ck3NXa0MI1sZHta1
eGX4aGSbKZXrrsiuu26u3MeDvP67mlava3KXLDJdA+l6c4buXmP85wjqb+d/Q94mma4t6ppOf1uy
c7aDvBEyXRvVFRmZrnRFpqvSQJHpSldkZLrSFZmuSgNFpuv6dFVKAp3eFVnvqjQjZLrSFRmZrnRF
pqvSjJDpSldkZLqG1FXmGjJdY+gqcw2ZrjF0tX8CMl1j6Gp3IuTmdB37ivd1QsnZCfHU7WN2QkRe
w06InWlRDeqamUDX+QP2GUZeyT7DmUFyqSvh4lT/lu5sC56zyXAa2mF4lK7j4nDsW48cYhf//CC5
nr8d+wP5/6rnjevRNSeeY/BJqTDIbelaNeomjUlbHfxXKS+BrqBrTTLXkEMk0E0Pkuv/5z3j3um6
nhqfz6Wr/gR5tb1rvhIz6pq/7FQwQjZbQ25I1/5kqilz17lOB2Vz11EnEWuhyDFWhkfpOnZluP+C
Z+YIueC6a/+P5WfbudKI3OLKsEru40GWQLcCXZO7ZJHpGkjXJHMNma6BdE0y15DpGkhXZGS60hWZ
rkoDRaYrXZGR6UpXZLoqDRSZruvTVSkJdHpXZL2r0oyQ6UpXZGS60hWZrkozQqYrXZGR6RpSV5lr
yHSNoavMNWS6xtDV/gnIdI2hq92JkO9T1y2EzRUcub3/kJvbCXELYXOnCAW/pp11kdvSda1hczmH
MfiR2LceuTld1xc2N7i5eeZHIhUG+d503U7YXP+YP19XmWvI96nrFsLmBo9N74q8rd41X7blw+by
z0pma8iNzl03FTaXOW22Forc6MrwdsLmBi/tSKBDlkAXu9zHgyyBLryuyV2yyHQNpGuSuYZM10C6
JplryHQNpCsyMl3pikxXpYEi05WuyMh0pSsyXZUGikzX9emqlAQ6vSuy3lVpRsh0pSsyMl3pikxX
pRkh05WuyMh0DamrzDVkusbQVeYaMl1j6Gr/BGS6xtDV7kTIEuhKXndKAt3gb2HvP2QJdOXHOW8C
XZmudtZFThLolk+g63/FZN96ZAl0qaUEuoL0EKkwyEkC3fIJdGUZOTLXkJMEuuUT6OS7Ikugk0Bn
HmjuKoGuQgJdwXnHWihykkC3fAJd2cqwK43IyV1NDZb7eJAl0IXXNblLFpmugXRNMteQ6RpI1yRz
DZmugXRFRqYrXZHpqjRQZLrSFRmZrnRFpqvSQJHpuj5dlZJAp3dF1rsqzQiZrnRFRqYrXZHpqjQj
ZLrSFRmZriF1lbmGTNcYuspcQ6ZrDF3tn4BM1xi62p0I+Z513WYIXcHvaO8/5NRCYOQGQ+gKfkc7
6yI3p+tGQuiSBDrkWAl0adshdPk9801JhUFO9x4YmanTlCfLXjRT1+khdJkficw15HvWVQhdvq76
E+SV9K75sjUYQme2htz63FUI3diTjrVQ5Bi6ptWF0CUJdMgS6NZR7uNBlkAXXtfkLllkugbSNclc
Q6ZrIF2TzDVkugbSFRmZrnRFpqvSQJHpSldkZLrSFZmuSgNFpuv6dFVKAp3eFVnvqjQjZLrSFRmZ
rnRFpqvSjJDpSldkZLqG1FXmGjJdY+gqcw2ZrjF0tX8CMl1j6Gp3IuT7D91oYQY/9nXnip/L37jU
3n/I6d63Bd94/Jx9hpFjJNCJnxulq33rkZvTdWvxcxLokANk5IifGzsYlrmGfJ+6ip9L8l2Rt9a7
5svWYPycuSty63NX8XMFc1drocgBdE2rjp9z3RVZAl3sch8PsgS68Lomd8ki0zWQrknmGjJdA+ma
ZK4h0zWQrsjIdKUrMl2VBopMV7oiI9OVrsh0VRooMl3Xp6tSEuj0rsh6V6UZIdOVrsjIdKUrMl2V
ZoRMV7oiI9M1pK4y15DpGkNXmWvIdI2hq/0TkOkaQ1e7EyFLoCt53bkS6PJ/TXv/IScJdDkvWi+B
Lv/XtLMucpJAd48JdKNCA+xbj5wk0N1jAl2SkYMsgS5JoJPmJoFu9gnhZhPo+r++qD9BlkDXYgKd
uSuyBLoYCXSjzjvWQpGTBLp7TKAb1Zm70oic3NXUYLmPB1kCXXhdk7tkkekaSNckcw2ZroF0TTLX
kOkaSFdkZLrSFZmuSgNFpitdkZHpSldkuioNFJmu69NVKQl0eldkvavSjJDpSldkZLrSFZmuSjNC
pitdkZHpGlJXmWvIdI2hq8w1ZLrG0NX+Cch0jaGr3YmQW9F1s2l0mTsq2vsPuRVdN5tGZ59h5BgJ
dP26biGNblQYrH3rkZvWdWtpdP1PSoVBbkJXaXQ5H4nMNeRWdN1yGp3+BHmjvWu+bC2n0ZmtITc6
d5VGZy0UOczK8MbT6PJ1daURObmrqcFyHw+yBLrwuiZ3ySLTNZCuSeYaMl0D6ZpkriHTNZCuyMh0
pSsyXZUGikxXuiIj05WuyHRVGigyXdenq1IS6PSuyHpXpRkh05WuyMh0pSsyXZVmhExXuiIj0zWk
rjLXkOkaQ1eZa8h0jaGr/ROQ6RpDV7sTId+nrltIncu5fSzn17T3H/J96rqR1LmCY7azLnJz+wxv
IXWuZ7PinvfWvvXIze3iv4XUuVPD4/zO+a+SCoN8b7puJHWuMGxO5hpyUwl0G0md61G3ZzysP0Fe
be+aL9vyqXP5h2G2htzo3HU7qXP5v5G1UORGV4Y3lTrXcxhJAh2yBLro5T4eZAl04XVN7pJFpmsg
XZPMNWS6BtI1yVxDpmsgXZGR6UpXZLoqDRSZrnRFRqYrXZHpqjRQZLquT1elJNDpXZH1rkozQqYr
XZGR6UpXZLoqzQiZrnRFRqZrSF1lriHTNYauMteQ6RpDV/snINM1hq52J0KWQFfyulMS6AZ/C3v/
IUugKz/OeRPoynS1sy5ykkC3fAJd/ysm+9YjS6BLLSXQFaSHSIVBThLolk+gK4ylk7mGLIFu+QQ6
+a7IEugk0JkHmrtKoKuQQFdw3rEWipwk0C2fQFe2MuxKI3JyV1OD5T4eZAl04XVN7pJFpmsgXZPM
NWS6BtI1yVxDpmsgXZGR6UpXZLoqDRSZrnRFRqYrXZHpqjRQZLquT1elJNDpXZH1rkozQqYrXZGR
6UpXZLoqzQiZrnRFRqZrSF2vr79fXb29vHxxfv7k27fd2dnji4tn37//cX0tzS0GucYnSNcWdf35
88/z89/2n/Hdx/6z//FDmlvr5EqfIF2b03V/Au78mG8/9j9TQLYzwzLkep8gXdvSdX9WHvykbx6n
ztD2Pbpfcr1PMJiumcc5429UHEs3eE9Z55P72c7tEdTHj7uXL3ePHh0eb97sPn06HlP9+mVXwbbI
9T7BYLpmhtnN+LtMjKUrePLq6u3tj/Pp08MBfPiwe//+8Ifnz7MGVPbsvUdyvU9wDbqe6tN6esI0
FGDX/3L9HW/+W9/5/OXli85R05cvh4N8+PD4+YsLO+K3Ra73CYbXdTAQoPNva2ztP9bVU391s+J/
9Pj8effq1eGw3707/quzM3kzbZHrfYKRdC0I0cn/J6lCLF2Zrp0n5tevD6/1++/dyxW5Y29pbouQ
632CwXTtiVEtjska/IbhxFi6WXrXBw8Or/j1a8cnrXcN0bvO8gmG7137O9WyRKwy38a6Onbmc+ph
7hpl7jr9Ewyja3GYXX6XO3ssXZmuR+uKN4+byr/Ubv22nZXhGT/B8LqmjLC5nAC7VC2WbqyuR1ft
+j9s113bv+464ycYbGV4ZeWuprWS3dW0IV2Te4bjk90zvCFd07++z/Hk9Pc5pLm1Tq70CdK1RV3T
6W9Lds52RpGluS1DrvEJ0rVRXZGR6UpXZLoqDRSZrnRFRqYrXZHpqjRQZLquT1elJNDpXZH1rkoz
QqYrXZGR6UpXZLoqzQiZrnRFRqZrSF2luSHTNYau0tyQ6RpDVzszINM1hq72PUKOoevYw5g9vao/
gKfnybkO3q6CyDF0zQyYq6FrWQjA3R1Sp+tqz17kqLoOupGzpXBO2FznOzXW4cwdifs/EjviI69K
1/wsubFhc1N61zQyWjLJm0EeSW5I14nD0VnC5kadLFJepNVYXaW5IcfQ9e6X/caG3PT885QRNje7
rv2vqD9B1ruOcK//PbqXwbDZGnLrug4GzHX2mVP64fxjmK7rqN7VWihyVF37F4HTfGFz+VnPo667
9sfbudKIHPi669bKfTzIse9qoutNuUsWma5hdE3S3JDpGkjXJM0Nma6BdEVGpitdkemqNFBkutIV
GZmudEWmq9JAkem6Pl2VkkCnd0XWuyrNCJmudEVGpitdkemqNCNkutIVGZmuIXWVuYZM1xi6ylxD
pmsMXe2fgEzXGLranQhZAt0wat4EuvwwnqPZjr3/kCXQ5XLmSqAr09XOushJAl1aPIHurycl0CFL
oAuQQJefCfJXSYVBThLo8t+LgkMa/F8JdMgS6JpOoJPviqx3lUBnHmjuKoGuQgJdwdzVWihykkCX
Fk+gK1sZdqURObmrqcFyHw+yBLrwuiZ3ySLTNZCuSeYaMl0D6ZpkriHTNZCuyMh0pSsyXZUGikxX
uiIj05WuyHRVGigyXdenq1IS6PSuyHpXpRkh05WuyMh0pSsyXZVmhExXuiIj0zWkrjLXkOkaQ1eZ
a8h0jaGr/ROQ6RpDV7sTIbela+b9VksuBuTvVzhqe8Q0MkzA3n/ILeoaYu2uP1cuc/PhUbraWRc5
kq49QXKDJvRvNdwfUTe4Nfkyutq3HjmMrvlBcj1/GPW3Y/Ovxoa+jh0MS4VBDjl3LUuXy/mxUSmS
PWeWnP3+x+oqcw055GC4LMOq/9/mkDOXmso6dv0Jcsjetawj7XGgbDBctn6bP9Ieu2JstoYcT9f8
3jXz3xZHqk9cahp7IrAWihxp7po51OxfK+4ZDE/vXV13Rd7WdVeV3MeDLIFuBbomd8ki0zWQrknm
GjJdA+maZK4h0zWQrsjIdKUrMl2VBopMV7oiI9OVrsh0VRooMl3Xp6tSEuj0rsh6V6UZIdOVrsjI
dKUrMl2VZoRMV7oiI9M1pK4y15DpGkNXmWvIdI2hq/0TkOkaQ1e7EyHH1nXUrv+1pbITIvK9kCPp
usyKXOdbc+qlJdAhL0kOr+upCLm7Wwr3P9nTK0qgQ976Lv4z6lqwnf9iu/hLoENeQ0bOXHPXskyd
zBi7/DNFkkCHXJ+8ksFw8ZP9g+H+paYkgQ5Z77qwrmXrt5mvKIEO2dx1RLcmgQ7ZynDTc9e5VoZd
d0V23fU+u+WFL9sWHFtyHw/ypnQ91Q8PdqSN6JrcJYvsnuEQPf/tM7TMNWS6xtA1yVxDpmsgXZGR
6UpXZLoqDRSZrnRFRqYrXZHpqjRQZLquT1elJNDpXZH1rkozQqYrXZGR6UpXZLoqzQiZrnRFRqZr
SF2vr79fXb29vHxxfv7k27fd2dnji4tn37//cX39jw2S6+XExTpmurao68+ff56f/7ZvPXcf+1b1
48ffN0WulxMX7pjp2pyu+1N7ZwO6/dj/zEbI9XZmiHjMdG1L1/35frAN3TxOnfvXRK6371HEYw6j
a+YtWgtIlb/pYcE+w/t51O2x2cePu5cvd48eHR5v3uw+fToerf36dblicr1dBSMeczBdl1mUu/vW
nHrdwfSq/oPs/Nurq7e3G8rTpwfmhw+79+8Pf3j+PGuothpyvT17Ix7zGnS9m3+Rs/H3UXTdxAS6
Tl0H39LOH7i8fNE5Hvvy5QB/+PD4+YuLZysm19sRP+Ixr0TXHjkHdR2bZJMfNleWH31zLeHo8fnz
7tWrA+fdu+O/Ojt7vGJyvbyZiMe8hrlrZiBdZxLslNCNzsPIObD+JztP+a9fH17r99+7F0JWTK6X
5hbxmNczGF5M19SbQDcuGzL7rP/gweEVv37taEMT+8DGyQv3ro0fM11LdD3V045dBB41pzr1mD7D
bJm8/Ny15WPehK4Ffy6YuxbAc1Ysbx43lX8RfzXkxVaGQxzz2uauqTfFfBZdy6675vfbR9cD+5vR
lKujIciLXXcNccyRdF1fuasph+yuJro2rWtyz/B/LfcM07VpXdO/viny5PQ3Rf62KXK9nLhwx0zX
FnVNp7+H2TmPWj25Xk5crGOma6O6IiPTla7IdFUaKDJd6YqMTFe6ItNVaaDIdF2frkpJoNO7Iutd
lWaETFe6IiPTla7IdFWaETJd6YqMTNeQutbLXEOOS6Zri7rWy1xDDk2ma3O61tuLADk6ma5t6Vpv
px/k6OTAus6eRpe56eGp1x17JAvvo4ccnRxY11HhUfnyD75Ez76ns+hab5da5OjkqLoO7sfdE2DT
kytXrGvnP09F+wzX2wMeOTp5PboOOnYqiqoHO6p3TSP3+0+LJ6wgRyevUNfOH8scOeeHzY2du44I
zqmWX4YcnbxOXe9+abBM19QbNpcyAt0Lcq70J8gbmruOHcGO7R5rD4bN1pA3tDKcmaq+5Nx1VO9q
LRQ5beq666gRbOZoNvN1B4/ElUZkCXQhy308yBLo1rBg5i5ZZLpGWt+ul7mGHJpM1xZ1TTUz15Dj
kunaqK7IyHSlKzJdlQaKTFe6IiPTla7IdFUaKDJd16erUhLo9K7IelelGSHTla7IyHSlKzJdlWaE
TFe6IiPTNaSuMteQ6RpDV5lryHSNoav9E5DpGkNXuxMhS6Ar8WfKToiDB2bvP2QJdJPkH3yJ/AS6
Ml3trIucJNClxRPo/npSAh2yBLoRve59JdB1/qv+30IqDHKSQDdW9TQ5ga4sI0fmGnKSQFega5qW
QCffFVnvOjB3lUCHbO4aZmW4qQS6grmrtVDkJIFuymB4ynXXsSvDrjQiJ3c1BZqBu48Hma6RFszc
JYtM10jr2zLXkOkaRtckcw2ZroF0RUamK12R6ao0UGS60hUZma50Raar0kCR6bo+XZWSQKd3Rda7
Ks0Ima50RUamK12R6ao0I2S60hUZma4hdZW5hkzXGLrKXEOmawxd7Z+ATNcYutqdCDmkrrNnzM0i
VWcGT+ftY/33lNn7D3k9OyHOnjFXfL4YdVT5h21nXeSV7DM8JWMuZe8P3L8VcH4sXdkpxr71yCvZ
xX9ixlznD+T/q54jGbuL/9htwaXCIK9K184fKxuj5nSGmbF0SQIdcmVyVF37M+Z6xr3TdU1doR6j
RgT6E+T19675Y92yfzVqyDrLqpLZGvJ6EuhmyZibXdfBF5o4GLYWiry26679GXNjV4bLBsM5I+GC
pSZXGpGTu5raPBl1Pu8+HmS6htE1uUsWma6BdE0y15DpGkjXJHMNma6BdEVGpitdkemqNFBkutIV
GZmudEWmq9JAkem6Pl2VkkCnd0XWuyrNCJmudEVGpitdkemqNCNkutIVGZmuIXW9vv5+dfX28vLF
+fmTb992Z2ePLy6eff/+x/X1P5BnJEugU1N1/fnzz/Pz3/bt8u5j315//Pg78ixkCXRqqq77TqOz
ad5+7H8GeSLZbhJqqq77nmSwdd48TvUqyDlkezWdpmfvoD3vzH767zVLAl3+se1naLdHfR8/7l6+
3D16dHi8ebP79Ol4HPjr1yVyAdlOiAMtcnqi3PK6TkmgK9tn+Orq7e0m+PTp4QA+fNi9f3/4w/Pn
WYNA5EGyfYaz+qXbfxgVEpeGQujuPtn/v6lyAt3g851PXl6+6BzpfflyOMiHD4+fv7h4hlxAtov/
6JfM6Y5G/WTPk8sn0JXpenOV4ujx+fPu1avDob57d/xXZ2ePkQvIMnLGveSUIWV+TE690I38Cfmo
5zs7k9evD6/1++/dSyzIBWQJdDPo2h8td3dYO7i0UyPSamwC3ajnO/uTBw8Or/j1a0frnNhTbZas
dx09d523I+1/oftKoBs7Qj41Wzv1mD4P3CbZ3LVwZbhTrdnFXj6BLhWlSB6thd48bir/9gBkK8O1
rrveHc3mGJWfMTe4Mlw2GB4cCQ/u5ZFzpbG/gU65hrlxsuuuap65vXuPliG7q0nNsxTnzt5lyO4Z
VjPomv71HZQnp7+D8jfkWcgS6NQMuqbT3/DsnKEhF5Ml0KkZdEVGpitdkemqNFBkutIVGZmudEWm
q9JAkem6Pl2VkkCnd0XWuyrNCJmudEVGpitdkemqNCNkutIVGZmuIXWNlYyGvAyZri3qGi4ZDXkZ
Ml2b0zXiLgfIy5Dp2pauEfcQQl6GHFLXGVPtCqQqSKDL3wkx4g59yMuQQ+o6b6pdznkh59ULDmk1
+98iL0OOp2t+MsCpXYjT0M7GR+TiBLr8qIHbFXF3eeRlyGvQddDbu3/of7L/FfMT6Aa/XbGa7Bbk
Zchb1DUtlUBXFskRMRkNeRnyanXNT7Ibq2san0A3Slf9CfK25q75K0ALJNCN1dVsDXlbK8P3Mnct
WHayFoq88pXh/oXfeVeG86+79gg5dqnJlUbk5K6msqHpvczD3ceDvHVdC+46usdlM3fJIutdw6xy
p4DJaMjLkOnaoq4pWjIa8jJkujaqKzIyXemKTFelgSLTla7IyHSlKzJdlQaKTNf16aqUBDq9K7Le
VWlGyHSlKzIyXemKTFelGSHTla7IyHQNqavMNWS6xtBV5hoyXWPoav8EZLrG0NXuRMh1da2x41EB
rX+r4X5yz+aJ/ZuSFh+wvf+Q72EnxEoxcFN0neVX6NlSuGdr/4lHa2dd5Iq6Dm6HfXfzwXQiYOZo
w+6e/+3k3P6ZI+U6/+2oLvou8O4/ydyRuP8w7FuPvKiug11Wf0xG/t/2/GT+y43VNX8wXLaLv1QY
5LZ0zZxq9j+ZaXj+yw0OgKfMXSXQITeRQDeLrj3D3aO/jaVr/9cX9SfI99+7TsxoLFBuLl2Lk5dn
HAybrSHfz8rwxFjkzInoXLqOipAbpeuo3tVaKPK9XXcdHOL2/+TdFp+5/jRW11P7bky87tofb+dK
I7IEujDlPh5kCXThdU3ukkWmayBdk8w1ZLoG0jXJXEOmayBdkZHpSldkuioNFJmudEVGpitdkemq
NFBkuq5PV6Uk0OldkfWuSjNCpitdkZHpSldkuirNCJmudEVGpmtIXWWuIdM1hq4y15DpGkNX+ycg
0zWGrnYnQpZAN0CePYFu8Pjt/YcsgW62X2FiAl2ZrnbWRU4S6JZPoDv1m/Yfhn3rkZMEunQfCXQF
mV1SYZCTBLq0eKRVWUaOzDXkJIEuiq76E+QkgS5JoEM2d00S6Gadu1oLRU4S6NLiCXRlK8OuNCIn
dzU1WO7jQZZAF17X5C5ZZLoG0jXJXEOmayBdk8w1ZLoG0hUZma50Raar0kCR6UpXZGS60hWZrkoD
Rabr+nRVSgKd3hVZ76o0I2S60hUZma50Raar0oyQ6UpXZGS6htT1+vr71dXby8sX5+dPvn3bnZ09
vrh49v37H9fX0twk0KmWdP3588/z89/2lt597O398UOamwQ61Yau+y60U9Tbj/3PFJDtzBCdTNe2
dN33q4Ou3jxO9bH2PVorubquE8PpCrLkZvSnZ2/E/B0SRx38fr56ewz88ePu5cvdo0eHx5s3u0+f
jkfFv37ZVdBOiBUEKHuJxXTtj5Abu7Fw8a92dfX2tpBPnx6YHz7s3r8//OH586whsT17V0muq2tZ
ON3Rn2fJs0tDu/72RMjl/C49wo/dZ/jy8kXnuPfLlwPn4cPj5y8u7IhvF//KSylT9vJPpXl2VUM3
7gpfFrpxc83m6PH58+7Vq8Pxv3t3/FdnZ/JmZOTE0TVTiZxh+Sknc6KWO/vnAl07u9bXrw8H8Pvv
3QtOuS8nzS04OZiumTl0KTuxLn9826/rqX67/+uL+b3rgwcHwtevHa7qXfWu1eeuE3vXKdqP7QMz
57EFJ4hRc9dTD3NXc9fqK8M5Hekshs8yGM5f4h6cNo9dGb553FT+zRJWWa0Mz3zdtfP5wQi5UXl2
03vXUweZOaA4NZbOv+7ar6vrrq67qoXKXU3IEujC65rcM4xM10C6pn99I+fJ6W/kSHOTQKea0TWd
/r5r53x1FFmaW1wyXRvVFRmZrnRFpqvSQJHpSldkZLrSFZmuSgNFpuv6dFVKAp3eFVnvqjQjZLrS
FRmZrnRFpqvSjJDpSldkZLqG1FUCHTJdY+gqgQ6ZrjF0tZsEMl1j6GqvJmQJdCWvNSWBbvDYJNAh
S6CbdFoZdfD9CXRlukqgQ04S6JZPoOt/xSSBDlkCXWopgS4/MeSvkkCHnCTQLZ9AV5aRI4EOOUmg
Wz6BbsZ8Vwl0yPc5d5VAlyTQIUugSy0l0BXMXSXQIScJdMsn0JWtDEugQ07uamqw3NWELIEuvK7J
PcPIdA2ka5JAh0zXQLomCXTIdA2kKzIyXemKTFelgSLTla7IyHSlKzJdlQaKTNf16aqUBDq9K7Le
VWlGyHSlKzIyXemKTFelGSHTla7IyHQNqavMNWS6xtBV5hoyXWPoav8EZLrG0NXuRMht6bqRWLr+
X9Pef8gBdkLcSCxd2bbgdtZFbkjX7cTSlQVG2rceuWldR5mZ+bctxNKVbQsuFQZ5c7rONV5NE2Lp
ykI3ZK4hr1nX9mPpRumqP0GOMXddXyxdga5ma8gxVoZXFktnZRg5/Mpw/wXJlcXSue6KLIFuJeU+
HmQJdOF1Te6SRaZrIF2TzDVkugbSNclcQ6ZrIF2RkelKV2S6Kg0Uma50RUamK12R6ao0UGS6rk9X
pSTQ6V2R9a5KM0KmK12RkelKV2S6Ks0Ima50RUama0hdr6+/X129vbx8cX7+5Nu33dnZ44uLZ9+/
/3F9/Y8NkuvlxMU6Zrq2qOvPn3+en/+2bz13H/tW9ePH3zdFrpcTF+6Y6dqcrvtTe2cDuv3Y/8xG
yPV2Zoh4zHRtS9f9+X6wDd08Tp3710Sut+9RxGMOoOvEuLrZpeo5nsFUnsGPZD+Puj02+/hx9/Ll
7tGjw+PNm92nT8ejtV+/LldMrrerYMRjDqDr9Li66WeKzOPJ3D+1/8mrq7e3G8rTpwfmhw+79+8P
f3j+PGuothpyvT17Ix5z67qOiqvL2WG8agLd2I6088nLyxed47EvXw7whw+Pn7+4eLZicr0d8SMe
czxde7Tp17V2Al2n2wW63lxLOHp8/rx79epwqO/eHf/V2dnjFZPr5c1EPOZV6XrkTI8/NRLocl4u
5/nOU/7r14fX+v337oWQFZPrpblFPOZt6Vovga4gGHLUWf/Bg8Mrfv3a0YYm9oGNkxfuXRs/5sBz
17G6Vk2g6/liceYZZ3BOdeoxfYbZMnn5uWvLxxx4Zbj4z5US6AZ/uGzF8uZxU/kX8VdDXmxlOMQx
x77uOtibjU2ym/e66+BeHjnXA/ub0ZSroyHIi113DXHMMXRda7mrKYfsria6tr6Q5p7h2+WeYbo2
rWv61zdFnpz+psjfNkWulxMX7pjp2qKu6fT3MDvnUasn18uJi3XMdG1UV2RkutIVma5KA0WmK12R
kelKV2S6Kg0Uma7r01UpCXR6V2S9q9KMkOlKV2RkutIVma5KM0KmK12RkekaUteIaW7Itcl0bVHX
iGluyAuQ6dqcrhF3OUBehkzXtnSNuIcQ8jLkJIFurFSndmDszOBpJ4Gu3g59yMuQA+gaJYFuMH0r
8yOJmIyGvAy5dV2jJNDl7Dmc+ZFETEZDXoYcT9ceGe4xge7USLhA14jJaMjLkFela7q/BLqyAJ7V
JKMhL0Pelq71EujKzgWrSUZD1rsOzF2bSqCbUdeIyWjI5q4jVmLvPYFuxsFwxGQ0ZCvDw9ddm0qg
y39y1HXXEMloyK67rr/c1YQsgS68rsk9w8h0DaRripnmhrwAma4t6ppiprkh1ybTtVFdkZHpSldk
uioNFJmudEVGpitdkemqNFBkuq5PV6Uk0OldkfWuSjNCpitdkZHpSldkuirNCJmudEVGpmtIXWWu
IdM1hq4y15DpGkNX+ycg0zWGrnYnQm5O18xbrvp/gcHIjBpS9Rxz/pPJ3n/IgXZC7NlwtB1dyzZG
HXyy55jtrIscQNfUmy6XTqTF3d2/f3Cn37tbDZ9K0MhPoJtRV/vWIwfTNX/3/cy/zfnJKbv497s9
SlepMMjxetd8h3P+NmXs3D8lgW5GXWWuIQceDE/UNT91bkoCXf4JQn+CvLbetaCrnB5qPiWB7tR5
oX/p22wNOerctSwtrmzuOjiyLZi7znUhx1oocrzrrplpccUrwz0v5LorsuuurVcL04Gbch8PMl0H
evimThDukkWma6T+XOYaMl0jDb9lriHTdf2zZeQVk+lKV2S6Kg0Uma50RaaroisyXZUGikzX6Loq
JYFO74qsd1WaETJd6YqMTFe6ItNVaUbIdKUrMjJdQ+p6ff396urt5eWL8/Mn377tzs4eX1w8+/79
j+traW4xyDU+Qbq2qOvPn3+en/+2/4zvPvaf/Y8f0txaJ1f6BOnanK77E3Dnx3z7sf+ZArKdGZYh
1/sE6dqWrvuz8uAnffM4dYa279H9kut9guvRtecerpy9gvN/4NRLZD7Z/9L72c7tEdTHj7uXL3eP
Hh0eb97sPn06HlP9+mVXwbbI9T7BtelasGrX/2OZCXSj0j36n7y6env743z69HAAHz7s3r8//OH5
86wBlT1775Fc7xNcs6495mRu5J+fQDejrpeXLzpHTV++HA774cPj5y8u7IjfFrneJ7g5XXP+kN9p
19D1ZsX/6PH58+7Vq8Nn9O7d8V+dncmbaYtc7xPcrq79XWiOroPBk2W6dp6YX78+YH//vXu5IpMs
zW0Zcr1PkK4p5+uFpya0nWPsGr3rgwcH+NevHZ+03jVE7zrLJ0jXwljHHAnnnbueepi7Rpm7Tv8E
t7IyHGjuerSuePO4qfxL7dZv21kZnvETXJuuOddd81eGR42fK1137f+wXXdt/7rrjJ/gqnRdwej9
ptzVFJ3srqYN6ZrcMxyf7J7hDema/vV9jienv88hza11cqVPkK4t6ppOf1uyc7YziizNbRlyjU+Q
ro3qioxMV7oi01VpoMh0pSsyMl3pikxXpYEi03V9uiolgU7viqx3VZoRMl3pioxMV7oi01VpRsh0
pSsyMl1D6irNDZmuMXSV5oZM1xi62pkBma4xdLXvEfJqdT1191b+1qT9f5uzE+Kp28cKdkK0qyDy
ynXtf35KFF1mAt3g6+bvM2zPXmS6dvhz1BWfMnOUrqM6UjviI48ib1TXwU33e/iDAZMTdZU3g2zu
Or+umRntY+eu0tyQ9a6z6ZpOJNDpXZH1ri3qmr/sZO6KbO7a4ty1f9nJyjCyleHCuWvPtdP8wXD+
xNV1V2TXXcOX+3iQN3dX0/p0Te6SRaZrIF2TNDdkugbSNUlzQ6ZrIF2RkelKV2S6Kg0Uma50RUam
K12R6ao0UGS6rk9XpSTQ6V2R9a5KM0KmK12RkelKV2S6Ks0Ima50RUama0hdZa4h0zWGrjLXkOka
Q1f7JyDTNYaudidCDqbr4P6Gi8kjgQ7ZToizyVP1FSXQIdtneKqug3tzn9oK+NST6fS+3sUJdINv
qX3rkVeyi/8UXQc36e/cMXz2BLq/DmbUSEEqDPIK5663zTyytEDXVCGBbnDKLXMNeSUJdJnJN8vr
mrIT6MrmrvoTZLrOqetc81izNeRNzF0L/lx77iqBDnnTK8OD1137V32mrwznX3dNEuiQt3zddQvl
Ph5kCXThdU3ukkWmayBdk8w1ZLoG0jXJXEOmayBdkZHpSldkuioNFJmudEVGpitdkemqNFBkuq5P
V6Uk0OldkfWuSjNCpitdkZHpSldkuirNCJmudEVGpmtIXWWuRSdfX3+/unp7efni/PzJt2+7s7PH
FxfPvn//4/paAt26dJW5Fp388+ef5+e/7S29+9jb++OHBLq16Gr/hOjkfRfaKertx/5n6BpeV7sT
RSfv+9VBV28ep/pYCXSF8hQn0A3eU2bvv1WS9/PV22Pgjx93L1/uHj06PN682X36dDwq/vVLAt1M
rzglga7sSTvrRidfXb29LeTTp4cm9OHD7v37wx+eP88aEkugWzqBruzUY9/66OTLyxed494vXw7s
hw+Pn7+4kEDXJXDPkzUS6HLe97tPSoWJTr65ZnP0+Px59+rVgf3u3fFfnZ1JoBupa6qQQFemq8y1
6OTOrvX16wPy99+7F5zWP3dtP4FO76p3/evx4MEB/PVrh6sr6V2b1XXispN54Dbnrqce65+7Fvx5
+QS6Ml2tsq5sZfjmcVP5N0tIoLufBLqxurqGubLrrv26ruS66xbKHUJrJW/urqYt65rcfxuf7J7h
DemaZK7FJ//zGzlPTn8jRwLdinRNMtfik09937VzvkrX2LoiI9OVrsh0VRooMl3pioxMV7oi01Vp
oMh0XZ+uSkmg07si612VZoRMV7oiI9OVrsh0VZoRMl3pioxM15C61sgvuyk5cXHJdG1R10r5ZUlO
XHAyXZvTtd5eBPZ8iE6ma1u61tvpx45K0cnBdM28UauqVP3bLHYm0+V/JPXyy+xXGJ0cUtflzw6n
DiA/3ip/W9N6+WV2A45OXomud3fxv9vLHbmX00vnJ9AVbDKcFs8vs9d+dPJ6dB3crf+UWmOl6s+n
7D9H5Pwu9fLLJNlEJ8eeuw7+bjlZOMW6TjlH9DxZL79MTlx08qoGwz1Kjwq2yVxqGjyYsrlrvfwy
PZXetTldy+Lnyha3auhaL7/MPNDctV1dcwarBa84YxrlwvllVlmtDLc7GO43J//67djrroNPjrru
OmN+mWuYrruqmU89yV1NyHQNpGtyzzAyXQPpmqrllyU5ccHJdG1R11Qnv+yv+ZWcuKBkujaqKzIy
XemKTFelgSLTla7IyHSlKzJdlQaKTNf16aqUBDq9K7LeVWlGyHSlKzIyXemKTFelGSHTla7IyHQN
qavMNWS6xtBV5hoyXWPoav8EZLrG0NXuRMhTde2JbKqt+tidCosXA+pteph/bPb+Q66r6/3O8eY6
jMywubIthfOP3M66yAv1rqeC3o7+Sc8PpNP5cZ1/2/+//cd293eZXdeCfYbtW4+8nK79m+jn/MDg
6aD4bwdH7/PqWraLv1QY5Hl0PfUdn/zkqIlhNgWZNKPGq6PC5qYHpctcQ66VQJc/GJ6o62B+XM9w
t+BUkrPU1HkMowbDelfkpXvXZXQd2zVN6XtHvUfFHfuo38tsDTmkrgvMbJeZu47qXa2FIofRdezK
cOfyVfG1ltmvu2YGN7vSiDyzrmqx68nu40Gmaxhdk7tkkekaSNckcw2ZroF0TTLXkOkaSFdkZLrS
FZmuSgNFpitdkZHpSldkuioNFJmu69NVKQl0eldkvavSjJDpSldkZLrSFZmuSjNCpitdkZHpGlJX
mWvRydfX36+u3l5evjg/f/Lt2+7s7PHFxbPv3/+4vpZAty5dZa5FJ//8+ef5+W97S+8+9vb++CGB
bi262j8hOnnfhXaKevux/xm6htfV7kTRyft+ddDVm8epPvYedC1OwZr3YPIPI2cnxFN3iuXcPpZz
GPb+i07ez1dvj4E/fty9fLl79OjwePNm9+nT8aj416/LFnWd2I5rL99lJtCN+oGCA7OzbnTy1dXb
20I+fXpoVx8+7N6/P/zh+fOsIfE965oZM3cq4aIgtqPnx071t6N0zdy4WALd1siXly86x71fvhzY
Dx8eP39x8awtXTN3x8/ZZzzfwx7alF38+88+Ofue9z8pFSY6+eaazdHj8+fdq1cH9rt3x391dva4
IV0zw5THhll09saZ2a1TEujGij36SZlrwcmdXevr1wfk7793Lzi1omvP4DNnlDtW1/7FoeKlplHz
cAl0ete7Qj54cAB//drhalu9a/6ccxZdZxwMl60qSaAzd828itPo3LVHm7LMxbITwVxz18xlJwl0
Vob/etxU/s0SbV13LUg0nrjmnDOdzk+gy1wElkDnumu/rg1dd1VlF4TdIRSdHPKuJlWma3L/bXyy
e4Y3pGuSuRaf/M9v5Dw5/Y0cCXQr0jXJXItPPvV91875Kl1j64qMTFe6ItNVaaDIdKUrMjJd6YpM
V6WBItN1fboqJYFO74qsd1WaETJd6YqMTFe6ItNVaUbIdKUrMjJdQ+oqzS06WQLdVnSV5hadLIFu
K7ramSE62W4SW9HVvkfRyRLoljiMeRPoBn8LuwqukiyBbonlu9kT6Mp0tWdvdLIEupAJdH8xJdDZ
xV8CXYAEupysraOSNxOdLIGu48n2E+gKY+mkuQUnS6DL1TW1lEAn31XvKoFOAp0ZpgQ6CXQVEugK
5q5WWVe2MiyBLkYCXdnKsGuYK7vuKoFuJeUOobWSJdBtSNfk/tv4ZPcMb0jXJM0tPlkC3YZ0TdLc
4pMl0G1IV2RkutIVma5KA0WmK12RkelKV2S6Kg0Uma7r01UpCXR6V2S9q9KMkOlKV2RkutIVma5K
M0KmK12RkekaUldpbtHJEui2oqs0t+hkCXRb0dXODNHJdpPYiq72PYpOjrpX08ZD6Ap+R7sKRidH
TaBLmw+hKzgqe/ZGJ0dNoEubD6FLEujs4h8lgS4JoZNAJyMnSgJdEkKX94v/lyeluQUnR02gS0Lo
xuuqp1pl7xoggS4JoRuvq3ngWueurSfQJSF0Eugk0EVJoEubD6FLEugk0EmgW0e5Q2itZAl0G9I1
uf82Ptk9wxvSNUlzi0+WQLchXZM0t/hkCXQb0hUZma50Raar0kCR6UpXZGS60hWZrkoDRabr+nRV
SgKd3hVZ76o0I2S60hUZma50Raar0oyQ6UpXZGS6htRVmlt0sgS6regqzS06WQLdVnS1M0N0st0k
tqKrfY+ik7eyV9PY7YL7f6VKh1SQSZf/y9pVMDo5cALdvNO55cMmp2TSjUqv+6vs2RudHDiBboHe
9W5yR8//pq5MnVO//sRMuvzf63bZET86OXACXW1d8/fOz88N6D+k/Ey6Ml3lzUQnB06ga1PXUcPm
4ky6wi5XmltwcuAEugV07UmyywlxzPl64akJbQ1d9VSr7F1jJNAt2btmdqSzSFU8ljYPlEBn7jrD
YHj2TLqyhW6rrCtbGY6UQFd24eRofDtqZXjU304ZDA+OhAf38nANcwvXXSXQpd0q7sFyh9BayRLo
1uZqcv/tqsnuGV5bSXNbN1kC3YZ0TdLc4pMl0G1IV2RkutIVma5KA0WmK12RkelKV2S6Kg0Uma7r
01UpCXR6V2S9q9KMkOlKV2RkutIVma5KM0KmK12RkekaUldpbsh0jaGrNDdkusbQ1c4MyHSNoat9
j5Cr6Drvv7r3U0Zx2Fzm7WM5v69dBZFj6HrvrhaHzZX9dvbsRR5FrqJr/5a/qSvZrfOZU0/mbBTc
EzxXNWxu1CbGdsRHHkVeTte7SVD9IY53e7z8LflHBc/1y5bzVwX/vOdJeTPIDel698myKKpZDiDT
t8ywuVkCI6W5Ia9B17Hj3um6ppFhc/25G/oT5A31rvmvO6OuU0a2Zb+F2Rry/eh6KnM1vyecd+5a
PBieqOuo3tVaKHJFXXuuQ2Yu9uYsI8+1Mlw2GC6euJ4aS7vSiHwP112XuRyaVlru40Fe9K6meu14
7B1Ca9I1uUsW2T3DsQYO0tyQ6RppnC/NDZmu65+WI6+YTFe6ItNVaaDIdKUrMl0VXZHpqjRQZLpG
11UpCXR6V2S9q9KMkOlKV2RkutIVma5KM0KmK12RkekaUleZa8h0jaGrzDVkusbQ1f4JyHSNoavd
iZAl0JUc2JQEusFfx95/yBLoyl2dN4GuTFc76yInCXTLJ9D1v2Kybz2yBLrUUgJdQR6XVBjkJIFu
+QS6wrG0zDVkCXTLJ9DJd0WWQDdujUcCHbK5a642G0+gKxjJWwtFThLolk+gK1sZdqUROUmgC/Sr
uY8HWQJdpDORu2SRQ/au29Q1yVxDpmuscb7MNWS6rn9ajrxiMl3pikxXpYEi05WuyHRVdEWmq9JA
kekaXVelJNDpXZH1rkozQqYrXZGR6UpXZLoqzQiZrnRFRqZrSF1lrkUnX19/v7p6e3n54vz8ybdv
u7OzxxcXz75//+P6WgLdunSVuRad/PPnn+fnv+0tvfvY2/vjhwS6tehq/4To5H0X2inq7cf+Z+ga
Xle7E0Un7/vVQVdvHqf62Ni69uzi279N8fRXKU6gK9PV3n/Ryfv56u0x8MePu5cvd48eHR5v3uw+
fToeFf/6dblCXTu3Ne0XeMpLpMm7k5fpamfd6OSrq7e3hXz69NCuPnzYvX9/+MPz51lD4tXqOhgC
cCqK7u67M28CXTqxTXE/wb710cmXly86x71fvhzYDx8eP39x8WyFunb+N39U3JNP1SNbzl8V/POe
J6XCRCffXLM5enz+vHv16sB+9+74r87OHtO1T9fM0enEBLqyn5e5Fp3c2bW+fn1A/v5794ITXfuW
hcYuNZX1rmlof3M91XZ61wcPDuCvXztc1bvuZuwDi0e2EujMXXMeq527Fv9h4mB4oq6jelerrCtb
Gb553FT+zRJb1DUNRdEVXHcde1GncyztGuZ2rrv267rO666rLHcIrZW89buaNqVrcv9tfLJ7hjek
a5K5Fp/8z2/kPDn9jRwJdCvSNclci08+9X3XzvkqXWPrioxMV7oi01VpoMh0pSsyMl3pikxXpYEi
03V9uiolgU7viqx3VZoRMl3pioxMV7oi01VpRsh0pSsyMl1D6irNLTpZAt1WdJXmFp0sgW4rutqZ
ITrZbhJb0dW+R9HJEujiJdANHoZdBVdJlkAXMoGuTFd79kYnS6ALmUD3F1MCnV38JdAFSKAriP+Q
NxOdLIEuZAJd4VhamltwsgS6kAl08l31rhLoJNCZYUqgk0BXIYGu4MRhlXVlK8MS6MZZel8JdGUr
w65hruy6qwS6lZQ7hNZKlkC3IV2T+2/jk90zvCFdkzS3+GQJdBvSNUlzi0+WQLchXZGR6UpXZLoq
DRSZrnRFRqYrXZHpqjRQZLquT1elJNDpXZH1rkozQqYrXZGR6UpXZLoqzQiZrnRFRqZrSF2luUUn
S6Dbiq7S3KKTJdBtRVc7M0Qn201iK7ra9yg62V5NIUPoCnS1q2B0sgS6/3+Up/53Fl1nD6Er0NWe
vdHJEugGdG02hC5JoLOL/wYT6FLYELqxnbC8mehkCXTz65o5QJ0xhC53IC3NLThZAt0kXRsJodNT
SaDbSgJdih9CZx4ogW4rCXQpbAjd2LOGVdaVrQxvMYEuxQyhSxLoJNBJoFtHuUNorWR3NW1I1+T+
2/hk9wxvSNckzS0+WQLdhnRN0tzikyXQbUhXZGS60hWZrkoDRaYrXZGR6UpXZLoqDRSZruvTVSkJ
dHpXZL2r0oyQ6UpXZGS60hWZrkozQqYrXZGR6RpSV2luyHSNoas0N2S6xtDVzgzIdI2hq32PkMPo
Ona33n7IqH+bvw1i5pMFutpVEDmYroNJczV0zYyfy3+yTFd79iKvR9fMni1zw+Gjn59F1/wu1474
yKPI7Q6G+8M18p8c1QFO1LVn83EJdMjTyRvSNee9yImfO/VkwStKc0MeRd6WroNfJsyMn7v7ZE+n
OjgC158g03WGwXB+91i2/mS2hrySuWsqipPLT3ytMXcd+4rWQpHXsDI8dnV31MrwqN514nXX/ld0
pRE5/HXX7ZT7eJDD39VE1+QuWWS6BtI1SXNDpmsgXZM0N2S6BtIVGZmudEWmq9JAkelKV2RkutIV
ma5KA0Wm6/p0VUoCnd4VWe+qNCNkutIVGZmudEWmq9KMkOlKV2RkuobUVeYaMl1j6CpzDZmuMXS1
fwIyXWPoanciZAl0hS9dvBPi4Evb+w9ZAl2hrrMn0JXpamdd5CSBLi2eQNeZczX4kdi3HjkJ3biX
BLqCnCupMMh0zXov5k2gK8vIkbmGTNf/MhheJoFOviuy3nW5wfDweVQCHbK56yjlWk6gKxiTWwtF
ThLo0uIJdGUrw640Iid3NTVY7uNBlkAXXtfkLllkugbSNclcQ6ZrIF2TzDVkugbSFRmZrnRFpqvS
QJHpSldkZLrSFZmuSgNFpuv6dFVKAp3eFVnvqjQjZLrSFRmZrnRFpqvSjJDpSldkZLqG1FXmGjJd
Y+gqcw2ZrjF0tX8CMl1j6Gp3IuRgGTmDt2LVmOvPuxNima72/kNOcQMj+w9sxsOePYGuTFc76yKv
RNejHqz/f1NXCEClBLrMA875SOxbj7wGXUdl4dztMKsm0OUf8OBHIhUGeQ1z1zJdR41RixPoTj1T
oKvMNeTAvWu/xncHuj3JNDnfJDw1oc0P78jPvNOfIK8kgW5sBzUlxzXzPZpySBLokDcxd60xGF4s
ga5/kGwtFHltK8P9o9mcleHpg+Hi6675w2ZXGpFD6rqdch8PsgS68Lomd8ki0zWQrknmGjJdA+ma
ZK4h0zWQrsjIdKUrMl2VBopMV7oiI9OVrsh0VRooMl3Xp6tSEuj0rsh6V6UZIdOVrsjIdKUrMl2V
ZoRMV7oiI9M1pK4y15DpGkNXmWvIdI2hq/0TkOkaQ1e7EyFLoCvxZ8pOiGUHb+8/5CSBLvM0cQo+
ZZ/hUQdvZ13kJIEuLZ5A9xdTAh2yBLqsv73fBLqCTBCpMMhJAt3yCXRlGTky15CTBLq0eAKdfFdk
CXTDbpShkgQ6ZHPXGrpGSaArOJtYC0VOEujS4gl0ZSvDrjQiJ3c1NVju40GWQBde1+QuWWS6BtI1
yVxDpmsgXZPMNWS6BtIVGZmudEWmq9JAkelKV2RkutIVma5KA0Wm6/p0VUoCnd4VWe+qNCNkutIV
GZmudEWmq9KMkOlKV2RkuobUVeYaMl1j6CpzDZmuMXS1fwIyXWPoanciZAl0Jf5M2QmxTFd7/yEn
CXSZp4lT8HnTPXp+0s66yEkCXaqZQDcYFJKvq33rkZMEugV28Z8l0koqDHKSQFc1ga4sX0PmGrIE
untIoOs5rQyOwPUnyOvUtefJ+02gmxjcbLaGvGZdoyTQnVpzthaKLIGurQS6lB3c7EojclRdt1Pu
40GWQBde1+QuWWS6BtI1yVxDpmsgXZPMNWS6BtIVGZmudEWmq9JAkelKV2RkutIVma5KA0Wm6/p0
VUoCnd4VWe+qNCNkutIVGZmudEWmq9KMkOlKV2RkuobUVeYaMl1j6CpzDZmuMXS1fwIyXWPoanci
ZAl0Jf5M2Qmx7ODt/YecJNBlniZOwafsMzzq4O2si5wk0KXFE+g6c64GPxL71iMnCXT3kkBXkAki
FQY5SaBbPoGuLCNH5hpykkCXFk+gk++KLIEuDQ6Vy1BJAh2yuWsNXaMk0BWcTayFIicJdGnxBLqy
lWFXGpGTu5oaLPfxIEugC69rcpcsMl0D6ZpkriHTNZCuSeYaMl0D6YqMTFe6ItNVaaDIdKUrMjJd
6YpMV6WBItN1fboqJYFO74qsd1WaETJd6YqMTFe6ItNVaUbIdKUrMjJdQ+oqcw2ZrjF0lbmGTNcY
uto/AZmuMXS1OxHyRnUdzAQYTKDK2R6x51XshIhsJ8TCHqzTvZ43KDOWbhBon2Hkde4zvIyutzcB
PnVfdX4s3eDf2sUfeZ27+C+pa8FguH/b8bJ++HZJhUE2d51t7tqZqTH2J/sclrmGrHcdnGGOXWrK
nBh3/qT+BFnvupCu+cNdc1dkc9f71DV/McnKMLKV4fl17Y+Ky4+l65k55x+bK43IyV1NgU4l7uNB
pmsYXZO7ZJHpGkjXJHMNma6BdE0y15DpGkhXZGS60hWZrkoDRaYrXZGR6UpXZLoqDRSZruvTVSkJ
dHpXZL2r0oyQ6UpXZGS60hWZrkozQqYrXZGR6RpS1+vr71dXby8vX5yfP/n2bXd29vji4tn3739c
X/+jWXK9NLeI70YNMl1b1PXnzz/Pz3/bf8Z3H/vP/sePvzdIrpfmFvHdqESma3O67k/AnR/z7cf+
Z5oi19s/IeK7UY9M17Z03Z+VBz/pm8epM/Ty5Hq7E0V8N+qR29I1/1asxVYF8ndCzHyy/5D2s53b
I6iPH3cvX+4ePTo83rzZffp0PKb69evy3sn19v6L+G7UI7eo62KLb/mnj1PH0x82V7bP8NXV29sf
59OnhwP48GH3/v3hD8+fZw2oFibX21k34rtRjxxM154eLJ1Il8vk9IRojNW1/ycHP5LLyxedo6Yv
Xw4H/PDh8fMXF8/unVxv3/qI70Y9ciRdBwOpTv05kzNlF/+cE0TmR3Kz4n/0+Px59+rVAf7u3fFf
nZ09vndyvVSYiO9GPXKkuevEUWj+P8nUdfAEUTZ37Twxv359gPz+e/dyxb2T62WuRXw36pGb7l1P
Ldv0uJHfD/dwMpeaKs1dO8/NDx4cXvHr145PeuJZfxbywr1r4+9GPXLrg+FRLb6gd818dwb/akZd
T818Tj2mz6mmk5efu7b8btQjR9V1cO66wGB4mZXhm8dN5V9qX5i82MpwiHejHnnNK8P98vRMjJu6
7tr/YU+5HjgjebHrriHejXrk5nSdV/WgB+yupujvxlbuapqykrym84t7hqO/G+4ZXltlfJ/jyenv
c/ytQXK9NLeI70YlMl0bHb2f+rZk52ynEXK9NLeI70YNMl3XNtlGXjGZrnRFpqvSQJHpSldkuiq6
ItNVaaDIdI2uq1IS6PSuyHpXpRkh05WuyMh0pSsyXZVmhExXuiIj0zWkrvXS3JDjkunaoq710tyQ
Q5Pp2pyu9XZmQI5Opmtbutbb9wg5Ojmqrjn7/Y/6pfL3Kxy16eHYHYzr7SqIHJ0cW9eCZ8bqOiWB
LvVG76TF9+xFjk5ep663A6ZOdcI5Ww3PkkA3Vtd6O+IjRyevWdfUm0aVP3IuTqArGwzXy5tBjk7e
1tx1Xl1zEugKdK2X5oYcnbyS3nWUlmlkCF1xAp3eFVnvOnqMmqnQqCSbzPOCuSuyueucus44d51F
V2uhyNtdapqyMuy6K7LrrmrgI3EfDzJdw+ia3CWLTNdAuqaaaW7Iocl0bVHXVDPNDTkuma6N6oqM
TFe6ItNVaaDIdKUrMjJd6YpMV6WBItN1fboqJYFO74qsd1WaETJd6YqMTFe6ItNVaUbIdKUrMjJd
Q+oqcw2ZrjF0lbmGTNcYuto/AZmuMXS1OxFyu7rm3HjV8zv0/6vpv1fOToj9t4+N2sHY3n/I7eqa
vytvmXsTf6/MBLr+32iUrnbWRQ6p66mtgHv2B+7fTDgTePdv83XtSejI/EjsW48cRtd+KzojbTKD
qvKBo04og66OHQxLhUGOPXctEHLsv03TEuhm1FXmGnKYleFT6zf5yuWER07RNXUl0A2KrXdFXkPv
WhzBOrZTnVHX/Hls/8DBbA059tz1VCxVvblr8WA485+PPRFYC0UOOXc9lXqcvzLcaftY3/IT6GbR
1ZVG5OSupgbLfTzIEujC65rcJYtM10C6JplryHQNpGuSuYZM10C6IiPTla7IdFUaKDJd6YqMTFe6
ItNVaaDIdF2frkpJoNO7IutdlWaETFe6IiPTla7IdFWaETJd6YqMTNeQuspci06+vv5+dfX28vLF
+fmTb992Z2ePLy6eff/+x/W1BLp16SpzLTr5588/z89/21t697G398cPCXRr0dX+CdHJ+y60U9Tb
j/3P0DW8rnYnik7e96uDrt48TvWx7W5cmhk/V1uVU1sBn9qisfjJ/le091908n6+ensM/PHj7uXL
3aNHh8ebN7tPn45Hxb9+BdkJcVT83PJrehPTAMZm1d2UnXWjk6+u3t4W8unTg1wfPuzevz/84fnz
rCFxMF2Le7C790lnupSZVTkxXmDwI7FvfXTy5eWLznHvly8H9sOHx89fXDwLqetc3dqof5hpV7Gu
YwfDUmGik2+u2Rw9Pn/evXp1YL97d/xXZ2ehMnIK4udG9dX9LmW+QWWnkswgn//ypMy14OTOrvX1
6wPy99+7F5xCrgz3x88NDoZz0jQyAzjm0rVg7qqnWmXv+uDBAfz1a4erYXrXUf1h2dB0+mB4FG26
ruaBa527nnpEnbsOxs8V/GQqCl/PvN5jZRh5cGX45nFT+TdLBJu7nlrXHfzJzh00ToXZ9a8Mn9qM
w3VX5Pzrrv26RrruuvFyh9Bayau9q4muneX+2+hk9wxvSNckcy0++Z/fyHly+hs5EuhWpGuSuRaf
fOr7rp3zVbrG1hUZma50Raar0kCR6UpXZGS60hWZrkoDRabr+nRVSgKd3hVZ76o0I2S60hUZma50
Raar0oyQ6UpXZGS6htS1Rn4ZcnQyXVvUtVJ+GXJ0Ml2b07XeXgTI0cl0bUvXejv9IEcnL6prZt5c
swkgR7/F4A8X7IRYL78MOTp5UV3z8+ba0bVzL9J+OXN+sufJevllyNHJreja2dBztu0dlSV16p/3
7HWc8nbxn1HXevllyNHJ96nrKc3S0Hb7qShLqix1Kl/X/oysfF3r5ZchRyc3MXedPdhixlyMlBfh
0a9r5kT3purllyFHJ9/nynBPt9afGZcfnFP2zzOXmlJG0E5ndEjBuXmW/DLk6OQm5q4FvevEfjh/
vJq5JDb4xeLpc9fp+WXI0clt6TplNFvc5RYPhvNPNFNWhmfML0OOTm7lumt+mHJOVl3+P+9ZnW7k
uuuM+WXI0cn3OXdV7uNBlkAXXtfkLllkugbSNVXLL0OOTqZri7qmOvllyNHJdG1UV2RkutIVma5K
A0WmK12RkelKV2S6Kg0Uma7r01UpCXR6V2S9q9KMkOlKV2RkutIVma5KM0KmK12RkekaUtd6yWjf
/+/3t2dvX/zHiyf//cnuv+0e/9vjZ//+7I///OMf/wd5TrIEuq3oWi8Z7c//9edv/+O3fbu8+9i3
17//T+R5yBLotqJrvb0I9p1GZ9O8/dj/DPJEst0ktqJrvZ1+9j3JYOu8eZzqVZDv9xO8f13vK5Yu
E5izE+Kp28eaSqDbz9BOjfo6x4GX/xu5hLySBLqcJrtkLF0OcFQC3dGTrSXQvT17m9k6ewaByPf4
CTat62AsXU4U3WDkXM991WMT6NLIKICF88te/MeLjoZ4U10N9Nm/I5eQV5JAN6qLy9mnvyAMridy
bvou/mOHBgvnl91cpchvoI//DbmEvJ4Euvy566jgnLv/LRigTkygS9mBzv0/Xy+/rLtp3q47bRS5
gLzOBLrMTnWKrvmRc6M6xlO5cvV611nyy/SB99i7xkugG9t3TdR1YjjdWAkLIAvnl5lh3u/cNVgC
XZmuozrGUfPVMl3z++fWEuis397LynDgBLpR113zY+l61OrvcnN23MhMoOuZuDaSQOfq6L1cd5VA
t5JyV9NayRLoNqRrcs9wfLJ7hjeka6qZjLbvVbrXRf856vvbOfI8ZAl0G9I11UxGO/UNz84ZGnJT
nyBdG9UVGZmudEWmq9JAkelKV2RkutIVma5KA0Wm6/p0VUoCnd4VWe+qNCNkutIVGZmudEWmq9KM
kOlKV2RkuobUVQJddLIEuq3oKoEuOlkC3VZ0tZtEdLLdJLaiq72aopM3sVfT2FuxlplA5u+EKIEO
Oa07ga5YxWV0zU+gq7TPsAQ6CXTxdO3Pkrv75GA3mCNVfgJdvo2DPyCBLjp5zQl0Oe04f2/+/A37
+1MCyg4m54Qy+JFIoItOXnkCXbEhmU+mjOid/EnyqFNDQfcrgS46eUMJdKcMycySK9N17JrWqQS6
zIMpODdLoJNAF7J3LehyU16w3agha86BlekqgW6tc9c1JNDNPnfN1HX2uetcukqgW9nK8NoS6GZf
Gc65QDrlckv/ddf8kbYEui1cd5VAt5JyV9NayRLoNqRrcs9wfLJ7hjeka5JAF58sgW5DuiYJdPHJ
Eug2pCsyMl3pikxXpYEi05WuyMh0pSsyXZUGikzX9emqlAQ6vSuy3lVpRsh0pSsyMl3pikxXpRkh
05WuyMh0DamrNDdkusbQVZobMl1j6GpnBmS6xtDVvkfIa9B11L1aY53J36+wJ2nuaDvV/uO0qyDy
KHLU3nXGox3MxchMoJvrSXv2Iq9Z11MJdHf/m07vV5yy43PyQyIH33o74iOPIq9W1ymZdP1v3GDA
5Kj3/e6T8maQVz4YvtuFZoo9Rdf+cXKxrtLckOnatyBUttSkd0XWuy7Uu05ZGZ647GS2hrzduWvB
ALjG3HUuXa2FItM1FawM5193nVFXVxqR0+rvaop4/O7jQV7zXU1rcjW5SxbZPcOrOctIc0Oma6RB
gTQ3ZLqufwyPvGIyXemKTFelgSLTla7IdFV0Raar0kCR6RpdV6Uk0OldkfWuSjNCpitdkZHpSldk
uirNCJmudEVGpmtIXWWuIdM1hq4y15DpGkNX+ycg0zWGrnYnQl5O18zkmHxaz/aFtRcDTm16OOXJ
/mOz9x9yVF17Ai8W0HVwf9OCJwePzc66yEsPhgdjL47+NjMB9fYP5wTM9f/v4KsPnikmmmnfeuQm
dvEf1QUNRjb2y1MQMJf56veiq1QY5FZ617KGPmXr/YmaDQ4Wcjij5q4y15DvYWX4VEbbqQC4nHnm
YLBNf8Bc8asvqav+BLkJXac39Mw+M2UnVuXomhNpNTaj2WwNubkEupwg4xq6Dsa3TplzjuJIoEMO
k0CXE2RcPHftGWz3qNtz/bYnaa7z1XOy7fr38nClEXmjCXQRy308yFtMoFuZrsldssh0DaRrkrmG
TNdAuiaZa8h0DaQrMjJd6YpMV6WBItOVrsjIdKUrMl2VBopM1/XpqpQEOr0rst5VaUbIdKUrMjJd
6YpMV6UZIdOVrsjIdA2p6/X196urt5eXL87Pn3z7tjs7e3xx8ez79z+ur/+BPCO5XgJdjWOma4u6
/vz55/n5b/vP+O5j/9n/+PF35FnI9RLoKh0zXZvTdX8C7vyYbz/2P4M8kVxvz4d6x0zXtnTdn5UH
P+mbx6kzNHIOud6OSvWOuWld+/fszdnCd/rv1bNDYv+TZTsh7mc7t0dQHz/uXr7cPXp0eLx5s/v0
6XhM9evXJXIBud5+hfWOOZKu/fuMV9K1U8v+V5mYkXN19fb2x/n06eEAPnzYvX9/+MPz51kDKuRB
cr3dgOsdc2Bdc4LtUu++4f3ngv4nR50URoVuXF6+6Bw1fflyOOCHD4+fv7h4hlxArrfXfr1jDjB3
PVJi7Pb8BRv/5w/I7x7bqGzbzr+6WfE/enz+vHv16gB/9+74r87OHiMXkOsl2dQ75jC6DvaE/XKO
iurJ1PVuPkDxBPt2dZ6YX78+8H//vXu5ArmAXC8nrt4xr0TXnOC5/hWgUVKNig6ZpXd98ODwil+/
dnzSE3uqzZIX7l1nOeY16DplMFwsVeZSU8Gc9tTM59Rj+jxwm+Tl567TjznGddf8GLgpc9eCi0k1
dD1aV7x53FT+pXbkdlaGZzzmNejaPzodtTI873XXMl2Prtr1f9hTrmFunLzYddcZjzmGrmst9x7d
L9ldTWoGXZM7e5ciu2dYzaBr+tf3OZ6c/j7H35BnIddLoKt0zHRtUdd0+tuSnbMd5GJyvQS6GsdM
10Z1RUamK12R6ao0UGS60hUZma50Raar0kCR6bo+XZWSQKd3Rda7Ks0Ima50RUamK12R6ao0I2S6
0hUZma4hda2XjIa8DFkC3VZ0rZeMhrwMWQLdVnStt8sB8jJku0lsRdd6ewghL0Ne/15NOWFzM+bK
Zb5H+blyg/eOZX4k9XboQ16GvIkEulFhczWONjNsrvMH8vcWHvwt6u1/i7wMeRMJdDn79GfGz6Xe
jLke8UbpmhOB1d/lLry7PPIy5K0k0OWHzeVvyZ+TOpXTh09Mgs5P+qiX3YK8DHkrCXT5cTj5gTej
xqs5YXP9rzuqI104GQ15GfJWEugKdE1DCRpTdE1dcR75vWvqisbTU22zd11hAl2ZrvmD4QJd85ed
5hoMmweude66wgS6/LC5grlr8WB41LLTqYxZq6zbXBlecwLdWBPGrgyXDYbzJ66D0XiuYW7tuqsE
upWUO4TWSpZAtyFdk/tv45PdM7whXVPNZDTkZcgS6Daka6qZjIa8DFkC3YZ0RUamK12R6ao0UGS6
0hUZma50Raar0kCR6bo+XZWSQKd3Rda7Ks0Ima50RUamK12R6ao0I2S60hUZma4hdZXmFp0sgW4r
ukpzi06WQLcVXe3MEJ1sN4mt6Grfo+hkCXTxEugGD9KugqskS6ALmUBXpqs9e6OTJdCFTKDrf8Vk
R/yVkiXQRU2gy4/e+qvkzUQnS6ALmUBXlpEjzS06WQJdyAQ6+a56Vwl0Myz8SKBDlkBX61JKjwmN
J9AVzF2tsq5sZVgCXYwEurKVYdcwV3bdVQLdSsodQmslS6DbkK7J/bfxye4Z3pCuSZpbfLIEug3p
mqS5xSdLoNuQrsjIdKUrMl2VBopMV7oiI9OVrsh0VRooMl3Xp6tSEuiUWvtZ3huhFF2VUnRViq5K
KboqpeiqFF2VUo3qqpQKUf8PSuUK/H8mPKEAAAAASUVORK5CYII=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2012-12-10 01:28:29 +1000" MODIFIED_BY="Harri Hemilä" NO="2" REF_ID="CMP-001.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:NO;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:NO;SHOW_RAW_DATA_COLUMNS:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Incidence of colds while taking &#8805; 0.2 g/day vitamin C regularly, outcome: 1.1 Proportion of participants developing &#8805; 1 cold episodes during the trial</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAApEAAAMACAMAAABLuMyrAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2012-12-11 18:25:01 +1000" MODIFIED_BY="Harri Hemilä" NO="3" REF_ID="CMP-002.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:NO;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:NO;SHOW_RAW_DATA_COLUMNS:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Duration of the colds occurring when on regular &#8805; 0.2 g/day vitamin C, outcome: 2.1 Duration of common cold symptoms (placebo group duration 100%)</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAmwAAALwCAMAAAAd79kvAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2013-04-17 09:34:51 +1000" MODIFIED_BY="Jenny Bellorini">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2013-04-17 09:01:47 +1000" MODIFIED_BY="Jenny Bellorini" NO="1">
<TITLE>Flaws in statistical analysis?</TITLE>
<DATE_SUBMITTED>
<DATE DAY="" MONTH="" YEAR=""/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2013-04-17 09:00:50 +1000" MODIFIED_BY="[Empty name]">
<P>There appear to be several instances where there is considerable overlap between studies, but they are treated as independent studies as far as the meta-analysis is concerned. For example, the Anderson 1974, 1974a, 1974b studies seem to be treated as independent in graph (comparison 01, outcome 04), but the control groups seem identical, and 275 people in the treatment group seem the same in each study. The effect is to inflate the value of this study. Indeed, the difference between the treatment groups for Anderson 1974a, 1974b (33 new people, *all* apparently with one or more respiratory episodes) raises further issues.</P>
<P>I certify that I have no affiliations with or involvement in any organisation or entity with a direct financial interest in the subject matter of my criticisms.</P>
<P>David Wooff</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2013-04-17 08:58:34 +1000" MODIFIED_BY="[Empty name]">
<P>In the new edition of the review we have avoided this problem described above by combining all trial arms that were compared with the one placebo group into one trial arm for purposes of the meta-analysis</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2013-04-17 09:01:42 +1000" MODIFIED_BY="Jenny Bellorini">
<P>Reply supplied by the Authors of the review<BR/>Comment and reply posted 28 August 2004</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
<FEEDBACK_ITEM ID="FBK-02" MODIFIED="2013-04-17 09:02:41 +1000" MODIFIED_BY="Jenny Bellorini" NO="2">
<TITLE>Unit of analysis issues</TITLE>
<DATE_SUBMITTED>
<DATE DAY="" MONTH="" YEAR=""/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2013-04-17 09:02:00 +1000" MODIFIED_BY="[Empty name]">
<P>Further to David Wooff's comment, I suspect there may be other statistical flaws in this review that could be placed under the heading, 'unit of analysis errors'.</P>
<P>At least one study (Lugviggson) appears to be a cluster randomised trial, yet there is no discussion of the possible over-weighting of this study when naively included in the meta-analyses.</P>
<P>At least two studies appear to be twin studies (Carr and Miller). Should the matching be taken into account in the analysis, in a similar way to a simple cross-over trial?</P>
<P>The particular meta-analysis for 'Mean symptom days per person' in the comparison 'Vitamin C 1G daily or more vs placebo' worries me considerably. Of the six studies (10 contributions) included in this analysis, I suspect that at most two are free of unit of analysis errors of various kinds. This makes it a wonderful teaching example, but for the wrong reasons.</P>
<P>I certify that I have no affiliations with or involvement in any organisation or entity with a direct financial interest in the subject matter of my criticisms.</P>
<P>Julian Higgins<BR/>
</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2013-04-17 09:02:36 +1000" MODIFIED_BY="[Empty name]">
<P>Ludvigsson writes explicitly "Every class was divided at random into two groups." In our opinion this statement means that Ludvigsson was taking one class and he divided the participants of that one class into to two groups 'at random,' and then he went to another class and similarly randomised the second class. We disagree that cluster randomisation applied here.</P>
<P>As to the two small twin trials: Miller 1977 explicitly stated that "analysis of the paired comparisons&#8230;" so we conclude their SE values in their main table are based on paired t-test, event though this is not explicitly stated in their methods; Carr 1981 explicitly stated "the results for the six summary cold variables of the paired analyses of variance between active and placebo groups are shown&#8230;" so we conclude their P-values refer to paired analyses. In any case, the mean difference between the groups is the same whether we calculate difference of means or mean of paired differences. Failure to take into account the pairing of data would mean that we would be over-conservative in our estimate of the precision of any effect, but it is unlikely that this issue would anyway have influenced our conclusions in a meaningful way.</P>
<P>In the current review we have not used as an outcome variable mean symptom days per person but have concentrated on mean symptom days per episode.<BR/>
</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2013-04-17 09:02:41 +1000" MODIFIED_BY="Jenny Bellorini">
<P>Reply supplied by the Authors of the review<BR/>Comment and reply posted 28 August 2004</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
<FEEDBACK_ITEM ID="FBK-03" MODIFIED="2013-04-17 09:03:09 +1000" MODIFIED_BY="Jenny Bellorini" NO="3">
<TITLE>Doses too small</TITLE>
<DATE_SUBMITTED>
<DATE DAY="" MONTH="" YEAR=""/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2013-04-17 09:03:09 +1000" MODIFIED_BY="[Empty name]">
<P>One gram daily is a small dose. Most mammals make 3 or more grams in their livers. Any practitioner of orthomolecular medicine knows that a minimum of several grams a day is needed to surely prevent a cold, and as much as 20 grams to cure one in progress. Not one trial in your RCT's qualifies.</P>
<P>I certify that I have no affiliations with or involvement in any organisation or entity with a direct financial interest in the subject matter of my criticisms</P>
<P>Reuven Gilmore</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2013-04-17 08:57:10 +1000" MODIFIED_BY="[Empty name]">
<P>The practitioners of orthomolecular medicine have not to our knowledge published any controlled trial evidence on which this comment is based. As we have said in the review, there is no reasonable doubt that vitamin C supplementation plays some biological role in defence, and there is tantalising evidence from the Anderson 1974 study that a single therapeutic dose of 8 grams at commencement of a cold may have had a useful therapeutic effect.</P>
<P>We believe there is a case for rigorous evaluation of the possibility that very large doses (of the order of 8 g daily in adults for periods up to five days after the onset of symptoms) could produce benefits that were not seen at lower doses.</P>
<P>In view of the greater propensity of children to catch colds and the greater benefits observed in the child prophylaxis studies, this may be the group in which to explore this approach (with an appropriately pro-rated dose for weight). We add however a caution. Although studies in which doses of 1 or 2 g daily of vitamin C have been used for several months have not produced convincing evidence of adverse effects to the volunteers, dosage of the kind discussed here needs to be carefully monitored for adverse effects - especially in children.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2013-04-17 09:03:03 +1000" MODIFIED_BY="Jenny Bellorini">
<P>Reply supplied by the Authors of the review<BR/>Comment and reply posted 28 August 2004<BR/>
</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
<FEEDBACK_ITEM ID="FBK-04" MODIFIED="2013-04-17 09:05:06 +1000" MODIFIED_BY="Jenny Bellorini" NO="4">
<TITLE>Vitamin C for preventing and treating the colds</TITLE>
<DATE_SUBMITTED>
<DATE DAY="10" MONTH="7" YEAR="2005"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2013-04-17 09:03:38 +1000" MODIFIED_BY="Harri Hemilä">
<P>This paper by Hemila and Douglas is highly misleading. Two fundamental scientific errors invalidate the conclusions of their review.</P>
<P>Their first error is the dose range: the doses employed are too small. Treatment of disease requires pharmacological doses of vitamin C, in the range 10 to 200 g per day [Cathcart, Medical Hypotheses, 7, 1359-76]. Prevention of disease requires a minimum of 2.5 g per day, in divided doses, to establish a dynamic flow through the body. In defending their review, Hemila and Douglas cite Levine [Levine et al. JAMA, 1999, 281,1415-23] as showing that the body is saturated by a dose of 0.5 g per day: this finding has been discredited. A more recent paper by Levine and colleagues shows that the body is not saturated by doses up to 18 g per day. [Padayatty et al, Ann Intern Med, 2004, 140, 533-7]. This discrepancy has been explained in a recent book [Hickey and Roberts, Ascorbate, 2004, Lulu press].</P>
<P>The second error concerns the dose frequency. Since high doses of vitamin C have a half-life of about 30 minutes, single or twice daily doses do not increase plasma levels for more than a few hours [Levine et al. JAMA 1999, 281,1415-23]. Such doses provide a minimal protective effect. Given these infrequent doses, even a small positive effect implies a powerful therapeutic potential.</P>
<P>Douglas and Hemila have not shown that vitamin C is ineffective against the common cold, unless the doses used are both inadequate and inappropriate. They have, however, made clear that the previous 65 years of research has been based on a range of doses that are too small and too infrequent. Thus, the research to date may grossly underestimate the therapeutic value of vitamin C. Tests of appropriate dose levels and timing regimes are urgently required.</P>
<P>Steve Hickey PhD. Manchester Metropolitan University<BR/>Hilary Roberts PhD<BR/>
</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2013-04-17 08:55:40 +1000" MODIFIED_BY="[Empty name]">
<P>Hickey and Roberts claim that the prophylactic and therapeutic trials that have been carried out to date have used a range of doses that are too small and too infrequent. They speculate, on the basis of pharmacodynamic studies, that prevention of disease would require a minimum of 2.5 g of vitamin C per day in divided doses. If they firmly believe in their reasoning (there are good grounds for debate), they or someone else need to undertake rigorous prophylactic trials at such dosage levels.</P>
<P>Nevertheless, while stating that "prevention of disease requires a minimum of 2.5 g/day", Hickey and Roberts ignore our finding that in six trials with participants under heavy physical or cold stress or both, vitamin C halved the incidence of common cold type of symptoms (our Fig 01). This benefit was seen with doses of 0.25 to 1.0 g/day which is substantially less than those speculated as minimal by Hickey and Roberts. Thus in our Fig 01 the living conditions rather than the vitamin C dosage provided the explanation to the heterogeneous trial results.</P>
<P>Our review does not claim that the issue is closed. It acknowledges that vitamin C plays some biological role in defence against respiratory infections but finds no evidence that at doses up to 1 to 2 g/day vitamin C would prevent colds in the general population or reduce common cold duration enough to justify regular supplementation.</P>
<P>Finally, we drew attention to one study in which an 8 g therapeutic dose seemed to be beneficial and underlined the fact that no therapeutic trials have been carried out in children even though the regular supplementation trials found greater effect in children.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2013-04-17 09:05:06 +1000" MODIFIED_BY="Jenny Bellorini">
<P>Harri Hemilä and Robert M Douglas<BR/>Comment and reply posted 16 November, 2005<BR/>
</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
<FEEDBACK_ITEM ID="FBK-05" MODIFIED="2013-04-17 09:26:29 +1000" MODIFIED_BY="Jenny Bellorini" NO="5">
<TITLE>Vitamin C doses in trial</TITLE>
<DATE_SUBMITTED>
<DATE DAY="24" MONTH="7" YEAR="2007"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2013-04-17 09:25:44 +1000" MODIFIED_BY="Harri Hemilä">
<P>Studies which find the effects of vitamin C on the common cold inconclusive invariably use less than 1 g of ascorbic acid a day. Proponents of Vitamin C therapy consistently use 3 or more grams a day. This debate will not be resolved until both camps start testing the same dosages. Since the ascorbic acid proponents acknowledge that &lt; 1 g a day will have little therapeutic effect, it is incumbent on researchers to analyze the effect of megadoses.</P>
<P>I routinely dose to bowel tolerance. 0.5 g every hour for eight hours will reach bowel tolerance for me. When I begin to become ill, I have dosed as high as 0.5 g every 20 minutes without reaching bowel tolerance. I can significantly reduce the effect of a cold in this fashion, and once was the only one functioning in my office when everyone else was sick.</P>
<P>My rule of thumb is 35 mg per pound of body weight per day. This must be distributed throughout the day to prevent overloading the ability of the stomach to absorb it, and to provide continuous saturation, because of the rapid decomposition of ascorbic acid once it is no longer in crystalline form. This dose is consistent with the levels of ascorbic acid produced by the liver of other mammals.</P>
<P>Submitter agrees with default conflict of interest statement:<BR/>I certify that I have no affiliations with or involvement in any organization or entity with a financial interest in the subject matter of my feedback.<BR/>
<BR/>Sean Emerson<BR/>
</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2013-04-17 09:26:00 +1000" MODIFIED_BY="Jenny Bellorini">
<P>Our review shows that the relation between vitamin C dosage and effect is not as simple as Sean Emerson suggests. We found statistically significant heterogeneity in the effect of vitamin C on common cold incidence. The heterogeneity was not explained by vitamin C dosage but by segregating trials with people under heavy acute physical stress to a separate group. In the latter subgroup, vitamin C halved the common cold risk, yet the doses in the trials were rather low, from 0.25 to 1 g/day. Prophylactic trials with the general population found no evidence that vitamin C would prevent colds, even though the highest prophylactic dose was 3 g/day (Karlowski 1975).</P>
<P>In the therapeutic trials, the dose-response is also complex. Several studies with 3 to 4 g/day failed to find therapeutic benefit (Cowan 1950, Elwood 1977, Tyrrell 1977, Audera 2001). Thus, the negative findings in therapeutic trials are not simply explained by the use of ascorbic acid in "doses less than 1 gram a day". On the other hand, Anderson 1975 found statistically significant 25% reduction in "days spent indoors per subject" with dosage of 1 to 1.5 g/day for five days. This benefit is not explained by the use of particularly high doses.</P>
<P>We pointed out that in the Karlowski 1975 trial 6 g/day was associated with a double benefit compared with 3 g/day. We also pointed out that Anderson 1974 reported that 8 g/day on the first day of the common cold appeared better than 4 g/day. Thus, there are scattered data suggesting dose dependency, but these findings are more relevant for planning further trials than for immediate conclusions to claim dose-dependency.</P>
<P>Based on the trials analysed in our review, we do not consider that regular supplementation of the ordinary people is justified. On the other hand, vitamin C is inexpensive and safe in doses of grams per day and, while waiting for new therapeutic trials, testing vitamin C for common cold treatment may be reasonable at an individual level. However, explicit evidence from well-conducted trials is required for broad recommendations to use vitamin C for treating the common cold, and such evidence is missing.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2013-04-17 09:26:29 +1000" MODIFIED_BY="Jenny Bellorini">
<P>Hemilä, Douglas and Liz Chalker<BR/>22 August, 2007</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
<FEEDBACK_ITEM ID="FBK-06" MODIFIED="2013-04-17 09:33:55 +1000" MODIFIED_BY="Jenny Bellorini" NO="6">
<TITLE MODIFIED="2008-06-13 16:19:03 +1000" MODIFIED_BY="Liz Dooley">Vitamin C and the common cold</TITLE>
<DATE_SUBMITTED>
<DATE DAY="2" MONTH="4" YEAR="2008"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2013-04-17 09:31:52 +1000" MODIFIED_BY="Liz Dooley">
<SUBSECTION>
<HEADING LEVEL="4">Introduction </HEADING>
<P>The Cochrane review provides a meta-analysis of low-dose studies of vitamin C and the common cold. Unfortunately, its authors limit the range of intakes to values that are marginally effective, and exclude clinical data on higher doses, which have been shown to provide positive results.</P>
<P>The review fails to understand orthomolecular claims for vitamin C in prevention and treatment of the common cold, repeated over a period of at least 50 years.[i]<SUP>,</SUP>[ii]<SUP>,</SUP>[iii]<SUP>,</SUP>[iv]<SUP>,</SUP>[v]<SUP>,</SUP>[vi] Orthomolecular nutrition and medicine are concerned with varying the concentrations of substances such as vitamin C, which are normally present in the body, to prevent or control disease; typically, this involves large doses of nutrients. The doses Douglas <I>et al</I>. refer to as &#8220;mega-dose vitamin C supplementation&#8221; range from 200 mg, once or twice daily. These are small doses.</P>
<P>To avoid misunderstanding, we state the orthomolecular claims for vitamin C:</P>
<P>Vitamin C given at frequent intervals (&lt; 6 hourly) and sufficiently high doses (8+ grams per day) will prevent common colds in the majority of subjects (individual variation is high).</P>
<P>Vitamin C, given at short intervals and very high doses to a subject with the common cold, can eliminate the symptoms and may bring about a cure within hours [1,2,3,3,5, 6,7]. Cathcart suggests 30-150 grams per day, at intervals of one hour or less.[vii] The Vitamin C Foundation recommends 8 grams every 20 minutes, from the onset of symptoms.</P>
<P>The dose-response relationship for the treatment claim is described as a threshold effect; unless a minimum threshold dose is reached, little or no clinical response is achieved.[viii]</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Review shortcomings</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Methodology</HEADING>
<P>1. If a reviewer is aware of author names, experimental details, and results, she can influence the outcome of the review by unfair selection; even honest experimenters are subject to unconscious effects. In this case, the reviewers had prior knowledge of the literature on vitamin C and the common cold, and specific knowledge of the papers under consideration. The researchers were aware that selection criteria would exclude ALL clinical reports of high (orthomolecular) doses. These problems have been communicated to the authors, though their response has been unsatisfactory. A clear and objective response might provide reassurance that the potential for bias was being addressed.</P>
<P>2. As described in another Cochrane review, the placebo effect is irrelevant in the case of definitive and objective clinical effects. The effects claimed for vitamin C are large, objective, and definitive [6]. Orthomolecular physicians report complete, dose-related, reversal of symptoms, or rapid cure. The review required placebo controls on the basis that the authors considered &#8220;that with the expected small effects of vitamin C, and the greatly subjective outcome definitions, only placebo-controlled trials could yield information of adequate rigour.&#8221; Such an expectation is based on a misconception of the claims for vitamin C. The explanation is particularly inadequate, as it restricts the doses studied to outliers of the range claimed to be effective.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Results</HEADING>
<P>3. The review does not include data for intakes of the order of magnitude described in the orthomolecular prevention or treatment claims. This objection was made by Hickey and Roberts, and Higgins, in response to an earlier version, later reinforced by Emerson. Douglas <I>et al.</I> responded tangentially and failed to explain how their data could be extrapolated to cover the doses claimed to be effective.</P>
<P>4. The review covers longer dose intervals than those claimed to be effective. Hickey and Roberts published this objection and again the response by Douglas and Hemilä did not indicate how their data could be extrapolated to more frequent doses.</P>
<P>5. The reviewers disregard the pharmacokinetics of vitamin C. The half-life for kidney excretion of high-dose vitamin C from plasma is about 30 minutes [6]. At the dose levels and intervals studied by Douglas <I>et al.</I>, there would be little, if any, consistent increase in plasma ascorbate levels or body content. The action of vitamin C depends on its ability to donate and transfer electrons: if the ascorbate has been excreted, it cannot exert this redox effect. A rigorous response is required, as this failure breaches basic principles of pharmacology.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Conclusions</HEADING>
<P>6. The reviewers dismiss the observations of Cathcart and others, on the grounds that &#8220;their uncontrolled observations do not provide valid evidence of benefit&#8221;. Scientifically, such experimental results are more valid than large-scale clinical trials or epidemiological studies. The scientific method involves hypothesis and refutation.[i] Easily replicable experiments, as reported by internationally-known physicians, such as Cathcart, Klenner, Hoffer, Levy, Kalokerinos, and Brighthope, have great scientific validity. If these observations were in error then, over the last half century, any physician or scientist could have refuted the claims, with little effort or cost. No such refutation exists in the literature.<SUP>6 </SUP>
</P>
<P>7. The authors failed to identify the limitations of their review. Their results relate to low doses: approximately an order of magnitude less than those claimed to be effective. The review did not specify that its results and conclusions exclude orthomolecular and other clinical claims for the effectiveness of vitamin C.</P>
<P>8. Taken as a whole, the review and resultant media generalisations are misleading, as they deflect attention away from the actual claims for vitamin C&#8217;s effectiveness. The authors have promoted their conclusions widely under the Cochrane name, resulting in generalisations that are out of proportion to a scientific interpretation of the data. A widely-quoted press release from Douglas&#8217; university begins &#8220;vitamin C has been proven ineffective in combating the common cold in most people.&#8221; Douglas claims, &#8220;vitamin C has proven not to be a magic bullet to solve the common cold&#8221;.[i] We can find no evidence in the Cochrane review to support such unscientific claims,<SUP>9 </SUP>let alone provide anything close to &#8220;proof&#8221;.<SUP>9 </SUP>The hypothesis that appropriate doses of vitamin C can prevent or cure the common cold has not been refuted and we ask that this review be withdrawn [6].</P>
<P>[1] Klenner F.R. (1953) The Use of Vitamin C as an Antibiotic, The Journal of Applied Nutrition, 6, 274-278.</P>
<P>[2] Stone I. (1972) Vitamin C Against Disease: The Healing Factor, Perigree Books.</P>
<P>[3] Cathcart R.F. (1981) The Method of Determining Proper Doses of Vitamin C for the Treatment of Disease by Titrating to Bowel Tolerance, Orthomolecular Psychiatry, 10(2),125-132.</P>
<P>[4] Lewin S. (1976) Vitamin C: Its Molecular Biology and Medical Potential, Academic press.</P>
<P>[5] Levy T. (2002) Vitamin C, Infectious Diseases and Toxins, Xlibris Corp.</P>
<P>[6] Hickey S. Roberts H. (2004) Ascorbate: The Science of Vitamin C, Lulu press.</P>
<P>[7] Cathcart R. (1981) Vitamin C, titrating to bowel tolerance, anascorbemia, and acute induced scurvy, Medical Hypotheses, 7, 1359-1376.</P>
<P>[8] Cathcart R.F. (1985) Vitamin C: the non-toxic,nonrate-limited, antioxidant free radical scavenger, Medical Hypotheses, 18, 61-77.</P>
<P>[9] Popper K. (1963) Conjectures and Refutations: The Growth of Scientific Knowledge. Routledge.</P>
<P>[10] Amanda Morgan (2005) News from The Australian National University, Tuesday 28 June.</P>
<P>Steve Hickey PhD and Hilary Roberts PhD<BR/>
</P>
</SUBSECTION>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2013-04-17 09:33:11 +1000" MODIFIED_BY="Jenny Bellorini">
<P>
<B>Reply to Hickey and Roberts&#8217; comments, May 2008</B>
</P>
<P>Hickey and Roberts reiterate comments to which we have already replied. See the earlier discussions. Here we focus on fundamental issues related to the evaluation of medical interventions.</P>
<P>First, Hickey and Roberts criticise us for excluding uncontrolled observations from our systematic review. The importance of control groups in the evaluation of medical interventions is discussed in basic textbooks of clinical trials and epidemiology and also in the Cochrane Handbook (1). We do not repeat the arguments here. The Cochrane Collaboration focuses mainly on randomised controlled trials, but non-randomised controlled studies can be included when justified; however, the inclusion of uncontrolled observations is not an option (Ref. 1, Chapter 13). With their opinion that &#8220;uncontrolled observations are more valid than large-scale clinical trials or epidemiological studies&#8221;, Hickey and Roberts challenge the whole Cochrane Collaboration and not just our review on the common cold.</P>
<P>Second, Hickey and Roberts state that &#8220;the placebo effect is irrelevant in the case of definitive and objective clinical effects.&#8221;  Even though the placebo effect has often been exaggerated, there is firm evidence of placebo effect on patient-reported continuous outcomes and on pain measured as a continuous outcome (2).  Moreover, in their meta-analysis examining the role of methodology in controlled trials, Balk et al. (3) found that the lack of placebo control biased the treatment effects of paediatric trials that measured soft outcomes of respiratory diseases. Therefore, the absence of placebo leads to a high risk of bias in trials on the common cold, which is a short-lasting and non-severe disease with soft outcomes.</P>
<P>Third, Hickey and Roberts are not consistent in their argumentations. They state that &#8220;even honest experimenters are subject to unconscious effects&#8221;, yet they ignore this wisdom when they lean on the uncontrolled observations by vitamin C enthusiasts.</P>
<P>Our review was largely motivated by the work of Linus Pauling, who hypothesised in the early 1970s that grams of vitamin C per day would prevent colds. We found that trials in the general community do not support Pauling&#8217;s hypothesis, whereas trials with individuals under heavy acute physical stress do. The statistically highly significant effect in the latter group of trials refutes Hickey and Roberts&#8217; argument that our &#8220;results relate to low doses: approximately an order of magnitude less than those claimed to be effective.&#8221; The heterogeneity we found indicates that the characteristics and conditions of people are important in determining the effect of vitamin C, whereas we do not see basis to assume that doses that are an order of magnitude higher than those used in the prophylactic trials (up to 3 grams per day) would prevent colds in the general community.</P>
<P>The purpose of our systematic review was not to test Hickey and Roberts&#8217; orthomolecular claims and none of the identified controlled trials directly test them. With their belief that frequent high-dose vitamin C supplementation prevents colds in all people, and their note that testing vitamin C effects requires &#8220;little effort or cost&#8221;, Hickey and Roberts should consider organizing by themselves a randomised controlled trial to examine their orthomolecular claims.</P>
<P>1 Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008.  Available at:  <A HREF="http://www.cochrane.org/resources/handbook/">http://www.cochrane.org/resources/handbook/</A>
</P>
<P>2 Hrobjartsson A, Gøtzsche PC. Placebo interventions for all clinical conditions. Cochrane Database Syst Rev 2004;(2): CD003974.</P>
<P>3 Balk EM, Bonis PAL, Moskowitz H, Schmid CH, Ioannidis JPA, Wang C, Lau J. Correlation of quality measures with estimates of treatment effect in meta-analyses of randomised controlled trials. JAMA 2002; 287: 2973-82.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2013-04-17 09:33:55 +1000" MODIFIED_BY="Liz Dooley">
<P>Harri Hemilä, Robert M Douglas, Elizabeth Chalker, Barbara Treacy<BR/>23 May, 2008<BR/>
</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
<FEEDBACK_ITEM ID="FBK-07" MODIFIED="2013-04-17 09:34:51 +1000" MODIFIED_BY="Jenny Bellorini" NO="7">
<TITLE MODIFIED="2009-11-13 16:05:12 +1000" MODIFIED_BY="[Empty name]">Vitamin C for preventing and treating the common cold</TITLE>
<DATE_SUBMITTED>
<DATE DAY="25" MONTH="11" YEAR="2008"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2013-04-17 09:34:42 +1000" MODIFIED_BY="[Empty name]">
<P>I would be interested in your results if you restricted studies to those using 1.0 grams or more.</P>
<P>Submitter agrees with default conflict of interest statement:<BR/>I certify that I have no affiliations with or involvement in any organization or entity with a financial interest in the subject matter of my feedback. </P>
<P>Roger Mann M.D.<BR/>Occupation Family Physician<BR/>
</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2013-04-17 08:53:09 +1000" MODIFIED_BY="Jenny Bellorini">
<P>We have previously replied to overlapping feedbacks on the dose-response issue (see the other comments). In this update, we calculated the effect of 1 g/day or more on common cold incidence in the general community trials and also with this restriction there is strong evidence that prophylactic vitamin C has no effect on the average incidence of colds. None of the five trials with physically stressed people used over 1 g/day and therefore the benefit in that group is not explained by particularly high dosage.</P>
<P>We note that Karlowski 1975 and Coulehan 1974 used two different doses within the same trials and with the same outcome definitions. Karlowski found that for adults, 6 g/day was associated with a double benefit compared with 3 g/day, and Coulehan found that for school children, 2 g/day caused about twice the benefit of 1 g/day (Hemilä 1996a; Hemilä 1999a). Although these findings do not establish dose dependency, they are interesting and support the case for examination of higher doses in therapeutic trials.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2013-04-17 09:34:51 +1000" MODIFIED_BY="[Empty name]">
<P>Harri Hemila, Liz Chalker, Bob Douglas<BR/>13 November, 2009</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
<FEEDBACK_ITEM ID="FBK-08" MODIFIED="2013-04-17 08:52:30 +1000" MODIFIED_BY="[Empty name]" NO="8">
<TITLE MODIFIED="2013-04-17 08:47:40 +1000" MODIFIED_BY="[Empty name]">Vitamin C for preventing and treating the common cold</TITLE>
<DATE_SUBMITTED>
<DATE DAY="11" MONTH="2" YEAR="2013"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2013-04-17 08:51:20 +1000" MODIFIED_BY="[Empty name]">
<P>Re review of studies about Vit C and prevention of urti. Linus Pauling recommended up to 16 gm /day. Were any of the studies using these doses?</P>
<P>I agree with the conflict of interest statement below:<BR/>I certify that I have no affiliations with or involvement in any organization or entity with a financial interest in the subject matter of my feedback.</P>
<P>Dr Robert McKillop<BR/>General Practitioner<BR/>
</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2013-04-17 08:52:16 +1000" MODIFIED_BY="[Empty name]">
<P>As a short answer to the question, none of the studies in the review used doses as high as 16 g/day, but we will briefly summarize the question of doses. </P>
<P>In our review we acknowledge Linus Pauling's role in the 1970s in promoting publicity about the possible role of vitamin C against the common cold and in leading to the conduct of dozens of placebo-controlled trials on the topic. However, conclusions about reasonable vitamin C doses should not be based on what Pauling said or wrote, but should be based on empirical evidence. </P>
<P>Doses of 3 g/day vitamin C have not prevented natural colds in ordinary people (Karlowski 1975) or laboratory colds (Walker 1967; Schwartz 1973). We do not see any basis to speculate that higher regular doses such as 16 g/day may have a different preventive effect for ordinary people. In our review we found a subgroup of five trials in which vitamin C halved the incidence of colds. However, the benefit was not explained by particularly high vitamin C dosage but by the special conditions of the participants: heavy acute physical stress. </P>
<P>The case for treating colds is different. The Karlowski 1975 study found significant dose dependency so that 6 g/day of vitamin C shortened colds in adults by twice as much as 3 g/day and Coulehan 1974 found that 2 g/day of vitamin C shortened colds of children twice as much as 1 g/day (Hemilä 1999a Table 2 and Fig. 2). Anderson 1974 found that a single dose of 8 grams of vitamin C was significantly more beneficial than a single dose of 4 grams at the beginning of the cold (Hemilä 2006a Table 19). Asfora 1977 found that 6 g/day caused such obvious clinical progress that it further led to the breakage of the double-blind code (this review Table 1). </P>
<P>We do not see any basis to assume that 6 or 8 g/day would lead to the maximal effect of vitamin C. Instead, linear extrapolation of the results of the Karlowski 1975 study, and of all adult trials, suggested that 18 g/day and 10 g/day, respectively, might decrease the duration of common cold episodes by half (Hemilä 1999a Figs. 1 and 2). Even though we must be cautious about simple linear extrapolation, if there is curvature in the dose dependency so that higher doses cause less than the assumed linear benefit, then the doses that halve the duration of colds would be even greater than those suggested by linear extrapolations. </P>
<P>Some clinicians have proposed 10 to 30 g/day vitamin C for treating colds on the basis of their personal empirical evidence with their patients (Bee 1980; Cathcart 1981). We do not know what the maximal therapeutic benefits are and the vitamin C doses leading to them. Nevertheless, as described in our review vitamin C is safe in high doses and we conclude that it may be worthwhile for common cold patients to test on an individual basis whether therapeutic vitamin C is beneficial for them. Therapeutic trials explicitly testing dose dependency are needed.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2013-04-17 08:52:30 +1000" MODIFIED_BY="[Empty name]">
<P>Harri Hemilä and Elizabeth Chalker<BR/>15 April, 2013</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2012-09-18 16:24:12 +1000" MODIFIED_BY="Harri Hemilä">History and search strategies prior to 2012</TITLE>
<APPENDIX_BODY MODIFIED="2012-12-10 01:51:23 +1000" MODIFIED_BY="[Empty name]">
<P>In the first <B>1998</B> edition of this Cochrane Review (<LINK REF="REF-Douglas-1998" TYPE="REFERENCE">Douglas 1998</LINK>), an analysis was made of the 30 published trials that had been selected by two previous systematic reviewers, <LINK REF="REF-Hemil_x00e4_-1992" TYPE="REFERENCE">Hemilä 1992</LINK> and <LINK REF="REF-Kleijnen-1989" TYPE="REFERENCE">Kleijnen 1989</LINK>. That selection of trials was one of convenience and was justified by the fact that all had been carried out post-Pauling in an era of relatively sophisticated trial methodology, and mainly using doses of vitamin C at the level recommended by Pauling (i.e. 1 g per day or more).</P>
<P>For the <B>2004</B> revised edition of this Cochrane Review (<LINK REF="REF-Douglas-2004" TYPE="REFERENCE">Douglas 2004</LINK>), all known publications on the topic in the past 64 years were included. Some of these trials had been carried out since the original 1998 review, but also the controlled trials published before 1970 (pre-Pauling period) were added. We set the limit of daily vitamin C administration to 0.2 g/day, so that controlled trials with lower doses were not included in the review, but were listed and commented on in the excluded studies table.</P>
<P>Twenty-five additional trials were then added to the review, including a number of trials which evaluated the utility of vitamin C in the prevention of post-race colds among marathon runners and further explored the role of vitamin C as a therapy for colds.</P>
<P>For the 2004 update, we again searched the following electronic databases: the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> Issue 2, 2004); MEDLINE (January 1966 to June 2004) and EMBASE (1990 to June Week 23 2004).</P>
<P>For the 2004 update, we also screened the reference lists incorporated in a series of systematic reviews of the literature published by <LINK REF="STD-Briggs-1984" TYPE="STUDY">Briggs 1984</LINK> and <LINK REF="REF-Kleijnen-1989" TYPE="REFERENCE">Kleijnen 1989</LINK> (for the search strategy of the latter, <I>see </I>
<LINK REF="REF-Kleijnen-1992" TYPE="REFERENCE">Kleijnen 1992</LINK>) and the references in those studies. One of the review authors (HH) has a research involvement spanning over a decade in this topic and has assembled a large personal reference list of papers published in the grey literature or listed in indexing services that preceded electronic searching. These were added to a primary database which was then systematically screened by two review authors (BD and Ron D'Souza - a previous review author) who worked together to exclude duplicate entries, preliminary reports of data more fully reported elsewhere, commentaries, editorials and other papers which did not contain unique reports of controlled or randomised clinical comparisons. These two review authors then separately reviewed hard copies or electronic abstract data on each of 84 papers, applying the selection criteria outlined above. A final list of 62 papers was selected, which contained unique data from one or more trials of vitamin C and the common cold. One of the papers (<LINK REF="STD-Bibile-1966" TYPE="STUDY">Bibile 1966</LINK> cited by <LINK REF="REF-Kleijnen-1989" TYPE="REFERENCE">Kleijnen 1989</LINK>) remains unassessed as we have been unable to retrieve a copy through library orders. Twenty-six of the 61 remaining papers failed to meet the selection criteria.</P>
<P>This left us with 36 papers, of which 12 contained reports of two or more (up to six) unique study comparisons and an entry for each comparison was made into the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' table, using the letters a, b, c, d, e and f to identify different study comparisons within the one publication. The review in 2004 included data from 56 distinct trial comparisons, which was 25 more than in the original 1998 review. In four of the papers (<LINK REF="STD-Anderson-1974a" TYPE="STUDY">Anderson 1974a</LINK>; <LINK REF="STD-Anderson-1975a" TYPE="STUDY">Anderson 1975a</LINK>; <LINK REF="STD-Audera-2001a" TYPE="STUDY">Audera 2001a</LINK>; <LINK REF="STD-Karlowski-1975a" TYPE="STUDY">Karlowski 1975a</LINK>) more than one actively treated group was compared with the same placebo-treated group. To avoid the 'unit of analysis problem' for which we were legitimately criticised in the original 1998 review, where multiple active arms were considered separately in the same meta-analysis, they were combined as one entry.</P>
<P>For the <B>2007</B> update (<LINK REF="REF-Douglas-2007" TYPE="REFERENCE">Douglas 2007</LINK>), we searched CENTRAL (<I>The Cochrane Library</I> Issue 4, 2006), MEDLINE (2004 to December 2006) and EMBASE (1990 to December 2006). In the 2007 update, only one new trial was identified (<LINK REF="STD-Sasazuki-2006" TYPE="STUDY">Sasazuki 2006</LINK>).<BR/>
</P>
<P>
<B>The 2007 MEDLINE search</B>
</P>
<P>1 exp Common Cold/<BR/>2 common cold$.mp.<BR/>3 exp RHINOVIRUS/<BR/>4 rhinovir$.mp.<BR/>5 or/1-4<BR/>6 exp Ascorbic Acid/<BR/>7 ascorbic acid.mp.<BR/>8 vitamin c.mp.<BR/>9 or/6-8<BR/>10 5 and 9</P>
<P>For the 2010 update, we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2010, issue 1), which contains the Acute Respiratory Infections Group's Specialised Register, MEDLINE (2006 to February 2010) and EMBASE (2006 to February 2010).</P>
<P>See below the search strategy for MEDLINE. The EMBASE and CENTRAL searches were slightly modified to fit the databases (see Appendix 2 for EMBASE search strategy).</P>
<SUBSECTION>
<HEADING LEVEL="5">MEDLINE (OVID)</HEADING>
<P>1 exp Common Cold/<BR/>2 common cold$.mp.<BR/>3 exp Rhinovirus/<BR/>4 rhinovir$.mp.<BR/>5 or/1-4<BR/>6 exp Ascorbic Acid/<BR/>7 ascorb$.mp.<BR/>8 (vitamin$ adj5 C).mp.<BR/>9 or/6-8 <BR/>10 5 and 9</P>
<P>
<B>EMBASE search run from 01 January 2006 to 03 February 2010</B>
</P>
<P>10. #5 AND #9  <BR/>9.  #6 OR #7 OR #8   <BR/>8.  ascorb*:ab,ti  <BR/>7.  (vitamin* NEAR/5 c):ab,ti<BR/>6.  'ascorbic acid'/exp<BR/>5.  #1 OR #2 OR #3 OR #4   <BR/>4.  rhinovir*:ab,ti<BR/>3.  'human rhinovirus'/exp OR 'rhinovirus infection'/exp OR 'rhinovirus'/de<BR/>2.  'common cold':ab,ti OR 'common colds':ab,ti<BR/>1.  'common cold'/de OR 'common cold symptom'/de</P>
<P>There were no language or publication restrictions in the literature searches. <BR/>
</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2012-09-18 16:22:25 +1000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2012-09-18 16:22:25 +1000" MODIFIED_BY="Harri Hemilä">Embase.com search strategy 2012</TITLE>
<APPENDIX_BODY MODIFIED="2012-05-10 15:52:31 +1000" MODIFIED_BY="[Empty name]">
<P>#11 #7 AND #10 361<BR/>#10 #8 OR #9 58878<BR/>#9 (vitamin* NEAR/5 c):ab,ti OR ascorb*:ab,ti 39136<BR/>#8 'ascorbic acid'/exp 50266<BR/>#7 #1 OR #2 OR #3 OR #4 OR #5 OR #6 8168<BR/>#6 ((viral OR virus*) NEAR/2 rhinit*):ab,ti 84<BR/>#5 'acute rhinitis':ab,ti 85<BR/>#4 rhinovir*:ab,ti 3158<BR/>#3 'human rhinovirus'/de OR 'rhinovirus infection'/de 1204<BR/>#2 'common cold':ab,ti OR 'common colds':ab,ti OR coryza:ab,ti 2466<BR/>#1 'common cold'/de OR 'common cold symptom'/de 4344</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2012-09-18 16:22:35 +1000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2012-09-18 16:22:35 +1000" MODIFIED_BY="[Empty name]">CINAHL (EBSCOhost) search strategy 2012</TITLE>
<APPENDIX_BODY MODIFIED="2012-05-10 15:37:04 +1000" MODIFIED_BY="[Empty name]">
<P>S13 S7 and S11 16 <BR/>S12 S7 and S11 91 <BR/>S11 S8 or S9 or S10 3342 <BR/>S10 TI vitamin* N5 c OR AB vitamin* N5 c 1762 <BR/>S9 TI ascorb* OR AB ascorb* 586 <BR/>S8 (MH "Ascorbic Acid") 2325 <BR/>S7 S1 or S2 or S3 or S4 or S5 or S6 1767 <BR/>S6 TI ((viral or virus*) N2 rhinit*) OR AB ((viral or virus*) N2 rhinit* ) 5 <BR/>S5 TI acute rhinitis OR AB acute rhinitis 30 <BR/>S4 TI coryza OR AB coryza 23 <BR/>S3 TI rhinovirus* OR AB rhinovirus* 153 <BR/>S2 TI common cold* OR AB common cold* 501 <BR/>S1 (MH "Common Cold") 1400 </P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2012-09-18 16:22:45 +1000" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2012-09-18 16:22:45 +1000" MODIFIED_BY="[Empty name]">LILACS (BIREME) search strategy 2012</TITLE>
<APPENDIX_BODY MODIFIED="2012-05-10 15:53:06 +1000" MODIFIED_BY="[Empty name]">
<P>VHL &gt; Search &gt; (MH:"Common Cold" OR "Resfriado Común" OR "Resfriado Comum" OR "Coriza Aguda" OR catarro OR coryza OR rhinovir$ OR MH:rhinovirus OR "acute rhinitis" OR "viral rhinitis") AND (MH:"ascorbic acid" OR "Ácido Ascórbico" OR "Vitamin C" OR MH:D02.241.081.844.107$ OR MH:D02.241.511.902.107$ OR D09.811.100$ OR "Vitamina C")</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2012-12-10 01:48:15 +1000" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2012-09-18 16:22:55 +1000" MODIFIED_BY="[Empty name]">Web of Science (Thomson Reuters) search strategy 2012</TITLE>
<APPENDIX_BODY MODIFIED="2012-12-10 01:48:15 +1000" MODIFIED_BY="[Empty name]">
<P>Topic=("common cold" or "common colds" or rhinovir* or coryza or "acute rhinitis" or "viral rhinitis" or (virus* NEAR/2 rhinitis)) AND Topic=("ascorbic acid" or ascorb* or (vitamin* NEAR/5 c)) Refined by: Publication Years=( 2011 OR 2010 OR 2012 )<BR/>Timespan=1955-2012. Databases=SCI-EXPANDED, CPCI-S, CCR-EXPANDED, IC.<BR/>Lemmatization=On  </P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2012-09-18 16:23:07 +1000" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2012-09-18 16:23:07 +1000" MODIFIED_BY="[Empty name]">Trials Registers search strategy 2012</TITLE>
<APPENDIX_BODY MODIFIED="2012-05-10 16:04:57 +1000" MODIFIED_BY="[Empty name]">
<P>common cold AND vitamin c<BR/>ascorbic acid AND common cold<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>